0001493152-23-006366.txt : 20230301 0001493152-23-006366.hdr.sgml : 20230301 20230301122526 ACCESSION NUMBER: 0001493152-23-006366 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIVOS INC CENTRAL INDEX KEY: 0001449349 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 800138937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53497 FILM NUMBER: 23691924 BUSINESS ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 BUSINESS PHONE: 509-736-4000 MAIL ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICAL ISOTOPE Corp DATE OF NAME CHANGE: 20081103 10-K 1 form10-k.htm
0001449349 false FY P2Y 0001449349 2022-01-01 2022-12-31 0001449349 2022-06-30 0001449349 2023-03-01 0001449349 2022-12-31 0001449349 2021-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2021-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2021-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2021-12-31 0001449349 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredMember 2020-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredMember 2020-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredMember 2020-12-31 0001449349 us-gaap:CommonStockMember 2020-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001449349 us-gaap:RetainedEarningsMember 2020-12-31 0001449349 2020-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredMember 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredMember 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredMember 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001449349 us-gaap:RetainedEarningsMember 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredMember 2021-01-01 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001449349 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredMember 2022-01-01 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesAPreferredMember 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesBPreferredMember 2022-12-31 0001449349 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001449349 us-gaap:PreferredStockMember RDGL:AdditionalPaidInCapitalSeriesCPreferredMember 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-12-31 0001449349 2021-09-14 2021-09-15 0001449349 2021-09-15 0001449349 2022-07-27 2022-07-31 0001449349 2022-07-31 0001449349 2022-10-30 2022-10-31 0001449349 srt:MaximumMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember RDGL:ProductionEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember RDGL:ProductionEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-01-01 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001449349 RDGL:CommonStockOptionsMember 2022-01-01 2022-12-31 0001449349 RDGL:CommonStockOptionsMember 2021-01-01 2021-12-31 0001449349 RDGL:CommonStockWarrantsMember 2022-01-01 2022-12-31 0001449349 RDGL:CommonStockWarrantsMember 2021-01-01 2021-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-06-01 2021-06-30 0001449349 us-gaap:CommonStockMember 2021-06-01 2021-06-30 0001449349 us-gaap:SeriesAPreferredStockMember 2021-06-01 2021-06-30 0001449349 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-06-01 2021-06-30 0001449349 srt:ChiefExecutiveOfficerMember 2021-09-30 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2021-09-01 2021-09-30 0001449349 srt:ChiefExecutiveOfficerMember 2022-03-31 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001449349 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001449349 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-08 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 0001449349 RDGL:SeriesAConvertiblePreferredStockMember srt:MinimumMember 2016-03-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember srt:MaximumMember 2016-03-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-01 2015-06-30 0001449349 srt:ChiefExecutiveOfficerMember RDGL:SeriesAConvertiblePreferredStockMember 2021-06-01 2021-06-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-01 2018-10-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2021-12-01 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-12-01 2021-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-01 2019-03-31 0001449349 us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001449349 us-gaap:WarrantMember 2022-03-01 2022-03-31 0001449349 2022-06-02 2022-06-30 0001449349 us-gaap:CommonStockMember 2022-07-05 2022-07-07 0001449349 2022-07-07 0001449349 us-gaap:CommonStockMember 2022-07-07 0001449349 RDGL:JuneTwoThousandTwentyFiveMember 2022-07-05 2022-07-07 0001449349 RDGL:JuneTwoThousandTwentyFiveMember 2022-07-07 0001449349 RDGL:DecemberTwoThousandTwentyTwoMember 2022-07-05 2022-07-07 0001449349 RDGL:DecemberTwoThousandTwentyTwoMember 2022-07-07 0001449349 us-gaap:AccountsPayableMember 2022-09-01 2022-09-30 0001449349 us-gaap:WarrantMember 2022-12-01 2022-12-31 0001449349 us-gaap:AccountsPayableMember 2021-01-01 2021-01-31 0001449349 us-gaap:AccountsPayableMember 2021-05-01 2021-05-31 0001449349 us-gaap:CommonStockMember 2021-01-01 2021-01-31 0001449349 2021-01-01 2021-09-30 0001449349 us-gaap:CommonStockMember 2021-03-01 2021-03-31 0001449349 us-gaap:CommonStockMember 2021-03-31 0001449349 2021-03-01 2021-03-31 0001449349 2021-03-31 0001449349 us-gaap:CommonStockMember 2021-01-08 2021-01-29 0001449349 us-gaap:WarrantMember 2021-01-08 2021-01-29 0001449349 us-gaap:CommonStockMember 2021-06-27 2021-06-28 0001449349 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2021-06-27 2021-06-28 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2021-06-01 2021-06-30 0001449349 us-gaap:CommonStockMember 2021-07-09 2021-09-24 0001449349 us-gaap:WarrantMember 2021-07-09 2021-09-24 0001449349 us-gaap:CommonStockMember 2021-10-01 2021-10-31 0001449349 us-gaap:WarrantMember 2021-10-01 2021-10-31 0001449349 2021-11-01 2021-11-30 0001449349 us-gaap:AccountsPayableMember 2021-12-01 2021-12-31 0001449349 2021-12-01 2021-12-31 0001449349 srt:MinimumMember 2020-12-31 0001449349 srt:MaximumMember 2020-12-31 0001449349 2020-01-01 2020-12-31 0001449349 2019-12-31 0001449349 srt:MinimumMember 2021-12-31 0001449349 srt:MaximumMember 2021-12-31 0001449349 srt:MinimumMember 2022-12-31 0001449349 srt:MaximumMember 2022-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001449349 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001449349 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001449349 us-gaap:WarrantMember 2021-03-31 0001449349 us-gaap:WarrantMember 2021-03-01 2021-03-31 0001449349 us-gaap:WarrantMember 2022-06-02 2022-06-30 0001449349 us-gaap:WarrantMember 2022-07-07 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:ConsultantsMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:OneConsultantsMember 2021-06-01 2021-06-30 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember RDGL:OnTheGrantDateMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember RDGL:BoardOfDirectorsMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefExecutiveOfficerMember 2022-02-02 2022-02-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefExecutiveOfficerMember 2022-03-02 2022-03-03 0001449349 RDGL:ConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2022-05-30 2022-06-01 0001449349 RDGL:ConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2022-10-29 2022-11-01 0001449349 us-gaap:WarrantMember 2020-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2020-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2020-12-31 0001449349 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001449349 us-gaap:WarrantMember 2021-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2021-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2021-12-31 0001449349 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember 2022-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2022-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2022-12-31 0001449349 srt:MinimumMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember 2021-01-01 2021-12-31 0001449349 srt:MaximumMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2020-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-01-01 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-12-31 0001449349 RDGL:EmploymentAgreementMember RDGL:DrMichaelKKorenkoMember 2019-06-03 2019-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to _________

 

Commission file number: 0-53497

 

VIVOS INC

(Exact name of registrant as specified in its charter)

 

Delaware   80-0138937
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

719 Jadwin Avenue ● Richland, Washington 99352

(Address of principal executive offices) (Zip Code)

 

(509) 736-4000

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 Par Value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-Accelerated Filer ☒ Smaller Reporting Company ☒
    Emerging growth company ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of Each Class   Trading Symbol   Name of Each Exchange on which registered
         

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $36,693,047. Shares of common stock held by each executive officer and director and by each person who owns 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. Without acknowledging that any individual director of registrant is an affiliate, all directors have been included as affiliates with respect to shares owned by them.

 

As of March 1, 2023, there were 362,541,528 shares of the registrant’s common stock outstanding, 2,071,007 shares of the registrant’s Series A Convertible Preferred Stock outstanding, 200,363 of the registrant’s Series B Convertible Preferred Stock outstanding and 385,302 of the registrant’s Series C Convertible Preferred Stock outstanding.

 

 

 

 
 

 

VIVOS INC

Report on Form 10-K

 

TABLE OF CONTENTS

 

    Page
PART I.    
     
Item 1. Business 3
Item 1A. Risk Factors 14
Item 1B. Unresolved Staff Comments 21
Item 2. Properties 21
Item 3. Legal Proceedings 21
Item 4. Mine Safety Disclosures 21
     
PART II.    
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 22
Item 6. Selected Financial Data 23
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 23
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 28
Item 8. Financial Statements and Supplementary Data 28
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 28
Item 9A. Controls and Procedures 29
Item 9B. Other Information 30
     
PART III.    
     
Item 10. Directors, Executive Officers and Corporate Governance 31
Item 11. Executive Compensation 34
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36
Item 13. Certain Relationships and Related Transactions, and Director Independence 39
Item 14. Principal Accountant Fees and Services 40
     
PART IV.    
     
Item 15. Exhibits and Financial Statement Schedules 41

 

2
 

 

PART I

 

FORWARD LOOKING STATEMENTS

 

Except for statements of historical fact, certain information described in this Annual Report on Form 10-K (“Annual Report”) contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would” or similar words. The statements that contain these or similar words should be read carefully because these statements discuss the Company’s future expectations, including its expectations of its future results of operations or financial position, or state other “forward-looking” information. Vivos Inc. believes that it is important to communicate its future expectations to its investors. However, there may be events in the future that the Company is not able to accurately predict or to control. Further, the Company urges you to be cautious of the forward-looking statements which are contained in this Annual Report because they involve risks, uncertainties and other factors affecting its operations, market growth, service, products and licenses. The risk factors in the section captioned “Risk Factors” in Item 1A of the Company’s Annual Report, as well as other cautionary language in this Annual Report, describe such risks, uncertainties and events that may cause the Company’s actual results and achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements. The occurrence of any of the events described as risk factors could have a material adverse effect on the Company’s business, results of operations and financial position.

 

ITEM 1. BUSINESS.

 

Vivos Inc. is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In 2013 the FDA issued the determination that RadioGel™ is a device for human therapy for non-resectable cancers in humans. This should result in a faster path than a drug for final approval.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGelTM should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGelTM will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGelTM are used synonymously throughout this document. The only distinction between IsoPet® and RadioGelTM is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGelTM” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

3
 

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP.

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, Y-90 phosphate particles. Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

Recently, the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

Intellectual Property

 

Our original license with Battelle National Laboratory reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.

 

Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

4
 

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.

 

We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

IsoPet Regional Clinics

 

We currently have four regional therapy clinics:

 

  ● Vista Veterinary Hospital – Kennewick, WA
  ● University of Missouri – Columbia, MO
  ● Johns Hopkins University – Baltimore, MD
  ● New England Equine Practice – Patterson, NY

 

Vista Veterinary Hospital (“Vista”) was selected as the pilot private clinic to initiate commercial sales of IsoPet®. It is good management practice to implement and learn from a pilot program before spreading to regional clinics across the country. Vista is located in the Tri-Cities Washington area which is convenient for interactions with key personnel of the Company. The pilot is being used to

 

  ● Refine the Memorandum of Understanding to define all the germane interfaces, roles and liabilities between Vista Inc and the private clinics, including the pilot responsivity to document and share the key aspects of all therapies with the Company;
  ● Create and implement proprietary certification training packages;
  ● Amend the production center radioactive material license at IsoTherapeutics, the Company’s IsoPet® production center, to allow distribution for commercial applications;
  ● Work with the pilot program to obtain a radioactive material licensing in an NRC agreement state;
  ● Create equipment and supplies list;
  ● Create and post regulatory signage;
  ● Explore different IsoPet® pricing options;
  ● Evaluate different approaches to obtain patients;
  ● Optimize patient scheduling practices to reduce cost to the pet owners;
  ● Develop communication material and a liability document for the pet owners; and
  ● Further refine the therapy techniques for advanced cancers.

 

5
 

 

Vista Veterinary Hospital has done well on two audits by the Washington State Department of Health. The Company is working closely with the Washington State Department of Health to refine and improve the radioactive material license. The Company has added several detailed procedures, which will benefit future regional clinics. In addition, a second veterinarian has completed all the preliminary requirements to become certified. All that remains is to demonstrate proficiency in three therapies.

 

The testing at the universities and at Vista Veterinary Hospital have demonstrated that IsoPet® is effective on killing cancer tissue near the injections. It is most effective in early cases before the cancer has begun to spread. Later stage cancers are more difficult to treat since the tendrils from the primary cancer site are not well defined and therefore can lead to recurrence.

 

There have been 115 expressions of interest in IsoPet® therapy from across the United States, but only about 10% of these were treated and they were very advanced cases. The reasons are instructive. Most of the cases were for so advanced that the pet parents found out about IsoPet® on the Internet as a last hope. Several others were internal cancers that could not be reached, for example deep in the throat. Several cases were treatable, but the pets weighed more than 20 pounds and the pet parents were not willing to fly them in the “Safe Cargo” holds. Those patients would have been treated by regional clinics once we implement that strategy. Several cases were mast cell cancers. The Company is confident that those tumors could have been treated, but once killed they release mast cells in a process called granulation. This could cause a shock to the animal’s system. The Company will focus one of our clinical studies on the optimum approach for those therapies.

 

Vista Veterinary Hospital accepted advanced cancer cases and has gained experience to extend the animal’s lives. The first cat was terminally ill and had previously had external beam, surgery and chemotherapy. The facial tumor was treated with 400 Gy and the biopsy confirmed that the cancer was killed. In about seven months the cancer returned in the throat and could not be treated so the cat had to be put down. Dr. Bauder, the veterinarian pet parent, was still elated about the life extension and is asking us to use him as a reference. The other cases were also very advanced with multiple tumors and they recurred since they had already spread before therapy. One animal, Yukon had a large tumor on his leg that was recommended for amputation. The tumor size decreased 50% after the first treatment, but then stopped decreasing. For the first time a second therapy was administered and the tumor has continued to decrease in size. Yukon’s life was extended for more than a year until she finally succumbed to metastatic cancer in another location.

 

Since IsoPet® has shown to be effective in killing cancer at the site of injection the current focus is in optimizing the techniques to help the pet resorb the necrotic tissue rapidly. In addition, IsoPet® was used to treat a mast cell tumor. When these cancers are destroyed, they release their mast cell. The animal was treated with a steroid to counter this effect and to date is doing well.

 

The Company’s efforts are now to obtain more early-stage cancer patients. The biggest obstacle is to convince the veterinarians of the pet parents to agree with IsoPet® therapy rather than using a more traditional method such as surgery. This is a slow process due to the conservative nature of the veterinarian professions. This is the prime motivation to continue with additional clinical trials and to publish the results.

 

The Company worked closely with FX Masse to develop nine certification training modules for use in potential regional clinics. These modules are necessary to satisfy the radioactive material handling licenses. This approach is very cost effective.

 

Johns Hopkins University VCTN, Veterinary Clinical Trials Network, is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific cancers. They have the required radioactive material license and have completed their training certification for Isopet®. This important relationship will also help meet our objective of obtaining high quality data on a range of cancers that can be published in leading journals. These publications are the optimal way to increase awareness of Isopet® and to gain broader acceptance from the veterinarian/oncology community.

 

Our objective is to open several regional clinics by the end of 2023 and to participate in a minimum of four conferences to spread the word about IsoPet in the veterinarian community for treating tumors in small animals and horses. We created a Marketing Steering Board to provide advice on obtaining new pet patients.

 

6
 

 

Regulatory History

 

Human Therapy

 

RadioGel™ has a long regulatory history with the Food and Drug Administration (“FDA”). Initially, the Company submitted a presubmission (Q130140) to obtain FDA feedback about the proposed product. The FDA requested that the Company file a request for designation with the Office of Combination Products (RFD130051), which led to the determination that RadioGel™ is a device for human therapy for non-resectable cancers, which must be reviewed and ultimately regulated by the Center for Devices and Radiological Health (“CDRH”). The Company then submitted a 510(k) notice for RadioGel™ (K133368), which was found Not Substantially Equivalent due to the lack of a suitable predicate, and RadioGel™ was assigned to the Class III product code NAW (microspheres). Class III products or devices are generally the highest risk devices and are therefore subject to the highest level of regulatory review, control and oversight. Class III products or devices must typically be approved by FDA before they are marketed. Class II devices represent lower risk products or devices than Class III and require fewer regulatory controls to provide reasonable assurance of the product’s or device’s safety and effectiveness. In contrast, Class I products and devices are deemed to be lower risk than Class I or II, and are therefore subject to the least regulatory controls.

 

A pre-submission meeting (Q140496) was held with the FDA on June 17, 2014, during which the FDA maintained that RadioGel™ should be considered a Class III device and therefore subject to pre-market approval. On December 29, 2014, the Company submitted a de novo petition for RadioGel™ (DEN140043). The de novo petition was denied by the FDA on June 1, 2015, with the FDA providing numerous comments and questions. On September 29, 2015, the Company submitted a follow-up pre-submission informational meeting request with the FDA (Q151569). This meeting took place on November 9, 2015, at which time the FDA indicated acceptance of the Company’s applied dosimetry methods and clarified the FDA’s outstanding questions regarding RadioGel™. Following the November 2015 pre-submission meeting, the Company prepared a new pre-submission package to obtain FDA feedback on the proposed testing methods, intended to address the concerns raised by the FDA staff and to address the suitability of RadioGel™ for de novo reclassification. This pre-submission package was presented to the FDA in a meeting on August 29, 2017. During the August 2017 meeting, the FDA clarified their position on the remaining pre-clinical testing needed for RadioGel™. Specifically, the FDA addressed proposed dosimetry calculating techniques, dosimetry distribution between injections, hydrogel viscoelastic properties, and the details of the Company’s proposed animal testing.

 

The Company believes that its submissions to the FDA to date have addressed all the FDA staff’s feedback over the past four years. Of particular importance, the Company has provided corresponding supporting data for proposed future testing of RadioGel™ to address any remaining questions raised by the FDA. We believe, although no assurances can be given, that the clinical testing modifications presented to the FDA in August 2017 will result in a de novo reclassification for RadioGel™ by the FDA. In addition, in previous FDA submittals, the Company proposed applying RadioGel™ for a very broad range of cancer therapies, referred to as Indication for Use. The FDA requested that the Company reduce its Indications for Use. To comply with that request, the Company expanded its Medical Advisory Board (“MAB”) and engaged doctors from respected hospitals who have evaluated the candidate cancer therapies based on three criteria: (1) potential for FDA approval and successful therapy; (2) notable advantage over current therapies; and (3) probability of wide-spread acceptance by the medical community.

 

In November 2020 the Company submitted a request for a Breakthrough Device Designation. Ultimately, this was denied, but the FDA acknowledged, “The FDA does believe that RadioGel™ meets criterion #2a: Device represents breakthrough technology. Your device does meet this criterion because it is a novel application of a brachytherapy device outside of the liver.” More importantly the process resulted in a rapid review of our existing data and approach. It led to a redirection of our efforts on writing the IDE and saved the Company much time in the review of that future application.

 

Based on advice from the FDA the Company has scheduled a Pre-Submission meeting on November 30, 2021 to discuss a draft of an Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies. Using this process results in more rapid feedback to prepare the final IDE.

 

7
 

 

The FDA was very supportive and had suggested this Q-Submission path for rapid turnaround and dialog. The Mayo Clinic physicians did an excellent job presenting the need for Radiogel™ to treat recurrent thyroid cancer and to answer a range of questions from the new FDA review team. The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing. They suggested having another Q-Sub Review and conference call dedicated to the details of the dosimetry calculations.

 

In May of 2022 the Company held another Pre-Sub meeting with the FDA. They concurred with our dosimetry techniques and requested one more animal test to confirm that the Y-90 stays at the injection site. We will be proposed a Pre-Sub meeting to discuss this new animal test of VX-2 tumors in rabbits at Johns Hopkins University. We have a meeting scheduled with the FDA in October to obtain their feedback on our new animal test plan. In the meantime, the Company is working to complete all the other required pre-clinical testing, such as biocompatibility since they are required for the submittal of the IDE.

 

We held another Pre-Sub meeting with the FDA on October 17, 2022 to obtain detailed feedback on the proposed VX-2/Rabbit Animal Test Plan and to submit the Risk Management Report. The RMR analyzed all hypothetical scenarios and concluded that RadioGel is inherently safe.

 

In parallel the Company is working with the Mayo Clinic’s principal investigators to improve the clinical trial protocol for their Institutional Review Board.

 

The MAB selected eighteen applications for RadioGel™, each of which meet the criteria described above. This large number confirms the wide applicability of the device and defines the path for future business growth. The Company’s application establishes a single Indication for Use - treatment of cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma.

 

We anticipate that this initial application will facilitate each subsequent application for additional s Indications for Use. After the second indication for use we intend to applied for a broad indication for use, which would target to obtain approval to treat all solid tumors.

 

Financing and Strategy

 

The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 shares at a price of $0.10 for a maximum of $5,000,000. The Company amended this and was able to raise $1,200,000 in July 2022 at $0.08 per share (15,000,0000 shares) and sold 20,000,000 warrants for $20,000. An amended Regulation A+ was filed in October 2022 to raise the remaining $3,800,000 of the $5,000,000.

 

The Company’s Regulation A+’s raised approximately $5,200,000 from the sale of shares and is using the proceeds generated as follows:

 

For the animal therapy market:

 

  ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.
  ● Conduct additional clinical studies to generate more data for the veterinary community
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated.
  ● Assist a new regional clinic with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.
  ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $2 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.

 

8
 

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.

 

As of December 31, 2022, the Company has $1,706,065 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.

 

There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

Product Features

 

The Company’s RadioGel™ device has the following product features:

 

  ● Beta particles only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the nearby normal tissues. In medical terms Y-90 beta emitter has a high efficacy rate;
     
  ● Benefitting from the short penetration distance, the patient can go home immediately with no fear of exposure to family members, and there is a greatly reduced radiation risk to the doctor. A simple plastic tube around the syringe, gloves and safety glasses are all that is required. Other gamma emitting products require much more protection;
     
  ● A 2.7-day half-life means that only 5% of the radiation remains after ten days. This is in contrast to the industry-standard gamma irradiation product, which has a half-life of 17 days;
     
  ● The short half-life also means that any medical waste can be stored for thirty days then disposed as normal hospital waste;
     
  ● RadioGel™ can be administered with small diameter needles (27-gauge) so there is minimal damage to the normal tissue. This is in contrast to the injection of metal seeds, which does considerable damage; and
     
  ● After about 120 days the gel resorbs by a normal biological cycle, called the Krebs Cycle. The only remaining evidence of the treatment are phosphate particles so small in diameter that it requires a high-resolution microscope to find them. This is in contrast to permanent presence of metal seeds.

 

9
 

 

Steps from Production to Therapy

 

Device Production

 

During the next two years, the Company intends to outsource material aspects of manufacturing and distribution. As future product volume increases, the Company will reassess its make-buy decision on manufacturing and will analyze the cost/benefit of a centrally located facility.

 

Production of the Hydrogel

 

RadioGel™ is manufactured with a proprietary process under ventilated sterile hood by following strict Good Laboratory Practices (“GLP”) procedures. It is made in large batches that are frozen for up to three months. When the product is ready to ship, a small quantity of the gel is dissolved in a sterile saline solution. It is then passed through an ultra-fine filter to ensure sterility.

 

Production of the Yttrium-90 Phosphate Particles

 

The Y-90 particles are produced with simple ingredients via a proprietary process, again following strict GLP procedures. They are then mixed into a phosphate-buffered saline solution. They can be produced in large batches for several shipments. The number of particles per shipment is determined by the dose prescribed by the doctor.

 

Pre-Mixing – RTU, Ready to Use

 

Vivos Inc now pre-mixes the particle solution and the hydrogel and places the RTU IsoPet in standard size vials. This innovation is cost effective and reduces the probability of any accidental spills or biological contamination at the therapy sites. It also simplified the certification training for new regional clinics.

 

Shipment

 

The vials are shipped via FedEx or UPS by following the proper protocols.

 

At the User

 

The quantities and activities are in the information on the product label.

 

The specific injection technique depends on the Indication for Use. For small tumors, one centimeter in diameter or less, the cancer is treated with a single injection. For larger tumors, the cancer is treated with a series of small injections from the same syringe or multiple syringes.

 

Principal Markets

 

The Company is currently pursuing two synergistic business sectors, medical and veterinary, each of which are summarized below.

 

Medical Sector

 

RadioGel™ is currently fully developed, requiring only FDA approval before commercialization.

 

Building on the FDA’s ruling of RadioGel™ as a device, the Company incorporated the FDA suggestions and has invested in the pre-clinical testing required for IDE submittal. This included two years of effort on biocompatibility testing. The last remaining animal test has been designed and has begun the initial scoping phase.

 

RadioGel™ is currently fully developed, requiring only FDA approval before commercialization. The Company has been seeking FDA approval of RadioGel™ for almost five years. Recent progress has been delayed due to a lack of adequate funding. The principal issue preventing approval is that the Company attempted to obtain regulatory approval for a broad range of Indications for Use, including all non-resectable cancers, without sufficient supporting data.

 

10
 

 

Veterinary Sector

 

There are approximately 150 million pet dogs and cats in the United States. Nearly one-half of dogs and one-third of cats are diagnosed with cancer at some point in their lifetime. The Veterinary Oncology & Hematology Center in Norwalk, Connecticut, reports that cancer is the number one natural cause of death in older cats and dogs, accounting for nearly 50 percent of pet deaths each year. The American Veterinary Medical Association reports that half of the dogs ten years or older will die because of cancer. The National Cancer Institute reports that about six million dogs are diagnosed with cancer each year, translating to more than 16,000 a day.

 

The Company’s IsoPet® operating division focuses on the veterinary oncology market. Dr. Alice Villalobos, a founding member of the Veterinary Cancer Society and the Chair of our Veterinary Medicine Advisory Board, has been providing guidance to management regarding this market. The Veterinary Medicine Advisory Board gives us recommendations regarding the overall strategy for our animal business sector. Specially, they recommended the university veterinary hospitals for demonstration therapies, the specific cancers to be treated, and have provided business contact information to the private clinics.

 

Development of the product and application techniques and animal testing is allowed under FDA regulation. Commercial sales of RadioGelTM for animals requires confirmation by the FDA Center for Veterinary Medicine (“CVM”). In January 2018, the Center for Veterinary Medicine Product Classification Group, the entity within the CVM that is responsible for determining the classification of a product, ruled that RadioGelTM should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas.

 

Additionally, after a legal review, the Company believes that the device classification obtained from the FDA Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most all solid tumors in animals. We expect the result of such classification and label approval will be that no additional regulatory approvals are necessary for the use of RadioGelTM for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

The Company currently intends to utilize university veterinary hospitals for therapy development, given that veterinary hospitals offer superior and plentiful veterinarians and students, a large number of animal patients, radioactive material handling licenses, and are respected by private veterinary centers and hospitals.

 

Competitors

 

The Company competes in a market characterized by technological innovation, extensive research efforts, and significant competition.

 

The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological changes. A number of companies are pursuing the development of pharmaceuticals and products that target the same diseases and conditions that our products target. We cannot predict with accuracy the timing or impact of the introduction of potentially competitive products or their possible effect on our sales. Certain potentially competitive products to our products may be in various stages of development. Also, there may be many ongoing studies with currently marketed products and other developmental products, which may yield new data that could adversely impact the use of our products in their current and potential future Indications for Use. The introduction of competitive products could significantly reduce our sales, which, in turn would adversely impact our financial and operating results.

 

There are a wide variety of cancer treatments approved and marketed in the U.S. and globally. General categories of treatment include surgery, chemotherapy, radiation therapy and immunotherapy. These products have a diverse set of success rates and side effects. The Company’s products, including RadioGel™, fall into the brachytherapy treatment category. There are a number of brachytherapy devices currently marketed in the U.S. and globally. The traditional iodine-125 (I-125) and palladium-103 (Pd-103) technologies for brachytherapy are well entrenched with powerful market players controlling the market. The industry-standard I-125-based therapy was developed by Oncura, which is a unit of General Electric Company. Additionally, C.R. Bard, a major industry player competes in the I-125 brachytherapy marketplace. These market competitors are also involved in the distribution of Pd-103 based products. Cs-131 brachytherapy products are sold by IsoRay. Several Y-90 therapies have been FDA approved including SIR-Spheres by Sirtex, TheraSphere by Biocompatibles UK and Zevalin by Spectrum Pharmaceuticals.

 

11
 

 

 

Raw Materials

 

The Company currently subcontracts the manufacturing of RadioGelTM at IsoTherapeutics. Prior to 2021, Eckert and Ziegler was the only supplier of Y-90 in the United States, and was the sole supplier of the Y-90 used by IsoTherapeutics to manufacture the Company’s RadioGel™. The Company obtains supplies, hardware, handling equipment and packaging from several different U.S. suppliers.

 

During 2021, the Company engaged Akina, Inc. as an alternate supplier of its hydrogel polymer component. We have now expanded to include SciPoly as another alternate polymer supplier.

 

In the future we will be looking to qualify an alternative particle supplier.

 

Customers

 

The Company anticipates that potential customers for our potential brachytherapy products likely would include those institutions and individuals that currently purchase brachytherapy products or other oncology treatment products.

 

Government Regulation

 

The Company’s present and future intended activities in the development, manufacturing and sale of cancer therapy products, including RadioGel™, are subject to extensive laws, regulations, regulatory approvals and guidelines. Within the United States, the Company’s therapeutic radiological devices must comply with the U.S. Federal Food, Drug and Cosmetic Act, which is enforced by FDA. The Company is also required to adhere to applicable FDA Quality System Regulations, also known as the Good Manufacturing Practices, which include extensive record keeping and periodic inspections of manufacturing facilities.

 

In the United States, the FDA regulates, among other things, new product clearances and approvals to establish the safety and efficacy of these products. We are also subject to other federal and state laws and regulations, including the Occupational Safety and Health Act and the Environmental Protection Act.

 

The Federal Food, Drug, and Cosmetic Act and other federal statutes and regulations govern or influence the research, testing, manufacture, safety, labeling, storage, record keeping, approval, distribution, use, reporting, advertising and promotion of such products. Noncompliance with applicable requirements can result in civil penalties, recall, injunction or seizure of products, refusal of the government to approve or clear product approval applications, disqualification from sponsoring or conducting clinical investigations, preventing us from entering into government supply contracts, withdrawal of previously approved applications, and criminal prosecution.

 

In the United States, medical devices are classified into three different categories over which the FDA applies increasing levels of regulation: Class I, Class II, and Class III. Most Class I devices are exempt from premarket notification 510(k); most Class II devices require premarket notification 510(k); and most Class III devices require premarket approval. RadioGel™ is currently classified as a Class III device.

 

Approval of new Class III medical devices is a lengthy procedure and can take a number of years and require the expenditure of significant resources. There is a shorter FDA review and clearance process for Class II medical devices, the premarket notification or 510(k) process, whereby a company can market certain Class II medical devices that can be shown to be substantially equivalent to other legally marketed devices.

 

The Company intends to apply for a de novo with an anticipated expenditure of $10.0 million over the next four years. This expenditure estimate includes anticipated costs associated with in vitro and in vivo pre-clinical testing, our application for an Investigational Device Exemption, Phase I and Phase II clinical trials and our application for a de novo.

 

As a registered medical device manufacturer with the FDA, we are subject to inspection to ensure compliance with FDA’s current Good Manufacturing Practices, or cGMP. These regulations require that we and any of our contract manufacturers design, manufacture and service products, and maintain documents in a prescribed manner with respect to manufacturing, testing, distribution, storage, design control, and service activities. Modifications or enhancements that could significantly affect the safety or effectiveness of a device or that constitute a major change to the intended use of the device require a new 510(k) premarket notification for any significant product modification.

 

12
 

 

The Medical Device Reporting regulation requires that we provide information to the FDA on deaths or serious injuries alleged to be associated with the use of our devices, as well as product malfunctions that are likely to cause or contribute to death or serious injury if the malfunction were to recur. Labeling and promotional activities are regulated by the FDA and, in some circumstances, by the Federal Trade Commission.

 

As a medical device manufacturer, we are also subject to laws and regulations administered by governmental entities at the federal, state and local levels. For example, our facility is licensed as a medical device manufacturing facility in the State of Washington and is subject to periodic state regulatory inspections. Our customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us.

 

In the United States, as a manufacturer of medical devices and devices utilizing radioactive byproduct material, we are subject to extensive regulation by not only federal governmental authorities, such as the FDA and FAA, but also by state and local governmental authorities, such as the Washington State Department of Health, to ensure such devices are safe and effective. In Washington State, the Department of Health, by agreement with the federal Nuclear Regulatory Commission (“NRC”), regulates the possession, use, and disposal of radioactive byproduct material as well as the manufacture of radioactive sealed sources to ensure compliance with state and federal laws and regulations. RadioGel™ constitutes both medical devices and radioactive sealed sources and are subject to these regulations.

 

Moreover, our use, management, and disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material. We believe that we are in compliance with all federal and state regulations for this purpose.

 

Environmental Regulation

 

Our business does not require us to comply with any extraordinary environmental regulations. Our RadioGel™ product is manufactured in an independently owned and operated facility. Any environmental effects or contamination event that could result would be from the shipping company during shipment and misuse by the treatment facility upon arrival.

 

Human Capital

 

As of December 31, 2022, the Company had one full-time personnel. The Company utilizes several independent contractors to assist with its operations. The Company does not have a collective bargaining agreement with any of its personnel and believes its relations with its personnel are good.

 

Available Information

 

The Company prepares and files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and certain other information with the United States Securities and Exchange Commission (the “SEC”). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov. Moreover, the Company maintains a website at http://www.RadioGel.com that contains important information about the Company, including biographies of key management personnel, as well as information about the Company’s business. This information is publicly available and is updated regularly. The content on any website referred to in this Annual Report is not incorporated by reference into this Annual Report, unless (and only to the extent) expressly so stated herein.

 

13
 

 

ITEM 1A. RISK FACTORS.

 

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our securities. The occurrence of any of the events or developments described below could harm our business, financial condition, operating results, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

 

RISKS ASSOCIATED WITH THE COMPANY’S BUSINESS

 

Our independent registered public accounting firms’ reports on its financial statements questions the Company’s ability to continue as a going concern.

 

The Company’s independent registered public accounting firms’ reports on the Company’s financial statements for the years ended December 31, 2022 and 2021 express substantial doubt about the Company’s ability to continue as a going concern. The reports include an explanatory paragraph stating that the Company has suffered recurring losses, used significant cash in support of its operating activities and based on its current operating levels, require additional capital or restructuring to sustain its operation for the foreseeable future. There is no assurance that the Company will be able to obtain sufficient additional capital to continue its operations and to alleviate doubt about its ability to continue as a going concern. If the Company obtains additional financing, such funds may not be available on favorable terms and likely would entail considerable dilution to existing shareholders. Any debt financing, if available, may involve restrictive covenants that restrict its ability to conduct its business. It is extremely remote that the Company could obtain any financing on any basis that did not result in considerable dilution for shareholders. Inclusion of a “going concern qualification” in the report of its independent accountants or in any future report may have a negative impact on its ability to obtain debt or equity financing and may adversely impact its stock price.

 

A combination of our current financial condition and the FDA’s determinations to date regarding our brachytherapy products raise material concerns about ability to continue as a going concern.

 

The Company will not be able to continue as a going concern unless the Company obtains financing. Depending upon the amount of financing, if any, the Company is able to obtain, the Company may not receive adequate funds to continue the approval process for RadioGel™ or other brachytherapy products with the FDA.

 

The Company has generated operating losses since inception, which are expected to continue, and has increasing cash requirements, which it may be unable to satisfy.

 

The Company has generated material operating losses since inception. The Company has had recurring net losses since inception which has resulted in an accumulated deficit of $79,556,028 and $77,085,867 as of December 31, 2022 and 2021, respectively including net losses of $2,470,161 and $2,527,766 for the years ended December 31, 2022 and 2021. Historically, the Company has relied upon investor funds to maintain its operations and develop its business. The Company needs to raise additional capital from investors for working capital as well as business expansion, and there is no assurance that additional investor funds will be available on terms acceptable to the Company, or at all. If the Company is unable to unable to obtain additional financing to meet its working capital requirements, the Company likely would cease operations.

 

The Company requires funding of at least $5 million per year to maintain current operating activities. Over the next 24 months, the Company believes it will cost approximately $9 million to fund: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.

 

The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies, which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

14
 

 

Recent economic events, including the COVID-19 pandemic, the inherent instability in global capital markets, as well as the lack of liquidity in the capital markets, could adversely impact the Company’s ability to obtain financing and its ability to execute its business plan.

 

The Company has a limited operating history, which may make it difficult to evaluate its business and prospects.

 

The Company has a limited operating history upon which one can base an evaluation of its business and prospects. As a company in the development stage, there are substantial risks, uncertainties, expenses and difficulties to which its business is subject. To address these risks and uncertainties, the Company must do the following:

 

  ● successfully develop and execute the business strategy;
     
  ● respond to competitive developments; and
     
  ● attract, integrate, retain and motivate qualified personnel.

 

There is no assurance that the Company will achieve or maintain profitable operations or that the Company will obtain or maintain adequate working capital to meet its obligations as they become due. The Company cannot be certain that its business strategy will be successfully developed and implemented or that the Company will successfully address the risks that face its business. In the event that the Company does not successfully address these risks, its business, prospects, financial condition, and results of operations could be materially and adversely affected.

 

The Company’s products are regulated and require appropriate clearances and approvals to be marketed in the U.S. and globally.

 

There is no assurance the FDA or other global regulatory authorities will grant the Company permission to market the Company’s brachytherapy Y-90 RadioGel™ device.

 

The Company has been working with the FDA to obtain clearance for its brachytherapy Y-90 RadioGelTM device, but no assurances have been received. On December 23, 2014, the Company announced that it submitted a de novo to the FDA for marketing clearance for its patented Y-90 RadioGelTM device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act (the “Act”). In June 2015, the FDA notified the Company the de novo was not granted. In February 2014, the FDA found the same device under Section 510(k) of the Act not substantially equivalent and concluded that the device is classified by statute as a Class III medical device, unless the device is reclassified. The Company is seeking reclassification of the product to Class II. If the Company is successful in seeking reconsideration of the Company’s de novo application, as a regulatory matter, the device could be on an easier and faster path to market in the United States. However, there would still be the requirements to complete the in vitro and in vivo testing, and then some human clinical trials. That testing date is submitted in a de novo pre-market application and if accepted we could then go to market. As a practical matter, the Company would still need to secure funding and commercial arrangements before marketing could commence. If the de novo is declined and if the Company obtains funding to permit it to continue operations, the Company will explore steps toward seeking approval for the device as a Class III medical device. Generally, the time period and cost of seeking approval as a Class III medical device is materially greater than the time period and cost of seeking approval as a Class II medical device. If the Company seeks approval as a Class III device, human clinical trials will be necessary. Generally, human trials for Class III products are larger, of longer duration and costlier than those for Class II devices.

 

If human clinical trials are necessary, there will be additional cost and time to reach marketing clearance or approval. Unless the Company obtains sufficient funding, it will be unable to do the foregoing activities. There can be no assurance that the product will be approved as either a Class II or Class III device by the FDA even if additional data is provided. In August 2017, the Company met again with the FDA in a pre-submission meeting to once again go through the requirements for pre-clinical testing and to answer the previous FDA questions submitted years before. There can be no assurance that the Company will receive FDA approval, or if it does, the timing thereof.

 

If the Company is successful in increasing the size of its organization, the Company may experience difficulties in managing growth.

 

The Company is a small organization with a minimal number of employees. If the Company is successful, it may experience a period of significant expansion in headcount, facilities, infrastructure and overhead and further expansion may be required to address potential growth and market opportunities. Any such future growth will impose significant added responsibilities on members of management, including the need to improve the Company’s operational and financial systems and to identify, recruit, maintain and integrate additional managers. The Company’s future financial performance and its ability to compete effectively will depend, in part, on the ability to manage any future growth effectively.

 

15
 

 

The Company’s business is dependent upon the continued services of the Company’s Chief Executive Officer, Michael Korenko. Should the Company lose the services of Dr. Korenko, the Company’s operations will be negatively impacted.

 

The Company’s business is dependent upon the expertise of its Chief Executive Officer, Michael Korenko. Dr. Korenko is essential to the Company’s operations. Accordingly, an investor must rely on Dr. Korenko’s management decisions that will continue to control the Company’s business affairs. The Company does not maintain key man insurance on Dr. Korenko’s life. The loss of the services of Dr. Korenko would have a material adverse effect upon the Company’s business. To mitigate this risk, David Swanberg has been groomed as a replacement candidate. He has extensive experience as a co-founder of IsoRay and has been actively working with Dr. Korenko as a consultant for the last two years.

 

The Company is heavily dependent on consultants for many of the services necessary to continue operations. The loss of any of these consultants could have a material adverse effect on the Company’s business, results of operations and financial condition.

 

The Company’s success is heavily dependent on the continued active participation of certain consultants and collaborating scientists. Certain key employees and consultants have no written employment contracts. Loss of the services of any one or more of its consultants could have a material adverse effect upon the Company’s business, results of operations and financial condition.

 

If the Company is unable to hire and retain additional qualified personnel, the business and financial condition may suffer.

 

The Company’s success and achievement of its growth plans depend on its ability to recruit, hire, train and retain highly qualified technical, scientific, regulatory and managerial employees, consultants and advisors. Competition for qualified personnel among pharmaceutical and biotechnology companies is intense, and an inability to attract and motivate additional highly skilled personnel required for the expansion of the Company’s activities, or the loss of any such persons, could have a material adverse effect on its business, results of operations and financial condition.

 

The Company’s revenues have historically been derived from sales made to a small number of customers. The Company has discontinued prior operations related to its core business. To succeed, we will need to recommence our operations and achieve sales to a materially larger number of customers.

 

The Company’s consulting revenues relate to their commercializing of its products or expanding the number of customers purchasing its products and services. The Company had $36,499 and $14,887 in operating revenues, net of discounts for the years ended December 31, 2022 and 2021, respectively as they have commenced sales of IsoPet®.

 

Many of the Company’s competitors have greater resources and experience than the Company has.

 

Many of the Company’s competitors have greater financial resources, longer history, broader experience, greater name recognition, and more substantial operations than the Company has, and they represent substantial long-term competition for us. The Company’s competitors may be able to devote more financial and human resources than the Company can to research, new product development, regulatory approvals, and marketing and sales. The Company’s competitors may develop or market products that are viewed by customers as more effective or more economical than the Company’s products. There is no assurance that the Company will be able to compete effectively against current and future competitors, and such competitive pressures may adversely affect the Company’s business and results of operations.

 

The Company’s future revenues depend upon acceptance of its current and future products in the markets in which they compete.

 

The Company’s future revenues depend upon receipt of financing, regulatory approval and the successful production, marketing, and sales of the various isotopes the Company might market in the future. The rate and level of market acceptance of each of these products, if any, may vary depending on the perception by physicians and other members of the healthcare community of its safety and efficacy as compared to that of any competing products; the clinical outcomes of any patients treated; the effectiveness of its sales and marketing efforts in the United States, Europe, Far East, Middle East, and Russia; any unfavorable publicity concerning its products or similar products; the price of the Company’s products relative to other products or competing treatments; any decrease in current reimbursement rates from the Centers for Medicare and Medicaid Services or third-party payers; regulatory developments related to the manufacture or continued use of its products; availability of sufficient supplies to either purchase or manufacture its products; its ability to produce sufficient quantities of its products; and the ability of physicians to properly utilize its products and avoid excessive levels of radiation to patients. Any material adverse developments with respect to the commercialization of any such products may adversely affect revenues and may cause the Company to continue to incur losses in the future.

 

16
 

 

The Company currently relies on a single supplier for Y-90 particles, and that supplier is the only supplier in the United States. An inability to procure Y-90 particles will harm the Company’s business.

 

There is only one supplier of Y-90 particles in the United States, requiring us to rely entirely on this supplier to provide the Y-90 particles needed to produce RadioGelTM. If we are unable to obtain a sufficient supply of Y-90 particles, we will not be able to proceed with our development of RadioGelTM and our business may be materially harmed.

 

The Company currently subcontracts the manufacturing of RadioGelTM to IsoTherapeutics. PerkinElmer Inc. is the sole supplier of the Y-90 particles used by IsoTherapeutics and is the only supplier of Y-90 particles in the United States. In the event PerkinElmer is unable to satisfy our supply requirements or stope producing Y-90 particles, we will be unable to continue with development of RadioGel™ and our business would be materially harmed.

 

The Company will rely heavily on a limited number of suppliers for the foreseeable future.

 

Some of the products the Company might market, and components thereof are currently available only from a limited number of suppliers, several of which are international suppliers. Failure to obtain deliveries from these sources could have a material adverse effect on the Company’s ability to operate.

 

The Company may incur material losses and costs as a result of product liability claims that may be brought against it.

 

The Company faces an inherent business risk of exposure to product liability claims in the event that products supplied by the Company fail to perform as expected or such products result, or is alleged to result, in bodily injury. Any such claims may also result in adverse publicity, which could damage the Company’s reputation by raising questions about the safety and efficacy of its products and could interfere with its efforts to market its products. A successful product liability claim against the Company in excess of its available insurance coverage or established reserves may have a material adverse effect on its business. Although the Company currently maintains liability insurance in amounts it believes are commercially reasonable, any product liability the Company may incur may exceed its insurance coverage.

 

The Company is subject to the risk that certain third parties may mishandle the Company’s products.

 

If the Company markets products, the Company likely will rely on third parties, such as commercial air courier companies, to deliver the products, and on other third parties to package the products in certain specialized packaging forms requested by customers. The Company thus would be subject to the risk that these third parties may mishandle its product, which could result in material adverse effects, particularly given the radioactive nature of some of the products.

 

The Company is subject to uncertainties regarding reimbursement for use of its products.

 

Hospitals and freestanding clinics may be less likely to purchase the Company’s products if they cannot be assured of receiving favorable reimbursement for treatments using its products from third-party payers, such as Medicare and private health insurance plans. Third-party payers are increasingly challenging the pricing of certain medical services or devices, and there is no assurance that they will reimburse the Company’s customers at levels sufficient for it to maintain favorable sales and price levels for the Company’s products. There is no uniform policy on reimbursement among third-party payers, and there is no assurance that the Company’s products will continue to qualify for reimbursement from all third-party payers or that reimbursement rates will not be reduced. A reduction in or elimination of third-party reimbursement for treatments using the Company’s products would likely have a material adverse effect on the Company’s revenues.

 

The Company’s future growth is largely dependent upon its ability to develop new technologies that achieve market acceptance with appropriate margins.

 

The Company’s business operates in global markets that are characterized by rapidly changing technologies and evolving industry standards. Accordingly, future growth rates depend upon a number of factors, including the Company’s ability to (i) identify emerging technological trends in the Company’s target end-markets, (ii) develop and maintain competitive products, (iii) enhance the Company’s products by adding innovative features that differentiate the Company’s products from those of its competitors, and (iv) develop, manufacture and bring products to market quickly and cost-effectively. The Company’s ability to develop new products based on technological innovation can affect the Company’s competitive position and requires the investment of significant resources. These development efforts divert resources from other potential investments in the Company’s business, and they may not lead to the development of new technologies or products on a timely basis or that meet the needs of the Company’s customers as fully as competitive offerings. In addition, the markets for the Company’s products may not develop or grow as it currently anticipates. The failure of the Company’s technologies or products to gain market acceptance due to more attractive offerings by the Company’s competitors could significantly reduce the Company’s revenues and adversely affect the Company’s competitive standing and prospects.

 

17
 

 

The Company may rely on third parties to represent it locally in the marketing and sales of its products in international markets and its revenue may depend on the efforts and results of those third parties.

 

The Company’s future success may depend, in part, on its ability to enter into and maintain collaborative relationships with one or more third parties, the collaborator’s strategic interest in the Company’s products and the Company’s products under development, and the collaborator’s ability to successfully market and sell any such products.

 

The Company intends to pursue collaborative arrangements regarding the marketing and sales of its products; however, it may not be able to establish or maintain such collaborative arrangements, or if it is able to do so, the Company’s collaborators may not be effective in marketing and selling its products. To the extent that the Company decides not to, or is unable to, enter into collaborative arrangements with respect to the sales and marketing of its products, significant capital expenditures, management resources and time will be required to establish and develop an in-house marketing and sales force with technical expertise. To the extent that the Company depends on third parties for marketing and distribution, any revenues received by the Company will depend upon the efforts and results of such third parties, which may or may not be successful.

 

The Company may pursue strategic acquisitions that may have an adverse impact on its business.

 

Executing the Company’s business strategy may involve pursuing and consummating strategic transactions to acquire complementary businesses or technologies. In pursuing these strategic transactions, even if the Company does not consummate them, or in consummating such transactions and integrating the acquired business or technology, the Company may expend significant financial and management resources and incur other significant costs and expenses. There is no assurance that any strategic transactions will result in additional revenues or other strategic benefits for the Company’s business. The Company may issue the Company’s stock as consideration for acquisitions, joint ventures or other strategic transactions, and the use of stock as purchase consideration could dilute the interests of its current stockholders. In addition, the Company may obtain debt financing in connection with an acquisition. Any such debt financing may involve restrictive covenants relating to capital-raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and pursue business opportunities, including potential acquisitions. In addition, such debt financing may impair the Company’s ability to obtain future additional financing for working capital, capital expenditures, acquisitions, general corporate or other purposes, and a substantial portion of cash flows, if any, from the Company’s operations may be dedicated to interest payments and debt repayment, thereby reducing the funds available to the Company for other purposes.

 

The Company will need to hire additional qualified accounting personnel in order to remediate a material weakness in its internal control over financial accounting, and the Company will need to expend any additional resources and efforts that may be necessary to establish and to maintain the effectiveness of its internal control over financial reporting and its disclosure controls and procedures.

 

As a public company, the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and the Sarbanes-Oxley Act of 2002. The Company’s management is required to evaluate and disclose its assessment of the effectiveness of the Company’s internal control over financial reporting as of each year-end, including disclosing any “material weakness” in the Company’s internal control over financial reporting. A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. As a result of its assessment, management has determined that there is a material weakness due to the lack of segregation of duties and, due to this material weakness, management concluded that, as of December 31, 2022 and 2021, the Company’s internal control over financial reporting was ineffective. This material weakness has the potential of adversely impacting the Company’s financial reporting process and the Company’s financial reports. Because of this material weakness, management also concluded that the Company’s disclosure controls and procedures were ineffective as of December 31, 2022 and 2021. The Company needs to hire additional qualified accounting personnel in order to resolve this material weakness. The Company also will need to expend any additional resources and efforts that may be necessary to establish and to maintain the effectiveness of the Company’s internal control over financial reporting and disclosure controls and procedures.

 

The Company’s patented or other technologies may infringe on other patents, which may expose it to costly litigation.

 

It is possible that the Company’s patented or other technologies may infringe on patents or other rights owned by others. The Company may have to alter its products or processes, pay licensing fees, defend infringement actions or challenge the validity of the patents in court, or cease activities altogether because of patent rights of third parties, thereby causing additional unexpected costs and delays to the Company. Patent litigation is costly and time consuming, and the Company may not have sufficient resources to pursue such litigation. If the Company does not obtain a license under such patents, if it is found liable for infringement, or if it is not able to have such patents declared invalid, the Company may be liable for significant money damages, may encounter significant delays in bringing products to market or may be precluded from participating in the manufacture, use or sale of products or methods of treatment requiring such licenses.

 

18
 

 

Protecting the Company’s intellectual property is critical to its innovation efforts.

 

The Company owns or has a license to use several U.S. and foreign patents and patent applications, trademarks and copyrights. The Company’s intellectual property rights may be challenged, invalidated or infringed upon by third parties, or it may be unable to maintain, renew or enter into new licenses of third party proprietary intellectual property on commercially reasonable terms. In some non-U.S. countries, laws affecting intellectual property are uncertain in their application, which can adversely affect the scope or enforceability of the Company’s patents and other intellectual property rights. Any of these events or factors could diminish or cause the Company to lose the competitive advantages associated with the Company’s intellectual property, subject the Company to judgments, penalties and significant litigation costs, or temporarily or permanently disrupt its sales and marketing of the affected products or services.

 

The Company may not be able to protect its trade secrets and other unpatented proprietary technology, which could give competitors an advantage.

 

The Company relies upon trade secrets and other unpatented proprietary technology. The Company may not be able to adequately protect its rights with regard to such unpatented proprietary technology, or competitors may independently develop substantially equivalent technology. The Company seeks to protect trade secrets and proprietary knowledge, in part through confidentiality agreements with its employees, consultants, advisors and collaborators. Nevertheless, these agreements may not effectively prevent disclosure of the Company’s confidential information and may not provide the Company with an adequate remedy in the event of unauthorized disclosure of such information, and as result the Company’s competitors could gain a competitive advantage.

 

The Company is subject to extensive government regulation in jurisdictions around the world in which it does business. Regulations address, among other things, environmental compliance, import/export restrictions, healthcare services, taxes and financial reporting, and those regulations can significantly increase the cost of doing business, which in turn can negatively impact operations, financial results and cash flow.

 

If the Company is successful in developing manufacturing capability, the Company will be subject to extensive government regulation and intervention both in the U.S. and in all foreign jurisdictions in which it conducts business. Compliance with applicable laws and regulations will result in higher capital expenditures and operating costs, and changes to current regulations with which the Company complies can necessitate further capital expenditures and increases in operating costs to enable continued compliance. Additionally, from time to time, the Company may be involved in proceedings under certain of these laws and regulations. Foreign operations are subject to political instabilities, restrictions on funds transfers, import/export restrictions, and currency fluctuation.

 

RISKS RELATED TO THE COMPANY’S COMMON STOCK

 

The Company’s common stock is currently quoted on the OTCQB Marketplace. Failure to develop or maintain a more active trading market may negatively affect the value of the Company’s common stock, may deter some potential investors from purchasing the Company’s common stock or other equity securities, and may make it difficult or impossible for stockholders to sell their shares of common stock.

 

The Company’s average daily volume of shares traded for the years ended December 31, 2022 and 2021 was 496,720 and 2,074,138, respectively. Failure to develop or maintain an active trading market may negatively affect the value of the Company’s common stock, may make some potential investors unwilling to purchase the Company’s common stock or equity securities that are convertible into or exercisable for the Company’s common stock, and may make it difficult or impossible for the Company’s stockholders to sell their shares of common stock and recover any part of their investment.

 

The Company’s outstanding securities, the stock or other securities that it may become obligated to issue under existing agreements, and certain provisions of those securities, may cause immediate and substantial dilution to existing stockholders and may make it more difficult to raise additional equity capital.

 

The Company had 362,541,528 shares of common stock outstanding on March 1, 2023. The Company also had outstanding on that date dilutive securities consisting of preferred stock, restricted stock units, options, and warrants (collectively, “Common Stock Equivalents”) that if they had been exercised and converted in full on March 1, 2023, would have resulted in the issuance of up to 64,762,379 additional shares of common stock. The issuance of shares upon the exercise of the Common Stock Equivalents may result in substantial dilution to each stockholder by reducing that stockholder’s percentage ownership of the Company’s total outstanding shares of common stock. The issuance of some or all those warrants and any exercise of those warrants will have the effect of further diluting the percentage ownership of the Company’s other stockholders.

 

Future sales of the Company’s securities, including sales following exercise or conversion of derivative securities, or the perception that such sales may occur, may depress the price of common stock and could encourage short sales.

 

The sale or availability for sale of substantial amounts of the Company’s shares in the public market, including shares issuable upon exercise of the Common Stock Equivalents, or the perception that such sales may occur, may adversely affect the market price of the Company’s common stock. Any decline in the price of the Company’s common stock may encourage short sales, which could place further downward pressure on the price of the Company’s common stock.

 

19
 

 

The Company’s stock price is likely to be volatile.

 

For the year ended December 31, 2022, the reported low closing price for the Company’s common stock was $0.04 per share, and the reported high closing price was $0.1264 per share. For the year ended December 31, 2021, the reported low closing price for the Company’s common stock was $0.068 per share, and the reported high closing price was $0.2592 per share. There is generally significant volatility in the market prices, as well as limited liquidity, of securities of early-stage companies, particularly early stage medical product companies. Contributing to this volatility are various events that can affect the Company’s stock price in a positive or negative manner. These events include, but are not limited to: governmental approvals, refusals to approve, regulations or other actions; market acceptance and sales growth of the Company’s products; litigation involving the Company or the Company’s industry; developments or disputes concerning the Company’s patents or other proprietary rights; changes in the structure of healthcare payment systems; departure of key personnel; future sales of its securities; fluctuations in its financial results or those of companies that are perceived to be similar to us; investors’ general perception of us; and general economic, industry and market conditions. If any of these events occur, it could cause the Company’s stock price to fall, and any of these events may cause the Company’s stock price to be volatile.

 

The Company’s common stock is subject to the “Penny Stock” rules of the SEC and the trading market in its securities is limited, which makes transactions in its common stock cumbersome and may reduce the value of an investment in the Company’s stock.

 

The SEC has adopted Rule 3a51-1, which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires that a broker or dealer approve a person’s account for transactions in penny stocks and that the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience and objectives of the person and must make a reasonable determination that the transactions in penny stocks are suitable for that person and that the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which sets forth the basis on which the broker or dealer made the suitability determination, and that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of the Company’s common stock and may cause a decline in the market value of its stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

As a result of the Company issuing preferred stock, the rights of holders of the Company’s common stock and the value of the Company’s common stock may be adversely affected.

 

The Company’s Board of Directors is authorized to issue classes or series of preferred stock, without any action on the part of the stockholders. The Company’s Board of Directors also has the power, without stockholder approval, to set the terms of any such classes or series of preferred stock, including voting rights, dividend rights and preferences over the common stock with respect to dividends or upon the liquidation, dissolution or winding-up of its business, and other terms. The Company has issued preferred stock that has a preference over the common stock with respect to the payment of dividends or upon liquidation, dissolution or winding-up, and with respect to voting rights. In accordance with that and with the issuance of preferred stock, our common stockholders voting rights have been diluted and it is possible that the rights of holders of the common stock or the value of the common stock have been adversely affected.

 

The Company does not expect to pay any dividends on common stock for the foreseeable future.

 

The Company has not paid any cash dividends on its common stock to date and does not anticipate it will pay cash dividends on its common stock in the foreseeable future. Accordingly, stockholders must be prepared to rely on sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination to pay dividends in the future will be made at the discretion of the Company’s board of directors and will depend on the Company’s results of operations, financial conditions, contractual restrictions, restrictions imposed by applicable law, and other factors that the Company’s board deems relevant.

 

20
 

 

Pandemics including COVID-19 may adversely affect our business.

 

The unprecedented events related to COVID-19 and the variants, the disease caused by the novel coronavirus (SARS-CoV-2), have had significant health, economic, and market impacts and may have short-term and long-term adverse effects on our business that we cannot predict as the global pandemic continues to evolve. The extent and effectiveness of responses by governments and other organizations also cannot be predicted.

 

Our ability to access the capital markets is unknown during the COVID-19 pandemic. Any such limitation on available financing would adversely affect our business.

 

GENERAL RISK FACTORS

 

Volatility in raw material and energy costs, interruption in ordinary sources of supply, and an inability to recover from unanticipated increases in energy and raw material costs could result in lost sales or could increase significantly the cost of doing business.

 

Market and economic conditions affecting the costs of raw materials, utilities, energy costs, and infrastructure required to provide for the delivery of the Company’s products and services are beyond the Company’s control. Any disruption or halt in supplies, or rapid escalations in costs, could adversely affect the Company’s ability to manufacture products or to competitively price the Company’s products in the marketplace. To date, the ultimate impact of energy costs increases has been mitigated through price increases or offset through improved process efficiencies; however, continuing escalation of energy costs could have a negative impact upon the Company’s business and financial performance.

 

General economic conditions in markets in which the Company does business can impact the demand for the Company’s goods and services. Decreased demand for the Company’s products and services could have a negative impact on its financial performance and cash flow.

 

Demand for the Company’s products and services, in part, depends on the general economic conditions affecting the countries and industries in which the Company does business. A downturn in economic conditions in a country or industry that the Company serves may adversely affect the demand for the Company’s products and services, in turn negatively impacting the Company’s operations and financial results. Further, changes in demand for the Company’s products and services can magnify the impact of economic cycles on the Company’s businesses. Unanticipated contract terminations by customers can negatively impact operations, financial results and cash flow. The Company’s earnings, cash flow and financial position are exposed to financial market risks worldwide, including interest rate and currency exchange rate fluctuations and exchange rate controls. Fluctuations in domestic and world financial markets could adversely affect interest rates and impact the Company’s ability to obtain credit or attract investors.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

This item is not applicable to the Company because the Company is a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934.

 

ITEM 2. PROPERTIES.

 

The Company is headquartered in Richland, Washington. Our Chief Executive Officer currently works from his home office in virtual communication with key personnel. Cadwell Laboratories, which is controlled by Carl Cadwell, a director of the Company, provides office space to management on an as-needed basis until such time as the Company leases permanent office space. Management believes that the Company’s sites are adequate to support the business and suitable for present purposes, and the properties and equipment have been well maintained.

 

ITEM 3. LEGAL PROCEEDINGS.

 

The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. There are no material pending or threatened legal proceedings at this time.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

21
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Market Information

 

The Company’s common stock is traded on the OTCQB Marketplace under the symbol “RDGL.” The following table sets forth, in U.S. dollars, the high and low closing prices for each of the calendar quarters indicated, as reported by the OTCQB Marketplace, for the past two fiscal years. Such OTCQB Marketplace quotations reflect inter-dealer prices, without markup, markdown or commissions and, particularly because our common stock is traded infrequently, may not necessarily represent actual transactions or a liquid trading market.

 

   High   Low 
2022          
Quarter ended December 31  $0.0695   $0.04 
Quarter ended September 30  $0.0809   $0.0461 
Quarter ended June 30  $0.1264   $0.0555 
Quarter ended March 31  $0.0855   $0.0405 
           
2021          
Quarter ended December 31  $0.122   $0.07 
Quarter ended September 30  $0.13   $0.0882 
Quarter ended June 30  $0.1227   $0.077 
Quarter ended March 31  $0.1179   $0.0853 

 

Holders

 

As of March 1, 2023, we had 362,541,528 shares of common stock, par value $0.001 per share, issued and outstanding, which were held by approximately 223 shareholders of record. Our transfer agent is Pacific Stock Transfer, 6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

The following table sets forth information as of December 31, 2022 with respect to the Company’s equity compensation plans previously approved by stockholders and equity compensation plans not previously approved by stockholders.

 

   Equity Compensation Plan Information 
Plan Category 

Number of securities to be issued upon exercise of outstanding

options, warrants

and rights

  

Weighted-average

exercise price of

outstanding options,

warrants and rights

  

Number of securities remaining available for future issuance under

equity compensation

plans (excluding

securities reflected in

column (a))

 
 (a) (b)   (c) 
Equity compensation plans approved by stockholders   25,777,500   $0.09    32,836,047 
Equity compensation plans not approved by stockholders   34,115,309   $0.07    - 
Total   34,115,309(1)  $0.07(1)   - 

 

(1) In addition to the 2015 Plan (defined below), the Company has individual compensation arrangements under which equity securities are authorized for issuance in exchange for consideration in the form of goods or services of certain individuals.

 

22
 

 

2015 Omnibus Securities and Incentive Plan

 

In October 2015, our Board of Directors and stockholders approved the adoption of the 2015 Omnibus Securities and Incentive Plan (the “2015 Plan”). The 2015 Plan authorizes an aggregate number of shares of common stock for issuance to all employees of the Company or any subsidiary of the Company, any non-employee director, consultants and independent contractors of the Company or any subsidiary, and any joint venture partners (including, without limitation, officers, directors and partners thereof) of the Company or any subsidiary. The aggregate number of shares that may be issued under the Plan shall not exceed twenty percent (20%) of the issued and outstanding shares of common stock on an as converted primary basis on a rolling basis. For calculation purposes, the As Converted Primary Shares (as defined in the 2015 Plan) shall include all shares of common stock and all shares of common stock issuable upon the conversion of outstanding preferred stock and other convertible securities, but shall not include any shares of common stock issuable upon the exercise of options, warrants and other convertible securities issued pursuant to the 2015 Plan. As of December 31, 2022, the Converted Primary Shares calculation results in 32,836,047 aggregate shares that may be issued under the 2015 Plan. The 2015 Plan is administered by the Company’s Compensation Committee, who may issue awards in the form of stock options and/or restricted stock awards. Effective December 31, 2022, an aggregate total of 44,462,500 restricted stock units (“RSUs”) under the 2015 Plan were authorized, but as of March 1, 2023, 18,085,000 had been issued.

 

Recent Sales of Unregistered Securities

 

Below is a description of all unregistered securities issued by the Company during and subsequent to the quarter ended December 31, 2022, through the date of this report. Each of the issuances identified below were issued in transactions exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 3(a)(9) and/or 4(2) thereof.

 

Issuances During the Quarter Ended December 31, 2022

 

During the month of December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.

 

Issuances Subsequent to December 31, 2022

 

Through March 1, 2023, there have been no shares of common or preferred stock issued.

 

ITEM 6. SELECTED FINANCIAL DATA.

 

This item is not applicable to the Company because the Company is a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis is intended as a review of significant factors affecting the Company’s financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with the Company’s financial statements and the notes presented herein. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. The Company’s actual results could differ significantly from those anticipated in these forward-looking statements as a result of the risk factors set forth above in Item 1A and other factors discussed in this Annual Report.

 

Results of Operations

 

Comparison for the Year Ended December 31, 2022 and December 31, 2021

 

The following table sets forth information from our statements of operations for the years ended December 31, 2022 and 2021:

 

   Year Ended
December 31, 2022		   Year Ended
December 31, 2021		 
Revenues  $36,499   $14,887 
Cost of goods sold   (28,779)   (12,000)
Gross profit   7,720    2,887 
Operating expenses   (2,525,469)   (2,504,685)
Operating loss   (2,517,749)   (2,501,798)
Non-operating income (expense)   47,588    (25,968)
Net loss  $(2,470,161)  $(2,527,766)

 

23
 

 

Revenues and Cost of Goods Sold

 

Revenue was $36,499 and $14,887 for the year ended December 31, 2022 and 2021, respectively. All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet® therapies.

 

Management does not anticipate that the Company will generate sufficient revenue to sustain operations until such time as the Company secures multiple revenue-generating arrangements with respect to RadioGel™ and/or any of our other brachytherapy technologies.

 

Operating Expenses

 

Operating expenses for the years ended December 31, 2022 and 2021, respectively consists of the following:

 

   Year Ended
December 31, 2022		   Year Ended
December 31, 2021		 
Professional fees, including stock-based compensation  $1,755,316   $1,838,323 
Payroll expenses   275,240    267,477 
Research and development   343,802    286,848 
General and administrative expenses   151,111    112,037 
Total operating expenses  $2,525,469   $2,504,685 

 

Operating expenses for the years ended December 31, 2022 and 2021 was $2,525,469 and $2,504,685, respectively. The increase in operating expenses from 2021 to 2022 can be attributed to the decrease in professional fees ($1,755,316 for the year ended December 31, 2022 versus $1,838,323 for the year ended December 31, 2021) as the Company utilized more services due to amending their Regulation A+ and the fees incurred for the consultants engaged in 2021 including stock-based compensation; the increase in general and administrative expense ($151,111 for the year ended December 31, 2022 versus $112,037 for the year ended December 31, 2021); the increase in research and development ($343,802 for the year ended December 31, 2022 versus $286,848 for the year ended December 31, 2021) as the Company ramped up the development of their products with the recent raising of capital, and an increase in payroll expenses ($275,240 for the year ended December 31, 2022 versus $267,477 for the year ended December 31, 2021) related to the CEOs employment contract taking effect.

 

Non-Operating Income (Expense)

 

Non-operating income (expense) for the years ended December 31, 2022 and 2021, respectively consists of the following:

 

   Years Ended
December 31, 2022		   Years Ended
December 31, 2021		 
Interest expense  $-   $(25,375)
Forgiveness of debt   47,588    136,445 
Loss on debt extinguishment   -    (137,038)
Non-operating income (expense)  $47,588   $(25,968)

 

Non-operating income (expense) for the year ended December 31, 2022 varied from the year ended December 31, 2021 primarily due to a decrease in interest expense from $25,375 for the year ended December 31, 2021 to $0 for the year ended December 31, 2022 as a result of conversions and repayments of notes payable. In addition, the Company converted a note in January 2021 which resulted in a loss on conversion and recognized a gain on forgiveness of debt on old payables as they satisfied agreements with vendors to pay a portion of the payable with the remaining amount forgiven in both 2021 and 2022.

 

Net Loss

 

Our net loss for the years ended December 31, 2022 and 2021 was $(2,470,161) and $(2,527,766), respectively.

 

24
 

 

Liquidity and Capital Resources

 

At December 31, 2022, the Company had working capital of $1,661,044, as compared to working capital of $1,467,383 at December 31, 2021. During the year ended December 31, 2022, the Company experienced negative cash flow from operations of $1,120,058 and realized $1,220,000 of cash flows from financing activities. As of December 31, 2022, the Company did not have any commitments for capital expenditures.

 

Cash used in operating activities increased from $963,819 for the year ended December 31, 2021 to $1,120,058 for the year ended December 31, 2022. Cash used in operating activities was primarily a result of the Company’s non-cash items, such as loss from operations, loss on conversion of debt and share based compensation offset by forgiveness of debt. Cash provided from financing activities decreased from $1,666,238 for the year ended December 31, 2021 to $1,220,000 for the year ended December 31, 2022. In 2021, the Company raised $1,811,238 from sales of common stock and warrants offset by repayments of convertible notes of $50,000 and related party notes of $100,000. In 2022, the Company raise $1,220,000 from sales of common stock and warrants.

 

The Company has generated material operating losses since inception. The Company had a net loss of $2,470,161 for the year ended December 31, 2022, and a net loss of $2,527,766 for the year ended December 31, 2021. The Company expects to continue to experience net operating losses for the foreseeable future. Historically, the Company has relied upon investor funds to maintain its operations and develop the Company’s business. The Company anticipates raising additional capital within the next twelve months for working capital as well as business expansion, although the Company can provide no assurance that additional capital will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing to meet its working capital requirements, it may have to curtail its business or cease all operations.

 

The Company requires funding of at least $5 million per year to maintain current operating activities. Over the next 24 months, the Company believes it will cost approximately $9 million to fund: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.

 

The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies, which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

Although the Company is seeking to raise additional capital and has engaged in numerous discussions with investment bankers and investors, to date, the Company has not received firm commitments for the required funding. Based upon its discussions, the Company anticipates that if the Company is able to obtain the funding required to retire outstanding debt, pay past due payables and maintain its current operating activities, that the terms associated with such funding will result in material dilution to existing shareholders.

 

Recent geopolitical events, including the inherent instability and volatility in global capital markets, as well as the lack of liquidity in the capital markets, could impact the Company’s ability to obtain financing and its ability to execute its business plan.

 

Our Chief Executive Officer currently works from his home office in virtual communication with key personnel. Cadwell Laboratories, which is controlled by Carl Cadwell, a director of the Company, provides office space to management on an as-needed basis until such time as the Company leases permanent office space.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on the Company’s financial condition, revenues, results of operations, liquidity or capital expenditures.

 

Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 

25
 

 

Fixed Assets

 

Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

 

Depreciation is computed using the straight-line method over the following estimated useful lives:

 

Production equipment:   3 to 7 years
Office equipment:   2 to 5 years
Furniture and fixtures:   2 to 5 years

 

Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

 

Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.

 

License Fees

 

License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the asset.

 

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such ten-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

26
 

 

Net Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period and does not include the impact of any potentially dilutive common stock equivalents. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. When the Company incurs a loss, the denominator is not increased by the potentially dilutive common shares as the effect would be anti-dilutive.

 

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

 

Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

The Company files income tax returns in the U.S. federal jurisdiction.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months.

 

Fair Value of Financial Instruments

 

The Company adopted ASC Topic 820 (“Fair Value Measurements”) as of January 1, 2008 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

  - Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
     
  - Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  - Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

27
 

 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

This item is not applicable to the Company because the Company is a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

All financial information required by this Item is included on the pages immediately following the Index to Financial Statements appearing on page F-1 and is hereby incorporated by reference.

 

ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None

 

28
 

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

Based on an evaluation as of the date of the end of the period covered by this report, the Company’s Chief Executive Officer and Interim Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, the Company’s Chief Executive Officer and Interim Chief Financial Officer concluded that, because of the disclosed material weaknesses in the Company’s internal control over financial reporting, the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this report to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Company’s Interim Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rule 13a-15(f). Management conducted an evaluation of the effectiveness of the internal control over financial reporting as of December 31, 2022, using the criteria established in Internal Control – Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. As a result of management’s assessment, management has determined that there are material weaknesses due to the lack of segregation of duties and, due to the limited resources based on the size of the Company. Due to the material weaknesses management concluded that as of December 31, 2022, the Company’s internal control over financial reporting was ineffective. In order to address and resolve the weaknesses, the Company will endeavor to locate and appoint additional qualified personnel to the board of directors and pertinent officer positions as the Company’s financial means allow. To date, the Company’s limited financial resources have not allowed the Company to hire the additional personnel necessary to address the material weaknesses.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this annual report.

 

29
 

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting that occurred during the Company’s last fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

(a) Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
   
(b) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
   
(c) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.

 

ITEM 9B. OTHER INFORMATION.

 

None.

 

30
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The Company’s current directors and executive officers are as follows:

 

NAME   AGE   POSITION
Michael K. Korenko   76   President, Chief Executive Officer, and Director
Michael Pollack   56   Interim Chief Financial Officer
Carlton M. Cadwell   78   Chairman of the Board and Secretary

 

Term of Office

 

All the Company’s directors hold office until the next annual meeting of the stockholders or until their successors is elected and qualified. The Company’s executive officers are appointed by the Company’s board of directors and hold office until their resignation, removal, death or retirement.

 

Background and Business Experience

 

The business experience during the past five years of each of the Company’s directors and executive officers is as follows:

 

Dr. Michael K. Korenko, President and Chief Executive Officer of the Company since December 2016, and a member of the Board of Directors since August 2017, joined the Company as an Advisor to the Board of the Company during 2009 and served as member of the Board from May 2009 to March 2010. Dr. Korenko has also served on the Hanford Advisory Board since 2009. Dr. Korenko served as Business Development Manager for Curtiss-Wright from 2006 to 2009, as Chief Operating Officer for Curtiss-Wright from 2000 to 2005 and was Executive Vice President of Closure for Safe Sites of Colorado at Rocky Flats from 1994 to 2000. Dr. Korenko served as Vice President of Westinghouse from 1987 to 1994 and was responsible for the 300 and 400 areas, including the Fast Flux Testing Facility (“FFTF”) and all engineering, safety analysis, and projects for the Hanford site.

 

Dr. Korenko is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year. Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense, reporting to Secretary Cap Weinberger.

 

Dr. Korenko brings to the Board over seven years’ experience working with and advising various small businesses, including companies involved in turnarounds. Dr. Korenko has also been involved as an advisor to the Company since 2009 in the development of medical isotopes.

 

Carlton M. Cadwell, Chairman of the Board and Secretary since December 2016, joined the Company as a director in 2006. Dr. Cadwell brings over 30 years of experience in business management, strategic planning, and implementation. He co-founded Cadwell Laboratories, Inc. in 1979 and has served as its President since its inception. Cadwell Laboratories, Inc. is a major international provider of neurodiagnostic medical devices. After receiving his bachelor’s degree from the University of Oregon in 1966 and a doctoral degree from the University of Washington in 1970, he began his career serving in the United States Army as a dentist for three years. From 1973 to 1980, Dr. Cadwell practiced dentistry in private practice and since has started several businesses.

 

Mr. Cadwell brings to the Board over ten years of service on the Board and over forty-five years of experience as a successful entrepreneur, as well as medical expertise.

 

Michael Pollack CPA, the Interim Chief Financial Officer, joined the Company as interim Chief Financial Officer in December 2018. Mr. Pollack has been a partner in a certified public accounting firm for the past fifteen years and specializes in accounting and auditing for small public companies. Mr. Pollack has approximately 30 years of experience in public accounting and consulting to over 100 publicly traded and 250 private companies. Mr. Pollack has also held CFO and Controller positions in an array of industries. Mr. Pollack graduated from the University of Maryland with a Bachelor of Arts in Economics. Mr. Pollack is a member of the American Institute of Certified Public Accountants, as well as licensed to practice in New Jersey, and New York.

 

31
 

 

Identification of Significant Consultants

 

David J. Swanberg, M.S., P.E. Mr. Swanberg has over 30 years’ experience in radiochemical processing, medical isotope production, nuclear waste management, materials science, regulatory affairs, and project management. Mr. Swanberg has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion dollar annual revenues. From 2005 to 2008, he served as Executive Vice President of Operations and as a member of the Board of Directors for IsoRay Medical Inc. from 2005 to 2008 managing day-to-day operations, R&D, and New Product Development. Mr. Swanberg was a co-founder of IsoRay and led the initial Cs-131 brachytherapy seed product development, FDA 510(k) submission/clearance, and NRC Sealed Source review and registration. Mr. Swanberg led the radiation dosimetry evaluations to meet American Association of Physicists in Medicine guidelines and is a current member of the AAPM. Mr. Swanberg and participated in several capital financing rounds totaling over $30.0 million. Mr. Swanberg also served as Assistant General Manager of IsoRay LLC from 2000 to 2003, and in additionally in key management roles as IsoRay transitioned from IsoRay LLC to IsoRay Medical, Inc. Mr. Swanberg holds a BA in Chemistry from Bethel University (MN) and an MS in Chemical Engineering from Montana State University. Mr. Swanberg has numerous technical publications and holds several patents.

 

Medical and Veterinarian Advisory Boards

 

Dr. Barry D. Pressman MD, FACR - Chairman Medical Advisory Board. Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Centre and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, California.

 

Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.

 

Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard’s Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography (CT).

 

Dr. Albert S. DeNittis MD, MS, FCPP - Medical Advisory Board. Dr. Albert S. DeNittis is currently is the Chief of Radiation Oncology at Lankenau Medical Center and Clinical Professor at Lankenau Institute for Medical Research in Wynnewood, Pennsylvania and the Director of Radiation Oncology at Brodesseur Cancer Center in New Jersey. He is also the Principal Investigator and in charge of a grant awarded by the NIH for its National Cancer Oncology Research Program (NCORP) at Main Line Health. Dr. DeNittis’ practice experience includes image-guided radiosurgery, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), high-dose rate (HDR) brachytherapy, cranial and extracranial stereotactic radiosurgery, respiratory gating, and Cyberknife.

 

Dr. DeNittis has served on numerous regional, national and government committees related to key issues in Dr. DeNittis earned a BA and a MS at Rutgers University and a MD from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. He completed postdoctoral training internships and residency at the Department of Radiation Oncology at the Hospital of the University of Pennsylvania. Dr. DeNittis is board certified by the American Board of Radiology and Licensed in New Jersey and Pennsylvania.

 

Dr. Alice Villalobos, DVM, FNAP - Chair of the Veterinary Medicine Advisory Board. Dr. Alice Villalobos is a well-known pioneer in the field of cancer care for companion animals and a founding member of the Veterinary Cancer Society. A 1972 graduate of UC Davis, she completed Dr. Gordon Theilen’s first mock residency program in oncology and has served the profession by consulting, writing and lecturing in the rapidly growing field of veterinary oncology and end of life care.

 

32
 

 

Dr. Alice Villalobos is President Emeritus of the Society for Veterinary Medical Ethics, Past President of the American Association of Human Animal Bond Veterinarians and Chair of the Veterinary Academy for the National Academies of Practice. She operated Coast Pet Clinic/Animal Cancer Center for 25 years, which is now VCA Coast Animal Hospital. She is the author of numerous articles, papers, and including her classic veterinarian textbook, Canine and Feline Geriatric Oncology: Honoring the Human-Animal Bond. She has lectured worldwide on oncology, quality of life, the human-animal bond and end of life care and bioethics. She founded Pawspice, an end of life care program that embraces kinder, gentler palliative cancer medicine and integrative care for pets with cancer and terminal illness (www.Pawspice.com). Dr. Alice is Director of Animal Oncology Consultation Service in Woodland Hill, California and Pawspice at VCA Coast Animal Hospital in Hermosa Beach, California. Dr. Alice was elected 2016 Hermosa Beach Woman of the Year.

 

Dr. Villalobos’ role with the Company is to support the commercialization of the Company’s yttrium-90 brachytherapy products for use in companion animals.

 

Dr. Richard Weller, DVM, DACVIM (Internal Medicine; Oncology) DipMS - Veterinary Medicine Advisory Board Member. Prior to his retirement in 2014, Dr. Weller was a Senior Program Manager in the Radiation Biology Group of the Biological Sciences Division at Pacific Northwest National Laboratory (PNNL), where he was involved in the development of RadioGel. A 1973 graduate of Washington State University. Dr. Weller has extensive experience in designing and executing clinical studies, treatment planning, mechanisms of carcinogenesis, radiation biology, targeted delivery systems for chemotherapeutic and radio-therapeutic agents, bio-markers of disease, and comparative oncology; as well as over 30 years of experience developing and using animal models, including the use of spontaneous tumors in companion animals, for bio-medical applications.

 

Dr. Weller is board-certified by the American College of Veterinary Internal Medicine in Internal Medicine (1980) and Oncology (1987), Past Chairperson of the Organizing Committee for the Specialty of Veterinary Medical Oncology, Past Chairperson of the Board of Regents of the American College of Veterinary Internal Medicine, Past President of the Board of Regents of the American College of Veterinary Internal Medicine, Past President of the Specialty of Oncology, and a Charter Member of the Veterinary Cancer Society which he served as Treasurer for 16 years. He is an Honorary Professor of the Institute of Veterinary Medicine in Kyiv, Ukraine. Dr. Weller has lectured and trained veterinarians worldwide and has authored or co-authored over 250 articles, technical reports, book chapters, and presentations in his fields of expertise.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934 requires the Company’s executive officers, directors and persons who own more than 10% of the Company’s common stock to file with the SEC initial reports of beneficial ownership on Form 3, changes in beneficial ownership on Form 4, and an annual statement of beneficial ownership on Form 5. Such executive officers, directors and greater than 10% stockholders are required by SEC rules to furnish the Company with copies of all such forms that they have filed.

 

Based solely on its review of such forms filed with the SEC and received by the Company and representations from certain reporting persons, the Company believes that all reports required to be filed by each of each of its executive officers, directors and 10% stockholders were filed during the year ended December 31, 2022 and that such reports were timely.

 

Code of Ethics

 

The Company’s Board of Directors has not adopted a code of ethics that applies to the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, because of the Company’s limited number of executive officers and employees that would be covered by such a code and the Company’s limited financial resources. The Company anticipates that it will adopt a code of ethics after it increases the number of executive officers and employees and obtain additional financial resources.

 

Audit Committee and Audit Committee Financial Expert

 

As of the date of this report, the Company has not established an audit committee, and therefore, the Company’s full board of directors performs the functions that customarily would be undertaken by an audit committee. The Company’s board of directors during 2022 and 2021 was comprised of two directors, one of whom the Company had determined satisfied the general independence standards of the NASDAQ listing requirements.

 

33
 

 

The Company’s Board of Directors has determined that none of its current members qualifies as an “audit committee financial expert,” as defined by the rules of the SEC. In the future, the Company intends to establish board committees and to appoint such persons to those committees as are necessary to meet the corporate governance requirements imposed by a national securities exchange, although it is not required to comply with such requirements until the Company elects to seek listing on a national securities exchange.

 

Board of Directors; Attendance at Meetings

 

The Board held no meetings and acted by unanimous written consent two times during the year ended December 31, 2022. In 2021, we conducted no board of director meetings and acted by unanimous written consent two times. We have no formal policy with respect to the attendance of Board members at annual meetings of shareholders but encourage all incumbent directors and director nominees to attend each annual meeting of shareholders.

 

ITEM 11. EXECUTIVE COMPENSATION.

 

Summary Compensation Table

 

The following table sets forth the compensation paid to the Company’s Chief Executive Officer and those executive officers that earned in excess of $100,000 during the year ended December 31, 2022 (collectively, the “Named Executive Officers”):

 

Name and Principal Position (1)  Year   Salary ($)   Bonus ($)   Stock
Awards ($)		  

Option

Awards
($)(2)

   Total
($)		 
                         
Dr. Michael K. Korenko   2022   $230,625   $30,000   $-   $    -   $260,625 
CEO, President and Director   2021   $225,000   $30,000   $    -   $-   $255,000 

 

  (1) Michael Pollack began serving as the Company’s Interim Chief Financial Officer in December 2018 and was paid no compensation directly in 2021 or 2022. Accordingly, he has not been included in this table.
     
  (2) The amounts in this column represent the grant date fair value of stock option awards, computed in accordance with FASB ASC Topic 718.

 

Narrative Disclosure to Summary Compensation Table

 

Dr. Michael K. Korenko. On October 24, 2018, Mr. Korenko entered into an employment agreement with the Company (the “Old Employment Agreement”), which was scheduled to terminate on December 31, 2019. On June 4, 2019, Mr. Korenko and the Company entered into a new employment agreement, effective June 11, 2019, which shall terminate on December 31, 2020 and December 31 of subsequent years (the “Termination Date”) if the agreement is extended pursuant to its terms. Under the terms of his employment agreement, the Company may terminate Dr. Korenko’s employment either with or without cause prior to the Termination Date, but in the event of a termination without cause, Dr. Korenko shall be entitled to receive monthly payments of his base salary for a period of six months thereafter, all of Dr. Korenko’s outstanding options, if any, shall vest, and Dr. Korenko shall be entitled to receive all past due compensation within three weeks of the date of termination.

 

The Company shall pay to Dr. Korenko an annual base compensation of $180,000, which is payable in equal monthly intervals. Of the $180,000 in annual base salary, $60,000 of annual pay shall be deferred and accrued until the Company’s cash balance exceeds $1,000,000, which occurred in December 2020. Dr. Korenko’s employment agreement provides that he shall receive a stock option grant issued under the Company’s 2015 Omnibus Securities and Incentive Plan in an amount equal to 21 million options ten days after the Company’s 1-for-8 reverse split, which was consummated in late June 2019. The options shall have a seven-year term, shall be exercisable at a price of $0.024 per share, and shall vest as follows: 50% shall vest in equal amounts at the end of each quarter for the two quarters after grant date, 25% shall vest upon the Company filing for a patent, and the remaining 25% shall vest upon the first commercial sale of IsoPet. In December 2020, Mr. Korenko exercised 2,500,000 of these options for $60,000.

 

34
 

 

The Company paid bonuses to certain employees based on their performance, the Company’s need to retain such employees, and funds available. All bonus payments were approved by the Company’s Board of Directors.

 

On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023.

 

Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $225,000. In addition, there is a discretionary bonus to be earned in the amount of $7,500 per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company.

 

Outstanding Equity Awards at Fiscal Year-End Table

 

The following table sets forth all outstanding equity awards held by the Company’s Named Executive Officers as of the end of last fiscal year.

 

   Option Awards 
Name  Number of
Securities
Underlying
Unexercised
Options(#)
Exercisable		   Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable		   Option
Exercise
Price ($)		   Option
Exercise Date		 
NONE                                       

 

Compensation of Directors

 

During the year ended December 31, 2022, the Company’s non-employee directors were not paid any compensation.

 

The following table sets forth, for each of the Company’s non-employee directors who served during 2022, the aggregate number of stock awards and the aggregate number of stock option awards that were outstanding as of December 31, 2022:

 

   Outstanding   Outstanding 
   Stock   Stock 
Name  Awards (#)   Options (#) 
Carlton M. Cadwell       -        - 

 

During June 2016, the Company granted to Mr. Cadwell options to purchase 12,500 shares of common stock at an exercise price of $8.00 per share, which options expired June 21, 2019. These options had a grant date fair value of $34,771, which amounts were calculated in accordance with ASC Topic 718.

 

Additionally, the Company granted warrants to purchase 6,425,503 shares of Company common stock to Carlton Cadwell in 2018 as a result of the Path Forward Agreements and conversion of his advances to the Company. These warrants expired in October 2020.

 

There are no employment contracts or compensatory plans or arrangements with respect to any director that would result in payments by the Company to such person because of his or her resignation as a director or any change in control of the Company.

 

Compensation Committee Interlocks and Insider Participation

 

None of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more officers serving as a member of our board of directors.

 

35
 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

Beneficial Ownership of the Company’s Common Stock

 

The following table sets forth, as of March 1, 2023, the number of shares of common stock beneficially owned by the following persons: (i) all persons the Company knows to be beneficial owners of at least 5% of the Company’s common stock, (ii) the Company’s current directors, (iii) the Company’s current executive officers, and (iv) all current directors and executive officers as a group.

 

As of March 1, 2023, there were 362,541,528 shares of common stock outstanding and up to 64,762,379 shares issuable upon exercise of common stock equivalents, assuming exercise and conversion occurred as of that date, for a total of 427,303,907 shares.

 

Name and Address of Beneficial Owner(1) 

Amount and
Nature

of Beneficial Ownership(2)

   Percent of Class 
Cadwell Family Irrevocable Trust   26,912    *%
           
Carlton M. Cadwell (3)   15,406,979    3.61%
           
Michael K. Korenko (4)   24,885,090    5.83%
           
Michael Pollack   16,000     *  
           
All Current Directors and Executive Officers as a group (3 individuals)   40,334,981    9.44%

 

*Less than 1%

 

(1) The address of each of the beneficial owners above is c/o Vivos Inc, 719 Jadwin Avenue, Richland, WA 99336, except that the address of the Cadwell Family Irrevocable Trust (the “Cadwell Trust”) is 909 North Kellogg Street, Kennewick, WA 99336.
   
(2) In determining beneficial ownership of the Company’s common stock as of a given date, the number of shares shown includes shares of common stock which may be acquired upon exercise of the common stock equivalents within 60 days of that date. In determining the percent of common stock owned by a person or entity on March 1, 2023, (a) the numerator is the number of shares of the class beneficially owned by such person or entity, including shares which may be acquired within 60 days on exercise of the common stock equivalents, and (b) the denominator is the sum of (i) the total shares of common stock outstanding on March 1, 2023, and (ii) the total number of shares that the beneficial owner may acquire upon conversion of the common stock equivalents. Subject to community property laws where applicable, the Company believes that each beneficial owner has sole power to vote and dispose of its shares, except that under the terms of the Cadwell Trust, Dr. Cadwell does not have or share voting or investment power over the shares beneficially owned by the Cadwell Trust.
   
(3) Includes 1,136,137 shares issuable upon conversion of Series A Preferred; and 4,816,275 shares issuable upon conversion of Series C Preferred, and 2,316,830 shares of common stock issued to AMIC Gift, LLC, an LLC controlled by Carlton and his wife.
   
(4) Includes 15,000,000 shares issuable for vested RSUs.

 

36
 

 

Beneficial Ownership of the Company’s Series A Convertible Preferred Stock

 

As of March 1, 2023, there were 2,071,007 shares of Series A Preferred issued and outstanding, convertible into 2,588,758 shares of the Company’s common stock.

 

The following table sets forth, as of March 1, 2023, the number of shares of Series A Preferred beneficially owned by the following persons: (i) all persons the Company known to be beneficial owners of at least 5% of the Company’s Series A Preferred, (ii) the Company’s current directors, (iii) the Company’s current executive officers, and (iv) all current directors and executive officers as a group.

 

Name and Address of Beneficial Owner (1) 

Amount and
Nature

of Beneficial

Ownership (2)

   Percent of Class 
Cadwell Family Irrevocable Trust   148,309    7.16%
           
Carlton M. Cadwell   908,910    43.89%
           
Michael K. Korenko   -    -%
           
All Current Directors and Executive Officers as a group (2 individuals)(3)   1,057,219    51.05%
           
Major Shareholder(s):          
           
L. Bruce Jolliff   197,979    9.56%
           
Stoel Rives   133,333    6.44%

 

(1) The address of each of the beneficial owners above is c/o Vivos Inc, 719 Jadwin Avenue, Richland, WA 99336, except that the address of (i) the Cadwell Family Irrevocable Trust (the “Cadwell Trust”) is 909 North Kellogg Street, Kennewick, WA 99336; (ii) L. Bruce Jolliff is 206 N 41st St. Unit 1, Yakima, WA 98901; and (iii) Stoel Rives is One Union Square, 600 University Street, Suite 3600, Seattle, WA 98101.
   
(2) Subject to community property laws where applicable, the Company believes that each beneficial owner has sole power to vote and dispose of its shares, except that Dr. Cadwell under the terms of the Cadwell Trust does not have or share voting or investment power over the Series A Convertible Preferred beneficially owned by the Cadwell Trust.
   
(3) Michael Pollack, the Company’s Interim Chief Financial Officer, does not hold any Company Series A Convertible Preferred, and has therefore been omitted from this table.

 

37
 

 

Beneficial Ownership of the Company’s Series B Convertible Preferred Stock

 

As of March 1, 2023, there were 200,363 shares of Series B Preferred issued and outstanding, convertible into 2,504.538 shares of the Company’s common stock.

 

The following table sets forth, as of March 1, 2023, the number of shares of Series B Preferred beneficially owned by the following persons: (i) all persons the Company known to be beneficial owners of at least 5% of the Company’s Series B Preferred, (ii) the Company’s current directors, (iii) the Company’s current executive officers, and (iv) all current directors and executive officers as a group.

 

Name and Address of Beneficial Owner (1)  Amount and
Nature of Beneficial Ownership (2)		   Percent of Class 
All Current Directors and Executive Officers as a group (3 individuals)   -    *%
           
Major Shareholder(s):          
           
Jason Adelman(3)   200,000    99%

 

*Less than 1%

 

(1) None of the Company’s directors and executive officers hold any shares of the Company’s Series B Convertible Preferred, and they have therefore been omitted from this table. The address of the beneficial owners is as follows: (i) Jason Adelman (JTA Resources LLC. is 40 East 66th St., New York, NY 10065.
   
(2) Subject to community property laws where applicable, the Company believes that each beneficial owner has sole power to vote and dispose of its shares.
   
(3) Represents 200,000 shares of Series B Preferred held by JTA Resources LLC.

 

Beneficial Ownership of the Company’s Series C Convertible Preferred Stock

 

As of March 1, 2023, there were 385,302 shares of Series C Preferred issued and outstanding, convertible into 4,816,275 shares of the Company’s common stock.

 

The following table sets forth, as of March 1, 2023, the number of shares of Series C Preferred beneficially owned by the following persons: (i) all persons the Company known to be beneficial owners of at least 5% of the Company’s Series C Preferred, (ii) the Company’s current directors, (iii) the Company’s current executive officers, and (iv) all current directors and executive officers as a group.

 

Name and Address of Beneficial Owner (1) 

Amount and

Nature

of Beneficial

Ownership (2)

  

Percent of

Class

 
Carlton M. Cadwell   385,302    100%
All Current Directors and Executive Officers as a group (3 individuals) (3)   385,302    100%

 

(1) The address of each of the beneficial owners above is c/o Vivos Inc, 719 Jadwin Avenue, Richland, WA 99336.,
   
(2) Subject to community property laws where applicable, the Company believes that each beneficial owner has sole power to vote and dispose of its shares, except that Dr. Cadwell under the terms of the Cadwell Trust does not have or share voting or investment power over the Series C Preferred beneficially owned by the Cadwell Trust.
   
(3) Neither Michael Korenko, the Company’s Chief Executive Officer, nor Michael Pollack, the Company’s Interim Chief Financial Officer, hold any shares of the Company’s Series C Preferred, and they have therefore been omitted from this table.

 

Changes in Control

 

The Company does not know of any arrangements, including any pledges of the Company’s securities that may result in a change in control of the Company.

 

38
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Indebtedness from Related Parties

 

On January 24, 2019, the Company entered into a note payable with a trust related to Mr. Cadwell in the amount of $60,000. The note is for a one-year period maturing January 24, 2020 and bears interest at an annual rate of 8.0%. This note was converted into shares of common stock in December 2021.

 

On March 27, 2019 the Company entered into a note payable with a trust related to Mr. Cadwell in the amount of $48,000. The note is for a one-year period maturing March 27, 2020 and bears interest at an annual rate of 8.0%. This note was repaid in December 2021.

 

On April 29, 2019, the Company entered into a note payable with a trust related to Mr. Cadwell in the amount of $29,000. The note is for a one-year period maturing April 29, 2020 and bears interest at an annual rate of 8.0%. This note was repaid in December 2021.

 

On May 20, 2019 and May 23, 2019, Mr. Korenko advanced $20,000 collectively to the Company. Mr. Korenko is not charging interest on these amounts advanced and they are short-term advances, due on demand. Of this amount $5,000 was repaid and the balance of $15,000 was converted into a convertible note payable at an annual interest rate of 8% due January 15, 2020. This note was converted in April 2020.

 

On July 5, 2019, the Company entered into a note payable with a trust related to Mr. Cadwell in the amount of $50,000. The note is for a one-year period maturing July 5, 2020 and bears interest at an annual rate of 8.0%. Of this amount, $23,000 was paid in December 2021, and the balance was converted into shares of common stock in December 2021.

 

On November 25, 2019, the Company entered into a note payable with a trust related to Mr. Cadwell in the amount of $50,000. The note is for a one-year period maturing November 25, 2020 and bears interest at an annual rate of 8.0%. This note was converted into shares of common stock in December 2021.

 

The Company borrowed $107,000 in the year ended December 31, 2020 from its CEO and repaid these amounts in full.

 

Independent Directors

 

The Company’s common stock is traded on the OTCQB Marketplace, which does not impose any independence requirements on the Board of Directors or the board committees of the companies whose stock is traded on that market. The Company has decided to adopt the independence standards of the Nasdaq listing rules in determining whether the Company’s directors are independent. Generally, under those rules a director does not qualify as an independent director if the director or a member of the director’s immediate family has had in the past three years certain relationships or affiliations with the Company, the Company’s auditors, or other companies that do business with the Company. The Company’s Board of Directors has determined that Mr. Cadwell is qualified as an independent director under those Nasdaq rules, and accordingly, would have been qualified under those rules to serve on a compensation committee or a nominating committee, if the Company had established such committees of the Company’s Board of Directors. Dr. Korenko is not an independent director due to his employment by the Company as an executive officer.

 

39
 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

Audit Fees

 

The aggregate fees incurred by the Company’s principal accountant for the audit of the Company’s annual financial statements, review of financial statements included in the quarterly reports and other fees that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the years ended December 31, 2022 and 2021 were $42,250 and $36,000, respectively, all of which was paid to Fruci & Associates II, PLLC.

 

Audit Related Fees

 

The aggregate fees billed for professional services that are reasonably related to the performance of the audit or review of the Company’s financial statements but are not reported “Audit Fees” for the years ended December 31, 2022 and 2021 in the amounts of $0 and $2,250, respectively. All services performed by the Company’s Registered Public Accounting Firm, Fruci & Associates II, PLLC have been pre-approved by the Company’s Board of Directors.

 

Tax Fees

 

The aggregate fees billed for professional services rendered by principal accountant for tax compliance, tax advice and tax planning during the years ended December 31, 2022 and 2021 were $3,250 and $3,250, respectively, all of which was paid to Fruci & Associates II, PLLC.

 

All Other Fees

 

Other fees billed for products or services provided by the Company’s principal accountant during the years ended December 31, 2022 and 2021 There were no fees incurred to Fruci & Associates II, PLLC related to all other fees.

 

40
 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

(a) Documents filed as part of this Report.

 

1. Financial Statements. The Vivos Inc. Balance Sheets as of December 31, 2022 and 2021, the Statements of Operations for the years ended December 31, 2022 and 2021, the Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2022 and 2021, and the Statements of Cash Flows for the years ended December 31, 2022 and 2021, together with the notes thereto and the reports of Fruci & Associates II, PLLC as required by Item 8 are included in this 2022 Annual Report on Form 10-K as set forth in Item 8 above.
   
2. Financial Statement Schedules. All financial statement schedules have been omitted since they are either not required or not applicable, or because the information required is included in the financial statements or the notes thereto.
   
3. Exhibits. The following exhibits are either filed as a part hereof or are incorporated by reference. Exhibit numbers correspond to the numbering system in Item 601 of Regulation S-K.

 

Exhibit

Number

   Description
3.1   Certificate of Incorporation of Savage Mountain Sports Corporation, dated January 11, 2000 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497) filed on November 12, 2008).
3.2   By-Laws (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497) filed on November 12, 2008).
3.3   Certificate of Amendment of Certificate of Incorporation changing the name of the Company to Advanced Medical Isotope Corporation, dated May 23, 2006 (incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497) filed on November 12, 2008).
3.4   Certificate of Amendment of Certificate of Incorporation increasing authorized capital dated September 26, 2006 (incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497) filed on November 12, 2008).
3.5   Certificate of Amendment to the Certificate of Incorporation increasing authorized common stock and authorizing preferred stock, dated May 18, 2011 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 18, 2011).
3.6   Certificate of Amendment to the Certificate of Incorporation authorizing a series of Preferred Stock to be named “Series A Convertible Preferred Stock”, consisting of 2,500,000 shares, which series shall have specific designations, powers, preferences and relative and other special rights, qualifications, limitations and restrictions as outlined in the Certificate of Designations, filed June 30, 2015 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on July 7, 2015).
3.7   Certificate of Amendment to the Certificate of Incorporation increasing the authorized series of “Series A Convertible Preferred Stock” to 5,000,000 shares, filed March 31, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 7, 2016).
3.8   Certificate of Amendment to the Certificate of Incorporation authorizing a series of Preferred Stock to be named “Series B Convertible Preferred Stock”, consisting of 5,000,000 shares, which series shall have specific designations, powers, preferences and relative and other special rights, qualifications, limitations and restrictions as outlined in the Certificate of Designations, filed October 10, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018).

 

41
 

 

4.1   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018).
10.1   Agreement and Plan of Reorganization, dated as of December 15, 1998, by and among HHH Entertainment, Inc. and Earth Sports Products, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497) filed on November 12, 2008).
10.2   Agreement and Plan of Merger of HHH Entertainment, Inc. and Savage Mountain Sports Corporation, dated as of January 6, 2000 (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497), filed on November 12, 2008).
10.3   Agreement and Plan of Acquisition by and between Neu-Hope Technologies, Inc., UTEK Corporation and Advanced Medical Isotope Corporation, dated September 22, 2006 (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497), filed on November 12, 2008).
10.4   Agreement and Plan of Acquisition by and between Isonics Corporation and Advanced Medical Isotope Corporation dated June 13, 2007 (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form 10-12G (File No. 000-53497), filed on November 12, 2008).
10.5   Form of Non-Statutory Stock Option Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 15, 2012).
10.6   Promissory Note dated December 16, 2008 between Advanced Medical Isotope Corporation and Carlton M. Cadwell (incorporated by reference to Exhibit 10.11 to the Company’s Annual Report on Form 10-K filed on March 3, 2012).
10.7   2015 Omnibus Securities and Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K, filed May 25, 2016).
10.8   Washington State University Sub-Award Agreement for the period December 15, 2017 through January 31, 2018.(incorporated by reference to Exhibit 10.13 to the Company’s Annual report on Form 10-K, filed April 2, 2018).
10.9   The Curators of the University of Missouri Sponsored Research Contract for the period November 1, 2017 through October 31, 2018. (incorporated by reference to Exhibit 10.14 to the Company’s Annual report on Form 10-K, filed April 2, 2018).
10.10   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018).
10.11   Employment Agreement by and between Vivos Inc. and Michael Korenko, dated June 4, 2019 (incorporated by reference to Exhibit 6.18 to the Company’s Offering Statement on Form 1-A filed on July 29, 2019).
23   Consent of Independent Registered Public Accounting Firm
31.1*   Certification of Chief Executive Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002 (4)
31.2*   Certification of Chief Financial Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002 (4)
32.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (4)
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

* Filed herewith.

 

42
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VIVOS INC.
     
Date: March 1, 2023 By: /s/ Michael K. Korenko
  Name: Michael K. Korenko
  Title: Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Date: March 1, 2023 By: /s/ Michael K. Korenko
  Name: Michael K. Korenko
  Title:

Chief Executive Officer

(Principal Executive Officer)

     
Date: March 1, 2023 By: /s/ Michael Pollack
  Name: Michael Pollack
  Title:

Interim Chief Financial Officer

(Principal Financial and Accounting Officer)

     
Date: March 1, 2023 By: /s/ Carlton M. Cadwell
  Name: Carlton M. Cadwell
  Title: Secretary and Chairman of the Board

 

43
 

 

Vivos Inc.

Index to Financial Statements

 

    Pages
     
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 5525)   F-1
     
Financial Statements:    
     
Balance Sheets as of December 31, 2022 and 2021   F-3
     
Statements of Operations for the years ended December 31, 2022 and 2021   F-4
     
Statement of Changes in Stockholders’ Equity for the years ended December 31, 2022 and 2021   F-5
     
Statements of Cash Flow for the years ended December 31, 2022 and 2021   F-6
     
Notes to Financial Statements   F-7

 

44
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of Vivos, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Vivos, Inc. (“the Company”) as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses, has utilized significant cash in operations, and its cash position is not sufficient to support operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

F-1
 

 

Equity Transactions (Notes 4 and 5 to the financial statements)

 

Description of the Critical Audit Matter

 

The Company’s evaluation of common shares issuances, including in exchange for stock warrants involved complexity and judgement in applying the relevant accounting standards when auditing management’s conclusions on the classification and recognition of warrants on issuance and on exercise and equity transactions upon issuance.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our principal audit procedures to evaluate management’s calculation and recording of common share issuances included the following:

 

●We evaluated the appropriateness and consistency of management’s methods and assumptions used in the identification, recognition, measurement, and disclosure of considerations of the underlying warrants and share issuances during the year, including the classification with respect to the terms and in considering applicable generally accepted accounting standards.
●We read the applicable agreements and compared the key terms to management’s analysis of the transaction.
●We read, evaluated, and tested the reasonableness of management’s calculation utilized in the determination of common shares issued, including exchange for stock warrants.
●We evaluated whether management had appropriately considered new information that could significantly change the measurement or disclosure of common shares issued including exchange for stock warrants, and evaluated the disclosures related to the financial statement impacts of the transactions.
●We reviewed current and subsequent period accounting records and third-party documentation to identify unrecorded equity transactions.

 

We have served as the Company’s auditor since 2016.

 

Spokane, Washington

  
March 1, 2023  

 

F-2
 

 

VIVOS INC

CONDENSED BALANCE SHEETS

DECEMBER 31, 2022 AND 2021

 

   DECEMBER 31,   DECEMBER 31, 
   2022   2021 
         
ASSETS          
           
Current Assets:          
Cash  $1,706,065   $1,606,123 
Accounts receivable   11,000    - 
Prepaid expenses   25,671    28,175 
           
Total Current Assets   1,742,736    1,634,298 
           
           
TOTAL ASSETS  $1,742,736   $1,634,298 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
LIABILITIES          
Current Liabilities:          
Accounts payable and accrued expenses  $81,692   $166,915 
           
Total Current Liabilities   81,692    166,915 
           
Total Liabilities   81,692    166,915 
           
Commitments and contingencies   -    - 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, par value, $0.001, 20,000,000 shares authorized, Series A Convertible Preferred, 5,000,000 shares authorized, 2,071,007 shares issued and outstanding, respectively   2,071    2,071 
Additional paid in capital - Series A Convertible preferred stock   8,842,458    8,842,458 
Series B Convertible Preferred, 5,000,000 shares authorized, 200,363 shares issued and outstanding, respectively   200    200 
Additional paid in capital - Series B Convertible preferred stock   290,956    290,956 
Series C Convertible Preferred, 5,000,000 shares authorized, 385,302 shares issued and outstanding, respectively   385    385 
Additional paid in capital - Series C Convertible preferred stock   500,507    500,507 
Common stock, par value, $0.001, 950,000,000 shares authorized, 362,541,528 and 343,530,678 issued and outstanding, respectively   362,541    343,531 
Additional paid in capital - common stock   71,217,954    68,573,142 
Accumulated deficit   (79,556,028)   (77,085,867)
           
Total Stockholders’ Equity   1,661,044    1,467,383 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $1,742,736   $1,634,298 

 

F-3
 

 

VIVOS INC

STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   2022   2021 
         
Revenues, net  $36,499   $14,887 
Cost of Goods Sold   (28,779)   (12,000)
           
Gross profit   7,720    2,887 
           
OPERATING EXPENSES          
Professional fees, including stock-based compensation   1,755,316    1,838,323 
Payroll expenses   275,240    267,477 
Research and development   343,802    286,848 
General and administrative expenses   151,111    112,037 
           
Total Operating Expenses   2,525,469    2,504,685 
           
OPERATING LOSS   (2,517,749)   (2,501,798)
           
NON-OPERATING INCOME (EXPENSE)          
Interest expense   -    (25,375)
Forgiveness of debt   -    136,445 
Gain (loss) on debt extinguishment   47,588    (137,038)
           
Total Non-Operating Income (Expenses)   47,588    (25,968)
           
NET LOSS BEFORE PROVISION FOR INCOME TAXES   (2,470,161)   (2,527,766)
           
Provision for income taxes   -    - 
           
NET LOSS  $(2,470,161)  $(2,527,766)
           
Net loss per share - basic and diluted  $(0.01)  $(0.01)
           
Weighted average common shares outstanding   351,425,912    325,851,906 

 

F-4
 

 

VIVOS INC

STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

                                                         
           Additional           Additional           Additional                     
           Paid-In           Paid-In           Paid-In       Additional         
   Series A Preferred   Capital - Series A   Series B Preferred   Capital - Series B   Series C Preferred   Capital - Series C   Common Stock   Paid-In Capital -   Accumulated     
   Shares   Amount   Preferred   Shares   Amount   Preferred   Shares   Amount   Preferred   Shares   Amount   Common   Deficit   Total 
                                                         
Balance - December 31, 2020   2,171,007   $2,171   $8,857,358    436,653   $436   $385,235    385,302   $385   $500,507    292,278,591   $292,279   $64,551,764   $(74,558,101)  $32,034 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    22,500,000    22,500    1,777,500    -    1,800,000 
Note conversions/settlements   -    -    -    -    -    -    -    -    -    3,576,080    3,576    408,435    -    412,011 
Accounts payable   -    -    -    -    -    -    -    -    -    1,305,298    1,305    120,805    -    122,110 
Services   -    -    -    -    -    -    -    -    -    77,768    78    3,678    -    3,756 
Stock option exercises   (100,000)   (100)   (14,900)   -    -    -    -    -    -    2,125,000    2,125    12,875    -    - 
RSUs   -    -    -    -    -    -    -    -    -    12,000,000    12,000    (12,000)   -    - 
Warrant exercises   -    -    -    -    -    -    -    -    -    6,714,316    6,714    (6,714)   -    - 
Conversion of preferred shares to common shares   -    -    -    (236,290)   (236)   (94,279)   -    -    -    2,953,625    2,954    91,561    -    - 
Warrants purchased for cash   -    -    -    -    -    -    -    -    -    -    -    11,238    -    11,238 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    1,614,000    -    1,614,000 
Net loss for the year   -    -    -    -    -    -    -    -    -    -    -    -    (2,527,766)   (2,527,766)
                                                                       
Balance - December 31, 2021   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507   $343,530,678   $343,531   $68,573,142   $(77,085,867)  $1,467,383 
                                                                       
                                                                       
Balance - December 31, 2021   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    343,530,678   $343,531   $68,573,142   $(77,085,867)  $1,467,383 
                                                                       
Stock issued for:                                                                      
Cash   -    -    -    -    -    -    -    -    -    15,000,000    15,000    1,185,000    -    1,200,000 
Accounts payable   -    -    -    -    -    -    -    -    -    984,840    984    48,258    -    49,242 
Fractional adjustment   -    -    -    -    -    -    -    -    -    (90)   -    -    -    - 
Services   -    -    -    -    -    -    -    -    -    76,250    76    4,804    -    4,880 
Warrant exercises   -    -    -    -    -    -    -    -    -    2,949,850    2,950    (2,950)   -    - 
Warrants purchased for cash   -    -    -    -    -    -    -    -    -    -    -    20,000    -    20,000 
RSUs granted to consultants that have vested   -    -    -    -    -    -    -    -    -    -    -    1,389,700    -    1,389,700 
Net loss for the year   -    -    -    -    -    -    -    -    -    -    -    -    (2,470,161)   (2,470,161)
                                                                       
Balance - December 31, 2022   2,071,007   $2,071   $8,842,458    200,363   $200   $290,956    385,302   $385   $500,507    362,541,528   $362,541   $71,217,954   $(79,556,028)  $1,661,044 

 

The accompanying notes are an integral part of these financial statements.

 

F-5
 

 

VIVOS INC

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   2022   2021 
CASH FLOW FROM OPERATING ACTIVITIES          
Net loss  $(2,470,161)  $(2,527,766)
Adjustments to reconcile net loss to net cash used in operating activities          
Common stock, stock options and warrants for services   4,880    3,756 
RSUs issued for services   1,389,700    1,614,000 
(Gain) loss on conversion of debt   (47,588)   137,038 
Forgiveness of debt   -    (136,445)
Changes in assets and liabilities          
Accounts receivable   (11,000)   - 
Prepaid expenses and other assets   2,504    5,660 
Accounts payable and accrued expenses   11,607    31,480 
Payroll liabilities   -    (66,143)
Accrued interest   -    (25,399)
Total adjustments   1,350,103    1,563,947 
           
Net cash used in operating activities   (1,120,058)   (963,819)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Payments of convertible debt   -    (45,000)
Payments of related party notes   -    (100,000)
Proceeds from common stock and warrants   1,220,000    1,811,238 
Net cash provided by financing activities   1,220,000    1,666,238 
           
NET INCREASE IN CASH   99,942    702,419 
           
CASH - BEGINNING OF PERIOD   1,606,123    903,704 
           
CASH - END OF PERIOD  $1,706,065   $1,606,123 
           
CASH PAID DURING THE PERIOD FOR:          
Interest expense  $-   $50,773 
           
Income taxes  $-   $- 
           
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:          
           
Conversion of preferred stock for common stock  $-   $94,515 
Conversion of notes payable and accrued interest for common and common stock  $-   $185,346 
Conversion of notes payable and accrued interest into common stock  $-   $50,370 
Common stock issued in cashless exercise of warrants  $2,950   $6,714 
RSUs vested into common stock  $-   $12,000 
Accounts payable converted into shares of common stock  $49,242   $90,000 
Stock options exercised for recission of common and preferred stock  $-   $60,000 
Common stock issued in settlement of accounts payable - related parties  $-   $32,110 
RSUs vested into common stock  $-   $12,000 

 

F-6
 

 

Vivos Inc.

Notes to Financial Statements

December 31, 2022 and 2021

 

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.

 

Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

F-7
 

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP.

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“Y-90”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

Intellectual Property

 

Our original license with Battelle National Laboratory is reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.

 

Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

F-8
 

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.

 

We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 

The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.

 

The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 shares at a price of $0.10 for a maximum of $5,000,000. The Company amended this and was able to raise $1,200,000 in July 2022 at $0.08 per share (15,000,000 shares) and sold 20,000,000 warrants for $20,000. An amended Regulation A+ was filed in October 2022 to raise the remaining $3,800,000 of the $5,000,000.

 

The Company’s Regulation A+’s raised approximately $5,200,000 from the sale of shares and is using the proceeds generated as follows:

 

For the animal therapy market:

 

  ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.
  ● Conduct additional clinical studies to generate more data for the veterinary community
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated.
  ● Assist new regional clinics with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.
  ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $2.5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.

 

F-9
 

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.

 

As of December 31, 2022, the Company has $1,706,065 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.

 

There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 

F-10
 

 

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2022 and 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 

Fixed Assets

 

Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

 

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment:   3 to 7 years
Office equipment:   2 to 5 years
Furniture and fixtures:   2 to 5 years

 

Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

 

Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.

 

F-11
 

 

License Fees

 

License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed.

 

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the years ended December 31, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet® therapies.

 

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.

 

F-12
 

 

The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:

   December 31, 2022   December 31, 2021 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   25,862,500    25,262,500 
Common stock options   2,252,809    2,252,809 
Common stock warrants   26,737,500    31,862,500 
Total potential dilutive securities   64,762,379    69,287,379 

 

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $343,802 and $286,848 in research and development costs for the years ended December 31, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.

 

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2022 and 2021, the Company incurred nominal advertising and marketing costs.

 

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2022 and 2021.

 

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2022 and 2021. The Company did not have any deferred tax liability or asset on its balance sheets on December 31, 2022 and 2021.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

F-13
 

 

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

Recent Accounting Pronouncements

 

In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

NOTE 2: RELATED PARTY TRANSACTIONS

 

Related Party Notes Payable

 

The $237,000 in related party notes payable that were outstanding during 2021 were either repaid or converted in December 2021. There are no outstanding related party notes payable as of December 31, 2022.

 

Related Party Payables

 

In December 2021, the Company converted the $32,110 in related party payables into 401,373 shares of common stock. There are no remaining related party payables as of December 31, 2022.

 

Preferred and Common Shares Issued to Officers and Directors

 

In June 2021, the Company’s Chief Executive Officer exercised 2,500,000 stock options for a value of $60,000 that was paid through the cancelation of 375,000 common shares and 100,000 Series A Convertible Preferred shares. The Chief Executive Officer in May 2021 rescinded 8,120,152 stock options and in June 2021 rescinded 16,000,000 stock options. In September 2021, the Chief Executive Officer exercised 150,000 warrants in a cashless exercise into 91,304 shares of common stock. In March 2022, the Chief Executive Officer exercised 75,000 warrants in a cashless exercise into 22,266 shares of common stock, and was issued 76,250 shares of common stock valued at $4,880 for services rendered.

 

NOTE 3: CONVERTIBLE NOTES PAYABLE

 

As of December 31, 2022 and 2021, there remains no outstanding balances in the convertible notes payable. All prior convertible notes had been either repaid or converted in 2021.

 

F-14
 

 

NOTE 4: STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of December 31, 2022 and 2021, the Company has 362,541,528 and 343,530,678 shares issued and outstanding, respectively.

 

Preferred Stock

 

As of December 31, 2022 and 2021, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others.

 

On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares.

 

On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares.

 

Series A Convertible Preferred Stock (“Series A Convertible Preferred”)

 

In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred:

 

Liquidation Preference. The Series A Convertible Preferred has a liquidation preference of $5.00 per share.

 

Dividends. Shares of Series A Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series A Certificate of Designation, each share of Series A Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series A Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A Certificate of Designation), currently $4.00.

 

In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares.

 

Redemption. Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.

 

F-15
 

 

 

Voting Rights. Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five (5) votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series A Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series A Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

In June 2021, 100,000 shares of Series A Convertible Preferred were canceled as partial payment for the exercise of stock options by the Chief Executive Officer.

 

Series B Convertible Preferred Stock (“Series B Convertible Preferred”)

 

In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred:

 

Liquidation Preference. The Series B Convertible Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series B Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series B Certificate of Designation, each share of Series B Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series B Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series B Certificate of Designation), currently $0.08.

 

Redemption. Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two (2) votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.

 

F-16
 

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series B Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series B Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

In December 2021, 236,290 Series B Convertible Preferred shares were converted into 2,953,625 shares of common stock.

 

Series C Convertible Preferred Stock (“Series C Convertible Preferred”)

 

In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred:

 

Liquidation Preference. The Series C Convertible Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series C Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series C Certificate of Designation, each share of Series C Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series C Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C Certificate of Designation), currently $0.08.

 

The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“Authorized Share Approval”) (such date, the “Initial Convertibility Date”), each share of Series C Convertible Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C Certificate of Designation under the definition “Conversion Rights”.

 

Redemption. Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference.

 

F-17
 

 

Voting Rights. Holders of Series C Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of thirty-two (32) votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Convertible Preferred. However, the Series C Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series C Convertible Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series C Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series C Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Common and Preferred Stock Issuances - 2022

 

In March 2022, the Company issued 299,577 shares of common stock in the cashless exercise of 825,000 warrants, and issued 76,250 shares of common stock to its CEO for services rendered valued at $4,880. In June 2022, there was a fractional adjustment recorded for 90 shares.

 

On July 7, 2022, the Company sold 15,000,000 shares under the Regulation A+ at $0.08 for $1,200,000, and 20,000,000 warrants (15,000,000 at $0.08 expiring June 2025 and 5,000,000 at $0.01 expiring December 2022) for $20,000.

 

In September 2022, the Company issued 984,840 shares valued at $49,242 in settlement of accounts payable.

 

In December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.

 

Common and Preferred Stock Issuances - 2021

 

In January 2021, the Company issued 384,445 shares of common stock in a settlement of accounts payable valued at $50,000. In May 2021, the Company issued 519,480 shares of common stock in a settlement of accounts payable valued at $40,000.

 

In January 2021, the Company issued 1,259,250 shares of common stock in conversion of a note payable and accrued interest totaling $50,370. The conversion resulted in a loss on conversion of $176,295 that is reflected in the Condensed Statement of Operations for the nine months ended September 30, 2021.

 

In March 2021, the Company issued 22,500,000 shares of common stock along with 11,237,500 warrants under the Regulation A+ for cash proceeds of $1,800,000 for the common stock and the warrants were purchased for $11,238.

 

F-18
 

 

Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 shares of common stock in the cashless exercise of 5,430,000 warrants.

 

On June 28, 2021, the Company issued 2,500,000 shares of common stock for the exercise of 2,500,000 stock options to the Chief Executive Officer. In this transaction, the Company canceled 375,000 shares of common stock as partial payment for the exercise of the stock options.

 

In June 2021, the Company issued 12,000,000 shares of common stock for vested RSUs with a fair value of $1,080,000.

 

From July 9 through September 24, 2021, the Company issued 838,195 shares of common stock in the cashless exercise of 1,800,000 warrants.

 

In October 2021, the Company issued 2,005,693 shares of common stock in the cashless exercise of 3,500,000 warrants.

 

In November 2021, the Company issued 77,768 shares of common stock for services valued at $3,756.

 

In December 2021, the Company issued 401,373 shares of common stock in conversion of accounts payable to a related party in the amount of $32,110; issued 2,316,830 shares of common stock in conversion of related party note payables and accrued interest valued at $185,346; and issued 2,953,625 shares of common stock in conversion of 236,290 Series B Convertible Preferred stock.

 

NOTE 5: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

The following schedule summarizes the changes in the Company’s stock options:

 

       Weighted       Weighted 
   Options Outstanding   Average       Average 
   Number   Exercise   Remaining   Aggregate   Exercise 
   Of   Price   Contractual   Intrinsic   Price 
   Shares   Per Share   Life   Value   Per Share 
Balance at December 31, 2020   28,885,461   $ 0.024-0.04    5.57 years   $1,661,429   $0.05 
                          
Options granted   -   $-    -        $- 
Options exercised   (2,500,000)  $-    -        $- 
Options expired   (24,132,652)  $-    -        $- 
                          
Balance at December 31, 2021   2,252,809   $0.024-0.04    7.70 years   $83,992   $0.04 
                          
Options granted   -   $-    -        $- 
Options exercised   -   $-    -        $- 
Options expired/canceled   -   $-    -        $- 
                          
Balance at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 
                          
Exercisable at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 

 

During the year ended December 31, 2021, the Company’s CEO exercised 2,500,000 stock options, and rescinded 24,120,152, stock options. In addition, 12,500 options expired.

 

During the years ended December 31, 2022 and 2021, the Company recognized no stock based compensation related to the vesting of its stock options.

 

F-19
 

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

 

 

   Warrants Outstanding   Weighted
Average		       Weighted
Average		 
   Number Of
Shares		   Exercise
Price Per
Share		   Remaining Contractual
Life		   Aggregate
Intrinsic
Value		   Exercise
Price Per
Share		 
Balance at December 31, 2020   32,064,375   $0.04-80.00    1.65 years   $1,614,567   $0.06 
                          
Warrants granted   11,237,500   $0.10    -        $- 
Warrants exercised   (10,730,000)  $-    -        $ 
Warrants expired/cancelled   (709,375)  $-    -        $ 
                          
Balance at December 31, 2021   31,862,500   $0.04-0.10    1.02 years   $538,875   $0.07 
                          
Warrants granted   20,000,000   $0.01 – 0.08    2.50        $0.0725 
Warrants exercised   (4,158,333)  $-    -        $ 
Warrants expired/cancelled   (20,966,667)  $-    -        $ 
                          
Balance at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 
                          
Exercisable at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 

 

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

 

   Year Ended   Year Ended 
  

December 31,

2022

  

December 31,

2021

 
Expected term   .5 – 3 years    2 - 5 years 
Expected volatility   66%   109 - 147%
Expected dividend yield   -    - 
Risk-free interest rate   3%   0.20 - 0.58%

 

Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 shares of common stock in the cashless exercise of 5,430,000 warrants.

 

In March 2021 the Company sold 11,237,500 warrants for $11,238. These warrants have a two-year term and have an exercise price of $0.10 per share.

 

From July 9 through September 24, 2021, the Company issued 838,195 shares of common stock in the cashless exercise of 1,800,000 warrants.

 

In October 2021, the Company issued 2,005,693 shares of common stock in the cashless exercise of 3,500,000 warrants.

 

In March 2022 the Company issued 299,577 shares of common stock in the cashless exercise of 825,000 warrants. In June 2022, 1,000,000 warrants expired.

 

On July 7, 2022, the Company sold 15,000,000 shares under the Regulation A+ at $0.08 for $1,200,000, and 20,000,000 warrants (15,000,000 at $0.08 expiring June 2025 and 5,000,000 at $0.01 expiring December 2022) for $20,000.

 

In December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.

 

F-20
 

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

 

   Number   Weighted
Average		 
   Of   Grant Date 
   Shares   Fair Value 
         
Balance at December 31, 2020 and 2019   262,500   $0.59 
           
RSU’s granted   42,700,000   $0.08 
RSU’s vested   (17,700,000)  $- 
RSU’s forfeited   -   $- 
           
Balance at December 31, 2021   25,262,500   $0.08 
RSUs granted   600,000   $0.066 
RSUs vested   (15,600,000)  $- 
Balance at December 31, 2022   10,262,500   $0.08 

 

During the years ended December 31, 2022 and 2021, the Company recognized $1,389,700 and $1,614,000 worth of expense related to the vesting of its RSU’s. As of December 31, 2022, the Company had $1,055,400 worth of expense yet to be recognized for RSU’s not yet vested.

 

On May 3, 2021, the Company has granted 12,000,000 RSUs to a consultant that vest on the grant date, and 700,000 RSUs to consultants that vest on the grant date. The Company has issued 12,000,000 common shares to the one consultant in June 2021.

 

On May 3, 2021, as part of an Employment Agreement with the CEO, the Company granted 30,000,000 RSUs to the CEO. Of the 30,000,000 RSUs, 15,000,000 of them vest as follows: 5,000,000 on the grant date, 5,000,000 on the first anniversary and 5,000,000 on the second anniversary. The remaining 15,000,000 RSUs vest as performance-based grants, with the Board of Directors determining the criteria of each 5,000,000 RUSs at the nine-month anniversary, eighteen-month anniversary and twenty-seven month anniversary intervals. The Board of Directors has 90 days from May 3, 2021 to determine the performance criteria.

 

On February 3, 2022, 5,000,000 of the RSUs valued at $450,000 to the CEO vested.

 

On May 3, 2022, 5,000,000 of the RSUs valued at $450,000 to the CEO vested.

 

On June 1, 2022, 100,000 RSUs were granted to a consultant valued at $8,200, and on November 1, 2022, 500,000 RSUs were granted to a consultant valued at $31,500, each that were vested immediately.

 

NOTE 6: COMMITMENT

 

On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023.

 

Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $225,000. In addition, there is a discretionary bonus to be earned in the amount of $7,500 per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company.

 

NOTE 7: INCOME TAXES

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Net deferred tax assets consist of the following components as of December 31, 2022 and 2021:

 

           
   December 31, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carryover  $6,500,000   $6,280,000 
Capital Loss Carryover   3,400    3,400 
Valuation allowance   (6,503,400)   (6,283,400)
Net deferred tax asset  $-   $- 

 

The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2022 and 2021 due to the following:

 

           
   December 31, 2022   December 31, 2021 
Book income (loss)  $(518,700)  $(530,800)
Forgiveness of debt   -    (28,700)
Depreciation   (1,100)   (1,100)
Related party accrual   -    (6,400)
Stock for services   291,800    339,700 
Other non-deductible expenses   10,500    25,700 
Valuation allowance   217,500    201,600 
Income tax expense  $-   $- 

 

At December 31, 2022, the Company had net operating loss carryforwards of approximately $30,955,700.

 

Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized.

 

The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017.

 

F-21

 

 EX-23 2 ex23.htm

 

Exhibit 23

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to incorporation by reference in the Post-Qualification Amendment No 1. to the Offering Statement on Form 1-A (File No. 024-11627) of our audit report dated March 1, 2023, with respect to the balance sheets of Vivos, Inc. as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2022. Our report relating to those financial statements includes an emphasis of matter paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern.

We also consent to the reference to us under the heading “Experts” in such Offering Statement.

 

Spokane, Washington

March 1, 2023

 

 

 

 EX-31.1 3 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael K. Korenko, certify that:

 

1. I have reviewed this annual report on Form 10-K of VIVOS INC;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2023

 

/s/ Michael K. Korenko  
Michael K. Korenko  
Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 EX-31.2 4 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF INTERIM CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael Pollack, certify that:

 

1. I have reviewed this annual report on Form 10-K of VIVOS INC;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 1, 2023

 

/s/ Michael Pollack  
Michael Pollack  
Interim Chief Financial Officer  
(Interim Principal Financial Officer)  

 

 

 

 EX-32.1 5 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying annual report of VIVOS INC (the “Company”) on Form 10-K for the year ended December 31, 2022 (the “Report”), the undersigned, Michael K. Korenko, Chief Executive Officer of the Company, and Michael Pollack, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 1, 2023

 

/s/ Michael K. Korenko  
Name: Michael K. Korenko  
Title: Chief Executive Officer  
   
/s/ Michael Pollack  
Name: Michael Pollack  
Title: Interim Chief Financial Officer  

 

 

 

 GRAPHIC 6 form10-k_001.jpg begin 644 form10-k_001.jpg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ex23_002.jpg begin 644 ex23_002.jpg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rdgl-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - COMMITMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 rdgl-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 rdgl-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 rdgl-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series A Preferred Stock [Member] Additional Paid-In Capital - Series A Preferred [Member] Series B Preferred Stock [Member] Additional Paid-In Capital - Series B Preferred [Member] Series C Preferred Stock [Member] Additional Paid-In Capital - Series C Preferred [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Long-Lived Tangible Asset [Axis] Production Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Antidilutive Securities [Axis] Restricted Stock Units [Member] Common Stock Options [Member] Common Stock Warrants [Member] Related Party [Axis] Chief Executive Officer [Member] Title of Individual [Axis] Debt Instrument [Axis] Convertible Notes Payable [Member] Warrant [Member] Award Date [Axis] June 2025 [Member] December 2022 [Member] Extinguishment of Debt [Axis] Accounts Payable [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Derivative Instrument [Axis] Equity Option [Member] Consultants [Member] One Consultants [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Employment Agreement [Member] Scenario [Axis] On The Grant Date [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Board of Directors [Member] Consultant [Member] Dr. Michael K. Korenko [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash Accounts receivable Prepaid expenses Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Current Liabilities: Accounts payable and accrued expenses Total Current Liabilities Total Liabilities Commitments and contingencies STOCKHOLDERS’ EQUITY Preferred stock value Additional paid in capital - Convertible preferred stock Common stock, par value, $0.001, 950,000,000 shares authorized, 362,541,528 and 343,530,678 issued and outstanding, respectively Additional paid in capital - common stock Accumulated deficit Total Stockholders’ Equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues, net Cost of Goods Sold Gross profit OPERATING EXPENSES Professional fees, including stock-based compensation Payroll expenses Research and development General and administrative expenses Total Operating Expenses OPERATING LOSS NON-OPERATING INCOME (EXPENSE) Interest expense Forgiveness of debt Gain (loss) on debt extinguishment Total Non-Operating Income (Expenses) NET LOSS BEFORE PROVISION FOR INCOME TAXES Provision for income taxes NET LOSS Net loss per share - basic and diluted Weighted average common shares outstanding Balance Beginning balance, shares Cash Cash, shares Note conversions/settlements Note conversions/settlements, shares Accounts payable Accounts payable, shares Services Services, shares Stock option exercises Stock option exercises, shares RSUs RSUs, shares Warrant exercises Warrant exercises, shares Conversion of preferred shares to common shares Conversion of preferred stock into common stock,shares Warrants purchased for cash RSUs granted to consultants that have vested Net loss for the year Fractional adjustment Fractional adjustment, shares Balance - December 31, 2022 Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOW FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities Common stock, stock options and warrants for services RSUs issued for services (Gain) loss on conversion of debt Forgiveness of debt Changes in assets and liabilities Accounts receivable Prepaid expenses and other assets Accounts payable and accrued expenses Payroll liabilities Accrued interest Total adjustments Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Payments of convertible debt Payments of related party notes Proceeds from common stock and warrants Net cash provided by financing activities NET INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD CASH PAID DURING THE PERIOD FOR: Interest expense Income taxes SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of preferred stock for common stock Conversion of notes payable and accrued interest for common and common stock Conversion of notes payable and accrued interest into common stock Common stock issued in cashless exercise of warrants RSUs vested into common stock Accounts payable converted into shares of common stock Stock options exercised for recission of common and preferred stock Common stock issued in settlement of accounts payable - related parties RSUs vested into common stock Accounting Policies [Abstract] BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ EQUITY Common Stock Options Warrants And Restricted Stock Units COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Commitments and Contingencies Disclosure [Abstract] COMMITMENT Income Tax Disclosure [Abstract] INCOME TAXES Business Overview IsoPet Solutions Intellectual Property Going Concern Use of Estimates Financial Statement Reclassification Cash Equivalents Fair Value of Financial Instruments Fixed Assets License Fees Patents and Intellectual Property Revenue Recognition Loss Per Share Research and Development Costs Advertising and Marketing Costs Contingencies Income Taxes Stock-Based Compensation Recent Accounting Pronouncements SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE SCHEDULE OF DILUTIVE EARNINGS PER SHARE SCHEDULE OF CHANGES IN STOCK OPTION SCHEDULE OF CHANGES IN STOCK WARRANTS SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS SCHEDULE OF NET DEFERRED TAX ASSETS SCHEDULE OF FEDERAL INCOME TAX RATE Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful life of asset Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potential dilutive securities Description of risk exposure Current operation activities Stock issued during period shares new issues Share price Number of shares issued, value Warrant sold during period Warrants outstanding Shares issued remaining value Proceeds from stock offering Offering term Cash on hand Production costs Other fixed assets cost Economic life of the patent Research and development costs Significant change in unrecognized tax benefits Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Notes payable related party, outstanding balance Related party payable conversion Conversion of common stock, shares Accounts payable, related parties, current Stock options exercised shares Stock options exercised value Cancelation shares Rescinded shares Warrants exercised shares Conversion of stock Stock issued for services, shares Stock issued for services, value Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Outstanding balances Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock shares authorized Preferred stock, liquidation preference per share Conversion price per share Gross proceeds from preferred stock Voting percentage Redemption percentage Cancelation of shares Conversion of convertible securities Shares, new issues Number of warrant exeercised Shares issued for services, shares Shares issued for services Functional adjustment, shares Value, new issues Number of warrants issued Converted shares issued Debt instrument, increase, accrued interest Gain (loss) on extinguishment of debt Proceeds from issuance of common stock Warrant purchase Number of share exercised Number of shares vested Fair value of vested shares Number of Options Outstanding Beginning Balance Exercise Price Per Share Outstanding Beginning Balance Weighted Average Remaining Contractual Life (in years) Outstanding, Ending Aggregate Intrinsic Value Outstanding Beginning Weighted Average Exercise Price Per Share Outstanding Beginning Number of Options granted Exercise Price Per Share granted Weighted Average Exercise Price Per Share Options granted Number of Options exercised Exercise Price Per Share exercised Weighted Average Exercise Price Per Share Options exercised Number of Options expired/cancelled Exercise Price Per Share expired/cancelled Weighted Average Exercise Price Per Share Options expired/cancelled Number of Options Outstanding Ending Balance Weighted Average Exercise Price Per Share Outstanding Ending Aggregate Intrinsic Value Outstanding Ending Weighted Average Exercise Price Per Share Outstanding Ending Number of Options Exercisable Exercise Price Per Share Exercisable Weighted Average Remaining Contractual Life (in years) Exercisable Aggregate Intrinsic Value Exercisable Weighted Average Exercise Price Per Share Exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Shares, Warrants Outstanding Beginning Exercise Price Per Share Warrants Outstanding Beginning Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning Aggregate Intrinsic Value Outstanding Beginning Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Number of Shares, Warrants granted Exercise Price Per Share Warrants granted Weighted Average Exercise Price Per Share Exercise Price Warrants granted Number of Shares, Warrants exercised Exercise Price Per Share Warrants exercised Number of Shares, Warrants expired/cancelled Exercise Price Per Share Warrants expired/cancelled [custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted] Number of Shares, Warrants Outstanding Ending Exercise Price Per Share Warrants Outstanding Ending Weighted Average Remaining Contractual Life Warrants Outstanding Ending Aggregate Intrinsic Value Outstanding Ending Weighted Average Exercise Price Per Share Exercise Price Warrants Ending Number of Shares, Warrants Exercisable Ending Exercise Price Per Share Exercisable Weighted Average Remaining Contractual Life Warrants Exercisable Aggregate Intrinsic Value Exercisable Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Expected term Expected volatility Expected dividend yield Risk-free interest rate Number of Shares, RSU's Beginning balance Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning Number of Shares, RSU's granted Weighted Average Grant Date Fair Value, RSU's granted Number of Shares, RSU's vested Weighted Average Grant Date Fair Value, RSU's vested Number of Shares, RSU's forfeited Weighted Average Grant Date Fair Value, RSU's forfeited Number of Shares, RSU's Ending balance Weighted Average Grant Date Fair Value, RSU's Ending balance Number of stock option rescinded Number of options expired Stock based compensation Number of warrant exercised Warrants Proceeds from issuance of warrant Warrants and rights outstanding term Warrants exercise price Warrants expired Warrants and rights outstanding Restricted stock expense vesting Restricted stock expenses yet to be recognized Number of restricted shares unit granted Restricted stock vested, shares Restricted stock vested, value Number of restricted shares unit granted, value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreement term description Compensation amount Discretionary bonus Deferred tax assets: Net operating loss carryover Capital Loss Carryover Valuation allowance Net deferred tax asset Book income (loss) Forgiveness of debt Depreciation Related party accrual Stock for services Other non-deductible expenses Valuation allowance Income tax expense Net operating loss carryforwards Unrecognized tax positions accrued interest or penalties Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Forgiveness of debt Additional Paid-In Capital - Series A Preferred [Member] Additional Paid-In Capital - Series B Preferred [Member] Additional Paid-In Capital - Series C Preferred [Member] Stock issued during period value warrant exercises. Stock issued during period value fractional adjustment Stock issued during period shares warrant exercises. Stock issued during period shares fractional adjustment Restricted stock units issued for services. Repayments of related party notes. Conversion of notes payable related parties and accrued interest into common stock. Rsus vested into common stock. Recission of common and preferred stock. Accounts payable converted into shares of common stock. Conversion of notes payable and accrued interest for common and common stock. Common stock issued in settlement of accounts payable related parties. Restricted Stock Units Vested into Common Stock. Business Overview [Policy Text Block] Intellectual Property [Policy Text Block] Going Concern [Policy Text Block] Shares issued remaining value. Offering term. Schedule of Depreciation Estimated Useful Life [TableText Block] Production Equipment [Member] License Fees [Policy Text Block] Stock Options Rescinded. Functional adjustment shares. June 2025 [Member] December 2022 [Member] Warrant Purchase. Common Stock Options, Warrants and Restricted Stock Units [Text Block] Stock Option Plans Exercise Price. Weighted Average Exercise Price Per Share Options granted. Weighted Average Exercise Price Per Share Options Exercised. Weighted average exercise price per share option expired. Exercisable Weighted Average Exercise Price Per Shares. The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares. Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan. Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value. Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value. Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Ending. Weighted Average Exercise Price Per Share Exercise Price Warrants Granted. Exercise Price Warrant Exercisable. Warrants expired. Restricted Stock Units [Member] Restricted Stock Expenses Yet To Be Recognized. Consultants [Member] One Consultants [Member] Employment Agreement [Member] On The Grant Date [Member] Board of Directors [Member] Consultant [Member] Number of restricted shares unit granted, value. Agreement term description. Dr. Michael K. Korenko [Member] Discretionary bonus. effective income tax rate reconciliation, nondeductible expense, amount, forgiveness of debt. Income Tax Reconciliation Related Party Accrual. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Repayments of Convertible Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations RestrictedStockUnitsVestedIntoCommonStock Stockholders' Equity Note Disclosure [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue ExercisePriceMinimum Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1 WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt EX-101.PRE 12 rdgl-20221231_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 01, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 0-53497    
Entity Registrant Name VIVOS INC    
Entity Central Index Key 0001449349    
Entity Tax Identification Number 80-0138937    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 719 Jadwin Avenue    
Entity Address, City or Town Richland    
Entity Address, State or Province WA    
Entity Address, Postal Zip Code 99352    
City Area Code (509)    
Local Phone Number 736-4000    
Title of 12(g) Security Common Stock, $0.001 Par Value    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 36,693,047
Entity Common Stock, Shares Outstanding   362,541,528  
Auditor Firm ID 5525    
Auditor Name Fruci & Associates II, PLLC    
Auditor Location Spokane, Washington    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 1,706,065 $ 1,606,123
Accounts receivable 11,000
Prepaid expenses 25,671 28,175
Total Current Assets 1,742,736 1,634,298
TOTAL ASSETS 1,742,736 1,634,298
Current Liabilities:    
Accounts payable and accrued expenses 81,692 166,915
Total Current Liabilities 81,692 166,915
Total Liabilities 81,692 166,915
Commitments and contingencies
STOCKHOLDERS’ EQUITY    
Common stock, par value, $0.001, 950,000,000 shares authorized, 362,541,528 and 343,530,678 issued and outstanding, respectively 362,541 343,531
Additional paid in capital - common stock 71,217,954 68,573,142
Accumulated deficit (79,556,028) (77,085,867)
Total Stockholders’ Equity 1,661,044 1,467,383
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 1,742,736 1,634,298
Series A Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 2,071 2,071
Additional paid in capital - Convertible preferred stock 8,842,458 8,842,458
Series B Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 200 200
Additional paid in capital - Convertible preferred stock 290,956 290,956
Series C Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY    
Preferred stock value 385 385
Additional paid in capital - Convertible preferred stock $ 500,507 $ 500,507
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 950,000,000 950,000,000
Common stock, shares issued 362,541,528 343,530,678
Common stock, shares outstanding 362,541,528 343,530,678
Series A Convertible Preferred Stock [Member]    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 2,071,007 2,071,007
Preferred stock, shares outstanding 2,071,007 2,071,007
Series B Convertible Preferred Stock [Member]    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 200,363 200,363
Preferred stock, shares outstanding 200,363 200,363
Series C Convertible Preferred Stock [Member]    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 385,302 385,302
Preferred stock, shares outstanding 385,302 385,302
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenues, net $ 36,499 $ 14,887
Cost of Goods Sold (28,779) (12,000)
Gross profit 7,720 2,887
OPERATING EXPENSES    
Professional fees, including stock-based compensation 1,755,316 1,838,323
Payroll expenses 275,240 267,477
Research and development 343,802 286,848
General and administrative expenses 151,111 112,037
Total Operating Expenses 2,525,469 2,504,685
OPERATING LOSS (2,517,749) (2,501,798)
NON-OPERATING INCOME (EXPENSE)    
Interest expense (25,375)
Forgiveness of debt 136,445
Gain (loss) on debt extinguishment 47,588 (137,038)
Total Non-Operating Income (Expenses) 47,588 (25,968)
NET LOSS BEFORE PROVISION FOR INCOME TAXES (2,470,161) (2,527,766)
Provision for income taxes
NET LOSS $ (2,470,161) $ (2,527,766)
Net loss per share - basic and diluted $ (0.01) $ (0.01)
Weighted average common shares outstanding 351,425,912 325,851,906
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Statement of Changes in Stockholders' Equity - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series A Preferred [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series B Preferred [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital - Series C Preferred [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 2,171 $ 8,857,358 $ 436 $ 385,235 $ 385 $ 500,507 $ 292,279 $ 64,551,764 $ (74,558,101) $ 32,034
Beginning balance, shares at Dec. 31, 2020 2,171,007   436,653   385,302   292,278,591      
Cash $ 22,500 1,777,500 1,800,000
Cash, shares             22,500,000      
Note conversions/settlements $ 3,576 408,435 412,011
Note conversions/settlements, shares             3,576,080      
Accounts payable $ 1,305 120,805 122,110
Accounts payable, shares             1,305,298      
Services $ 78 3,678 3,756
Services, shares             77,768      
Stock option exercises $ (100) (14,900) $ 2,125 12,875
Stock option exercises, shares (100,000)           2,125,000     2,500,000
RSUs $ 12,000 (12,000)
RSUs, shares             12,000,000      
Warrant exercises $ 6,714 (6,714)
Warrant exercises, shares             6,714,316      
Conversion of preferred shares to common shares $ (236) (94,279) $ 2,954 91,561
Conversion of preferred stock into common stock,shares     (236,290)       2,953,625      
Warrants purchased for cash 11,238 11,238
RSUs granted to consultants that have vested 1,614,000 1,614,000
Net loss for the year (2,527,766) (2,527,766)
Balance - December 31, 2022 at Dec. 31, 2021 $ 2,071 8,842,458 $ 200 290,956 $ 385 500,507 $ 343,531 68,573,142 (77,085,867) 1,467,383
Ending balance, shares at Dec. 31, 2021 2,071,007   200,363   385,302   343,530,678      
Cash $ 15,000 1,185,000 1,200,000
Cash, shares             15,000,000      
Accounts payable $ 984 48,258 49,242
Accounts payable, shares             984,840      
Services $ 76 4,804 $ 4,880
Services, shares             76,250      
Stock option exercises, shares                  
Warrant exercises $ 2,950 (2,950)
Warrant exercises, shares             2,949,850      
Warrants purchased for cash 20,000 20,000
RSUs granted to consultants that have vested 1,389,700 1,389,700
Net loss for the year (2,470,161) (2,470,161)
Fractional adjustment
Fractional adjustment, shares             (90)      
Balance - December 31, 2022 at Dec. 31, 2022 $ 2,071 $ 8,842,458 $ 200 $ 290,956 $ 385 $ 500,507 $ 362,541 $ 71,217,954 $ (79,556,028) $ 1,661,044
Ending balance, shares at Dec. 31, 2022 2,071,007   200,363   385,302   362,541,528      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOW FROM OPERATING ACTIVITIES    
Net loss $ (2,470,161) $ (2,527,766)
Adjustments to reconcile net loss to net cash used in operating activities    
Common stock, stock options and warrants for services 4,880 3,756
RSUs issued for services 1,389,700 1,614,000
(Gain) loss on conversion of debt (47,588) 137,038
Forgiveness of debt (136,445)
Changes in assets and liabilities    
Accounts receivable (11,000)
Prepaid expenses and other assets 2,504 5,660
Accounts payable and accrued expenses 11,607 31,480
Payroll liabilities (66,143)
Accrued interest (25,399)
Total adjustments 1,350,103 1,563,947
Net cash used in operating activities (1,120,058) (963,819)
CASH FLOWS FROM FINANCING ACTIVITIES    
Payments of convertible debt (45,000)
Payments of related party notes (100,000)
Proceeds from common stock and warrants 1,220,000 1,811,238
Net cash provided by financing activities 1,220,000 1,666,238
NET INCREASE IN CASH 99,942 702,419
CASH - BEGINNING OF PERIOD 1,606,123 903,704
CASH - END OF PERIOD 1,706,065 1,606,123
CASH PAID DURING THE PERIOD FOR:    
Interest expense 50,773
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Conversion of preferred stock for common stock 94,515
Conversion of notes payable and accrued interest for common and common stock 185,346
Conversion of notes payable and accrued interest into common stock 50,370
Common stock issued in cashless exercise of warrants 2,950 6,714
RSUs vested into common stock 12,000
Accounts payable converted into shares of common stock 49,242 90,000
Stock options exercised for recission of common and preferred stock 60,000
Common stock issued in settlement of accounts payable - related parties 32,110
RSUs vested into common stock $ 12,000
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.

 

Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP.

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“Y-90”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 

Intellectual Property

 

Our original license with Battelle National Laboratory is reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.

 

Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.

 

We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 

The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.

 

The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 shares at a price of $0.10 for a maximum of $5,000,000. The Company amended this and was able to raise $1,200,000 in July 2022 at $0.08 per share (15,000,000 shares) and sold 20,000,000 warrants for $20,000. An amended Regulation A+ was filed in October 2022 to raise the remaining $3,800,000 of the $5,000,000.

 

The Company’s Regulation A+’s raised approximately $5,200,000 from the sale of shares and is using the proceeds generated as follows:

 

For the animal therapy market:

 

  ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.
  ● Conduct additional clinical studies to generate more data for the veterinary community
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated.
  ● Assist new regional clinics with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.
  ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $2.5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.

 

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.

 

As of December 31, 2022, the Company has $1,706,065 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.

 

There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 

 

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2022 and 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 

Fixed Assets

 

Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

 

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment:   3 to 7 years
Office equipment:   2 to 5 years
Furniture and fixtures:   2 to 5 years

 

Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

 

Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.

 

 

License Fees

 

License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed.

 

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the years ended December 31, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet® therapies.

 

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.

 

 

The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:

   December 31, 2022   December 31, 2021 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   25,862,500    25,262,500 
Common stock options   2,252,809    2,252,809 
Common stock warrants   26,737,500    31,862,500 
Total potential dilutive securities   64,762,379    69,287,379 

 

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $343,802 and $286,848 in research and development costs for the years ended December 31, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.

 

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2022 and 2021, the Company incurred nominal advertising and marketing costs.

 

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2022 and 2021.

 

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2022 and 2021. The Company did not have any deferred tax liability or asset on its balance sheets on December 31, 2022 and 2021.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

 

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

Recent Accounting Pronouncements

 

In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.4
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 2: RELATED PARTY TRANSACTIONS

 

Related Party Notes Payable

 

The $237,000 in related party notes payable that were outstanding during 2021 were either repaid or converted in December 2021. There are no outstanding related party notes payable as of December 31, 2022.

 

Related Party Payables

 

In December 2021, the Company converted the $32,110 in related party payables into 401,373 shares of common stock. There are no remaining related party payables as of December 31, 2022.

 

Preferred and Common Shares Issued to Officers and Directors

 

In June 2021, the Company’s Chief Executive Officer exercised 2,500,000 stock options for a value of $60,000 that was paid through the cancelation of 375,000 common shares and 100,000 Series A Convertible Preferred shares. The Chief Executive Officer in May 2021 rescinded 8,120,152 stock options and in June 2021 rescinded 16,000,000 stock options. In September 2021, the Chief Executive Officer exercised 150,000 warrants in a cashless exercise into 91,304 shares of common stock. In March 2022, the Chief Executive Officer exercised 75,000 warrants in a cashless exercise into 22,266 shares of common stock, and was issued 76,250 shares of common stock valued at $4,880 for services rendered.

 
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.4
CONVERTIBLE NOTES PAYABLE
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

NOTE 3: CONVERTIBLE NOTES PAYABLE

 

As of December 31, 2022 and 2021, there remains no outstanding balances in the convertible notes payable. All prior convertible notes had been either repaid or converted in 2021.

 

 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 4: STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of December 31, 2022 and 2021, the Company has 362,541,528 and 343,530,678 shares issued and outstanding, respectively.

 

Preferred Stock

 

As of December 31, 2022 and 2021, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others.

 

On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares.

 

On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares.

 

Series A Convertible Preferred Stock (“Series A Convertible Preferred”)

 

In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred:

 

Liquidation Preference. The Series A Convertible Preferred has a liquidation preference of $5.00 per share.

 

Dividends. Shares of Series A Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series A Certificate of Designation, each share of Series A Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series A Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A Certificate of Designation), currently $4.00.

 

In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares.

 

Redemption. Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.

 

 

 

Voting Rights. Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five (5) votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series A Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series A Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

In June 2021, 100,000 shares of Series A Convertible Preferred were canceled as partial payment for the exercise of stock options by the Chief Executive Officer.

 

Series B Convertible Preferred Stock (“Series B Convertible Preferred”)

 

In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred:

 

Liquidation Preference. The Series B Convertible Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series B Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series B Certificate of Designation, each share of Series B Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series B Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series B Certificate of Designation), currently $0.08.

 

Redemption. Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.

 

Voting Rights. Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two (2) votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.

 

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series B Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series B Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

In December 2021, 236,290 Series B Convertible Preferred shares were converted into 2,953,625 shares of common stock.

 

Series C Convertible Preferred Stock (“Series C Convertible Preferred”)

 

In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred:

 

Liquidation Preference. The Series C Convertible Preferred has a liquidation preference of $1.00 per share.

 

Dividends. Shares of Series C Convertible Preferred do not have any separate dividend rights.

 

Conversion. Subject to certain limitations set forth in the Series C Certificate of Designation, each share of Series C Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “Series C Conversion Shares”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C Certificate of Designation), currently $0.08.

 

The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“Authorized Share Approval”) (such date, the “Initial Convertibility Date”), each share of Series C Convertible Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C Certificate of Designation under the definition “Conversion Rights”.

 

Redemption. Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference.

 

 

Voting Rights. Holders of Series C Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of thirty-two (32) votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Convertible Preferred. However, the Series C Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series C Convertible Preferred.

 

Liquidation. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of Series C Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Certain Price and Share Adjustments.

 

a) Stock Dividends and Stock Splits. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.

 

b) Merger or Reorganization. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series C Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.

 

Common and Preferred Stock Issuances - 2022

 

In March 2022, the Company issued 299,577 shares of common stock in the cashless exercise of 825,000 warrants, and issued 76,250 shares of common stock to its CEO for services rendered valued at $4,880. In June 2022, there was a fractional adjustment recorded for 90 shares.

 

On July 7, 2022, the Company sold 15,000,000 shares under the Regulation A+ at $0.08 for $1,200,000, and 20,000,000 warrants (15,000,000 at $0.08 expiring June 2025 and 5,000,000 at $0.01 expiring December 2022) for $20,000.

 

In September 2022, the Company issued 984,840 shares valued at $49,242 in settlement of accounts payable.

 

In December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.

 

Common and Preferred Stock Issuances - 2021

 

In January 2021, the Company issued 384,445 shares of common stock in a settlement of accounts payable valued at $50,000. In May 2021, the Company issued 519,480 shares of common stock in a settlement of accounts payable valued at $40,000.

 

In January 2021, the Company issued 1,259,250 shares of common stock in conversion of a note payable and accrued interest totaling $50,370. The conversion resulted in a loss on conversion of $176,295 that is reflected in the Condensed Statement of Operations for the nine months ended September 30, 2021.

 

In March 2021, the Company issued 22,500,000 shares of common stock along with 11,237,500 warrants under the Regulation A+ for cash proceeds of $1,800,000 for the common stock and the warrants were purchased for $11,238.

 

 

Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 shares of common stock in the cashless exercise of 5,430,000 warrants.

 

On June 28, 2021, the Company issued 2,500,000 shares of common stock for the exercise of 2,500,000 stock options to the Chief Executive Officer. In this transaction, the Company canceled 375,000 shares of common stock as partial payment for the exercise of the stock options.

 

In June 2021, the Company issued 12,000,000 shares of common stock for vested RSUs with a fair value of $1,080,000.

 

From July 9 through September 24, 2021, the Company issued 838,195 shares of common stock in the cashless exercise of 1,800,000 warrants.

 

In October 2021, the Company issued 2,005,693 shares of common stock in the cashless exercise of 3,500,000 warrants.

 

In November 2021, the Company issued 77,768 shares of common stock for services valued at $3,756.

 

In December 2021, the Company issued 401,373 shares of common stock in conversion of accounts payable to a related party in the amount of $32,110; issued 2,316,830 shares of common stock in conversion of related party note payables and accrued interest valued at $185,346; and issued 2,953,625 shares of common stock in conversion of 236,290 Series B Convertible Preferred stock.

 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.4
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS
 12 Months Ended
Dec. 31, 2022
Common Stock Options Warrants And Restricted Stock Units  
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

NOTE 5: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

The following schedule summarizes the changes in the Company’s stock options:

 

       Weighted       Weighted 
   Options Outstanding   Average       Average 
   Number   Exercise   Remaining   Aggregate   Exercise 
   Of   Price   Contractual   Intrinsic   Price 
   Shares   Per Share   Life   Value   Per Share 
Balance at December 31, 2020   28,885,461   $ 0.024-0.04    5.57 years   $1,661,429   $0.05 
                          
Options granted   -   $-    -        $- 
Options exercised   (2,500,000)  $-    -        $- 
Options expired   (24,132,652)  $-    -        $- 
                          
Balance at December 31, 2021   2,252,809   $0.024-0.04    7.70 years   $83,992   $0.04 
                          
Options granted   -   $-    -        $- 
Options exercised   -   $-    -        $- 
Options expired/canceled   -   $-    -        $- 
                          
Balance at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 
                          
Exercisable at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 

 

During the year ended December 31, 2021, the Company’s CEO exercised 2,500,000 stock options, and rescinded 24,120,152, stock options. In addition, 12,500 options expired.

 

During the years ended December 31, 2022 and 2021, the Company recognized no stock based compensation related to the vesting of its stock options.

 

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

 

 

   Warrants Outstanding   Weighted
Average		       Weighted
Average		 
   Number Of
Shares		   Exercise
Price Per
Share		   Remaining Contractual
Life		   Aggregate
Intrinsic
Value		   Exercise
Price Per
Share		 
Balance at December 31, 2020   32,064,375   $0.04-80.00    1.65 years   $1,614,567   $0.06 
                          
Warrants granted   11,237,500   $0.10    -        $- 
Warrants exercised   (10,730,000)  $-    -        $ 
Warrants expired/cancelled   (709,375)  $-    -        $ 
                          
Balance at December 31, 2021   31,862,500   $0.04-0.10    1.02 years   $538,875   $0.07 
                          
Warrants granted   20,000,000   $0.01 – 0.08    2.50        $0.0725 
Warrants exercised   (4,158,333)  $-    -        $ 
Warrants expired/cancelled   (20,966,667)  $-    -        $ 
                          
Balance at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 
                          
Exercisable at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 

 

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

 

   Year Ended   Year Ended 
  

December 31,

2022

  

December 31,

2021

 
Expected term   .5 – 3 years    2 - 5 years 
Expected volatility   66%   109 - 147%
Expected dividend yield   -    - 
Risk-free interest rate   3%   0.20 - 0.58%

 

Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 shares of common stock in the cashless exercise of 5,430,000 warrants.

 

In March 2021 the Company sold 11,237,500 warrants for $11,238. These warrants have a two-year term and have an exercise price of $0.10 per share.

 

From July 9 through September 24, 2021, the Company issued 838,195 shares of common stock in the cashless exercise of 1,800,000 warrants.

 

In October 2021, the Company issued 2,005,693 shares of common stock in the cashless exercise of 3,500,000 warrants.

 

In March 2022 the Company issued 299,577 shares of common stock in the cashless exercise of 825,000 warrants. In June 2022, 1,000,000 warrants expired.

 

On July 7, 2022, the Company sold 15,000,000 shares under the Regulation A+ at $0.08 for $1,200,000, and 20,000,000 warrants (15,000,000 at $0.08 expiring June 2025 and 5,000,000 at $0.01 expiring December 2022) for $20,000.

 

In December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.

 

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

 

   Number   Weighted
Average		 
   Of   Grant Date 
   Shares   Fair Value 
         
Balance at December 31, 2020 and 2019   262,500   $0.59 
           
RSU’s granted   42,700,000   $0.08 
RSU’s vested   (17,700,000)  $- 
RSU’s forfeited   -   $- 
           
Balance at December 31, 2021   25,262,500   $0.08 
RSUs granted   600,000   $0.066 
RSUs vested   (15,600,000)  $- 
Balance at December 31, 2022   10,262,500   $0.08 

 

During the years ended December 31, 2022 and 2021, the Company recognized $1,389,700 and $1,614,000 worth of expense related to the vesting of its RSU’s. As of December 31, 2022, the Company had $1,055,400 worth of expense yet to be recognized for RSU’s not yet vested.

 

On May 3, 2021, the Company has granted 12,000,000 RSUs to a consultant that vest on the grant date, and 700,000 RSUs to consultants that vest on the grant date. The Company has issued 12,000,000 common shares to the one consultant in June 2021.

 

On May 3, 2021, as part of an Employment Agreement with the CEO, the Company granted 30,000,000 RSUs to the CEO. Of the 30,000,000 RSUs, 15,000,000 of them vest as follows: 5,000,000 on the grant date, 5,000,000 on the first anniversary and 5,000,000 on the second anniversary. The remaining 15,000,000 RSUs vest as performance-based grants, with the Board of Directors determining the criteria of each 5,000,000 RUSs at the nine-month anniversary, eighteen-month anniversary and twenty-seven month anniversary intervals. The Board of Directors has 90 days from May 3, 2021 to determine the performance criteria.

 

On February 3, 2022, 5,000,000 of the RSUs valued at $450,000 to the CEO vested.

 

On May 3, 2022, 5,000,000 of the RSUs valued at $450,000 to the CEO vested.

 

On June 1, 2022, 100,000 RSUs were granted to a consultant valued at $8,200, and on November 1, 2022, 500,000 RSUs were granted to a consultant valued at $31,500, each that were vested immediately.

 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENT
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENT

NOTE 6: COMMITMENT

 

On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023.

 

Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $225,000. In addition, there is a discretionary bonus to be earned in the amount of $7,500 per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company.

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 7: INCOME TAXES

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Net deferred tax assets consist of the following components as of December 31, 2022 and 2021:

 

           
   December 31, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carryover  $6,500,000   $6,280,000 
Capital Loss Carryover   3,400    3,400 
Valuation allowance   (6,503,400)   (6,283,400)
Net deferred tax asset  $-   $- 

 

The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2022 and 2021 due to the following:

 

           
   December 31, 2022   December 31, 2021 
Book income (loss)  $(518,700)  $(530,800)
Forgiveness of debt   -    (28,700)
Depreciation   (1,100)   (1,100)
Related party accrual   -    (6,400)
Stock for services   291,800    339,700 
Other non-deductible expenses   10,500    25,700 
Valuation allowance   217,500    201,600 
Income tax expense  $-   $- 

 

At December 31, 2022, the Company had net operating loss carryforwards of approximately $30,955,700.

 

Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized.

 

The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Business Overview

Business Overview

 

The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.

 

Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“FDA”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet® for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet®” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. The only distinction between IsoPet® and RadioGel™ is the FDA’s recommendation that we use “IsoPet®” for veterinarian usage, and reserve “RadioGel™” for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet® for animal therapy, through the Company’s IsoPet® Solutions division.

 
IsoPet Solutions

IsoPet Solutions

 

The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.

 

The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“RECIST”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.

 

 

The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy.

 

The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program.

 

The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP.

 

Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet® during 2019.

 

Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“Y-90”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.

 
Intellectual Property

Intellectual Property

 

Our original license with Battelle National Laboratory is reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.

 

Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries.

 

The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™.

 

Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.

 

 

We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.

 

We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.

 

We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.

 
Going Concern

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.5 million annually to maintain current operating activities.

 

The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.

 

The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 shares at a price of $0.10 for a maximum of $5,000,000. The Company amended this and was able to raise $1,200,000 in July 2022 at $0.08 per share (15,000,000 shares) and sold 20,000,000 warrants for $20,000. An amended Regulation A+ was filed in October 2022 to raise the remaining $3,800,000 of the $5,000,000.

 

The Company’s Regulation A+’s raised approximately $5,200,000 from the sale of shares and is using the proceeds generated as follows:

 

For the animal therapy market:

 

  ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.
  ● Conduct additional clinical studies to generate more data for the veterinary community
  ● Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated.
  ● Assist new regional clinics with their license and certification training.

 

For the human market:

 

  ● Enhance the pedigree of the Quality Management System.
  ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.
  ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.

 

Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $2.5 million annually to maintain current operating activities. Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.

 

 

The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.

 

Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.

 

As of December 31, 2022, the Company has $1,706,065 cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.

 

There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

 
Financial Statement Reclassification

Financial Statement Reclassification

 

Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.

 

 
Cash Equivalents

Cash Equivalents

 

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2022 and 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ASC”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.

 
Fixed Assets

Fixed Assets

 

Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

 

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment:   3 to 7 years
Office equipment:   2 to 5 years
Furniture and fixtures:   2 to 5 years

 

Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

 

Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.

 

 
License Fees

License Fees

 

License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed.

 
Patents and Intellectual Property

Patents and Intellectual Property

 

While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.

 

The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

 

There have been no such capitalized costs in the years ended December 31, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.

 
Revenue Recognition

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.

 

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

 

The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.

 

All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet® therapies.

 
Loss Per Share

Loss Per Share

 

The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.

 

 

The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:

   December 31, 2022   December 31, 2021 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   25,862,500    25,262,500 
Common stock options   2,252,809    2,252,809 
Common stock warrants   26,737,500    31,862,500 
Total potential dilutive securities   64,762,379    69,287,379 

 
Research and Development Costs

Research and Development Costs

 

Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

 

The Company incurred $343,802 and $286,848 in research and development costs for the years ended December 31, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.

 
Advertising and Marketing Costs

Advertising and Marketing Costs

 

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2022 and 2021, the Company incurred nominal advertising and marketing costs.

 
Contingencies

Contingencies

 

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2022 and 2021.

 
Income Taxes

Income Taxes

 

To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

 

The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2022 and 2021. The Company did not have any deferred tax liability or asset on its balance sheets on December 31, 2022 and 2021.

 

Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.

 

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.

 

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment:   3 to 7 years
Office equipment:   2 to 5 years
Furniture and fixtures:   2 to 5 years
SCHEDULE OF DILUTIVE EARNINGS PER SHARE

The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:

   December 31, 2022   December 31, 2021 
Preferred stock   9,909,570    9,909,570 
Restricted stock units   25,862,500    25,262,500 
Common stock options   2,252,809    2,252,809 
Common stock warrants   26,737,500    31,862,500 
Total potential dilutive securities   64,762,379    69,287,379 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.4
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)
 12 Months Ended
Dec. 31, 2022
Common Stock Options Warrants And Restricted Stock Units  
SCHEDULE OF CHANGES IN STOCK OPTION

The following schedule summarizes the changes in the Company’s stock options:

 

       Weighted       Weighted 
   Options Outstanding   Average       Average 
   Number   Exercise   Remaining   Aggregate   Exercise 
   Of   Price   Contractual   Intrinsic   Price 
   Shares   Per Share   Life   Value   Per Share 
Balance at December 31, 2020   28,885,461   $ 0.024-0.04    5.57 years   $1,661,429   $0.05 
                          
Options granted   -   $-    -        $- 
Options exercised   (2,500,000)  $-    -        $- 
Options expired   (24,132,652)  $-    -        $- 
                          
Balance at December 31, 2021   2,252,809   $0.024-0.04    7.70 years   $83,992   $0.04 
                          
Options granted   -   $-    -        $- 
Options exercised   -   $-    -        $- 
Options expired/canceled   -   $-    -        $- 
                          
Balance at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 
                          
Exercisable at December 31, 2022   2,252,809   $0.024-0.04    6.70 years   $16,032   $0.04 
SCHEDULE OF CHANGES IN STOCK WARRANTS

The following schedule summarizes the changes in the Company’s stock warrants:

 

 

   Warrants Outstanding   Weighted
Average		       Weighted
Average		 
   Number Of
Shares		   Exercise
Price Per
Share		   Remaining Contractual
Life		   Aggregate
Intrinsic
Value		   Exercise
Price Per
Share		 
Balance at December 31, 2020   32,064,375   $0.04-80.00    1.65 years   $1,614,567   $0.06 
                          
Warrants granted   11,237,500   $0.10    -        $- 
Warrants exercised   (10,730,000)  $-    -        $ 
Warrants expired/cancelled   (709,375)  $-    -        $ 
                          
Balance at December 31, 2021   31,862,500   $0.04-0.10    1.02 years   $538,875   $0.07 
                          
Warrants granted   20,000,000   $0.01 – 0.08    2.50        $0.0725 
Warrants exercised   (4,158,333)  $-    -        $ 
Warrants expired/cancelled   (20,966,667)  $-    -        $ 
                          
Balance at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 
                          
Exercisable at December 31, 2022   26,737,500   $0.08-0.10    1.52 years   $-   $0.09 
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

 

   Year Ended   Year Ended 
  

December 31,

2022

  

December 31,

2021

 
Expected term   .5 – 3 years    2 - 5 years 
Expected volatility   66%   109 - 147%
Expected dividend yield   -    - 
Risk-free interest rate   3%   0.20 - 0.58%
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS

The following schedule summarizes the changes in the Company’s restricted stock units:

 

 

   Number   Weighted
Average		 
   Of   Grant Date 
   Shares   Fair Value 
         
Balance at December 31, 2020 and 2019   262,500   $0.59 
           
RSU’s granted   42,700,000   $0.08 
RSU’s vested   (17,700,000)  $- 
RSU’s forfeited   -   $- 
           
Balance at December 31, 2021   25,262,500   $0.08 
RSUs granted   600,000   $0.066 
RSUs vested   (15,600,000)  $- 
Balance at December 31, 2022   10,262,500   $0.08 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF NET DEFERRED TAX ASSETS

Net deferred tax assets consist of the following components as of December 31, 2022 and 2021:

 

           
   December 31, 2022   December 31, 2021 
Deferred tax assets:          
Net operating loss carryover  $6,500,000   $6,280,000 
Capital Loss Carryover   3,400    3,400 
Valuation allowance   (6,503,400)   (6,283,400)
Net deferred tax asset  $-   $- 
SCHEDULE OF FEDERAL INCOME TAX RATE

The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2022 and 2021 due to the following:

 

           
   December 31, 2022   December 31, 2021 
Book income (loss)  $(518,700)  $(530,800)
Forgiveness of debt   -    (28,700)
Depreciation   (1,100)   (1,100)
Related party accrual   -    (6,400)
Stock for services   291,800    339,700 
Other non-deductible expenses   10,500    25,700 
Valuation allowance   217,500    201,600 
Income tax expense  $-   $- 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details)
 12 Months Ended
Dec. 31, 2022
Minimum [Member] | Production Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 3 years
Minimum [Member] | Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 2 years
Minimum [Member] | Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 2 years
Maximum [Member] | Production Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 7 years
Maximum [Member] | Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 5 years
Maximum [Member] | Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life of asset 5 years
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 64,762,379 69,287,379
Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 9,909,570 9,909,570
Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 25,862,500 25,262,500
Common Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 2,252,809 2,252,809
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potential dilutive securities 26,737,500 31,862,500
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Oct. 31, 2022
Jul. 31, 2022
Sep. 15, 2021
Dec. 31, 2022
Dec. 31, 2021
Jul. 07, 2022
Property, Plant and Equipment [Line Items]            
Common stock, shares authorized       950,000,000 950,000,000  
Common stock, par value       $ 0.001 $ 0.001  
Preferred stock, shares authorized       20,000,000 20,000,000  
Preferred stock, par value       $ 0.001 $ 0.001  
Description of risk exposure       half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.    
Current operation activities       $ 2,500,000    
Stock issued during period shares new issues   15,000,000 50,000,000      
Share price   $ 0.08 $ 0.10     $ 0.08
Number of shares issued, value $ 5,000,000 $ 1,200,000 $ 5,000,000 $ 1,200,000 $ 1,800,000  
Warrant sold during period   20,000,000        
Warrants outstanding   $ 20,000       $ 20,000
Shares issued remaining value $ 3,800,000          
Offering term       Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.    
Cash on hand       $ 1,706,065 1,606,123  
Production costs       2,500    
Other fixed assets cost       $ 1,500    
Economic life of the patent       10 years    
Research and development costs       $ 343,802 $ 286,848  
Significant change in unrecognized tax benefits       The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months    
Maximum [Member]            
Property, Plant and Equipment [Line Items]            
Proceeds from stock offering       $ 5,200,000    
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.4
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 28, 2021
Mar. 31, 2022
Dec. 31, 2021
Nov. 30, 2021
Oct. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
May 31, 2021
Jan. 31, 2021
Sep. 24, 2021
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]                        
Notes payable related party, outstanding balance     $ 237,000               $ 0 $ 237,000
Accounts payable, related parties, current                     $ 0  
Stock options exercised shares                     2,500,000
Stock options exercised value                      
Stock issued for services, shares       77,768                
Stock issued for services, value       $ 3,756             $ 4,880 $ 3,756
Chief Executive Officer [Member]                        
Related Party Transaction [Line Items]                        
Stock options exercised shares                       2,500,000
Rescinded shares             16,000,000 8,120,152       24,120,152
Warrants exercised shares   75,000       150,000            
Series A Preferred Stock [Member]                        
Related Party Transaction [Line Items]                        
Cancelation shares             100,000          
Chief Executive Officer [Member]                        
Related Party Transaction [Line Items]                        
Stock options exercised shares             2,500,000          
Stock options exercised value             $ 60,000          
Common Stock [Member]                        
Related Party Transaction [Line Items]                        
Related party payable conversion                       $ 32,110
Conversion of common stock, shares     2,316,830           1,259,250     401,373
Stock options exercised shares 2,500,000       2,005,693         838,195   2,125,000
Stock options exercised value                       $ 2,125
Cancelation shares 375,000           375,000          
Stock issued for services, shares                     76,250 77,768
Stock issued for services, value                     $ 76 $ 78
Common Stock [Member] | Chief Executive Officer [Member]                        
Related Party Transaction [Line Items]                        
Stock options exercised shares 2,500,000                      
Conversion of stock   22,266       91,304            
Stock issued for services, shares   76,250                    
Stock issued for services, value   $ 4,880                    
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.4
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Convertible Notes Payable [Member]    
Short-Term Debt [Line Items]    
Outstanding balances $ 0 $ 0
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2022
Jul. 31, 2022
Jul. 07, 2022
Mar. 03, 2022
Feb. 03, 2022
Sep. 15, 2021
Jun. 28, 2021
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Nov. 30, 2021
Oct. 31, 2021
Jun. 30, 2021
May 31, 2021
Mar. 31, 2021
Jan. 31, 2021
Jan. 29, 2021
Mar. 31, 2019
Oct. 31, 2018
Jun. 30, 2015
Sep. 24, 2021
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Mar. 27, 2019
Oct. 08, 2018
Mar. 31, 2016
Class of Stock [Line Items]                                                          
Common stock, shares authorized               950,000,000       950,000,000                         950,000,000 950,000,000      
Common stock, par value               $ 0.001       $ 0.001                         $ 0.001 $ 0.001      
Common stock, shares issued               362,541,528       343,530,678                         362,541,528 343,530,678      
Common stock, shares outstanding               362,541,528       343,530,678                         362,541,528 343,530,678      
Preferred stock shares authorized               20,000,000       20,000,000                         20,000,000 20,000,000      
Preferred stock, par value               $ 0.001       $ 0.001                         $ 0.001 $ 0.001      
Shares, new issues   15,000,000       50,000,000                                              
Shares issued for services, shares                         77,768                                
Shares issued for services                         $ 3,756                       $ 4,880 $ 3,756      
Functional adjustment, shares                   90                                      
Share price   $ 0.08 $ 0.08     $ 0.10                                              
Value, new issues $ 5,000,000 $ 1,200,000       $ 5,000,000                                     1,200,000 1,800,000      
Number of warrants issued   20,000,000                                                      
Warrants outstanding   $ 20,000 $ 20,000                                                    
Debt instrument, increase, accrued interest                       $ 185,346                                  
Gain (loss) on extinguishment of debt                                               $ 176,295 $ (47,588) $ 137,038      
Proceeds from issuance of common stock                                 $ 1,800,000                        
Warrant purchase                                 $ 11,238                        
Number of share exercised                                                 2,500,000      
Fair value of vested shares                                                 $ 1,389,700 $ 1,614,000      
Restricted Stock Units (RSUs) [Member]                                                          
Class of Stock [Line Items]                                                          
Number of shares vested                             12,000,000                            
Fair value of vested shares                             $ 1,080,000                            
Accounts Payable [Member]                                                          
Class of Stock [Line Items]                                                          
Shares, new issues                 984,840     401,373       519,480   384,445                      
Value, new issues                 $ 49,242     $ 32,110       $ 40,000   $ 50,000                      
June 2025 [Member]                                                          
Class of Stock [Line Items]                                                          
Shares, new issues     15,000,000                                                    
Share price     $ 0.08                                                    
December 2022 [Member]                                                          
Class of Stock [Line Items]                                                          
Shares, new issues     5,000,000                                                    
Share price     $ 0.01                                                    
Common Stock [Member]                                                          
Class of Stock [Line Items]                                                          
Cancelation of shares             375,000               375,000                            
Conversion of convertible securities                       2,953,625                           2,953,625      
Shares, new issues     15,000,000               299,577     2,005,693     22,500,000   3,870,428       838,195   15,000,000 22,500,000      
Shares issued for services, shares                                                 76,250 77,768      
Shares issued for services                                                 $ 76 $ 78      
Share price     $ 0.08                                                    
Value, new issues     $ 1,200,000                                           15,000 $ 22,500      
Number of warrants issued     20,000,000                           11,237,500                        
Converted shares issued                       2,316,830           1,259,250               401,373      
Debt instrument, increase, accrued interest                                   $ 50,370                      
Number of share exercised             2,500,000             2,005,693                 838,195     2,125,000      
Fair value of vested shares                                                      
Warrant [Member]                                                          
Class of Stock [Line Items]                                                          
Shares, new issues               2,650,273                                          
Number of warrant exeercised               3,333,333     825,000     3,500,000         5,430,000       1,800,000            
Number of warrants issued     20,000,000                           11,237,500                        
Warrants outstanding     $ 20,000                                                    
Chief Executive Officer [Member]                                                          
Class of Stock [Line Items]                                                          
Number of share exercised                                                   2,500,000      
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]                                                          
Class of Stock [Line Items]                                                          
Fair value of vested shares       $ 450,000 $ 450,000                                                
Chief Executive Officer [Member] | Common Stock [Member]                                                          
Class of Stock [Line Items]                                                          
Shares issued for services, shares                     76,250                                    
Shares issued for services                     $ 4,880                                    
Number of share exercised             2,500,000                                            
Series B Convertible Preferred Stock [Member]                                                          
Class of Stock [Line Items]                                                          
Preferred stock shares authorized               5,000,000       5,000,000                 5,000,000.0       5,000,000 5,000,000   5,000,000  
Preferred stock, par value                                                       $ 0.001  
Preferred stock, liquidation preference per share                                         $ 1.00                
Conversion price per share                                         $ 0.08                
Voting percentage                                         Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.                
Redemption percentage                                         100.00%                
Conversion of convertible securities                       236,290                                  
Series C Convertible Preferred Stock [Member]                                                          
Class of Stock [Line Items]                                                          
Preferred stock shares authorized               5,000,000       5,000,000               5,000,000.0         5,000,000 5,000,000 5,000,000    
Preferred stock, par value                                                     $ 0.001    
Preferred stock, liquidation preference per share                                       $ 1.00                  
Conversion price per share                                       $ 0.08                  
Voting percentage                                       Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference                  
Redemption percentage                                       100.00%                  
Series A Convertible Preferred Stock [Member]                                                          
Class of Stock [Line Items]                                                          
Preferred stock shares authorized               5,000,000       5,000,000                   2,500,000     5,000,000 5,000,000      
Preferred stock, liquidation preference per share                                           $ 5.00              
Conversion price per share                                           $ 4.00              
Gross proceeds from preferred stock                                           $ 5,000,000.0              
Voting percentage                                           Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference              
Redemption percentage                                           100.00%              
Series A Convertible Preferred Stock [Member] | Chief Executive Officer [Member]                                                          
Class of Stock [Line Items]                                                          
Cancelation of shares                             100,000                            
Series A Convertible Preferred Stock [Member] | Minimum [Member]                                                          
Class of Stock [Line Items]                                                          
Preferred stock shares authorized                                                         2,500,000
Series A Convertible Preferred Stock [Member] | Maximum [Member]                                                          
Class of Stock [Line Items]                                                          
Preferred stock shares authorized                                                         5,000,000
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF CHANGES IN STOCK OPTION (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Number of Options Outstanding Beginning Balance 2,252,809 28,885,461  
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending 6 years 8 months 12 days 7 years 8 months 12 days 5 years 6 months 25 days
Aggregate Intrinsic Value Outstanding Beginning   $ 83,992 $ 1,661,429
Weighted Average Exercise Price Per Share Outstanding Beginning $ 0.04 $ 0.05  
Number of Options granted  
Exercise Price Per Share granted  
Weighted Average Exercise Price Per Share Options granted  
Number of Options exercised (2,500,000)  
Exercise Price Per Share exercised  
Weighted Average Exercise Price Per Share Options exercised  
Number of Options expired/cancelled (24,132,652)  
Exercise Price Per Share expired/cancelled  
Weighted Average Exercise Price Per Share Options expired/cancelled  
Number of Options Outstanding Ending Balance 2,252,809 2,252,809 28,885,461
Aggregate Intrinsic Value Outstanding Ending $ 16,032   $ 83,992
Weighted Average Exercise Price Per Share Outstanding Ending $ 0.04 $ 0.04 $ 0.05
Number of Options Exercisable 2,252,809    
Weighted Average Remaining Contractual Life (in years) Exercisable 6 years 8 months 12 days    
Aggregate Intrinsic Value Exercisable $ 16,032    
Weighted Average Exercise Price Per Share Exercisable $ 0.04    
Minimum [Member]      
Exercise Price Per Share Outstanding Beginning Balance 0.024 0.024  
Weighted Average Exercise Price Per Share Outstanding Ending 0.024 0.024 0.024
Exercise Price Per Share Exercisable 0.024    
Maximum [Member]      
Exercise Price Per Share Outstanding Beginning Balance 0.04 0.04  
Weighted Average Exercise Price Per Share Outstanding Ending 0.04 $ 0.04 $ 0.04
Exercise Price Per Share Exercisable $ 0.04    
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) - Warrant [Member] - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares, Warrants Outstanding Beginning 31,862,500 32,064,375
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning 1 year 7 days 1 year 7 months 24 days
Aggregate Intrinsic Value Outstanding Beginning $ 538,875 $ 1,614,567
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning $ 0.07 $ 0.06
Number of Shares, Warrants granted 20,000,000 11,237,500
Exercise Price Per Share Warrants granted   $ 0.10
Weighted Average Exercise Price Per Share Exercise Price Warrants granted $ 0.0725
Number of Shares, Warrants exercised (4,158,333) (10,730,000)
Exercise Price Per Share Warrants exercised
Number of Shares, Warrants expired/cancelled (20,966,667) (709,375)
Exercise Price Per Share Warrants expired/cancelled
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted] 2 years 6 months  
Number of Shares, Warrants Outstanding Ending 26,737,500 31,862,500
Weighted Average Remaining Contractual Life Warrants Outstanding Ending 1 year 6 months 7 days  
Aggregate Intrinsic Value Outstanding Ending $ 538,875
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending $ 0.09 $ 0.07
Number of Shares, Warrants Exercisable Ending 26,737,500  
Weighted Average Remaining Contractual Life Warrants Exercisable 1 year 6 months 7 days  
Aggregate Intrinsic Value Exercisable  
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable $ 0.09  
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise Price Per Share Warrants Outstanding Beginning 0.04 0.04
Exercise Price Per Share Warrants granted 0.01  
Exercise Price Per Share Warrants Outstanding Ending 0.08 0.04
Exercise Price Per Share Exercisable 0.08  
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise Price Per Share Warrants Outstanding Beginning 0.10 80.00
Exercise Price Per Share Warrants granted 0.08  
Exercise Price Per Share Warrants Outstanding Ending 0.10 $ 0.10
Exercise Price Per Share Exercisable $ 0.10  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Expected volatility 66.00%  
Expected dividend yield
Risk-free interest rate 3.00%  
Minimum [Member]    
Expected term 6 months 2 years
Expected volatility   109.00%
Risk-free interest rate   0.20%
Maximum [Member]    
Expected term 3 years 5 years
Expected volatility   147.00%
Risk-free interest rate   0.58%
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) - Restricted Stock Units [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares, RSU's Beginning balance 25,262,500 262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning $ 0.08 $ 0.59
Number of Shares, RSU's granted 600,000 42,700,000
Weighted Average Grant Date Fair Value, RSU's granted $ 0.066 $ 0.08
Number of Shares, RSU's vested (15,600,000) (17,700,000)
Weighted Average Grant Date Fair Value, RSU's vested
Number of Shares, RSU's forfeited  
Weighted Average Grant Date Fair Value, RSU's forfeited  
Number of Shares, RSU's Ending balance 10,262,500 25,262,500
Weighted Average Grant Date Fair Value, RSU's Ending balance $ 0.08 $ 0.08
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.4
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 01, 2022
Oct. 31, 2022
Jul. 31, 2022
Jul. 07, 2022
Jun. 01, 2022
Mar. 03, 2022
Feb. 03, 2022
Sep. 15, 2021
Jun. 28, 2021
May 03, 2021
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Oct. 31, 2021
Jun. 30, 2021
May 31, 2021
Mar. 31, 2021
Jan. 29, 2021
Sep. 24, 2021
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Stock option exercises, shares                                       2,500,000
Number of options expired                                       24,132,652
Cash, shares     15,000,000         50,000,000                          
Warrants     20,000,000                                    
Share price     $ 0.08 $ 0.08       $ 0.10                          
Number of shares issued, value   $ 5,000,000 $ 1,200,000         $ 5,000,000                       $ 1,200,000 $ 1,800,000
Warrants and rights outstanding     $ 20,000 $ 20,000                                  
Restricted stock expense vesting                                       1,389,700 1,614,000
Restricted stock expenses yet to be recognized                                       1,055,400  
Restricted stock vested, value                                       $ 1,389,700 $ 1,614,000
Restricted Stock Units (RSUs) [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   12,000,000                      
Restricted stock vested, value                             $ 1,080,000            
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   30,000,000                      
Restricted stock vested, shares                   15,000,000                      
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   5,000,000                      
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   5,000,000                      
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member] | On The Grant Date [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Restricted stock vested, shares                   5,000,000                      
June 2025 [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Cash, shares       15,000,000                                  
Share price       $ 0.08                                  
December 2022 [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Cash, shares       5,000,000                                  
Share price       $ 0.01                                  
Common Stock [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Stock option exercises, shares                 2,500,000         2,005,693         838,195   2,125,000
Cash, shares       15,000,000                 299,577 2,005,693     22,500,000 3,870,428 838,195 15,000,000 22,500,000
Warrants       20,000,000                         11,237,500        
Share price       $ 0.08                                  
Number of shares issued, value       $ 1,200,000                               $ 15,000 $ 22,500
Restricted stock vested, value                                      
Warrant [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Cash, shares                     2,650,273                    
Number of warrant exercised                     3,333,333   825,000 3,500,000       5,430,000 1,800,000    
Warrants       20,000,000                         11,237,500        
Proceeds from issuance of warrant                                 $ 11,238        
Warrants and rights outstanding term                                 2 years        
Warrants exercise price                                 $ 0.10        
Warrants expired                       1,000,000                  
Warrants and rights outstanding       $ 20,000                                  
Equity Option [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Stock based compensation                                       $ 0 $ 0
Chief Executive Officer [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Stock option exercises, shares                                         2,500,000
Number of stock option rescinded                             16,000,000 8,120,152         24,120,152
Number of options expired                                         12,500
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Restricted stock vested, shares           5,000,000 5,000,000                            
Restricted stock vested, value           $ 450,000 $ 450,000                            
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   30,000,000                      
Chief Executive Officer [Member] | Common Stock [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Stock option exercises, shares                 2,500,000                        
Consultants [Member] | Restricted Stock Units (RSUs) [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   700,000                      
One Consultants [Member] | Restricted Stock Units (RSUs) [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Cash, shares                             12,000,000            
Board of Directors [Member] | Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted                   5,000,000                      
Consultant [Member] | Restricted Stock Units (RSUs) [Member]                                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                          
Number of restricted shares unit granted 500,000       100,000                                
Number of restricted shares unit granted, value $ 31,500       $ 8,200                                
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENT (Details Narrative) - Employment Agreement [Member] - Dr. Michael K. Korenko [Member]
Jun. 04, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Agreement term description The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023
Compensation amount $ 225,000
Discretionary bonus $ 7,500
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF NET DEFERRED TAX ASSETS (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets:    
Net operating loss carryover $ 6,500,000 $ 6,280,000
Capital Loss Carryover 3,400 3,400
Valuation allowance (6,503,400) (6,283,400)
Net deferred tax asset
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF FEDERAL INCOME TAX RATE (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Book income (loss) $ (518,700) $ (530,800)
Forgiveness of debt (28,700)
Depreciation (1,100) (1,100)
Related party accrual (6,400)
Stock for services 291,800 339,700
Other non-deductible expenses 10,500 25,700
Valuation allowance 217,500 201,600
Income tax expense
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Details Narrative)
Dec. 31, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Net operating loss carryforwards $ 30,955,700
Unrecognized tax positions accrued interest or penalties $ 0
XML 45 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001449349 2022-01-01 2022-12-31 0001449349 2022-06-30 0001449349 2023-03-01 0001449349 2022-12-31 0001449349 2021-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2021-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2021-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2022-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2021-12-31 0001449349 2021-01-01 2021-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredMember us-gaap:PreferredStockMember 2020-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredMember us-gaap:PreferredStockMember 2020-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredMember us-gaap:PreferredStockMember 2020-12-31 0001449349 us-gaap:CommonStockMember 2020-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001449349 us-gaap:RetainedEarningsMember 2020-12-31 0001449349 2020-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredMember us-gaap:PreferredStockMember 2021-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredMember us-gaap:PreferredStockMember 2021-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredMember us-gaap:PreferredStockMember 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001449349 us-gaap:RetainedEarningsMember 2021-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001449349 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001449349 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesAPreferredMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesBPreferredMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001449349 RDGL:AdditionalPaidInCapitalSeriesCPreferredMember us-gaap:PreferredStockMember 2022-12-31 0001449349 us-gaap:CommonStockMember 2022-12-31 0001449349 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001449349 us-gaap:RetainedEarningsMember 2022-12-31 0001449349 2021-09-14 2021-09-15 0001449349 2021-09-15 0001449349 2022-07-27 2022-07-31 0001449349 2022-07-31 0001449349 2022-10-30 2022-10-31 0001449349 srt:MaximumMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember RDGL:ProductionEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember RDGL:ProductionEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001449349 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-01-01 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001449349 RDGL:CommonStockOptionsMember 2022-01-01 2022-12-31 0001449349 RDGL:CommonStockOptionsMember 2021-01-01 2021-12-31 0001449349 RDGL:CommonStockWarrantsMember 2022-01-01 2022-12-31 0001449349 RDGL:CommonStockWarrantsMember 2021-01-01 2021-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-06-01 2021-06-30 0001449349 us-gaap:CommonStockMember 2021-06-01 2021-06-30 0001449349 us-gaap:SeriesAPreferredStockMember 2021-06-01 2021-06-30 0001449349 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-06-01 2021-06-30 0001449349 srt:ChiefExecutiveOfficerMember 2021-09-30 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2021-09-01 2021-09-30 0001449349 srt:ChiefExecutiveOfficerMember 2022-03-31 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001449349 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001449349 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-08 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-27 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-30 0001449349 srt:MinimumMember RDGL:SeriesAConvertiblePreferredStockMember 2016-03-31 0001449349 srt:MaximumMember RDGL:SeriesAConvertiblePreferredStockMember 2016-03-31 0001449349 RDGL:SeriesAConvertiblePreferredStockMember 2015-06-01 2015-06-30 0001449349 srt:ChiefExecutiveOfficerMember RDGL:SeriesAConvertiblePreferredStockMember 2021-06-01 2021-06-30 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2018-10-01 2018-10-31 0001449349 RDGL:SeriesBConvertiblePreferredStockMember 2021-12-01 2021-12-31 0001449349 us-gaap:CommonStockMember 2021-12-01 2021-12-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-31 0001449349 RDGL:SeriesCConvertiblePreferredStockMember 2019-03-01 2019-03-31 0001449349 us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001449349 us-gaap:WarrantMember 2022-03-01 2022-03-31 0001449349 2022-06-02 2022-06-30 0001449349 us-gaap:CommonStockMember 2022-07-05 2022-07-07 0001449349 2022-07-07 0001449349 us-gaap:CommonStockMember 2022-07-07 0001449349 RDGL:JuneTwoThousandTwentyFiveMember 2022-07-05 2022-07-07 0001449349 RDGL:JuneTwoThousandTwentyFiveMember 2022-07-07 0001449349 RDGL:DecemberTwoThousandTwentyTwoMember 2022-07-05 2022-07-07 0001449349 RDGL:DecemberTwoThousandTwentyTwoMember 2022-07-07 0001449349 us-gaap:AccountsPayableMember 2022-09-01 2022-09-30 0001449349 us-gaap:WarrantMember 2022-12-01 2022-12-31 0001449349 us-gaap:AccountsPayableMember 2021-01-01 2021-01-31 0001449349 us-gaap:AccountsPayableMember 2021-05-01 2021-05-31 0001449349 us-gaap:CommonStockMember 2021-01-01 2021-01-31 0001449349 2021-01-01 2021-09-30 0001449349 us-gaap:CommonStockMember 2021-03-01 2021-03-31 0001449349 us-gaap:CommonStockMember 2021-03-31 0001449349 2021-03-01 2021-03-31 0001449349 2021-03-31 0001449349 us-gaap:CommonStockMember 2021-01-08 2021-01-29 0001449349 us-gaap:WarrantMember 2021-01-08 2021-01-29 0001449349 us-gaap:CommonStockMember 2021-06-27 2021-06-28 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2021-06-27 2021-06-28 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2021-06-01 2021-06-30 0001449349 us-gaap:CommonStockMember 2021-07-09 2021-09-24 0001449349 us-gaap:WarrantMember 2021-07-09 2021-09-24 0001449349 us-gaap:CommonStockMember 2021-10-01 2021-10-31 0001449349 us-gaap:WarrantMember 2021-10-01 2021-10-31 0001449349 2021-11-01 2021-11-30 0001449349 us-gaap:AccountsPayableMember 2021-12-01 2021-12-31 0001449349 2021-12-01 2021-12-31 0001449349 srt:MinimumMember 2020-12-31 0001449349 srt:MaximumMember 2020-12-31 0001449349 2020-01-01 2020-12-31 0001449349 2019-12-31 0001449349 srt:MinimumMember 2021-12-31 0001449349 srt:MaximumMember 2021-12-31 0001449349 srt:MinimumMember 2022-12-31 0001449349 srt:MaximumMember 2022-12-31 0001449349 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001449349 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001449349 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001449349 us-gaap:WarrantMember 2021-03-31 0001449349 us-gaap:WarrantMember 2021-03-01 2021-03-31 0001449349 us-gaap:WarrantMember 2022-06-02 2022-06-30 0001449349 us-gaap:WarrantMember 2022-07-07 0001449349 us-gaap:RestrictedStockUnitsRSUMember 2021-05-02 2021-05-03 0001449349 RDGL:ConsultantsMember us-gaap:RestrictedStockUnitsRSUMember 2021-05-02 2021-05-03 0001449349 RDGL:OneConsultantsMember us-gaap:RestrictedStockUnitsRSUMember 2021-06-01 2021-06-30 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember 2021-05-02 2021-05-03 0001449349 RDGL:OnTheGrantDateMember us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-05-02 2021-05-03 0001449349 us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-05-02 2021-05-03 0001449349 RDGL:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember RDGL:EmploymentAgreementMember 2021-05-02 2021-05-03 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-02-02 2022-02-03 0001449349 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-02 2022-03-03 0001449349 RDGL:ConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2022-05-30 2022-06-01 0001449349 RDGL:ConsultantMember us-gaap:RestrictedStockUnitsRSUMember 2022-10-29 2022-11-01 0001449349 us-gaap:WarrantMember 2020-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2020-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2020-12-31 0001449349 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001449349 us-gaap:WarrantMember 2021-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001449349 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001449349 us-gaap:WarrantMember 2022-12-31 0001449349 srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001449349 srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001449349 srt:MinimumMember 2022-01-01 2022-12-31 0001449349 srt:MinimumMember 2021-01-01 2021-12-31 0001449349 srt:MaximumMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2020-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-01-01 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2021-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-01-01 2022-12-31 0001449349 RDGL:RestrictedStockUnitsMember 2022-12-31 0001449349 RDGL:DrMichaelKKorenkoMember RDGL:EmploymentAgreementMember 2019-06-03 2019-06-04 iso4217:USD shares iso4217:USD shares pure 0001449349 false FY P2Y 10-K true 2022-12-31 --12-31 2022 false 0-53497 VIVOS INC DE 80-0138937 719 Jadwin Avenue Richland WA 99352 (509) 736-4000 Common Stock, $0.001 Par Value No No Yes Yes Non-accelerated Filer true false false 36693047 362541528 5525 Fruci & Associates II, PLLC Spokane, Washington 1706065 1606123 11000 25671 28175 1742736 1634298 1742736 1634298 81692 166915 81692 166915 81692 166915 0.001 0.001 20000000 20000000 5000000 5000000 2071007 2071007 2071007 2071007 2071 2071 8842458 8842458 5000000 5000000 200363 200363 200363 200363 200 200 290956 290956 5000000 5000000 385302 385302 385302 385302 385 385 385 385 500507 500507 500507 500507 0.001 0.001 950000000 950000000 362541528 362541528 343530678 343530678 362541 343531 71217954 68573142 -79556028 -77085867 1661044 1467383 1742736 1634298 36499 14887 28779 12000 7720 2887 1755316 1838323 275240 267477 343802 286848 151111 112037 2525469 2504685 -2517749 -2501798 25375 136445 47588 -137038 47588 -25968 -2470161 -2527766 -2470161 -2527766 -0.01 -0.01 351425912 325851906 2171007 2171 8857358 436653 436 385235 385302 385 500507 292278591 292279 64551764 -74558101 32034 22500000 22500 1777500 1800000 3576080 3576 408435 412011 1305298 1305 120805 122110 77768 78 3678 3756 -100000 -100 -14900 2125000 2125 12875 12000000 12000 -12000 6714316 6714 -6714 -236290 -236 -94279 2953625 2954 91561 11238 11238 1614000 1614000 -2527766 -2527766 2071007 2071 8842458 200363 200 290956 385302 385 500507 343530678 343531 68573142 -77085867 1467383 2071007 2071 8842458 200363 200 290956 385302 385 500507 343530678 343531 68573142 -77085867 1467383 2071007 2071 8842458 200363 200 290956 385302 385 500507 343530678 343531 68573142 -77085867 1467383 15000000 15000 1185000 1200000 984840 984 48258 49242 -90 76250 76 4804 4880 2949850 2950 -2950 20000 20000 1389700 1389700 -2470161 -2470161 2071007 2071 8842458 200363 200 290956 385302 385 500507 362541528 362541 71217954 -79556028 1661044 2071007 2071 8842458 200363 200 290956 385302 385 500507 362541528 362541 71217954 -79556028 1661044 -2470161 -2527766 4880 3756 1389700 1614000 47588 -137038 136445 11000 -2504 -5660 11607 31480 -66143 -25399 1350103 1563947 -1120058 -963819 45000 -100000 1220000 1811238 1220000 1666238 99942 702419 1606123 903704 1706065 1606123 50773 94515 185346 50370 2950 6714 12000 49242 90000 60000 32110 12000 <p id="xdx_802_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zpbsmmfKP4Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_82B_zbJhXSWiZZd4">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--BusinessOverviewPolicyTextBlock_zCBCOBjz55u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_znHu3TFxckrf">Business Overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z8HOMPTxwIda" title="Common stock, shares authorized">950,000,000</span> shares of common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zZiF2E2kB5gi" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zFTRjIEs4la9" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zfsRd3BiQJe9" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zXWulSUY1VY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMsa5ECG1Rv7">IsoPet Solutions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the <i>FDA</i> to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“<i>Y-90</i>”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a <span id="xdx_903_eus-gaap--DescriptionOfCreditRiskExposure_c20220101__20221231_zeafPj5oeRo1" title="Description of risk exposure">half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--IntellectualPropertyPolicyTextBlock_zKvGMEiWsTw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_znbMoTQirgXj">Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory is reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a <span>continuation-in-part applications</span> number 1774054 in the USA to expand the claims on our particle patent. <span>T</span>he US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, <span>US Patent Application Serial No: 16-459,466</span>. <span>We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the <span>Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_z2B9qL1eqCwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_znJ1M998LDqd">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20221231_zDSHqpdvGj92" title="Current operation activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210914__20210915_z5nuXbesBHqh" title="Stock issued during period shares new issues">50,000,000</span> shares at a price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210915_zZcKdGQrzDic" title="Share price">0.10</span> for a maximum of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210914__20210915_zo60VlQPfcFc" title="Number of shares issued, value">5,000,000</span>. The Company amended this and was able to raise $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220727__20220731_zU2XGYytgw0a" title="Number of shares issued, value">1,200,000</span> in July 2022 at $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220731_zCW66hf40y1" title="Share price">0.08</span> per share (<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220727__20220731_zbzQoXaHrIjj" title="Stock issued during period shares new issues">15,000,000</span> shares) and sold <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220731_zYpVa3dvnqC7" title="Warrant sold during period">20,000,000</span> warrants for $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220731_zpJSTDqI4p27" title="Warrants outstanding">20,000</span>. An amended Regulation A+ was filed in October 2022 to raise the remaining $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueRemainingNewIssues_c20221030__20221031_zrvaErfQzHXd" title="Shares issued remaining value">3,800,000</span> of the $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221030__20221031_zX2aF3qGQ0D7">5,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Regulation A+’s raised approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zWkceUTiZxNg" title="Proceeds from stock offering">5,200,000</span> from the sale of shares and is using the proceeds generated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct additional clinical studies to generate more data for the veterinary community</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>® </sup>therapies, if necessary, to ensure that all viable candidates are treated.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist new regional clinics with their license and certification training.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20221231_zHsrzqVOrBzc">2.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain current operating activities. <span id="xdx_903_ecustom--OfferingTerm_c20220101__20221231_zLiaUbGWjLU6" title="Offering term">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet<sup>®</sup> across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_zDkuxxMBVTQl" title="Cash on hand">1,706,065</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_zWtP8V82zF18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNeutFnCZiYk">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpro8JFVubrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrgGcZGwClF1">Financial Statement Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znnEd5JHhLu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zp5v8plAlxTg">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx4Wk9ED6FV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zi2cH1mhAp85">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2022 and 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9RLPUnQRGJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zMWinxriyuy3">Fixed Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $<span id="xdx_901_eus-gaap--ProductionCosts_c20220101__20221231_zkKHuN0Dkhzb" title="Production costs">2,500</span> or greater and other fixed assets with a cost of $<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentOther_iI_c20221231_zkVRXfF27ELa" title="Other fixed assets cost">1,500</span> or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z2LmjhzCTp27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z4r0A8UdSsF1" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z2BzH4DGawi1" title="Estimated useful life of asset">3</span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zT8Bm1nealll" title="Estimated useful life of asset">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zGgtLGkKeF92" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zLJStNZywgT7" title="Estimated useful life of asset">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzQ9Ll8eudq5" title="Estimated useful life of asset">2</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQzVopeBFzm8" title="Estimated useful life of asset">5</span> years</span></td></tr> </table> <p id="xdx_8A7_z8fYvC5qE291" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--LicenseFeesPolicyTextBlock_zt9Y4QoAt8Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zUGIyE7M5tU1">License Fees</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zhN8Kd6G3WYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zHrFi56sS4Mk">Patents and Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231_zCq3Hvve5Sn4" title="Economic life of the patent">10</span>-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the years ended December 31, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>®</sup> commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zycVipRAklRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zkTwJ1ccbwR1">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“F<i>ASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zz32U7JfljVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zpEJQL4rbnXf">Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zAOjwZEjyMIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zkhj1xx3emb3" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_z27ZkgDqS9fe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zmqzGYCdpHgd" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zq6idCymO0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zdQmjsIx44zc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,862,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zeWvLRj7Zkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zEKlNvbxxWa5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,737,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z8tCBOiCXb3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">64,762,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zsJUrxeWnBpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zD88MnoZQIA" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z60WLFLvTQwg">Research and Development Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231_zp3oyet7xyr3" title="Research and development costs">343,802</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231_zrstU4YSFDI2">286,848</span> in research and development costs for the years ended December 31, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zMAoCAxtizbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zRATI1sZgcd7">Advertising and Marketing Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2022 and 2021, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zaBRBgMSuMOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zQtCsomTCKk8">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zK7ZkpNjD23i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zwmJmGtHabU5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did <span title="Income tax expense (benefit)"><span title="Income tax expense (benefit)">no</span></span>t have any tax expense for the years ended December 31, 2022 and 2021. The Company did <span title="Deferred tax liabilities"><span title="Deferred tax liabilities">no</span></span>t have any deferred tax liability or asset on its balance sheets on December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes.<span id="xdx_908_eus-gaap--SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible_c20220101__20221231_zFQlYCh7E6c2" title="Significant change in unrecognized tax benefits"> The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4e9gMrpr0N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zbaH56IY0Uyd">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqfpFxHDRUZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zcA8XWLwhks">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p id="xdx_85C_z8MbnubLfBm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--BusinessOverviewPolicyTextBlock_zCBCOBjz55u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_znHu3TFxckrf">Business Overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z8HOMPTxwIda" title="Common stock, shares authorized">950,000,000</span> shares of common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zZiF2E2kB5gi" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zFTRjIEs4la9" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zfsRd3BiQJe9" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 950000000 0.001 20000000 0.001 <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zXWulSUY1VY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zMsa5ECG1Rv7">IsoPet Solutions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the <i>FDA</i> to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“<i>Y-90</i>”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a <span id="xdx_903_eus-gaap--DescriptionOfCreditRiskExposure_c20220101__20221231_zeafPj5oeRo1" title="Description of risk exposure">half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days. <p id="xdx_848_ecustom--IntellectualPropertyPolicyTextBlock_zKvGMEiWsTw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_znbMoTQirgXj">Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory is reached its end of life in 2022. During the past several years, in anticipation of this we have expanded our proprietary knowledge, our trademark and patent protection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our RadioGel trademark protection is in 17 countries. We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a <span>continuation-in-part applications</span> number 1774054 in the USA to expand the claims on our particle patent. <span>T</span>he US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, <span>US Patent Application Serial No: 16-459,466</span>. <span>We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that Precison Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). Vivos Inc will focus its near-term effort on the <span>Yttrium-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_z2B9qL1eqCwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_znJ1M998LDqd">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20221231_zDSHqpdvGj92" title="Current operation activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210914__20210915_z5nuXbesBHqh" title="Stock issued during period shares new issues">50,000,000</span> shares at a price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210915_zZcKdGQrzDic" title="Share price">0.10</span> for a maximum of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210914__20210915_zo60VlQPfcFc" title="Number of shares issued, value">5,000,000</span>. The Company amended this and was able to raise $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220727__20220731_zU2XGYytgw0a" title="Number of shares issued, value">1,200,000</span> in July 2022 at $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220731_zCW66hf40y1" title="Share price">0.08</span> per share (<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220727__20220731_zbzQoXaHrIjj" title="Stock issued during period shares new issues">15,000,000</span> shares) and sold <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220731_zYpVa3dvnqC7" title="Warrant sold during period">20,000,000</span> warrants for $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220731_zpJSTDqI4p27" title="Warrants outstanding">20,000</span>. An amended Regulation A+ was filed in October 2022 to raise the remaining $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueRemainingNewIssues_c20221030__20221031_zrvaErfQzHXd" title="Shares issued remaining value">3,800,000</span> of the $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221030__20221031_zX2aF3qGQ0D7">5,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Regulation A+’s raised approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zWkceUTiZxNg" title="Proceeds from stock offering">5,200,000</span> from the sale of shares and is using the proceeds generated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct additional clinical studies to generate more data for the veterinary community</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>® </sup>therapies, if necessary, to ensure that all viable candidates are treated.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist new regional clinics with their license and certification training.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20221231_zHsrzqVOrBzc">2.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million annually to maintain current operating activities. <span id="xdx_903_ecustom--OfferingTerm_c20220101__20221231_zLiaUbGWjLU6" title="Offering term">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet<sup>®</sup> across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_zDkuxxMBVTQl" title="Cash on hand">1,706,065</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2500000 50000000 0.10 5000000 1200000 0.08 15000000 20000000 20000 3800000 5000000 5200000 2500000 Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. 1706065 <p id="xdx_84E_eus-gaap--UseOfEstimates_zWtP8V82zF18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNeutFnCZiYk">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpro8JFVubrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrgGcZGwClF1">Financial Statement Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znnEd5JHhLu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zp5v8plAlxTg">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx4Wk9ED6FV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zi2cH1mhAp85">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2022 and 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9RLPUnQRGJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zMWinxriyuy3">Fixed Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $<span id="xdx_901_eus-gaap--ProductionCosts_c20220101__20221231_zkKHuN0Dkhzb" title="Production costs">2,500</span> or greater and other fixed assets with a cost of $<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentOther_iI_c20221231_zkVRXfF27ELa" title="Other fixed assets cost">1,500</span> or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z2LmjhzCTp27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z4r0A8UdSsF1" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z2BzH4DGawi1" title="Estimated useful life of asset">3</span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zT8Bm1nealll" title="Estimated useful life of asset">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zGgtLGkKeF92" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zLJStNZywgT7" title="Estimated useful life of asset">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzQ9Ll8eudq5" title="Estimated useful life of asset">2</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQzVopeBFzm8" title="Estimated useful life of asset">5</span> years</span></td></tr> </table> <p id="xdx_8A7_z8fYvC5qE291" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2500 1500 <p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z2LmjhzCTp27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z4r0A8UdSsF1" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z2BzH4DGawi1" title="Estimated useful life of asset">3</span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zT8Bm1nealll" title="Estimated useful life of asset">7</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zGgtLGkKeF92" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zLJStNZywgT7" title="Estimated useful life of asset">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures:</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zzQ9Ll8eudq5" title="Estimated useful life of asset">2</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zQzVopeBFzm8" title="Estimated useful life of asset">5</span> years</span></td></tr> </table> P3Y P7Y P2Y P5Y P2Y P5Y <p id="xdx_841_ecustom--LicenseFeesPolicyTextBlock_zt9Y4QoAt8Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zUGIyE7M5tU1">License Fees</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zhN8Kd6G3WYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zHrFi56sS4Mk">Patents and Intellectual Property</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231_zCq3Hvve5Sn4" title="Economic life of the patent">10</span>-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the years ended December 31, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>®</sup> commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y <p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zycVipRAklRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zkTwJ1ccbwR1">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“F<i>ASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the years ended December 31, 2022 and 2021 relate to consulting income with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zz32U7JfljVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zpEJQL4rbnXf">Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zAOjwZEjyMIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zkhj1xx3emb3" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_z27ZkgDqS9fe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zmqzGYCdpHgd" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zq6idCymO0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zdQmjsIx44zc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,862,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zeWvLRj7Zkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zEKlNvbxxWa5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,737,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z8tCBOiCXb3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">64,762,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zsJUrxeWnBpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zAOjwZEjyMIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of December 31, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zkhj1xx3emb3" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_z27ZkgDqS9fe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zmqzGYCdpHgd" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zq6idCymO0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zdQmjsIx44zc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,862,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zeWvLRj7Zkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zEKlNvbxxWa5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,737,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z8tCBOiCXb3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">64,762,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 9909570 9909570 25862500 25262500 2252809 2252809 26737500 31862500 64762379 69287379 <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zD88MnoZQIA" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z60WLFLvTQwg">Research and Development Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231_zp3oyet7xyr3" title="Research and development costs">343,802</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231_zrstU4YSFDI2">286,848</span> in research and development costs for the years ended December 31, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 343802 286848 <p id="xdx_841_eus-gaap--AdvertisingCostsPolicyTextBlock_zMAoCAxtizbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zRATI1sZgcd7">Advertising and Marketing Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2022 and 2021, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zaBRBgMSuMOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zQtCsomTCKk8">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zK7ZkpNjD23i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zwmJmGtHabU5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did <span title="Income tax expense (benefit)"><span title="Income tax expense (benefit)">no</span></span>t have any tax expense for the years ended December 31, 2022 and 2021. The Company did <span title="Deferred tax liabilities"><span title="Deferred tax liabilities">no</span></span>t have any deferred tax liability or asset on its balance sheets on December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes.<span id="xdx_908_eus-gaap--SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible_c20220101__20221231_zFQlYCh7E6c2" title="Significant change in unrecognized tax benefits"> The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4e9gMrpr0N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zbaH56IY0Uyd">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqfpFxHDRUZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zcA8XWLwhks">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zk4GJA7dgUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2: <span id="xdx_82C_zftXL7lcoFkk">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Notes Payable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_906_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231_zXGnNzEw5JOi" title="Notes payable related party, outstanding balance">237,000</span> in related party notes payable that were outstanding during 2021 were either repaid or converted in December 2021. There are <span id="xdx_90B_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_do_c20221231_zAg5ZZzsA5V6" title="Notes payable related party, outstanding balance">no</span> outstanding related party notes payable as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Payables</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company converted the $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvKMlWsfTBNl" title="Related party payable conversion">32,110</span> in related party payables into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5LuzjcmueGc" title="Conversion of common stock, shares">401,373</span> shares of common stock. There are <span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_do_c20221231_z6Hge69C21R4" title="Accounts payable, related parties, current">no</span> remaining related party payables as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred and Common Shares Issued to Officers and Directors</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, the Company’s Chief Executive Officer exercised <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zFbKWmspZ0Of" title="Stock options exercised shares">2,500,000</span> stock options for a value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zncL8zwHtAT9" title="Stock options exercised value">60,000</span> that was paid through the cancelation of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210601__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHeag7RtT795" title="Cancelation shares">375,000</span> common shares and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210601__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziZCUWnaKGua" title="Cancelation shares">100,000</span> Series A Convertible Preferred shares. The Chief Executive Officer in May 2021 rescinded <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_c20210501__20210531__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdTwSKV3mRM" title="Rescinded shares">8,120,152</span> stock options and in June 2021 rescinded <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_c20210601__20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuu9VZlak6dl" title="Rescinded shares">16,000,000</span> stock options. In September 2021, the Chief Executive Officer exercised <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmxvy3DPwLTk" title="Number of securities warrant exercise, share">150,000</span> warrants in a cashless exercise into <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20210901__20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS7qIFJ5x7C" title="Conversion of stock, shares converted">91,304</span> shares of common stock. In March 2022, the Chief Executive Officer exercised <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zu81lBg2YZD5" title="Warrants exercised shares">75,000</span> warrants in a cashless exercise into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20220301__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ5s5dCGyRg7" title="Conversion of stock">22,266</span> shares of common stock, and was issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220301__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeR5HcfZRDq2" title="Stock issued for services, shares">76,250</span> shares of common stock valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFBsIvjTnOdd" title="Stock issued for services, value">4,880</span> for services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 237000 0 32110 401373 0 2500000 60000 375000 100000 8120152 16000000 150000 91304 75000 22266 76250 4880 <p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zJCyeVpdMUEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3: <span id="xdx_820_zzk71c92wbUh">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, there remains <span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_do_c20221231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z09EcjWwAi57" title="Outstanding balances"><span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_do_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z3RiE2RsCQM9" title="Outstanding balances">no</span></span> outstanding balances in the convertible notes payable. All prior convertible notes had been either repaid or converted in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbpylWGQqbqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4: <span id="xdx_821_zuSUjYqUbt12">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zogCp4sDyIUf" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zWH9CsJAlCG7" title="Common stock, shares authorized">950,000,000</span></span> shares of common stock authorized, with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_z2XumHJ4XUa2" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_z2Y38y4AriRf" title="Common stock, par value">0.001</span></span>, and as of December 31, 2022 and 2021, the Company has <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20221231_zTm20VsHDSSh" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zPCVAYBN3K7a" title="Common stock, shares outstanding">362,541,528</span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20211231_zlNwNoQMhmZc" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z2kEsDrI74M2" title="Common stock, shares outstanding">343,530,678</span></span> shares issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zVphigi78Ge2" title="Preferred stock shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zhIWDPXXArRk" title="Preferred stock shares authorized">20,000,000</span></span> shares of Preferred stock authorized with a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zqaFBeHpsHag" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zVgspjxrsDp7" title="Preferred stock, par value">0.001</span></span>. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20181008__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z6H4MYAitFp4" title="Preferred stock, par value">0.001</span> per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (<span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20181008__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zfScfersubBe" title="Preferred stock, shares authorized">5,000,000</span>) shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zW3wzwwwOedf" title="Preferred stock, par value">0.001</span> per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (<span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zMRD3zbIasm1" title="Preferred stock, shares authorized">5,000,000</span>) shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Convertible Preferred Stock (“Series A Convertible Preferred”)</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z1y08Qrumpvh" title="Preferred stock shares authorized">2.5</span> million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20160331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zC0yBIMGrk1" title="Preferred stock, shares authorized">2,500,000</span> shares to <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20160331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zQNFDKshmPdd" title="Preferred stock, shares authorized">5,000,000</span> shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series A Convertible Preferred has a liquidation preference of $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2E5wU8m6kBe" title="Preferred stock, liquidation preference per share">5.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series A Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series A Certificate of Designation, each share of Series A Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series A Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A Certificate of Designation), currently $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zRXjunTkWRwi" title="Conversion price, per share">4.00</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20150601__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQ8jk3YFZTn2" title="Gross proceeds from preferred stock">5.0</span> million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_905_eus-gaap--PreferredStockVotingRights_c20150601__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z7f1groLHH43" title="Preferred stock voting rights, description">Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to <span id="xdx_909_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20150601__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z66xWZo452Hj" title="Redemption percentage">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five (5) votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series A Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series A Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210601__20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z31ch7cPQOBl" title="Cancellation of shares">100,000</span> shares of Series A Convertible Preferred were canceled as partial payment for the exercise of stock options by the Chief Executive Officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Convertible Preferred Stock (“Series B Convertible Preferred”)</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP4EO07S0U73" title="Preferred stock shares authorized">5.0</span> million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series B Convertible Preferred has a liquidation preference of $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvfQ89wWrSj2" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series B Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series B Certificate of Designation, each share of Series B Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series B Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series B Certificate of Designation), currently $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zpRl6AZTZcAj" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_908_eus-gaap--PreferredStockVotingRights_c20181001__20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdgYl0Njw561" title="Voting percentage">Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to <span id="xdx_90E_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20181001__20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zfMlJSNClV9d" title="Redemption percentage">100</span>% of the Liquidation Preference.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two (2) votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series B Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series B Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211201__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHWHjgLRtiZ5" title="Conversion of preferred stock into common stock">236,290</span> Series B Convertible Preferred shares were converted into <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211201__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDZdEeHvyp7h" title="Conversion of preferred stock into common stock">2,953,625</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Convertible Preferred Stock (“Series C Convertible Preferred”)</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zm3gxfzJpUFa" title="Preferred stock shares authorized">5.0</span> million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series C Convertible Preferred has a liquidation preference of $<span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zo8MBbPLJC1f" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series C Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series C Certificate of Designation, each share of Series C Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series C Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C Certificate of Designation), currently $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zbOmvp5f1mIk" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“<i>Authorized Share Approval</i>”) (such date, the “<i>Initial Convertibility Date</i>”), each share of Series C Convertible Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C Certificate of Designation under the definition “<i>Conversion Rights</i>”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_90E_eus-gaap--PreferredStockVotingRights_c20190301__20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zL3AKVEcP9t8" title="Voting percentage">Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to <span id="xdx_900_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20190301__20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zpPTpEblLUBa" title="Redemption percentage">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series C Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of thirty-two (32) votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Convertible Preferred. However, the Series C Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series C Convertible Preferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series C Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series C Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances - 2022</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLZs5qVHDSof" title="Common stock issued, shares">299,577</span> shares of common stock in the cashless exercise of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV87JcgtLjta" title="Warrants exercise shares">825,000</span> warrants, and issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziIwGEDJiSL1" title="Shares issued for services">76,250</span> shares of common stock to its CEO for services rendered valued at $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgtVhpvRziSg" title="Shares issued for services, value">4,880</span>. In June 2022, there was a fractional adjustment recorded for <span id="xdx_900_ecustom--FunctionalAdjustmentShares_c20220602__20220630_zrgjKpMzu7mb" title="Functional adjustment, shares">90</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2022, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7sVhKVKJVv2" title="Number of shares sold">15,000,000</span> shares under the Regulation A+ at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20220707_zA06GxdNyIee" title="Share price">0.08</span> for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQKirWeQk4Zc" title="Number of shares issued, value">1,200,000</span>, and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJN0uqMEdFa" title="Warrants">20,000,000</span> warrants (<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zQpCIM0R8hga" title="Number of shares issued">15,000,000</span> at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_z5UBEicA7bFi" title="Share price">0.08</span> expiring June 2025 and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_zQ0oeYxLCmHi" title="Number of shares issued">5,000,000</span> at $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_zezx3oT8zmm6" title="Share price">0.01</span> expiring December 2022) for $<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220707_zyLKWZ3bqLO1" title="Warrants outstanding">20,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220901__20220930__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zif8lPcTPPLc" title="Number of shares issued">984,840</span> shares valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220901__20220930__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zlgqNjv5PEv" title="Number of shares issued, value">49,242</span> in settlement of accounts payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sDoOjkz4Pl" title="Number of shares issued">2,650,273</span> shares of common stock in the cashless exercise of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkGiAeCxyYCg" title="Number of warrant exeercised">3,333,333</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances - 2021</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210131__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zOZGh8SzWVYj" title="Number of shares issued">384,445</span> shares of common stock in a settlement of accounts payable valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210131__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zCoEJnr0Irnc" title="Number of shares issued, value">50,000</span>. In May 2021, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210501__20210531__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zPjYrls6rQ9h" title="Number of shares issued">519,480</span> shares of common stock in a settlement of accounts payable valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210501__20210531__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zf3RJVpzRPI1" title="Number of shares issued, value">40,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcTdwfOXrqKd" title="Debt conversion, share">1,259,250</span> shares of common stock in conversion of a note payable and accrued interest totaling $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlNgUTCfjtIf" title="Debt instrument, accrued interest">50,370</span>. The conversion resulted in a loss on conversion of $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210101__20210930_za79yBZiMLK1" title="Gain (loss) on extinguishment of debt">176,295</span> that is reflected in the Condensed Statement of Operations for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkq01bl4hO2h" title="Number of shares issued">22,500,000</span> shares of common stock along with <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD4jVcPHJrM" title="Number of warrants issued">11,237,500</span> warrants under the Regulation A+ for cash proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210301__20210331_zTd7ShXlKKwa" title="Proceeds from issuance of common stock">1,800,000</span> for the common stock and the warrants were purchased for $<span id="xdx_905_ecustom--WarrantPurchase_iI_c20210331_zJiE6fmGiue6" title="Warrant purchase">11,238</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between January 8, 2021 and January 29, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRlut5gALGK4" title="Number of shares issued">3,870,428</span> shares of common stock in the cashless exercise of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV4EdBqx0gx5" title="Number of warrant exercised">5,430,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210627__20210628__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1kCu1VcGIUc" title="Number of share exercised">2,500,000</span> shares of common stock for the exercise of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210627__20210628__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhnW6vc7Xj75" title="Number of share exercised">2,500,000</span> stock options to the Chief Executive Officer. In this transaction, the Company canceled <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210627__20210628__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsP6WmgFEnHc" title="Cancelation of shares">375,000</span> shares of common stock as partial payment for the exercise of the stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, the Company issued <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210601__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWtsqTpJJcFf" title="Number of shares vested">12,000,000</span> shares of common stock for vested RSUs with a fair value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210601__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuoY8gH9Cj8" title="Fair value of vested shares">1,080,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 9 through September 24, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYtxL53yM7Aj" title="Number of share exercised">838,195</span> shares of common stock in the cashless exercise of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvzvdqiC4myf" title="Number of warrant exercised">1,800,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTAIr6TtItx4" title="Number of share exercised">2,005,693</span> shares of common stock in the cashless exercise of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqE5YNE7cfY3" title="Number of warrant exeercised">3,500,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211101__20211130_zJFtYcbwBVKi" title="Shares issued for services, shares">77,768</span> shares of common stock for services valued at $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20211101__20211130_zbFFjh8Kpnpj" title="Shares issued for services">3,756</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211201__20211231__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zzCvuiv2X4ol" title="Shares, new issues">401,373</span> shares of common stock in conversion of accounts payable to a related party in the amount of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211201__20211231__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zgZWzQpi1m2b" title="Value, new issues">32,110</span>; issued <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211201__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLb9u24Bbrl" title=" Converted shares issued">2,316,830</span> shares of common stock in conversion of related party note payables and accrued interest valued at $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20211201__20211231_zSluQTJaaIA3" title="Debt instrument, increase, accrued interest">185,346</span>; and issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211201__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK8U27mFVMg9" title="Conversion of convertible securities">2,953,625</span> shares of common stock in conversion of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211201__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zoTqBMgmODNe" title="Conversion of convertible securities">236,290</span> Series B Convertible Preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 950000000 950000000 0.001 0.001 362541528 362541528 343530678 343530678 20000000 20000000 0.001 0.001 0.001 5000000 0.001 5000000 2500000 2500000 5000000 5.00 4.00 5000000.0 Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference 1 100000 5000000.0 1.00 0.08 Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference. 1 236290 2953625 5000000.0 1.00 0.08 Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference 1 299577 825000 76250 4880 90 15000000 0.08 1200000 20000000 15000000 0.08 5000000 0.01 20000 984840 49242 2650273 3333333 384445 50000 519480 40000 1259250 50370 -176295 22500000 11237500 1800000 11238 3870428 5430000 2500000 2500000 375000 12000000 1080000 838195 1800000 2005693 3500000 77768 3756 401373 32110 2316830 185346 2953625 236290 <p id="xdx_808_ecustom--CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock_zjJnQAvfAdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5: <span id="xdx_82D_zi8rqSG6EfIl">COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUakXJy2Y1Kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0cgkl5B6Pf4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CHANGES IN STOCK OPTION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Average</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Price</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zavK6CACzfpf" style="width: 9%; text-align: right" title="Number of Options Outstanding Beginning Balance">28,885,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zU5upAmHLShe" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zTvYAMHVG25i" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zDMIoYKT8ZRk" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">5.57</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUFpusp2j01c" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,661,429</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20210101__20211231_zg0DNhS1dzVb" style="width: 9%; text-align: right" title="custom:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zH43F78dkDwi" style="text-align: right" title="Number of Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zcTnw1wzjJHk" style="text-align: right" title="Exercise Price Per Share granted"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20210101__20211231_zusc3DN0mj03" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zbxvM8mclzn6" style="text-align: right" title="Number of Options exercised">(2,500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zHrZjNXAxZ5g" style="text-align: right" title="Exercise Price Per Share exercised"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20210101__20211231_zkVx8qWAfxH5" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zFM1e5yPba3c" style="text-align: right" title="Number of Options expired/cancelled">(24,132,652</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zCmJuQKkqlXd" style="text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20210101__20211231_zMUX6Z5Uzole" style="text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zwVJOK3YyaJ3" style="text-align: right" title="Number of Options Outstanding Beginning Balance">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zST9PDauE977" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zASLt3QrdaL5" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zEPKBnIpsQ25" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">7.70</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_zTPeUnkEBNr5" style="text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">83,992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20220101__20221231_zjjZwqtc4Ew6" style="text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zsPgvD11w0M3" style="text-align: right" title="Number of Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z6WFCIvHawof" style="text-align: right" title="Exercise Price Per Share granted"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20220101__20221231_zWkEW1TJnKdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1092">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zfWevhNcA1Bh" style="text-align: right" title="Number of Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zkFbEcZ8Hvzl" style="text-align: right" title="Exercise Price Per Share exercised"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20220101__20221231_z25ModhePFjf" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options expired/canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zMDEtsZ9xX74" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCryBPIsPv5l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20220101__20221231_zUZllhAfG2Y6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_z9gq1HmYtLhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending Balance">2,252,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdN3rhxHuall" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z1kxnFmQk8lh" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRwO8mhe0Iua" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Ending">6.70</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zTXYcjfOci48" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending">16,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20220101__20221231_zuRZcOEN6KIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfquzvcWjGq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">2,252,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zzZJNifBJEY7" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zO3TqABTc9mh" title="Exercise Price Per Share Exercisable">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zbnaWZVuQNta" title="Weighted Average Remaining Contractual Life (in years) Exercisable">6.70</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zQFIoA4oaejj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">16,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20220101__20221231_zoXOWNOAtbcb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zl9jHsBnZi28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company’s CEO exercised <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsys9f2h4DX1" title="Number of shares exercised">2,500,000</span> stock options, and rescinded <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxjuepBC2z9c" title="Number of stock option rescinded">24,120,152</span>, stock options. In addition, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0lu4l8Loow6" title="Number of options expired">12,500</span> options expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, the Company recognized <span id="xdx_90D_eus-gaap--ShareBasedCompensation_do_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQrB6aNf8ss8" title="Stock based compensation"><span id="xdx_90C_eus-gaap--ShareBasedCompensation_do_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrXFVOrshgeb" title="Stock based compensation">no</span></span> stock based compensation related to the vesting of its stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2fqtkL7cDRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zmmhlAFEfble" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number Of <br/>Shares</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/>Price Per <br/>Share</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Remaining Contractual <br/>Life</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/>Price Per <br/>Share</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaidBA6P1Zb1" style="width: 9%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">32,064,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmcFrOnA4g81" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zuShprIUZHRf" title="Exercise Price Per Share Warrants Outstanding Beginning">80.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHfwxiIYTmj" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.65</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z95Lgfm01avi" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,614,567</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ExercisePriceMinimum_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLy37ThdXqv2" style="width: 9%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKuh8VpLjOyi" style="text-align: right" title="Number of Shares, Warrants granted">11,237,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq3sFTE8MJWb" title="Exercise Price Per Share Warrants granted">0.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOUzSUFJWCXe" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziVHBh7zqRGg" style="text-align: right" title="Number of Shares, Warrants exercised">(10,730,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8fSECGBqKg6" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSkztAqSdjzf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(709,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUfcSS3ksBRb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zt1lZvIwmM1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">31,862,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmR18JW1end5" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zfBAciif9qhj" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwhlYwREk1nf" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.02</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFzzJ5nO5bJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">538,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ExercisePriceMinimum_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0U0d52lGRC7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z67VJ7igC3ba" style="text-align: right" title="Number of Shares, Warrants granted">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUGJYXdbu9tb" title="Exercise Price Per Share Warrants granted">0.01</span> – <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zFttDDWCQZde" title="Exercise Price Per Share Warrants granted">0.08</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6k91EGEKpCk">2.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zY8kdQXFmPef" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted">0.0725</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDMiEALLqK2d" style="text-align: right" title="Number of Shares, Warrants exercised">(4,158,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQn1EljUAfHc" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNjLXhudKd9h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(20,966,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5crgpM7EGib" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJHi6eMkuy1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">26,737,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYDo75oLauGc" title="Exercise Price Per Share Warrants Outstanding Ending">0.08</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z8Lx0bYQmrk8" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSeHqYakFDv4" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.52</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z42TI7KlQWCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ExercisePriceMinimum_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ6hmY57alca" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zbQSERJTFfqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable Ending">26,737,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ziNKEleCat6" title="Exercise Price Per Share Exercisable">0.08</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zm2efMw7EB7f" title="Exercise Price Per Share Exercisable">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeyIBPiBZ923" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.52</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBkzrycTEc0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcTrsH13jYbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zZNmn2wPEU9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5Y0oscj6j3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zUQxp7zBzrZ5" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zSb9aMRAf4u6">.5</span> – <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zZJeFJEpM77h">3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zZtiZaclSDhf" title="Expected term">2</span> - <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zMStj2wnJYY6" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zIw8Qvc36dFa" style="width: 14%; text-align: right" title="Expected volatility">66</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zCQegvP1ucra" title="Expected volatility">109</span> - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zmyxrJ3ja3ea" title="Expected volatility">147</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231_z1TVf2YE8UUb" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zeanyH3MyHh2" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zmoEZa8Qqm64" style="text-align: right" title="Risk-free interest rate">3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzi9MqOte26" title="Risk-free interest rate">0.20</span> - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zR7gRMiANsvi" title="Risk-free interest rate">0.58</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zvRK5ySTiVz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between January 8, 2021 and January 29, 2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAIGG5gwU3kk" title="Number of shares issued">3,870,428</span> shares of common stock in the cashless exercise of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYRYSHkU2Qpd" title="Number of warrant exercised">5,430,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021 the Company sold <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqMXRfaGA7rk" title="Number of warrants issued">11,237,500</span> warrants for $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMUJlvM4PU99" title="Proceeds from issuance of warrant">11,238</span>. These warrants have a <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxyzxeDOIIKh" title="Warrants and rights outstanding term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1253">two-year term</span></span> and have an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPP5bbOlNPY9" title="Warrants exercise price">0.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 9 through September 24, 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zimkX1EGlGm" title="Number of shares issued">838,195</span> shares of common stock in the cashless exercise of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSMwqOBPgywj" title="Number of warrant exercised">1,800,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjoQLfW02Fcb" title="Number of shares issued">2,005,693</span> shares of common stock in the cashless exercise of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg15Wi9K0s4e" title="Number of warrant exercised">3,500,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022 the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPzyd3VGLjL5" title="Number of shares issued">299,577</span> shares of common stock in the cashless exercise of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsTlsJyZVuik" title="Number of warrant exercised">825,000</span> warrants. In June 2022, <span id="xdx_904_ecustom--WarrantsExpired_c20220602__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVdyPmk2azBi" title="Warrants expired">1,000,000</span> warrants expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2022, the Company sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTogNbgzgqYb" title="Number of shares sold">15,000,000</span> shares under the Regulation A+ at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUEJxKUoZJKg" title="Share price">0.08</span> for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbWvnIM8ttMd" title="Number of shares issued, value">1,200,000</span>, and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYjFK6URi1ue" title="Warrants">20,000,000</span> warrants (<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zK6EZ2ROWsc" title="Number of shares issued">15,000,000</span> at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zAYTxQOcSZ5k" title="Share price">0.08</span> expiring June 2025 and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220705__20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_z7hZ7sZnfsPe" title="Shares new issues">5,000,000</span> at $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_zp0dPu0JaO2a" title="Share price">0.01</span> expiring December 2022) for $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhsgCkS1jXCd" title="Warrants and rights outstanding">20,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2022, the Company issued 2,650,273 shares of common stock in the cashless exercise of 3,333,333 warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z695KI3qsql5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B3_zMb5DdpJgidd" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/> Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Grant Date</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Balance at December 31, 2020 and 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zOkxGe3AAH6k" style="width: 14%; text-align: right" title="Number of Shares, RSU's Beginning balance">262,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zcdIz8VnNVPb" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Beginning balance">0.59</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSU’s granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zvXLIRvqZAhi" style="text-align: right" title="Number of Shares, RSU's granted">42,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zmYDljX6MnEe" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSU’s vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zAJzV2Qw77V7" style="text-align: right" title="Number of Shares, RSU's vested">(17,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zolx0qwAm0E7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSU’s forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zCVuahAdUvNd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zBRptQmJZXcf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z9VUHtKJsOB5" style="text-align: right" title="Number of Shares, RSU's Beginning balance">25,262,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zY7SnlxsRNt9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zuYJNLyKe3H1" style="text-align: right" title="Number of Shares, RSU's granted">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zVSgHTdvRgEk" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zF9zk4cSv6wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's vested">(15,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zYLylqWZnMvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zneFDmWIJ5V2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance">10,262,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zaRP6bmix9ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zSHoqafpQno5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_908_eus-gaap--RestrictedStockExpense_c20220101__20221231_zjVbmk4yziD6" title="Restricted stock expense vesting">1,389,700</span> and $<span id="xdx_905_eus-gaap--RestrictedStockExpense_c20210101__20211231_zzG1cETHB0mc" title="Restricted stock expense vesting">1,614,000</span> worth of expense related to the vesting of its RSU’s. As of December 31, 2022, the Company had $<span id="xdx_90D_ecustom--RestrictedStockExpensesYetToBeRecognized_c20220101__20221231_zckAwZN25oP3" title="Restricted stock expenses yet to be recognized">1,055,400</span> worth of expense yet to be recognized for RSU’s not yet vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2021, the Company has granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlTAXeFVuqy9" title="Number of restricted shares unit granted">12,000,000</span> RSUs to a consultant that vest on the grant date, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zee1fJLtauR" title="Number of restricted shares unit granted">700,000</span> RSUs to consultants that vest on the grant date. The Company has issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--OneConsultantsMember_zIQJZSOncUJa" title="Number of shares issued">12,000,000</span> common shares to the one consultant in June 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2021, as part of an Employment Agreement with the CEO, the Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXZcPAoGyKFj" title="Number of restricted shares granted">30,000,000</span> RSUs to the CEO. Of the <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zbIZEGmrpUEh" title="Number of restricted shares unit granted">30,000,000</span> RSUs, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBAakEKRLTsb" title="Number of restricted shares unit vested">15,000,000</span> of them vest as follows: <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--StatementScenarioAxis__custom--OnTheGrantDateMember_zGMzQzjeoVEc" title="Number of shares vested on grant date">5,000,000</span> on the grant date, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z0rA25RePyf6" title="Number of shares grant date">5,000,000</span> on the first anniversary and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zVKsJj1Ws0Uh" title="Number of RSU shares grant">5,000,000</span> on the second anniversary. The remaining <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_ziaXrD7bYcja" title="RSUs vested as performance based grants">15,000,000</span> RSUs vest as performance-based grants, with the Board of Directors determining the criteria of each <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zZgNoeyYVtpc" title="Number of shares grant date">5,000,000</span> RUSs at the nine-month anniversary, eighteen-month anniversary and twenty-seven month anniversary intervals. The Board of Directors has 90 days from May 3, 2021 to determine the performance criteria.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 3, 2022, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20220202__20220203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zT5rA9Mn6CK8" title="Restricted stock vested, shares">5,000,000</span> of the RSUs valued at $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220202__20220203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zEfsOpaFoWD3" title="Restricted stock vested, value">450,000</span> to the CEO vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2022, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20220302__20220303__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2o2JLz4yLI1" title="Restricted stock vested, shares">5,000,000</span> of the RSUs valued at $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220302__20220303__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zRf3O6P9zsm6" title="Restricted stock vested, value">450,000</span> to the CEO vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2022, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220530__20220601__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zywebK1lXKP2" title="Number of restricted shares unit granted">100,000</span> RSUs were granted to a consultant valued at $<span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_c20220530__20220601__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLYkedCMPY79" title="Number of restricted shares unit granted, value">8,200</span>, and on November 1, 2022, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20221029__20221101__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmkPbaRMOG9c" title="Number of restricted shares unit granted">500,000</span> RSUs were granted to a consultant valued at $<span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_c20221029__20221101__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs96Lzt1yKPj" title="Number of restricted shares unit granted, value">31,500</span>, each that were vested immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUakXJy2Y1Kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0cgkl5B6Pf4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CHANGES IN STOCK OPTION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Average</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Price</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zavK6CACzfpf" style="width: 9%; text-align: right" title="Number of Options Outstanding Beginning Balance">28,885,461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zU5upAmHLShe" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zTvYAMHVG25i" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zDMIoYKT8ZRk" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">5.57</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUFpusp2j01c" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,661,429</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20210101__20211231_zg0DNhS1dzVb" style="width: 9%; text-align: right" title="custom:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zH43F78dkDwi" style="text-align: right" title="Number of Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zcTnw1wzjJHk" style="text-align: right" title="Exercise Price Per Share granted"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20210101__20211231_zusc3DN0mj03" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zbxvM8mclzn6" style="text-align: right" title="Number of Options exercised">(2,500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zHrZjNXAxZ5g" style="text-align: right" title="Exercise Price Per Share exercised"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20210101__20211231_zkVx8qWAfxH5" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zFM1e5yPba3c" style="text-align: right" title="Number of Options expired/cancelled">(24,132,652</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zCmJuQKkqlXd" style="text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20210101__20211231_zMUX6Z5Uzole" style="text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zwVJOK3YyaJ3" style="text-align: right" title="Number of Options Outstanding Beginning Balance">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zST9PDauE977" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zASLt3QrdaL5" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zEPKBnIpsQ25" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">7.70</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_zTPeUnkEBNr5" style="text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">83,992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20220101__20221231_zjjZwqtc4Ew6" style="text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zsPgvD11w0M3" style="text-align: right" title="Number of Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z6WFCIvHawof" style="text-align: right" title="Exercise Price Per Share granted"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20220101__20221231_zWkEW1TJnKdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="-sec-ix-hidden: xdx2ixbrl1092">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zfWevhNcA1Bh" style="text-align: right" title="Number of Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zkFbEcZ8Hvzl" style="text-align: right" title="Exercise Price Per Share exercised"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20220101__20221231_z25ModhePFjf" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options expired/canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zMDEtsZ9xX74" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCryBPIsPv5l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20220101__20221231_zUZllhAfG2Y6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_z9gq1HmYtLhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending Balance">2,252,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdN3rhxHuall" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z1kxnFmQk8lh" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRwO8mhe0Iua" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Ending">6.70</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20221231_zTXYcjfOci48" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending">16,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20220101__20221231_zuRZcOEN6KIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfquzvcWjGq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">2,252,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zzZJNifBJEY7" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zO3TqABTc9mh" title="Exercise Price Per Share Exercisable">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zbnaWZVuQNta" title="Weighted Average Remaining Contractual Life (in years) Exercisable">6.70</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20221231_zQFIoA4oaejj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">16,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20220101__20221231_zoXOWNOAtbcb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 28885461 0.024 0.04 P5Y6M25D 1661429 0.05 2500000 24132652 2252809 0.024 0.04 P7Y8M12D 83992 0.04 2252809 0.024 0.04 P6Y8M12D 16032 0.04 2252809 0.024 0.04 P6Y8M12D 16032 0.04 2500000 24120152 12500 0 0 <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2fqtkL7cDRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zmmhlAFEfble" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number Of <br/>Shares</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/>Price Per <br/>Share</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Remaining Contractual <br/>Life</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/>Price Per <br/>Share</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Balance at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zaidBA6P1Zb1" style="width: 9%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">32,064,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmcFrOnA4g81" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zuShprIUZHRf" title="Exercise Price Per Share Warrants Outstanding Beginning">80.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNHfwxiIYTmj" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.65</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z95Lgfm01avi" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,614,567</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ExercisePriceMinimum_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLy37ThdXqv2" style="width: 9%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKuh8VpLjOyi" style="text-align: right" title="Number of Shares, Warrants granted">11,237,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq3sFTE8MJWb" title="Exercise Price Per Share Warrants granted">0.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOUzSUFJWCXe" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziVHBh7zqRGg" style="text-align: right" title="Number of Shares, Warrants exercised">(10,730,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8fSECGBqKg6" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSkztAqSdjzf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(709,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUfcSS3ksBRb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zt1lZvIwmM1l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">31,862,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmR18JW1end5" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zfBAciif9qhj" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwhlYwREk1nf" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.02</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFzzJ5nO5bJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">538,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ExercisePriceMinimum_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0U0d52lGRC7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z67VJ7igC3ba" style="text-align: right" title="Number of Shares, Warrants granted">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUGJYXdbu9tb" title="Exercise Price Per Share Warrants granted">0.01</span> – <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zFttDDWCQZde" title="Exercise Price Per Share Warrants granted">0.08</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6k91EGEKpCk">2.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zY8kdQXFmPef" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted">0.0725</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDMiEALLqK2d" style="text-align: right" title="Number of Shares, Warrants exercised">(4,158,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQn1EljUAfHc" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1191">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNjLXhudKd9h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(20,966,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5crgpM7EGib" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJHi6eMkuy1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">26,737,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYDo75oLauGc" title="Exercise Price Per Share Warrants Outstanding Ending">0.08</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z8Lx0bYQmrk8" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSeHqYakFDv4" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.52</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z42TI7KlQWCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ExercisePriceMinimum_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ6hmY57alca" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zbQSERJTFfqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable Ending">26,737,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ziNKEleCat6" title="Exercise Price Per Share Exercisable">0.08</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zm2efMw7EB7f" title="Exercise Price Per Share Exercisable">0.10</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeyIBPiBZ923" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.52</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBkzrycTEc0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcTrsH13jYbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 32064375 0.04 80.00 P1Y7M24D 1614567 0.06 11237500 0.10 10730000 709375 31862500 0.04 0.10 P1Y7D 538875 0.07 20000000 0.01 0.08 P2Y6M 0.0725 4158333 20966667 26737500 0.08 0.10 P1Y6M7D 0.09 26737500 0.08 0.10 P1Y6M7D 0.09 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5Y0oscj6j3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zUQxp7zBzrZ5" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zSb9aMRAf4u6">.5</span> – <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zZJeFJEpM77h">3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zZtiZaclSDhf" title="Expected term">2</span> - <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zMStj2wnJYY6" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zIw8Qvc36dFa" style="width: 14%; text-align: right" title="Expected volatility">66</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zCQegvP1ucra" title="Expected volatility">109</span> - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zmyxrJ3ja3ea" title="Expected volatility">147</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231_z1TVf2YE8UUb" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zeanyH3MyHh2" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zmoEZa8Qqm64" style="text-align: right" title="Risk-free interest rate">3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zzi9MqOte26" title="Risk-free interest rate">0.20</span> - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zR7gRMiANsvi" title="Risk-free interest rate">0.58</span></span></td><td style="text-align: left">%</td></tr> </table> P0Y6M P3Y P2Y P5Y 0.66 1.09 1.47 0.03 0.0020 0.0058 3870428 5430000 11237500 11238 0.10 838195 1800000 2005693 3500000 299577 825000 1000000 15000000 0.08 1200000 20000000 15000000 0.08 5000000 0.01 20000 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_z695KI3qsql5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B3_zMb5DdpJgidd" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/> Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Grant Date</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Balance at December 31, 2020 and 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zOkxGe3AAH6k" style="width: 14%; text-align: right" title="Number of Shares, RSU's Beginning balance">262,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zcdIz8VnNVPb" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Beginning balance">0.59</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSU’s granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zvXLIRvqZAhi" style="text-align: right" title="Number of Shares, RSU's granted">42,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zmYDljX6MnEe" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSU’s vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zAJzV2Qw77V7" style="text-align: right" title="Number of Shares, RSU's vested">(17,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zolx0qwAm0E7" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSU’s forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zCVuahAdUvNd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zBRptQmJZXcf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z9VUHtKJsOB5" style="text-align: right" title="Number of Shares, RSU's Beginning balance">25,262,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zY7SnlxsRNt9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zuYJNLyKe3H1" style="text-align: right" title="Number of Shares, RSU's granted">600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zVSgHTdvRgEk" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zF9zk4cSv6wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's vested">(15,600,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zYLylqWZnMvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zneFDmWIJ5V2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance">10,262,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zaRP6bmix9ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 262500 0.59 42700000 0.08 17700000 25262500 0.08 600000 0.066 15600000 10262500 0.08 1389700 1614000 1055400 12000000 700000 12000000 30000000 30000000 15000000 5000000 5000000 5000000 15000000 5000000 5000000 450000 5000000 450000 100000 8200 500000 31500 <p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_z3MwX2Oumx8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6: <span id="xdx_825_zXYhmvbFtHP3">COMMITMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. <span id="xdx_908_ecustom--AgreementTermDescription_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_z4D3iPxZTcF3" title="Agreement term description">The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $<span id="xdx_904_eus-gaap--OfficersCompensation_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_z8Zhl0UoyHo" title="Compensation amount">225,000</span>. In addition, there is a discretionary bonus to be earned in the amount of $<span id="xdx_909_ecustom--DiscretionaryBonus_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zvqaIuBSfTwc" title="Discretionary bonus">7,500</span> per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023 225000 7500 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zQ1NCAYiiZW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7: <span id="xdx_82A_zOpIvB1DjQZ5">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrqSlKXtLcl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets consist of the following components as of December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zIN6r7wCy4uh" style="display: none">SCHEDULE OF NET DEFERRED TAX ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_495_20221231_zS68k7ir78lg" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_497_20211231_zvB9neKE4G67" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid">December 31, 2021</td><td> </td></tr> <tr id="xdx_403_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zEQeJ28X2Mqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTANzxxR_z7A2HK9IFvY4" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Net operating loss carryover</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,280,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzxxR_z1nPgDmkn5s2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Capital Loss Carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzxxR_zZ67rTzEpxJ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,503,400</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,283,400</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzxxR_z0A9xEGavmW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net deferred tax asset</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1391">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zcjGxlEaBezd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--FederalIncomeTaxNoteTextBlock_zauWoYAgz9f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2022 and 2021 due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zM92dLzxlZpc" style="display: none">SCHEDULE OF FEDERAL INCOME TAX RATE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20221231_z4agb02s39qc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20210101__20211231_zFV7HWCxw107" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzAdq_zVO1wnADIvg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Book income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(518,700</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(530,800</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt_msITEBzAdq_zv8F9zYP5Nej" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Forgiveness of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,700</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciation_maITEBzAdq_zkikI7RS6eV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,100</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,100</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--IncomeTaxReconciliationRelatedPartyAccrual_msITEBzAdq_z4ScFbdWjaq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Related party accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,400</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzAdq_z6IUhxZx6Lce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock for services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">339,700</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzAdq_z8Bz1CHLbDEk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,700</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzAdq_zOY0tXXVGH23" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">217,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">201,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzAdq_zm9plaUHtlWl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Income tax expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1417">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zr9dKoJjwT86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, the Company had net operating loss carryforwards of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231_zuvjQR8Onf6g" title="Net operating loss carryforwards">30,955,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2022, the Company had <span id="xdx_901_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20221231_zg2vpauupit7" title="Unrecognized tax positions accrued interest or penalties">no</span> accrued interest or penalties related to uncertain tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrqSlKXtLcl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets consist of the following components as of December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zIN6r7wCy4uh" style="display: none">SCHEDULE OF NET DEFERRED TAX ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_495_20221231_zS68k7ir78lg" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_497_20211231_zvB9neKE4G67" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid">December 31, 2021</td><td> </td></tr> <tr id="xdx_403_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zEQeJ28X2Mqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTANzxxR_z7A2HK9IFvY4" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Net operating loss carryover</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,280,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzxxR_z1nPgDmkn5s2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Capital Loss Carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzxxR_zZ67rTzEpxJ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,503,400</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,283,400</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzxxR_z0A9xEGavmW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net deferred tax asset</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1391">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left"> </td></tr> </table> 6500000 6280000 3400 3400 6503400 6283400 <p id="xdx_89C_eus-gaap--FederalIncomeTaxNoteTextBlock_zauWoYAgz9f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2022 and 2021 due to the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zM92dLzxlZpc" style="display: none">SCHEDULE OF FEDERAL INCOME TAX RATE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20221231_z4agb02s39qc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20210101__20211231_zFV7HWCxw107" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzAdq_zVO1wnADIvg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Book income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(518,700</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(530,800</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt_msITEBzAdq_zv8F9zYP5Nej" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Forgiveness of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,700</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciation_maITEBzAdq_zkikI7RS6eV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,100</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,100</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--IncomeTaxReconciliationRelatedPartyAccrual_msITEBzAdq_z4ScFbdWjaq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Related party accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,400</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzAdq_z6IUhxZx6Lce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock for services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">339,700</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzAdq_z8Bz1CHLbDEk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,700</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzAdq_zOY0tXXVGH23" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">217,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">201,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzAdq_zm9plaUHtlWl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Income tax expense</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1417">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="text-align: left"> </td></tr> </table> -518700 -530800 -28700 -1100 -1100 -6400 291800 339700 10500 25700 217500 201600 30955700 0 EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

3."Y=4CY;3;N<<'8V7RV7[Q^7BX^/ MD] 2GUL-TSWVKL$F)[!Q DLE;6%@(3/,7A.$)*15DQS4W"5G&>\Q'< P[D,2 M)! M+"WHK4M3-,91[Y!IX/EI7=R0$8ON*O7)!T$X[P^7)"KK$5QP8F<&##W6]!Z3 M>"Y/\C6Q.62Q2W9KCCC(.&N5V$*K>E/\A(A[VX(+I,=8XD99SMQE\AJ-\YB! MI%>X6\M*PI+M8-CPO*XP%SP_[TYR(ZPYXFWUSMHZEU4F:^H\L/>&&)F%@@+* MFL)1+CM$XW-E7J7]QU ,X8NKLEXKJ@%WI^*UNZ9@0D!%T: +Y2[!OO))A>LO MKCZIY1KFNQ:Q_@9),NY'4027_3']=CTJX5$'*%%O?)\S1%5+VS2#=K5MI;=- M!WDYWO3A)=,;+@T(S D:#2[' >BFMS43JRK?3];*4G?RPX(^!U"[ [2?*V4/ M$V>@_<"8_0]02P,$% @ *V-A5B;%NRK'!@ ZP\ !D !X;"]W;W)K M&ULC5=M;]LV$/ZN7T&XPY "CBW;29-F20 G=K . M?4/LM@.&?:"EL\56$C6*BN/]^CU'RK+<.ND^Q!')N^-S+WR.O%QK\ZU,B*QX MS-*\O.HDUA87_7X9)93)LJ<+RK&RU":3%D.SZI>%(1D[I2SM#\/P53^3*N]< M7[JYC^;Z4EGW5&72V$_=JE5B>Z%]?%G)%,[*?BH\& MHWYC)589Y:72N3"TO.J,!QM;\&>++3^QH,W\54G9$"44F39 M@L2_![JE-&5#@/%/;;/3;,F*[>^M]3OG.WQ9R))N=?I%Q3:YZIQW1$Q+6:7V M7J]_I]J?4[87Z;1TOV+M94>CCHBJTNJL5@:"3.7^OWRLX]!2. ^?4!C6"D.' MVV_D4$ZDE=>71J^%86E8XP_GJM,&.)5S4F;68%5!SUZ_>7_[X=U4S,=_3F>7 M?0N+/-^/:NT;KSU\0GLP%.]T;I-23/.8XGT#?4!I\ RW>&Z&SUJ<4-03HT%7 M#,/A\!E[H\:_D;,W>LJ_/-(9B;E\%!-51JDN*T/BK_&BM 85\?:#.]:\O!J_"WY[!>]+@/7G.^D_S\;SV^P_S:7!V(=I6 MQ(269 S%@96/5 H)_PNC'Q02)OATT!32% M+$NR7MU0I%>Y^A5P72^;( #?'B3V)B'ED#B6P*Z3)Z.'<&$: 9;!@TPKZ?DI M!4%*H.#PYUVA/ I=J)R7L7DF<_ D&-%BU0I5BDS#7JJ^4;J!L,Q%KBU_6%%R MU3-^IVO8.IMP_OZ(*U@KK+/R@O')E"/[A ??NPX$,OX*IMKF EL0(AKYB$6 MM8(V=C#& <$ YSB0[V!/OR0:'ZB_2: BEW3JSU!PVE!46 MD.2<.%'2[0PJH6Q!IJ$3MR\^!A=B=OO[=/+I[51\N!/OIW,QF=Y-[^^G$SXR M8CR;3>>SX$?][V<&P8$(702 OBMWXZ"4/AN?UP*'X,8#8\]C]S1,*E"=' M7G2,X#JM/PZE6!J=N1#[\N>(MN1CLF30C^HZ+HITP\ZR_*?>K"?N*$8 TK8* M9UQ8C:V(A_4*;Q,@J8A5Q1;JP"'+335M2 (/<8=Y)JDBKISYO:K8S_3==#*] M'[]MT:.X'X,Q_T^F;W"QV&(^XIR^1!B/3@?GW3,7>QZ,PNZYBSTN#"M<-G(J M727&M+ (^=&P%L:&"$*D?#*/!MV!3U_]$=Q3*ODX%=* E&44F0JA/.;\^MS. MK(Z^N?AP_U',7,/7 [?Y:/2:-PD^( X&1SH_;M$S/>(R!W(2@Y"+4 Q/G>RA MPAH.SKQ(..B^@LR;72)K*TTIC>V/$>RZ/-SB3,I\(Q(9B_R)4]&0/M-K@3I\ M5+AL,:/](A#0UZ<.HYB#"*/@["3<-J]2K"H5.ZPUBR!07*ELGD-38PZC/$S<5/!^RS MI2C)502@&1GE*9?GMR9[XHV?8 S''L,Q8SCV&.!#HM/8H23TE9T_&3!@3KH+ MD]NJC;3M;=!B"90F[8M7VBK#L?9':^LT2+YNKUAH$#+MZV!<3J M<$,[&)NV(TN5.@ [#B9;F=V>CJJ7-55_K>!6K")?-O.6911'JB-'26UG&-,7 M628(A67N0(Q:0R<2Q!H N-3J$U,71.JH?OF=FU^430!GC8*/R%5%N>^B8EO M@AL%/RP77UU^]9X?W1J8#B'*_?,Y+L*CH1_BS6SS4MV[!]P.W'_#'XGT3J M)Z4E5,/>V6E'&/^T] .K"_><6VB+QZ'[3/ :)\,"6%]J;;<#WJ!YWU__!U!+ M P04 " K8V%6J'Z4?MDF K;@ &0 'AL+W=OMOVTB6[W?^%87,["#!E65+?B?= 1S;Z?9L'KZ1TXW%Q7Z@ MR)+$#D6J6:0=[5^_YW=.O2A+Z@=P@9F.+).GJL[[6?[AJ6Z^F876K?J^+"OS MXXM%VZY>'QZ:;*&7J1G6*UW1;V9ULTQ;^K&9'YI5H].<7UJ6A^.CH[/#95I4 M+][^P-_=-V]_J+NV+"I]WRC3+9=ILWZGR_KIQQ>C%^Z++\5\T>*+P[<_K-*Y MGNCVZ^J^H9\./92\6.K*%'6E&CW[\<75Z/6[\1@O\!._%/K)1)\5CC*MZV_X MX2[_\<41=J1+G;4 D=(_C_I:ER4@T3Y^MT!?^#7Q8OS907_/AZ?#3%.CK^OR MUR)O%S^^N'BAW]W??7I M05U=7W_^^NGA[M-/ZO[SA[OKN]N)>GE?ET56://JA\.6=@)XAYE=]9VL.MZQ MZFBL/M95NS#JMLIUW@=P2$?PYQB[<[P;[X5XH[.A.AX-U/AH/-X#[]CCY9CA M'>^ =Y5E=5>U1357[ISJ_UU-3=L0'_WWMA,+O)/M\"! M]8NW__K'Z.SHS9[=GOC=GNR#_O9=9^@;8]3G1X),G+MM@WM!;-^@@YLXN.IA MH9/K>KE*J[5Z2HTJJJQN5G63MCI7'1&S4>U"JS)],JJ>J1M-G])&*Q) (I%> M3NF!\?% C2XO3Q2]/TD?2?B)&PC9I$/4A&"U1EU;H!#==7I@?I29(LRK?*!^O5*75X>GXZ' *I:4B:K15UI575\ M$H+T\O3H\I4Z/SX[.*$=R',>)U=@P_1+X_?QPK>Z+ZIOZF#;?="MG#.@W MZ^645(E%W)>;GSX,^?/H38^ M$"JL E!=$VT+.OY6BUU7F2$NEP_%@0WLX_K M:DZTRHGFO C]EI3ZBE1T"_061+9UVS9%MSRX/&)5F:LIBZ?-&_PY&+\1MU5R;_3JB.S0-0<70P8_C4!IO.0Y5&_:/I45/C]1^R-Z*CN MFSKOLE9=EZDQQ8PVS(?XJ:F[E6JZDE9O%T3?9XN]O[FBSZ/SDS?J'3:96)S2 M]T#2Z/R-(7L#2N@J9Z!;=FP!;/ZS\+ Q!WE\;:ZM\N*Q8,L-):%-FT[+@JP4,\_'E,E\ MIMJ:J$M&SG'U8R!SX$5F\(&JTJ4N'0]:GDNZBDQZ0Q*V#N\6::46M5D5+7$P MK6#9U+(L*1GA#.'(55-G.N_HL'BT);^F56E5+/%JMZP;$I"*]%K9TEB7=#KC:;=%+.9 MAGBK/SH'8\CBN,\W($9>SPD\09(#T"*0F8S.06)BZEFKVL*8CCZG#;%U.E1? MM%D1E;32CVG9B>!D38&54U#(D,G+'0:\_OUR>WTW>> E6R(I;".A"ZCX&O9/ MR/E(J]5=4Y >:5DMU-/?-'M?0@_2<+"CA"S65>E,RWL[#Z@)3_P^J^]]3SJ$ MIV2ZH?Y;$!9:8-:U1&70>T8[&JAB1L^L!T2.LE13< ;1#YAKZB41AN2_I9V5 MFI?[ ^F_9E5!2FD.1OAW5S)[7UHM9G<$C3*OBO^!"!!*9D5C6E;WNLD*8CE HN1!9Q! MF;>Z8AC#'K66-8E"83%S5^5.EX.-OQ*7\H',-T(N,76F6:SY$^EZXYB;GNVQ M+1%_ >F$)2.*$'IJ0G3K1) \@+K1U= *FK3'CAP2:.7%=$U)+5=S4;S$4'.2[@:G@3U/B(D6%&0R]BM- MSI#%Y(Q/2/Z91RWM/\TR4@P%$#XEKZ8B%!*[PWT$&D28*ZWS$LC\3>+!GH+V M=NRC]7RN(#4I)GH\PYI6\<-PD!(EC0W#M^QH MHT3$@C!F%3])<$5^=.&Y?+C/]I]YVW^VW_:3JU0BTNUH ^09T>G;]38'8"^8 M'0Y !#MQL%DE>1&G $G#G/ 9WZ4MOZ ^\?GHUQ_2*905X1,*C&Q4MK#"3AX6 M] 6K&,(A@K>ANB';0<@%4ZQ(3)0A"P[.6.NT@>JN@GHG^ F;XP(64/A>?R>2 MYO"5._!I3:Q*XD9K?ZOJ)]*/33[?WSX,K,C >A (L3VFU2OVP H6"X]E M?Q355](D19I-)$#<"[:N:RMGM-P#?(^U]Q;NKQ^LI_MJ8\\3(B-MYHM&J ?' MANDD -/5JG3:_^6G>CBZ&(V&H\O1JV$RH?U5."0>)R51+*W34RP1KXA[)GX_ M29[5Q55-SE^[!M/0VZP/^-R@.(E@9UA8W;+3HB1CAF,3IN;TL%&=H(RB&3:] M">EG\"QPNP16F"ITR62S+&[?=CN@5TDS0@N3PP"#:[^OH:R=2D^%6$M(RPUZNPX MHCUYJ'4W7]2=.'CD290Y,R.OFZ3T*+(CXCL>%-4!=A&3C^($]77B&.4JHNM$ M,\X_U:_5B*+FT\O!R=D90)/6K.VY:.02W6Y!=1?"]D M)>$(%&*O>7*E7H[.CH\N7X_.#R]/C@?'H]$KRYN1Q!"%\-C%Y6L2JL.OD_'X M\.3X_.25C;%M\%1"57(24FMP -)KT(UQF,X.(:&S7E% 0WS&"/2[A"VO*WJ. M!9\]#]%%#85(F5?)-;DL[ %P_ T4$3!MMYTU,'?V4>*>5=M? :9"5K(XIL7%^H4DY"U&UZ;* :\(^ SGM3YJ=]Y+4I@W@U;PK M<@VS9GJ4H,U*/(J$D!#AI>-#2>6<'9\C5\!MA5B1D]1D1(15Z)8 @Y' MGZSX\6NS*%8K')CW1PLW8ET>V:E?%+K,!PD_N(95T^X[QA>^OR<%!?\@6Y"G MI!O) _F(R05VM45-O)Y!($->7L-N8LCCD.6IR9O3LH:N%G"5H?<:T6^)4%>R M,<:'0&3Q)1PMF.4Z(_DQBM9K=2U1+:NT14>:+[@[INUR: R.G.5(-H9Q[K6$ MI=TA#8A1A.5=$\23DY7)2:QZF@%XKT'&ZG;71*/ZHC-:)]$%+(C:1 K M&^KQV=D&,\Q'XE@1=-HIODN"'R>'HU,S]A(L:&'S2D48J12B#PMX4;,=3 M-CTXNC@9'$42'_"!*C(A!P1YB3C7FD2<(S(5UJ%V M=IPV15Q?:+"DM4\4C]-_* S4RX+I$185W15+EA#%A&\3<+JL!]9 FM0K38ARYHNEVD"*&E)!C!@ MT^[=['6)S[U+?+[7)?ZIQJ:O:X2)U397>._KVUUAAIE8F.P=4>@A_A$6FT$[ M231/P9W5$ZSDIM#)!(>.*AH[5?/::@V&Q0Z&HR]4B::XRJ8OH(!3<@MLEG;& MH7XK=##TI8%NM9YP68@7 XFT\E"A>L5^76-ZB?"ANC*D3^JGRCWZAZ?IYS20 MUC(=)[%Z?31:(&XF,DJ04"@N@ MW1*D,0Q2<87SP24:AGM36#ZVX)-MKWN7E1T!(]XHUMI(:&][MY_/MB90@7<8 M&4SF6<=N/SL>G%_4N4G8UY=TE^1Y$'JW:[ON%$$.H<^>VXAE2Y&>)\XK) LU M;V#Z^HE%&\$;7I2=HAE$KZF_NX3E/]5X>-ISY%W(+A%8 ]5@M"TY&)+:UFD9 MK+]BBYZW84UVU4K(:G3*8$1OBM"!\9:EDF*'^>B6IT9$Z]3^. M!N-0FKH &/>;J&HE']7QX,)^$9[:ALC>_D/% KO*GQ'_U&_@?=VP.+CTMN5A MR:^_3O[UC\NS\\LWZCT1AI^SQHB=[^6RJR3(%&-3Z1E+K4M7VAC%9G*B-+Y] MU3(ZNX\:232X&6;H%R6-"D%*TCPO;)3XS+\@X)(BHEUP?,-93Z!_UYH>_*2; MFB(G?S,=%YO,]T%$T?A4!QM!'WVS%TPDJ(BUAQ[5 MXBEM8OA6'+)$L)$7<]0"K+[YO^!$PM;'M')ECLF:/+=EC"L17WF?Q+>H.U.B MN#;C;!]]=1!R42Y/#V,;D.N^AB&J'$V/JL'GQP)&]Z6Z:9.9)=:8P?A6%^-G&A&ZG*:DJ:P&A-Q MG3P+D$\H4C#@NYM;]?*.HGHZR=RE%FZD8'G[G:PGOGH593ZLJLS%S2%,A&J- M3]H%@Y#\?S8(ZB\8!';8O0K2!>DE1FWOD?H%@Z&Z@5D59MP/_<.(? M/GXE3@;H[Y)>SR2>%DUSBC:116@VBC(/+'C6L$LD:K6O)RJ298308%@VC(X- MN=@]DO,AF<)QGD4&<6S$?F)2W6/@D%59KV/&W,J(8C)32=\\%1S*\SZ0BO6( MMIJ>-[6%LTBB2?XS:W^)12A&JW0I7!GZ+!Y1LIR6P>]$BL&IGB422]BJ66GA M4Z>X=^S;^:Z!Y<8GEN4\]C:*]DG6[P3X*Q++3A=W$JB[.]1)W.<['R:_1/8" MKST1J25+$WE@XNO3H6(;YDR7Z" (+GFMJ%.L?6IET\S9X).++");>S M>K28V%F[EW9!1JG/U((:^<*N M3UX_%X)\?FTX&>+91)=&/P&M?><9239$L$[H@*,H_+ I4"6UZGF1P<)71F(M M!#X(&TRT42DC-"TY*1Z MB(8C3C'6!%J2+[3WCI-NSG/IUSUX*SEA&E;#VMK!5FT*'G_6,-!K--J4FA!H MD]9G8'3RC--<>B5XW?8:.6(:(@Z.:;CPPW'XJIL2]CB4MPV,LZ)9LC>BOR.5 M@9W060UR9E@TKSMR-U*SU.)^PJXUF U;T&P&=\XZ/C',OB:$P\$3$K]$7KB%$,<>GN7D!8B$8I% M7\)IEK#KS[_EKRC8D5P:TQ8-@='F&03QI,A=I@2-YSMP^V/H' ;>0C' :,C9:\%G#,)2LG M&RNS,6V1\W)92,EI,V)L-MM"*'SE@=_R(:'E,N9[K@^5:^2W$FY"M8VGKC_X M>1;KGQ2IGQ^=#8[.3L4 )YQ64G-"-(F)MBGJ;9SDB"]I@0V/G#LRT/14*U-+ MBIP>>220%-ZA>86L>R9F*=F:/C];=M45<<347Y3.S N1$"8]#PC)SVYM*<4:$T3G]$K,AM:65/=*VM91N+ C1;H M8.A=241RK4@_=XU-8>P0"NN)S;I268Q(D&&V2@K*DLP+-J>&BD*VX/J&(TKY M3*D&LYG\>7F)V%T2%4$!D]?#Q2773M*!+T%0,,.>>L2%KT=<[*U'?)7D^ZT1 MUMO:GKL7PO:2!/(F,5A6)5)I\ *_5;,@*\.ZDMF+DQ.V!0O9GPR6%_G$X$;8 M0 0.GD\[+T.>BD7@FT:SK^Q$*CS$*Y*+LC_P\K>-KN5A32KFA63=%' #"L2+( M4;AE9R;];C%!MD^:P5P^+H,^3Z3EV#$]@BI/KKU,?NF9_'(OD[_W")XX!%,, MTS=!VQA_+]3MC.^72G8OQ?U1),*)96,R :5@S49C:&(4PL6%NL:#\=,.1F]G M'EAUEZ*"KN:/KE>4 6\8X/UX'AV%N:VCO9B^ANF[)3$DIL!.M@YA[06Q':V MFT1P?3*;(C-RQ*04Q7E+CW5(HC/$&PG!P/;$L13>S!>D7,J"P-LL9X%FRDYP M22MD"Q8!UD;D*OD&PR72#DCIN_X1EPLB^I4V23C5L@T=-M_WONN,?N\Z:IRY MMN5$SQ@%9"ZS?>:28;J[QC8["!C'-'V7-Z^U5"#=6<5\-(7Y9G?EHNC]E(\F M]D;[92PE'_@7;JJF+0:)NPNHW,H,>Z'ND#%:*MF_E.)G'MTS04ABRGI[T=?? MG._':>3UHI(I4XYXGQ::^P^(P$!NW#Y?V9:\4OI:,/O(S\-K;^&CK#"DAWX^ M\56=BA,#Q&MQZ7M;:,!Z%I6^0;R("<9!1BL0P+*1+8)9&#@M8VS. .L/E/]R ME:[M-Q7;U0:)7/]RG"7?1,Q49VD8/"G0=(2$K14*SAI&5&!/6FI!J7$IQ,R> MWB?[0CLGO%I4FRLQ'=(E7N0R$$-^+PQ&ZJWJ6OIOZ2EB=?C/(2>&!I0GTI^) MC>JDKZ-8<<>6=127Y)EVDGEDJPP[Y3T,4N15GC8YYO_RH,3] ,K5Y%I]0%(\ M&0WB,]93\"N3NZA671N2$MCJF>JMB='"0.4]XM,OTQGN N\:@661T=;0YCG$A'8_6X0\71 MN.E]*Z*5-SSGQ-B)3[XQSB(\;I0-('8H17$$.<-M'63NK>"$)WZ-J98\]C6M M/X%IIJ ;.,#UO3<2X^XW-.-@:,9_X,Q]IPUPWW0*:3N4].R3;L31-ZR7*NXJY(0N^,VJ\OO0B0HNLJVN[$+8-V>H@@Y. MN2$#_[W1*S0;2A4;8[9$N8XGF'WO*H)KQ(D'7,M=DC$BU->N%#ISB7AO7+C7 M"?%NB:[-UVIR_?/MS= $#\2,,>Q@U,KC< M8\BK8Z#S)I?V4%96! MGX*I(-$/>;(E!+=-'9EFQ8 @?MZD*_(V6!FB4 %V=,X1TLA%L[0]Y;(>TIGD MZ2(&L5W&LC7KNW!&A)$67DZXK>(@)PV[7W6$VQ-&>Z\[>/O!=LF\U]L3'?M? MWZXZ+,P$,)7[888?P, @RJY=%%A3"AE38_)6?D_JH:3/.K2:A;N/Z%W(<<&?=IKAS;S^5PJT1H_W7 M1LBT@VB&/SU!MA_F=M+9A9*="ZE?%T6I[8"+$'2J>9A2' #H)43JMNY&J%Q[ M%T4>] HLUCDL#%YL\I#$]S2*B6-7MRT=F)R1Z1[;P>#Y92 ZDMV/4:]'S\U3 M^[;=7C8>NHQBSFK.DXK""H/(#5A%Y"AB+*T MU"BKZMSGT#)[5PC%@M"T4$P",V01;,(Y"3F9JA:$6PO&IHI'(%P\*+32W&JU M+ZRCO:WRZY%/7!8^&4#M<524\S#V2ME8>2%-^(LT^1#;H([F3J2[5 M?Y(K67VK>:V;])%"J,E36M$V;!.,,=)2MU%@[DWQ;)9-HMFQQ/?)]TKP+IDO M2B7T;W 6@O:('_FF%C\G@G /P<(-(\.SKC M?@F.=&4"Q^8@0DF[U\6PT6/((==LS>Z*:Z/VVIR-/3H4BM;7758<"RTC#DVB M4M8@0&Q@AHSW+, 7:]]U%<7CC9ZG,BLWKVO?=.*">O8//$Q1@-)2!GUI?(<6 MOYOTWB*)D7>L.O7'@KZ-+S60-H-,VF7CM]S\H5C?J!V!6T]+[U>EKL>?$#AE M!XS;SM)<8B:\;&E%H77.FDRFRER-?9=@114ZF]&)-$\\].K23K[ ;,3\O"Q> M.>P5=F+-H<$V##-QY XO#.2\+)Z_$5?X JTY"4DO)PX@OTQO]TQ9G]:2X[$O MJOC%QU&N[ M]>A#]36\5(9LLZUP)M*.+E<.M*X/4RYPL:])AX'9>?M&CXZIZ'O';7NI0DYC MB=L1Y/7G"V1V<:*OR-$3POO4\+AKH#1_LL"/M3D M&M_3YB8+:O\V%I<"Y514B^NW4(36X;XK?F4*.N$J*UMM MQ#6!TK_602WD1.:$9;?8"0-YDO,$;RJ1_>N/)Q#\Y1"<6W#ZW 7D_=OBG M:[Z\B-4F/Y8^ID49^A["!5T(L9$->LD!5K?4?,?!*S=$\B3#N/E!*L-WB9T* MY'Q&.+;A?CO8):S(L$A'<*L40W-J6+(_$M'YFH,K)MKF)=9WTKJYJEL_RLGX M0(Y0UDUD%">JD]A^JPB*SQ-#*Q\X .)C"*I\Z+2'+H7QR4;8'D;]%+-]N')@%FEN.[B%?8HBF1G 2+&681:M"*6QA;%=Q' -A;Y9%6C M65ZKMG_17,P)UCI;ZGML;,S6[BF>;'X[LC,824PXOZ6-1-G=AZ\/=[_W7]3DYZLOM\GSU9ZME-PWKA(N![L<7!Y=#D[/C\(G#BS/)$=+'L7R$!@MH/S2W5V.1A?G//'?>H_S,6.]@_&]F8> M;Z(1EVN$4UO-P=\8E>T-TCQ;9>>Z 91O!W'BZ"H"F80= MPUYB6^KR8:6-DR#@$#]GYXDX-1XZ(5*S^^P;&X.*\R:U[U([-*M_JN,3S#R. MU?CB;'!QF?"P$>X@R1$UR,5=<9*>X]$ U$FA M<1J;H$NZRO_H;M:9HTT&11+NLD [9QR0VWIQU" 0NMP=Z[@J1']@B;UKN1#, MU.@L7MLLN@_S?8^-M(WHG2?B?;6N1S4-(+4=N;)MQ,[!= W L@?N6H7<:=<) M"/3IT$JX'B:W/K_O#V[O.? CR*UE/'R; 88$(WK8;A)NH =%EK9X+ MV=8KV6*6H<%&,^5 +LK2*/C)<"K)8,N^ M8H03=*#CL6+IXK%!W(C&R@EIL,+?"^F=%>3X3810.BK)4-4?,9SIG(>(?R-# M:_+B^?62-C6)_]W9_2;6"X@W;5-#+LKU-'Q^6VW?*7,X\$Y8&(PI[>1_ST>V M'G9<"!DDQ1_-IL6$=,'OW_$G7)HV9-/=""#C1G=5Q,0$/O&77* _+C0"R>ANX_H?_.U;R$#%,\OMDRX? M?9?J/L44^C['^_L^)]PCSI.$?&K7([Y52?V-9L\(?A+#WYX0-_T^=6%GN=3E MO=12KDG3K8I,G>-"]QY YJ[1&\4K]G\%GD$9!M? 'QR=#RU]"ZGR)WT]E,I< MF$U);>P%907D0+9UU?>&2GOU-[YDYX#G!:(F*WL'L)P\<6ZYV:?M0A^-M;>V MD4N<]V#VTJ8WC.A4(N[]X;GSH(4]P6 M0?@[#=",\A@J5CZ0M/6FX,AJ[:#9EFV9D)(+I;IL,7A.$,BC:WQQR'9C&8QT MV_1%. ^(I\-SS;='.Q':H!1[[4N)1WM0;^K17G<29>G8\9<2$J^^WWD(+7/C M_2US7Z02'O_UD*:N:ACVG8W9?PIDLA,DPIBK;M[!!O[UNB>)JK\RR78<;GWM MZXJ)Y=XC$?6OH2J.*Y8.CLX&R0V:^CD=3[$6WPEOA?HS1RN?;0KMY:2;MJP= M3LZ/#L9'KVPRBB_1YVL/\?//.I_3-@ZN?5V-!.Z6FT.]@?K\5/$8!*Z>=4"3 MB]'IP.7?>!]+#& M:VV.5B1A[-G-./'=8AB3U;W6;O>*T!!-%[*Q9TXF;'V>2TG;T7FF^78($U## MIPR=L(G1Z B6JR#K2E+V4<>Q/S.O(%0-1572CG(SPMI;\-QSC#(9;G:4[(F= M(.!;S'#R%:JFK>!)P"8[P;KYC@W*QHEV]/E93R0DY+.TS-Q=#6@WM+%/"O\@ M0"Q,='$:7Q?"%_+XGI_(225Z$?=7[+7SG>M;,NNLDE/TX?N*>&'L<=VTPHQ< M77=[]DZ8B;WA[&BP=2O>O:EY$"H ?!XM/F^WDF1!4%FA?"6E>I_.34+)/KJO MY'D0X;T1#PCN?&>,ZT1:]35DOZ/=7SO*]O9YMP!"3>[OCOW.WG8\ZPY\IQ/R M,5%'5.@G8"_1!QMFN,W,'$9_OVNIFSG_E3(CMS'+G_+RW_J_A'8E?_\K/"Y_ M1NUCVLPQU%3J&;UZ-#P_?2'FV_U "I+_&MBT;MMZR1]QHX!N\ #]?E;7K?L! M"_B_#_?V?P%02P,$% @ *V-A5E95+BJT P .0@ !D !X;"]W;W)K M&ULE59?;^)&$'_WIQBY4M5*-#@F0$@!R0%SL40( MPG!]J/JPV&.\BNWE=M!#R6:6(&E[SK% C M.]5Z?]=NJRC%G*DKL<>"7A(A.%/1Y6=TLY M'HI29[S I015YCF3W^\Q$X>1?6V_7:SX+M7FHCT>[MD.0]2;_5+2J=V@Q#S' M0G%1@,1D9'O7=_==PU\Q?.5X4"A&:)RM9(FXWAADA)J2:^^O@:0'>8@IA M\&41S(*)MUB#-YD\;1;K8/$%ED_S8!+X(?RV9ML,U>_#MB8[#%H[.NJ\KW6Z MG^B\=N%1%#I5X!Q%QBM$5=*Y;X#JN>P&OTT2E4^%U M/L'SHDB4A>;%#I8BXQ%'!7][6Z4E5=$_YSRN\6[.XYG.NE-[%N'(IM91*%_0 M'O_ZRW7/^?."M3>-M3>7T,?AY,&?;N:^2>/4IT1.@CJ-?K@.'KVU/X5-Z,\V MLI M27B$I[,2W MUD*S#/9"4\ Y44V0%4:EY-K,C]Y-JT_LG?X >H.6>]NOR'/EUSX9YSG*7;6T M3-O12*HG>W/;[$6O7@?O[/52?61RQ\G!#!,2=:[Z5'"R7E3U08M]M1RV0M.J MJCH/FW,/X74$L#!!0 ( "MC85;),D''!08 " 1 M 9 >&PO=V]R:W-H965TK9 MU3ZK%2B?\(W*F4YO18@-UE&Q.,93?G#:=-I;@>F;+E2 M>J#=/UF3)8VHFJ^O!?;:E9:$9327C.<@Z.*T.7".ST(M;P2^,_H@]]J@+;GE M_$YW+I/3IJT!T93&2FL@^'-/AS1-M2*$\:/4V:RVU OWVUOM%\9VM.662#KD MZ0U+U.JTV6U"0A=DDZHI?_A*2WM\K2_FJ31?>"AD@[ )\48JGI6+$4'&\N*7 M_"S]L+>@:[^RP"T7N 9WL9%!>4X4Z9\(_@!"2Z,VW3"FFM4(CN7Z4"(E<);A M.M4?3JZN)F.(9I/AGS"YGEU.QI$%-X/I=#">13 8G\-T%,VFE\/9Z+P4FX\O M<>KCC-RF5'XZ:2O$H;6UXW+/LV)/]Y4]'1>N>*Y6$D9Y0I.G"MIH0&6%N[7B MS*W5>$[C%GB.!:[MNC7ZO,HKGM'GO>85GF48,I'B\1U,UCI^)-P0(4BN) SR M!*94*L%B19-2:IXS)0_YHMBIS/-79T M*CLZ==K[T?#KZ'S^;023"QA^'8R_C"*X?'K:AR#7*CT,>;:BC05/D>,L7X+. M'"DPQV]_&>)/=4@&CGU3$3%(\39V_C.1R M*>B2*%I--B8+N,:CUG!S)3"-;$@*E]ADF)KB8JX1K0CZ JY1JVG"-[:@\)VD M&[H;;)R1E.2HB2C D*4&1!FV-KA=J]OUK4[@P!^@?>+U/H/=LMV._G; ;_DA MSCA6$#A6Q^UA&\?]RN"ECD[TQ!%.'!7?:HZ6QB3PT;5\V[9LVX9/!P773!BQ MCN5XKA7X[A.Y&@L<<"W7=ZVN74+; @];H8TC7<_J]=QBJO,?41^>-5#;L0:4 M/A.JP>F^AC,H<#J!97L5SC(,=*[[W\J@AM)^16G_URF]S=N'2%VK]K>3^J%, MGCM6UQK0J)+M/HU?DKTD,E+T )?W^7J U[5DQ-"W@X[EA?[V[+KXM<%I!7Y! M0J=C^4%8S 8[O-MX=AS+]4+--2/BV&5@5H)[E'1L*_2><7)?<#_.=:!_#.V> M@;:3KN4E-KJ!6V&Q.P4@!Z,5!WP/$\_6SO"E):Y!9M 9$4=_NN"V_'(@=/V# M9F$&\;N6YWEOM HWZ@4!IK?P;88A]P)TW,[)B*HTS'>- C/8>P.'WZ2GCKY! M1=_@S?0=1-'\JBBY8!YA>84TN!A<3N'[X-M\!%>C032?CJY&X]DA/M?O,RQ( MV5!;+130;)ESA8,3T&EC[!"6J%?N #D/#86A FX M-Y=81HG<"(KUN&H!)H;].;X 2N)5>7.W2ZX#PU.6BF'IC$S=2$U)G2#.4A+? M'47QBF/Y:#004Z!G/*%IJ;M*.D1BMBD3/B*BL-&AA8\1HVI-!>.)1*ERR;/\ M\G8/-_ZB1!3U*.R:C9>A\H)=&%UK:@I!144&+1\\<,'?#=_S% U,F7J$((#W MX& D.9T0WN]$$G;/$HIEY2.CJ;[(CAI3)N^.%H+JDT/%Z$@0.GUYJ,%N88:R M6WX7WM>$9%B%9/@K-\KALO]0)-:J_XTWB]C5X,4EL]$U^*LWS'.#&L:@[16R MJQ\7\,6$+[ZGJKKN0@>[J>;JKPV\J+#A]#"C[/*MWVM,HWD%>YM7.ZX5[N?5 M[A.I>S3.W UA)662XA,AY,&"LJI\^I?JS+?V417[[> $^UB"H)BL4/A6\ 1% M;5K&^^SI3@.R2[Y , !0) 9 >&PO=V]R:W-H965T,LJL5E2BY4"B'!20N0:=2;P)ZSDJK?3#) %&3 M.,=V2OGW.W9"2D\IZ@/!CF<^?S/SV9/^CHMGN454\)K$J1Q86Z6RGFW+8(L) MDTV>84HK:RX2IF@J-K;,!++0."6Q[3E.QTY8E%K#OGGW*(9]GJLX2O%1@,R3 MA(G]&&.^&UBN=7@QCS9;I5_8PW[&-KA ]90]"IK9%4H8)9C*B*<@<#VP1FYO MW-;VQN!'A#MY- 8=R8KS9SVY"0>6HPEAC('2"(S^7G""<:R!B,:O$M.JMM2. MQ^,#^LS$3K&LF,0)CW]&H=H.K*X%(:Y9'JLYWWW',AY#,."Q-$_8%;:MC@5! M+A5/2F=BD$1I\<]>RSP<.72=3QR\TL$SO(N-#,LI4VS8%WP'0EL3FAZ84(TW MD8M2792%$K0:D9\:WMQ/'NY\6([^\1=07[)5C/*B;RN"U@9V4,*,"QCO$QC7 M@SN>JJT$/PTQ? ]@$Z>*F'<@-O;.(DXQ:$++;8#G>-X9O%85:,O@M3X+- UX M@K!DKS"-9!!SF0N$?T(5Z<1]7'IR8P%.+#H/$@4+V@-__K# M[3A_G^%[5?&].H<^7$R^^].G6Q\>9G#O+V'JS_SYW)_J4L%HL?"7BU.4SX*> MIGR/JD8Z1B$P!$7Y85*BDA!P.GI2 5^#VB*L>4PG.$HWM)!D/,64;)C4RU0K M3%8HJGH!2T,]<'OPA3AJ'_U_?^.2S0>&O1I1![J?!%.:%]646#,A]OR%7/^$ M3J/M. W'<W\'9R83Y:^J?$V!9%N]U M9;3]4W/1A!F&5*WXV(6*1P-.6Z&>EBMZFQHID J;:X2RRB1)$J(P@'MDQ ?U M?7-&@1#F!OZ=A-_+\I.,?DF68^HW!\YU+< +JGF][78;UT8H>M)R&ETC%.HC M&^I!*4IS;$)<*=)'W2N-:4-*0A 5RJN[#;?06CFHS3&F7(60,:$HN4$@)WJ#Z$!K^#U!+ P04 " K8V%6TY(>.T<# 8$ &0 'AL M+W=OW.0&K"9Q:CNEE?;C9RP%_WW./+28XN_0WC#V(- M(-%S'"5B8*VE3,]M6_AKB(DX82DD:B=D/"923?G*%BD'$N1!<62[CM.U8T(3 M:]C/UQ9\V&>9C&@""XY$%L>$OXP@8IN!A:W7A1NZ6DN]8 _[*5G!$N1=NN!J M9I\8>]&06#"Q',X((?*DA MB/IZ@C%$D492/!ZWH%:94P?NCE_1I_GEU67NB8 QBW[00*X'UJF% @A)%LD; MMKF$[84Z&L]GD<@_T:8XV^E9R,^$9/$V6#&(:5)\D^=M(78" M1:*I!?-8]6Y&BB?Y6EY&J7JC@Y7(XOONIVCB M+6Z\\>SB=G;]#7G+V]G\XM:;H+NE-[V[0E>SJ8<^34 2&HG/?5NJ[!K#]K>9 M1D4F]T F[*(Y2^1:("\)(/@;P%:T2^[N*_>1:T2<@'^"6O@+"UREJT MCG'.)[X+_0;[3@+,@*_7B/&4V5'F6YOZ\&Q@SZ$3L7*?%A M8*EG2 !_ FOX\0/N.E\-_-LE_W:.WCK 7Y%-@"WT H0+ [-N MR:S[5DUR;W7H!YZ#3 _+9F?OK,>S'CN43V8&G]%F/A5$5QAPU:XN=ZI7O-*B++?@[D]_Q*_S.TC@">%P;V*W( MN69UD.?_=A!SBKKUK3P0MYH41Q/^ARL#Q$:7JB,.,V#ON#@JC\-F4]HCCC=9 MB1F^;FTK(\3=)H71A!'BR@FQT:[J",,,V#DNC,KLL-F=]@BCAJ>8D]2M<.6+ M^*Q)>33AB&[EB*[1M&K(XPB@01[V3K,6 U_E+:E /LL26?1MY6K9]EX4S5YU MO.B9YX2O:")0!*$*=4YZZ@W!BS:TF$B6YJW?/9.JD)PNN[LP2): 1 MQ(*R&'%8CXRQ?3JQ79V017REL!,'UTB7.)0UHF&IGHA7X*:>2@BKWW@]353%:O[)=ZT.=1"V!503KE()UFM"]+TR2$"5,@E).797BB5*\NOIS4#<#U>^I M.\_M]%SL] 9#\^ZPMIK >[W#@,KO+LE[VXC[X5ZUP#G:D57DOFWZ/LE1#? M:Q>K$>FYB]426*5HMRS:?1'N=ML4K"6PBF"]4K#>_W!W[Y%I!P-KT.U91^;^ M[KF$K1:/%&P.>N6$M@E=H'9>V#%V'Q09N"M016 M$NA=W^R[N6LQV[DKA8R4FN8V_QSHA>T MV>C->,]=N+;0JM7C??7X19B]H-&6:"VA547;=WAV8S_TSW9W'IM8N;AO'7SF7JMB]F^$#/CLA6L)K5K^OF.SNR_#[:WV>VVA547; M=WQV8W_TSVYW'YO855UWS[N;!'C<"OLFV_@+Y+(UEOF$L1\OC MA7&VJ3X:/]/'#MG>>0^3GUE<$KZAZA\@A+6"M$YZ2GR>'P/D-Y(EV4[ZADFU M+\\NMT "X#I /5\SI51QHREZXT( "1 M-@ &0 'AL+W=O=H97Q??S>7X6N0ZYBF;2Z+R)*'RY0N+Q>:F MXW1>O_C&5VMMONB.KS.Z8@NFOV=S"9^Z6TK$$Y8J+E(BV?*F<^M[ "!0M M_L/91NU<$S.41R%^F ^SZ*;3,QJQF(7:("C\]\0F+(X-"?3XLX)VMGT:P=WK M5_JT&#P,YI$J-A'Q[SS2ZYO.98=$;$GS6'\3FU]9-:!"P5#$JOA+-E7;7H>$ MN=(BJ81!@X2GY?_TN9J('0&G_XZ 6PFXAPI<5 (7APKT*X'^GL"[8QA4 H-# M>QA6 L-#!4:5P*@P5CF[A6D\JNGX6HH-D:8UT,Q%8=]"&BS"4^.*"RWA5PYR M>OSE=C%;D/LIF7_S%_[=P^W#[/Z.W-YY9#$+[F;3V>3V[H'<3B;WW^\>9GYJ4,YTT0TK1?Q2$?<= M11R7?!6I7BOBIQ&+FH NC&H[-/=U:%_<5N)]J,_)A7-&W)[K6A2:M(O_.X]; MQ;UV\07+SHDS*,0=VW2TBWLL;.U]>KBXK??@@+'W1K;>&Z:XV'K91<&[>(+S:C8\(\3)B/"9MBP@(D6,-U^EO7Z;?1QQ.1)+!E M02 ,?YP1M:;0!:&Y7@O)_]J/$Z6_M */]1=,F(<)\TO8L("9$\?3^/.@5_Z[ M[C[M.L/!+0,D!1N6'FPM/3C"TAF5Y(G&.;-9N!5TK(4Q81XFS"]AHQV[]U"I 4:UAVN+7LL-6R,BE9=-0R;F4>:V1,F(<)\X=O%J=K7\6' M-@R0U&N8>K0U]>@X4[>NXU;6L2;&A'F8,']TT#H^J%6 I%C#N)=;XUZV&M=C M*I0\*W)(L222JQ^$/6="Y=)JWE;:L>;%A'F8,+]]TM8T7OX<\R4S4^:>CTA$ M7]09T6M&)(VX*))QKE](!(=D1;0@@W^:IEPK L%QQ5,:ERN(T*5FDFB6%HQS MV[D/;HBX!1<1*_GB)1M MRM^MGM&./]8U*MKN-NP,;-NP9VEI/W7[J!I.46D!%JUI_)WRE--N?&-ADDD> M6G>8=NFC;5O2+IM;\.6^76VMG'V38BHV1:4%'PVS:2JW-I7;:JJ[/'F$[0FV MKFI9EDOV[/WC7P46:K/.$IB0$#7D(+;3D- 853MS3;9/YFBI& M9F-R** \.,N**!>R99;"Z70L)$Z1Q.]]R TB+)!Y5A2O(EC*@XPIP5 MMPI/!J?0"%)_(PACRX$@Y,MV;C]5<\O*[8Y'1:W%J/0=I"! +C1(V@LFJ+X7 M8-&:4: NOCKMU=<)56L"T[Z&6;,& =2"*RK-0Z7Y%:UQ;!_UAKWA8/]\/WJ; MST,SQ[W8/]__'957IRZ].NUEQ'F]J$P4LE97M$;&,7B;NZ%6 M0[%H30>HZZ%.>T'T'N(9A$S^#/&,0JR#L[UQ!*L?H!9#46D>*LUWWM9#'8L? MH%9#L6C-AYKJ MG!YY853: N<459$ B]9TD+IDZK:73+\!D\IP71R=(C@1QJ)\SNK=?:,=>+2/ M8-(\5)I?T1II+3C TJYIZKKDZK:77!=\E?(EY /& MNG#H6YG#-,E3R4(!O_P%6X6FSY#'I&S)W[$]4MFRLCTFS4.E^1_,Y8,M\=-K MJDWVQQ5)A8;<@RI(4AXA[\L@:>*/<9G(F!!,$Y,]*1.1]PWPZ=4 )A52MHZNMM>1Y^;PA&+%%E*D92/K$$ +TNI5J=!??(4E>:A MTGSW[0V#@?4&*6JW 1:M](?NSHLQ"9.KXITG5=8YRQ=)MM]NWZNZ+=XFVOO> M=ZZFY=M1-:9\6>LKE2N>*A*S)2![YR,8@"S??RH_:)$5K]\\"JU%4ERN&8V8 M- W@]Z40^O6#Z6#[%MKX?U!+ P04 " K8V%6#TW _50* ";C &0 M 'AL+W=OB$SYL9@OTXO.?9:MSKK=='(O%E'Z,5Z)9?Z7:9PLHBQ_F]QU MTU4BHMMUT&+>U7J]07<1S9:=R_/U9]?)Y7G\D,UG2W&=*.G#8A$E/W\3\_CI MHJ-VGC_X,KN[SXH/NI?GJ^A.W(CL]]5UDK_K;I7;V4(LTUF\5!(QO>AA M/B@"UE/\>R:>TA>OE6)6OL7Q]^*->WO1Z17?2,S%)"N(*/_O48S%?%Y(^??X MJT0[VS:+P)>OGW5K/?/YS'R+4C&.YW_,;K/[B\ZHH]R*:?0PS[[$3XXH9ZA? M>)-XGJ[_59XVT_:''67RD&;QH@S.O\%BMMS\'_TH%\2+ /7D0(!6!FB[ ?T# M 7H9H!_;PDD9<')L0+\,Z!\;,"@#!L<&#,N X;$!HS)@M!N@'P@X+0-.CVU! M[3VON=ZQ:T+=KNR]M3TX%/*\NM6]]7WPBSVO<'6]QKN;;7&](1M1%EV>)_&3 MDA33YU[Q8IT-Z_A\^YTMB\2]R9+\K[,\+KO\8@977TU#N;[Z\O4_RM]F>>N%T9V4+8TW M+6D'6E*5,%YF]ZEB+F_%;4.\+X_77XL/7FE?DP#=?+%MEYWVO.Q^TZ2B][#\ MJ&BC#XK6T]2F!2(/#Z/DHZ*KZW"M(=R0AQMBL@UO:MV4AW^*'_/PWL%P2Q[^ M>9))6[?EX3=B)6W=.6+)2\+=UY;\3]EW]UYI/%I*9]T_8M:UDX/AP?&KO6FK M"=^\U=1R0-_V'_K:TP_U'V(>9>)6N8Z2[*?R-8F6:;39)?\9Y),J;B86Z7\; MON=O&_>DV2V.5\[25301%YW\@"05R:/H7/[C;^J@]Z^F3",Q@\1,$K-(S"8Q MA\1<$O-(S">Q@,1""*MU B?;3N!$IN?[DDRDRBKZ&7V;B_QP?M,EK(HNX8.2 MGRVD6;2\G2WO\D/L>;2UL/.&KVU@M+_O;O.Q+\_)J,HD?EMDV-3_4 M23FDUC0?S5OH>9J MV3W89O= FMTW63SYKL2KXF@[5<0/D4QF:9[;Z7V4-]:4T5*O;4:3F$%B)HE9 M)&:3F$-B+HEY).:36/ &3&DZVMXX@Y?[ZWZO=W"'/=RF]/!-*?T8S1\:CYJE M7-N,)C&#Q$P2LTC,)C&'Q%P2\TC,)[& Q,(W8(ID3S[:IOWHB+2?I>E#GNO3 M.%$*>S8ICL\/[\RE9-O4)S&#Q,S17D\[' X'H_IQF$4V:9.80V(NB7DDYI-8 M0&(AA-42^W2;V*=O3>R#NW2IV#:O2VBUH:JKWJ+G=/FHCC^YF8*N8/,7DH;F0KGZ?3/ T3 MY<]0++Z)I/$&E9QLFXFH9J":B6H6JMFHYJ":BVH>JOFH%J!:2&GUSN!%R8OZ M3O>L2YCJ$DC-0#43U2Q4LU'-0347U3Q4\U$M0+60TNI=@E9U"1I\+5T.MNX* M2,U -1/5+%2S4365'\*[E%Y9/6-ZDR9_>G'*E:3^UK]0D]] OZJ!:@6MBP M2+23G652S\>J;$R5EM%<_E$4EA?U*4?M<,F2G'&IU:XK]_>V!P-MU$0U"]7L MA@6B]OUU/0RO2 M4,U -1/5+%2S4FR@O9QL7///)>H>@$)(?T M:/D:JAFH9J*:A6HVJCFE5CN/:#S31NO34,U'M0#50DJK)W95J:;*2]7>=",= M+55#-0/53%2S4,U&-0?57%3S4,U'M0#50DJK=P95=9MZ^EX'_FB5&ZH9J&:B MFH5J-JHYJ.:BFH=J/JH%J!926GU$E*K03I,7VK6_D2X'VW8%J&:@FHEJ%JK9 MJ.:4FNP6[B;+T68]5/-1+4"UD-+J65Y5T&G2ZV3'"V<0S43U2Q4 MLU'-*;67I=J#IA1'*^)0S4>U -5"2JNG>%41I\DKXL;Q8I$?R+]^6T_NM$YM MM! .U4Q4LU#-1C4'U5Q4\U#-1[4 U4)*J_< 5;6<]EY#NVEH#1VJ&:AFHIJ% M:C:J.:CFHIJ':CZJ!:@64EJ]2Z@*]C1I7=&V2U@/[;8=\&T2+Q]%4@SEW-@9 MD(5/8U0S4,U$-0O5;%1S4,U%-0_5?%0+4"TLM=IO9355/5 FKU75?9J\NF^\ MS6I:N#D;X[B"/:K(5J-JHYJ.:B MFM>PNE2M?ZKU=U:7CS8;H%K8,!,G/54?Z@?2LRJWT^AQW[37AZLJLPZMH$,U M$]6LID72Z_4'IWI]D=AHLPZJN:CFH9K?L(!'^D@][=>7;X"V&C:M5E7K'_SM MF%95M&GPT&QRK_7^$"UN0S43U2Q4LU'-0347U3Q4\U$M0+6PU/H[27X@PZO2 M-NV5TK:C:E:U_0')](9?CHWEC;5.6+1,#=4L5+-1S3ER;;EHJQZJ^:@6H%I( M:?64K0K0M#>/KR;)8+3V#-4,5#-1S4(U&]4<5'-1S4,U']6"4JO]#'JP=YX= M-DU6&X6S_NR@JEI,/Z9:K-WXB'*R;?JBFH%J)JI9J&:CFH-J+JIYJ.:C6E!J M_5KZ[N1NTS2'$K/&T4/D(;.WO7>D-PT\UWKN2M]PZR]F'@+)/ 64? \H^!Y1]$"C[ M)%#V4:#LLT#9AX&^1YF87I6)Z?(RL7H!R;IRI#&UTE8[IQY2.M;S>CH[1 M5FKRA\ 8:)LFJEFH9J.:@VHNJGFHYJ-:@&HAI6V2O)O>"Y$9419=GB]$WQ0-/,7)]_7L7/X?4$L#!!0 ( "MC858MD0UV3@( /<% 9 M>&PO=V]R:W-H965TI6B-G$B::F+405+_T@:MM-V@%KQ-3MBK038196M(5S #ORXFV4=BX M+)@ :9B21,.R&_1:EX.VR_<)#PRV9F=,',E[XU?VG9[.?9%OE=BX"DJ\-*E&+[0D$D]6;/M?WL"-HM8\(XEH0OU>0U(+$@U8G M\UA#BC1+M=H2[;*MFQOXN_%J2\.D^XHSU':561UF@]OQP]7T;M2_OB+CV[NK M&9GT_O1<=#($I(P;,J9:4W?9I^2,W,^&Y.3S:1JBW=Q9A'F]4;_:*#ZRT1#R M6B1&^ZXX8Z]7_L8MY(;T,CF',A8(1@RH2_418\W M(.:@_QY"?-/3%=RE*6D.W/?D"/ZL M4!K/[D +,H0YDL=KFT!&",(_B.N$FB])PLTOQ5D9UM'"G+%U+O*%ZQ:0A')96$YU_LV)=M9DJ M0%7Z2ITKM'7OAX7MS*!=@EU?*ONGUH$K_J;79_\!4$L#!!0 ( "MC85;: MA JOEBT &.Q P 9 >&PO=V]R:W-H965TEK8]WV;R@&;ABQF)-)#4G9/*A\^I$09 M@@0!A.<_.YOKE?KN]EV]\?UI_>;S^MJ]O%AH[O;]^.3D[/W=[/% M\MV'7QZ^YZ\__+*ZW]XNEI6_EC;W=W>S]=]_JVY77W]]-WKW](UP\>EFN__& M^P^_?)Y]JJ)JFWSVU[L_O?^F?%S<5W>VMV3OQW8 M=]]6W6_X_.LG77UX^+N'\_ML4UVM;K/%Q^W-K^\NWDD?J^O9_>TV7'W5J\-# MFNZ]^>IV\_#_TM?#;4_>2?/[S79U=]AX=P_N%LO'_\[^.#P5SS88G;ZQP?BP MP?C8#2:'#2;';G!ZV.#TV VFAPVFQVYP=MC@[-@-S@\;G!^[P<5A@XN7&TS? MV.#RL,'EL2N,3I[VW,G1FWS;V4?O[='3[AX=O;]'3SM\=/0>'SWM\M'1^WST MM--'1^_UT=-N'[W:[Y.W-GG:\:.C]_SH:=>/7NW[-S=YVOFCH_?^^&GOCU_N M_3=?Z>.GO3]^N???WN3;B_WEWG][DZ>]/WZU]]_ZT1\_[?WQJ[W_YB9/>W_\ M:N^?O;7)T]X?'_VJ'S_M_?'1>W_\M/?'1^_]\=/>'Q^]]R=/>W_RL/??/_YS M_S KY-EV]N&7]>JKM-[??N?MOW@8. _;[T;$8KF?CM%VO?O;Q6Z[[84(#'B0OI!KK:SQ>U&%QI_,9*(\E9+;?/NS-!G])(U/QN.6.W35O;EY?]NYN7S$ MYB?G;VZN=&_NS-:[S2=O;JYV;ZY6OW=NKG5O'E6??Y9&TX?-1RV;ZWV/??FS M-+YXW.YFG<^\^81=WYR\N;FUA%WOF-S^X@=UW'GG>,?>]M3YW9O[JZ^ M?+OS;9M[Q[]DVC;WCW_JVC8/^IZZOW7+9NG1^^WT47+YMG1^VTT;1L=1[S@QJ=O/O;B^-=KV^;E/_:OA1#_ MV"M.](R9AUTW/G]SUXF>.?.P[TXNWMQWHF?0//_1.>L8FY-OD67RX$W>\*YN M9YN-M+J6HNUJ_E?I+_;N[R5C6]UM_J/EWOWVB)VV8_LW'_Z\^3R;5[^^^[RN M-M7Z2_7NP[_^R^CLY-_;)C*)R22FD)A*8AJ)Z21FD)A)8A:)V23FD)A+8AZ) M^206D%A(8A&)Q226D%A*8AF)Y216D%A)8D*@&CK3!3K4!375&]'H]%LT.NW2 M/URM[NY62VFS#T8_29N;V6X):7:_O5FM%__5^J;';YW@T'A$8C*)*22FDIA& M8CJ)&8_8V0.V/\KVY3GDY/1BQA"+FF1 MF$UBSE%/ADLNZ9&83V(!B84D%I%83&()B:4DEI%83F(%B95'O8*%..YFZ-P4 MZ. 4U.1L1(^S;]'C;/B[(8O-YK[]G9!.;&C\(#&9Q!024TE,(S&=Q(RS5[\' M3,[&T]/1='SQ(H*0RUHD9I.8T_*$G$ZFDY.S\Q=/B$LNZY&83V(!B84D%I%8 M3&()B:4DEI%83F(%B95'_[,FQ-$O>('.48$.4D%-TD8<.?\61\Z'QY'5_7:S MG2T_+I:?VC))IS@TDY"83&(*B:DDII&83F+&^=&9A%S6(C&;Q)R6)^2-3$(N MZY&83V(!B84D%I%83&()B:4DEI%83F(%B95'_[,FQ-$O>('.48$.4D%-TD8F MN?B622XZ,XF_KJZK];KZ^!A+CCMEI),<&DI(3"8QA<14$M-(3"^R(6 MXNA;HC-4H$-44%.T$4@NOP62RR&!I.>,D4YK:!(A,9G$%!)324PC,9W$C,NC MSA@AE[1(S"8QYZ@GPR67]$C,)[& Q$(2BT@L)K&$Q%(2RT@L)[&"Q,JC7L%" M''2/Z.$-D)^D9?7U\52135ONZ$:&!H^# M]CPVCJ9ML5%&UU50344UK>4Y:3_S6D?7-5#-1#4+U6Q47P^/S\_>W% MC%".G>,"&^3-9#2ND]'X.Y-1:R+JQ 8G(E*344U!-175-%334@39\EHLGY].QE("+7]%$M0+40U2)4BU$M0;44U3)4RU&M0+6RY?5W M>G'QZ@R:HUZF@IVZ@AV[ IN[S0!3]^...COF/JCWRX<+S\QNI=G'_[S?;.^J MY;;S71VT(Q?59%134$U%-0W5=%0S4,U$->N@-5J:7OR[8J,K.JCFHIJ':CZJ M!:@6HEJ$:C&J):B6HEJ&:CFJ%:A6HIKH&>+#W])A.W%9#IOBS414U^+NKY?4 M]Y:.]'F]F+>>1MR]]>#\\ZA=-$_"NGAY*L\QMU+0>Z:BFM;Z"$8OS\XAES10 MS40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R5"M0K40UT3-CAP<6 ME+MB.9GBFH&E+LT==;?FIOM///6>A3Q]]5Y9ZVG#5RTW'(U;SR]&BVY1344U M[=CG3D>7-5#-1#4+U6Q4?E MMJLOM]L:_*[)ZX;!]L_.R^BZ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J M :J%J!:A6HQJ":JEJ):A6HYJ!:J5J"9ZQOCPMV+8REZ6P^9],Q/5K;VC[MK> M["D)]53U=C.#X]#YJ_A]4U%-0S4=U0Q4,U'-0C4;U1Q4 M=?< R]7O6VFQW&S7]X\G"R^6\W4UVU0_2;/Y?+W_(-1BN:UV2V];LP]:"8QJ M,JHIJ*:BFH9J.JH9J&:BFH5J-JHY!ZUQZ/9B.CE]\8D(%UW50S4?U0)4"U$M M0K48U1)42U$M0[4E^L;G9)Z;],;./NQ#5FH[0FF)4DU%-0345U314TU'- M0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RU&M.&B-WV+.S\:7 MT^9O,67+[?[M]'QZ\>K23VW@Y/QD\NK"3^CC$.SP%=CT;22:<5UV/.XN._;7 MJWE5?=Q(U^O5W<.9/K/EO-I'F?FS:U6V19IN>&BD0349U1144U%-0S4=U0Q4 M,U'-0C4;U1Q4S3>MGQ[N)P4D(;41& M-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5PH/62$*C\.@2EZH]J M/5]LVC\6UFT-#D1H(3*J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6 MHEJ$:C&J):B6HEJ&:CFJ%:A6?H\FM4>F1ZGQ$>MIZX?DT4<@V"$NL"G>3$-U MO?*XIUYYMCAM2 MH+9;GHU.V_(.6Y[,]F.]33K0_'TA*EHOM1OHA MC)+-C])?G&K_YM!_M$:?3GAP]"$U&=445%-134,U'=4,5#-1S4(U&]4<5'-1 MS4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M13?3,_>&'T%".'?<"F_?-$%47 M.H\?FQLG;X2HJ]O99K-_O^@Q0OW%WOV]9&RKNTU[U -5"5(M0+4:U!-525,M0+4>U M5*5!." MY=AI+]AQ+[!YWTQ.=2?U^-A.ZL=C;(3,1U8W4X^Y&ZJ$G(*'%U*@FHYJ":BJJ::BFHYJ! M:B:J6:AFHYJ#:BZJ>:CFCU_WS(].+MI"$=I@C6H1JL6HEJ!:BFH9JN6H5J!: MB6JB9XX/#T5L@S7+8:.\&8KJ!NMQ=X.UF,]7]_O+=/BSO\]^OZVZ3TQ"^ZI1 M348U!=545--034U -5"5(M0+4:U!-525,M0 M+4>U M5*5!,]HWYX;F);K5D.F_?-W%2W6H\OT1.3T"YK5)-134$U%=4T5--1 MS4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"U$M6$8#EV MV@MVW MLWC>2TZ1NSYYTMV='#T?'[NSVHV_=R-# A&HRJBFHIJ*: MAFHZJAFH9AZTY^>O7%Z<7IR^.%!CH:O:J.:T/(;3D]'D?/+BHF?HJAZJ^:@6 MM#PCT]'EZ<6+O1JBJT8MJTXN3D]/7URV(49735 M1;4,U7)4*U"M1#71,TL' M!Q.68\>JP.9J,YC4M=63[MKJ=']J4&\N07NK44U&-0755%334$U'-0/5S,GK M'N'3R_'I^&4L00NI40B3\6AT\C*5H$W3J.:C6M"V3U^?$Q2BBT8MBTY? M+QJCBR:HEJ):AFHYJA6H5J*:Z!FCPS,)6R'-3D3M&4: MU6144U!-134-U714,U#-1#4+U6Q4H3T\ ;']T2PG4UPS =7]T9/N_FBYFC^<<+0_ M^VCZDEW#_619Q^A!=2H)A^T1M=(^\E':+\3T\"['=TBPG4UPS"]7=TI/.!L;>DX_0+FE4DP_:BY./1B\3$-H1C6H: MJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN6H5J!:B6JB M9V@/3T!L1S3+R1372$"G=4?T:7=']-7J[FZU?#J*UG'N4;L.-> M8/.^F9S&=7+J+MF^FBWGU>ULNU@M]_EI\W J4FMF0GNV44U&-0755%334$T_ M:(V+-9U/7YVU9:"KFJAFH9J-:@ZJN:CFH9I_Y$]2@*X:HEJ$:C&J):B6HEJ& M:CFJ%:A6HIKH&[#9=W(X)A#:O)!.Z+:&EU7134-U714,U#-1#4+ MU>R6GZ7QY>7T_+SYD^2@J[JHYK4]AI.3Z=GEBVO=^^BR :J%;0]B/&UY44?H MNG'+NI.+\Y/3\8N2V 1=-D6U#-7REJ?D8G(QNGPQ9PMTU?+H?]6%./IG1;!S M3+"#3,@4UXP"=;'SZ1'%SIO'%/!1NEZMI?T:B_D^'G0<^$'[GE%-1C4%U514 MTU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U3\=N1IC3IHFS.J MR:BFH)J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJ MY:A6H%IYT*:-J/,JY[3:CFHUJ :B&J1:@6HUJ":BFJ M9:B6HUJ!:B6JB9ZA/91CI[A@Q[B0*:Z9@.H&Y=/N!N5T=GM?]9[C@A8HHYI\ MT)Z'X-&X]107M$ 9U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M M0;44U3)4RU&M0+7R]'6?_^CUI_F$:!E;#V?FO'K[AJT\9CF9XIKAI:X\/NVN M/';O'ZXUNKJ6OL[6Z]ER^W2\JC7$H 7(J"8?M!(:>6=:%QQ/^PJ.'SY\77T\G'3U -5"5(M: M=M=H/+U\==IHC"Z;H%J*:AFJY:A6H%J):D*T_"R=GHPFYY.7[]JPZ[+C5V#S MMYEBZLKA:6Y^GTK+9:;[?K^KEIN?]I]/5]7LTWUDS2;S]?[TXT7RVVU M6WK;FFS0"F)4DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U:*# M]OPXP_1DJ#W^AA.7:."VR0-R/2N(Y( MW=W"]8&MAS=ZI.J/:CU?;-YXJP?M%T8U&=445%-134,U??JZ%;:UM\% ES51 MS4(U&]4<5'-1S6O;^:TU->BR :J%J!:A6HQJ":JEJ):A6M[R@]G:=X.N6J*: M$&VOKM&XY1P==K *=K(*;+0V(TI="SSMK@569XNU]&5_]O ^IGRI-O5AJ=:0 M@K8!HYJ,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:@FJ MI:B6H5J.:@6JE=^C2>UYB)+8&2_8(2^P*=_,2W6;\.[+KKR4/9ZAW'E=\FYB M<$@B-1G5%%1344U#-1W5#%0S4N23]&J952344U! M-175-%334IU&CA,ZK)J*:@ MFHIJ&JKIJ&84I&%RT_]\J"&PFYK*.A$%TW1K4$U5)4RU M1[4"U4I4$STC>GC> M81N964ZFN&;>J1N9I]V-S-E3REG=;S?;V?+C8OFI->J@9-Y/3N$Y.8'MTMS4X-Z'MT:BFH)J*:AJJ MZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%J):N)I MU/=>"$"P@URPDUQ@H[P9B>JVZK/NMNJ^8W'2?TMAM=FN%_-]C?7C.T[)GW760@Z]GEJW-C@YH877J*8< MM.JR:BFH)J*:AJJZ:AFH)J):A:JV6>O&Z#/S\;3E]<401=U4G] M=C)J341HL3>JR:BFH)J*:AJJZ:AFH)J):A:JV6>OB^1/+RY>!2*TUQO5/%3S M42U M1#5(E2+42U!M135,E3+4:U M1+51,\,'QZ(V%YOEL/F>",0G=>]WN?= MO=Z#ZI6ZK:%Y"-5D5%-0344U#=7T@];;R6&@RYJH9J&:C6H.JKFHYJ&:CVH! MJH6H%J%:C&H)JJ6HEJ%:CFH%JI6H)GJF^.!(Q'+L)!?8*&]&HKJK^[RST?)# M5*T7U4;Z3;I:+;]4Z^WB]]M*\M?5=;5>?^M3ZCJ'N]L?')/0]FY44U!-134- MU714,U#-1#4+U6Q4S]N69O?;F]5Z\5]O'*!#R[M1348U!=545--0 M34+3OQ>$^$UW60C4;U9QCGQ(77=9#-1_5 E0+42U"M1C5$E1+ MC_W!S-!E?3D@8?PD?9X=2AM; MHT4G-CA:D)J,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J, M:@FJI:B6H5J.:@6JE:@F>F;]\+=F4.YIW)\_RT0G/Y^>O*_U'+]_'0=NN M4:U M1+51,]<'YY^V+9KEL.&>#,DU6W7YSUMUP]G16\>(]&B-PVA?=:H)J.: M@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FKI0;MHOB-P M\3(0H3W5J%:@6HEJHF>&#P]$;$\URV%SO!F(ZI[J\\XVQP_I:KM8?MK'H'FU MW,X^M><@M)T:U6144U!-134-U714,U#-1#4+U6Q4GVU9?=M-J_YIFMOST M<,/=+_?;]>I6^N%C=;V[*Q\/-_[3$; TVSRXV\5=);Q?QF_\W9[MN+ M]S_45!ORYV]WZ_V=7J[O-L^7=IM9;V_[E9W7ZL MU@\?':H?V)_>^DSVYF9V>RO=S+[L5I[_[7ZQ^][#XUPMJP=PW_*WO_\[;5W= M/BR\7<^6F]G\X8G\2:IV&^WNW*::WZ]W3V[U;>&GN[6N'O;F MY^Y)DZX7U[O-#J-?FI[\_Z?M5O?;S7:VVU.[9/#E,2"\B?_XT_,__;1_\A;; MW8T^/^ZOKXNGQ[:_U7KQZ6;_\_"GW6.LJCMI_\ ?'N+GW0_"?C>TW(&H^Q/M M^Q^JV>9FO^[LY7LZ#Y_=ZMS\3[OG;G:[_PD=G=2/WWYVY,S_=N3LY]9COFBE M.JH5J%:BFNC)I<-#/ENISG)82&V&_+I2_;R[4CW".X.^FB+.JK) MJ*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6GK0+KL. M_Z(-ZJA6H%J):J)G=@\/0FR#.LMA0[P9A.H&]?/N!O5GAW]W47_^[#>"^O>; MUER$=JFCFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJSD%K-+A.SL:7KSZ^B+:IHYJ/ M:@&JA:@6H5J,:@FJI:B6H5J.:@6JE:@F>N;Y\'#$MJFS'#;)&^'HHFY3O^AN M4S^\4WKUW=6AW?[0E(1J,JHIJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH% MJ!:B6H1J,:HEJ):B6H9J.:H5J%:BFN@9_X.S%,NQXUY@\[Z9I>H:]HO':E*H M.O0"+5U'-1G5%%1344U#-1W5#%0S4ODU%E-^GW5H=WFX/R$5J^C MFH)J*JIIJ*:CFG'0^JM#T64M5+-1S3GV*7'193U4\U$M0+40U2)4BU$M.?9' M*467S5 M1[4"U:CFHUJ :B&J1:@6HUIRT#K*/E-T MP0S5G'Y1C9[C AG@S)-7]ZA?=_>K#JD.[L<%I""U21S4% MU514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K7DH'67?:;HFAFJ MY:A6H%J):J)GA@\/1&R7.LMA<[P9B.HN]8ON+O6CJD.[C<$Y"*U01S4%U514 MTU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6D9QI\7]GGE?1/*OOL M@O\WRC[?^A3U_Y5]'E/V^=:S=V39YQN;#RG[;#WD2[Z>,E3+4:U M1+51$\L M'9[QVV3T\ M"+$5ZBR'#?%F$*HKU"^Z*]0/OUF([R_'0JO544U&-0755%334$U'-0/53%2S M4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+4"U'M0+52E03/>-_>)9B6]A9 M#IOWS2Q5M[!?/!:94N58:/DZJLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH> MJOFH%J!:B&H1JL6HEJ!:BFH9JN6H5J!:B6I"L!P[[04[[@4V[QO)Z;*N:+_L MKFCWOZ<JCF MHUJ :B&J1:@6HUJ":BFJ92T_YN-IRX]YCBY;H%IY[&M5B*-OR0Y-P4Y-@8W- M9@RIV\TO.SM F;Z([C4&QQ*T\QS5%%1344U#-1W5#%0S4#,DC>N0U%UD/JPOHAL;G(;0!G-44U!-134-U714,U#-1#4+U6Q47+5"M1#71,\^'AR.48R>YP$9Y,QS5_>N[+[O"T5%-6MW&X"A$:C*J*:BF MHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEK6,ZF^K^5+ M2/^DEJ\N^'^CY>NMCX/_7\O7,2U?;SU[1[9\O;'Y/]CRE:.OIP+52E03/;%T M>,9'.3:B"BRC-C-^??F R^[+!QS=I-7M#,[YZ)4#4$U!-175-%334TJ0E_??NE\%%=2TI?^Q^6]DN=K]T>+M?UG:_ M>W:6;77?A<$9"KWJ *HIJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B M6H1J,:HEJ):B6H9J.:H5J%:BFNA)",/C%MO@SG+8O&_&K;K!_?*Q&!4JV[I$ M>]Q1348U!=545--034U -5"5(M0+4:U!-52 M5,M0+4>U M5*5!."Y=AI+]AQ+[!YWTQ.=>7[97?E^]5L.=\?G#\3$-U:?ME9[7IX,-V MSF*YN+N_ZSY,AS:[HYJ,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&J MA:@6H5J,:@FJI:B6H5J.:@6JE:@F>A+!\'C%-KNS'#;O&_%J]RO&)Y6264UA.93F-Y726,UC.9#F+Y6R6A9L!K45G_<17-ZT.'Q"NVG M9SF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.9[F Y4*6BU@N9KF$Y5*6RU@N M9[F"Y4J6$WUAX#OB%=MQ#WO?DD#7%9Q>)*?QL^3476$_^)C?[(_>8WX]:PX/ M5FC5/RG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,R M7,9R.RG.C+"M\1K-BZ?-CCDL"+]#5YEKXF[ %!M"N?Y6264UA.93F- MY726,UC.9#F+Y6R6FS8'7ZSS@@V(D.CUO_J^,?IS-FKY?KF[O7CXB_>U_^&7S[-/E3-;?UHL-])M=;U; MZ^3G\^F[QRL)//UAN_J\"W7OI-]7V^WJ[N'+FVKVL5KO;[#[^^O5:OOTA_T" M7U?KOSX\G@__ U!+ P04 " K8V%6$TGN1IX% !T)0 &0 'AL+W=O M2#=4QI__W:29H0&APG2GL!2;#?8S\\ M)H2!E\ /X[&V9FQSH>NQLR8!CL^B#0GY)\N(!ICQ6[K2XPTEV$TZ!;X.#W!@[=:,_% GXPV>$46 MA#UN[BF_TW,5UPM(&'M1""A9CK5+\P+U#-$A:?'3([MX[QJ(J3Q%T6]Q<^.. M-4.,B/C$84("\[=G,B6^+Y3X./[+1+72Y; MC[6!!ERRQ%N?/42[:Y)-R!)Z3N3'R2O8I6W/+0TXVYA%0=:9CR#PPO0=OV0@ M]CK 8QU@U@&J=NAE'7JJ'?I9AWY")IU*P@%AABZ&9#:]_(OH)7K](WIWV^") M4! MP7PC5D0,YEL6,QRZ7K@"5V3EA6%RA7T<.J3J"T@-V(D!L=Z?)Q!:<& , M1_KS/I>*=H/!P.K;9KDADHY81*2+>(,=,M9XR(D)?2;:Y,\_3-OX*N'1SWGT MI3Q^)2N6N.#RF5 >@< #$6%,()AR/Z(\8&RQ#[Y[2P).O!"\$DRYA^Y!^R(\ MC;]7H9+;ME,U, !!ZK+<>5W\&ETQWP$_M;4NV"53RE!M0])46:BEE[_CGH#8?PP#G?MS)M MV^S#PMM+,.P3, ]]1S^RA?I8HUI SBIP<'>2(TSHW^P*"L; M60=SE@Z]Y8(\S\&<-PQ0*XI#=AC*TRE+I:H'"JI0@COJ M0!)^4L4&_#K202UT:OD-&Y/U@/:R8[/=VI5SDHHVX=21$&HC5(\1%AAA MQTM8SE=JK0G?CH10&Z%ZOD7M8#8M'LC+QJ/$U1U1+/C^$8XM$OQJCN]+BE/8 M-WO0M@[3MC8VZTD5584I3Z,E"UH%F%2\";".A% ;H7J<1>5@RDN'-@M;A7.+ M>J*:>B*#'E58E\=V"6%2''MP8R^?J] =6&J*KAX2Y">;)%H6'* M*PVU>O1X<9_)ETM#HP&^T7+66813%@RFO'MK5HQ(X Y5J5*D5 MJFYE'9ERD>^;\H3_O;-G<\9/?K5W#U6]NZ-T.YO^1R3OL$C>H3QY;[E#5L.R MQFB3K3&Y5%/:7:F5:1>5 )17 L>#4AU04RD:RINE(BD9FKQZ/6#M6W*T^\ MR)VA/'=N'7MLQ0EVM"N?8?B(/7Y8Y-Y0GGO?XI?ZZ--EXCSM5 UUI5;&5V3K ML.5>?_/HDQHRS9I_?4K-D'S8;;$4&3WL; M?+?8,U> ,5:J8NE;EG_.+]+PG MSY3;AIU,MB;ED1MONFJZ4DM1Z7O'40)"5\FQGA@XT39DZ?&._&E^=.@R.3!S M\/S*O$#I :!")CV/=(LI7T,Q\,F22QIGX@ /38_XI#1_4$L#!!0 ( "MC858].,VY)P8 /8B 9 M >&PO=V]R:W-H965T^4$F$\.^/; O?$,(8,N4!?%GM[K>K77_( MZJP"^HO-">'@S7-]=EF;<[ZX, PVGA,/L_-@07QQ9QI0#W-Q2F<&6U"")]$@ MSS60:=J&AQV_UNU$UQYHMQ,LN>OXY($"MO0\3-=]X@:KRQJL;2X\.K,Y#R\8 MW#&P&N& 2.*[0U8L ^.Q,^OZRU:F!"IGCI\L=@]95(0)&#X\!ET3=825FS!L9+Q@-/#A8>>(X? M_^(W&8C, &3M&(#D %0<4-\QP)(#K AH[%D$ZPISW.W08 5H*"VTA0=1;*+1 M HWCAVD<<2KN.F(<[XX&7X=7WVZ&X/XS&'SMW7T9CL#U'1@]W0_^ \^]Q\?> MW=,(?+@B'#LN^P@^@6=,*?8Y^'%+O!="?XI+WT97X,/?'SL&%QZ%>HVQM-Z/ MK:,=UB$"MX'/YPP,_0F9Y!48 DJ"!VWP])%6XQ49GP,+G@%D(J1P:%!^.-2X M8R7AM2)]UJ[PSC$EG_IBGDW (/!$\3$<3=]>&,09$07!P\#JZW%MA M.@$_;H1*<,V)QWZJ AS;KZOMATW@@BWPF%S61)4S0E])K?O/7] V_U4%YT3* MGQZ8U#L":8@B:8X#53I;?D<"\N2517*,I% MQ4ZB8FLU]V8S2F:8BWDL8N"(9\ 8?,?NDI3/;&R@D4E8PVJU,NF*$6Z+01O6 M&W93G=9F J!Y6%J';X2.'4; W7&XEM,W&C6%F\D.=:"BXVW,EZ;YV;3S'U@ M :ERC*V&V4I@MJJ6X"S\*7;HV/O65BTAZ7/!Y6U!")$HN8Q@SNUVXG9;Z_;. M9)3Q7JOZT/[95B0%JL%!,WU"F^\\^33PI6V("I,/%2M+[Z0Z4$#3.V"&H<"J MLY)(P&IH<&N^?:K#1LNRK"(VA20TFU9N#N>]1ZGWZ,C)J0>AU5XJ[!+C\8KR M$4@I$-32!GW^%@XE$V.,_;%@\CM"8&UG!YEM6WR:Q40J1)MF>^=C':;D!.K9 M29DTEL&BM7)(.H]7E(]$RG"@GB;\B/^57$3P(\::);897MM?IR*2TT:4]B[P M[Q>A[/#WTN'K:Y]QN@SOL@P;V#0]V?,2&I5A44^$>E_BSJ9DQGMPH(CN,&!+ MOJ.,LE9%14(,4]H$];RI)"4>1C_*$-C;SV:[F7_D2J3;DEO4.8\BY4[P0/)T M("?6X=-;EHQVDV$-,]8KJIKHE'=!/?$J1Y U<="J/Z2MM/;Q[#S"E*)!/4<[ MGL1HT*MHE]DNSG"EU$Z6G5]]2,D:TI,U3M-EJ]GO:*JL4E)']*3OMWUO"\ IZ)[513M#T#*^9">\YV@ MW/<$RBI3\WHOJT8A)8U(3QIO13EX2R]9*E4"J4#D=O\!/96V/."4&Z+&'U[N M1"=B9#)<[\'O4,KOD)[?[?]347I]3%J",%\0]6)![!/+(TDY'M(SK:.68*3N MHE/%%2^]"U63E7(TI.=HAR5+\X!O*=&VBFC58KLRE1(Q5'&Q;%_#;9=S^T3K M:?FW+2G]LO3TZQ:_[>VX>A4'OS)Y#Q9FI2S,@G_Z!=.)J)0,UWL0,RLE9M:Q MJW&E.ZZT5"B(8M.24EDZW]KQC]K*O%34LZNCNJW4O:^0]2Y4351*G:QCU]O* M=5MI9E^6ZN47[JV4#5GZ%::JK5:JW>6-=/FDU,7(["#P")U%&RL8& =+G\:-7K1EH7"]#R\&\1:,5$V\(^064U%-#+AD*E2:YTT!@,:;+.(3'BRB M?0HO >>!%QW."9X0&@J(^],@X)N3T$"RU:7[/U!+ P04 " K8V%6W6/" M*T4# M#0 &0 'AL+W=OF0LRN;9N/IA!C7J S2.2=,64Q%K+))C:? M,<"A%L61[3F.;\>8)%:CIOMZK%&CB3Y=WL $J*[\1C;C^1FF+O3<:+6D(8E: MQH%@\BZ1.M$8M.Z"]O ^0(^WJ#D8#+N]I\[CPP -!T$;=1[0;;/31\_-^V& MND%S,.P'W>#A"7UI@\ DXE]KMI!1*"][M!GQ)AW1.S&BZZ$N3<24HR )(3PT ML&7X&8.W9;CQC(YM&!50T?V&/,?S<@)JO5_N&L(I9E-:U'ZE$W[!:B;W*(1H M02,L2$3$.F^64I,K;:*2;=%P"KY?LQ?[D1M'4BE^S6=X!'5+YC 'M@"K\?F3 MZSL_#!REC*/T/HZ0+$@(28C6!*(PC\5HE!\FRENHC_L%L8 M3*P3]1_H\X"NJ#=V:0'B2YF$Y)P%,%86CJ%BORXLK0V3QN"SG1Y^T*%+);U MY52>9X"I!^3],:5BVU #9">DQE]02P,$% @ *V-A5C&Q9KF[ P O0T M !D !X;"]W;W)K&ULK5=K<]HX%/TK=[P[[>Y, M$S\ 0U+P#*\TS#:/P:']T.D'85_ $]MB)0'-OU])!@<3XTUH^( M^=ZC M[0UECWR!*.!7$J>\8RR$6%Z:)@\6F!!^3I>8RB\SRA(B9)'-3;YD2$*=E,2F M8UFNF9 H-;RVKKMG7INN1!RE>,^ KY*$L*<>QG33,6QC5S&.Y@NA*DROO21S M]%%,EO=,ELP<)8P23'E$4V XZQA=^[)OUU2"CO@6X8;OO8.2,J7T415&8<>P M%".,,1 *@LC'&OL8QPI)\OAW"VKD;:K$_?<=^I46+\5,"<<^C;]'H5ATC)8! M(<[(*A9CNKG&K:"&P@MHS/4_;+:QE@'!B@N:;),E@R1*LR?YM35B+\%VCR0X MVP3G,*%^)*&V3=#.F1DS+6M !/':C&Z J6B)IEZT-SI;JHE2U8V^8/)K)/.$ MY_>OAX/)UR'<74'_NGO[9>C#Z!;&0_]A/.H_# ?@/]SU_X')[>C!A[\&*$@4 M\[_A#,;(!8L"@2'X@@:/,$DCP>''#2939#]EQ)]@ E\0AKQM"LE5M6@&6UZ] MC)=SA)?MP U-Q8+#, TQ+ *84F2NU-DI[3F5B ,,SJ%F?P+'V%W&2#I'.54$3)]@/^Z>/.GJ[H:P M$'Y\E9 P$ICPGV4&9^W7R]M7R\,E7Y( .X:<_QS9&@WOPQ^V:WTN,^>=P I6 MU7.KZE7HWNU*C2B@L\P,_@G&_N0CAQ[.HS2-TKF MTW!V8U2V\LBFU6^7^2D+][1]^-2*ELI7WF@; 7[?9R"#;;U MO,-:)_6>/(/-,#JBNAKSK:OW*6B5XO>.%_8[CH)J2RI;>K,E)Z!56N(\6^*< M-!Z&V;I?L9=M@?8[&)S0YCWO7K0MZOD*D ^7U&J=@55 /YC/E^?E?,RI]\FR]NQZORR\75Z?)N48PO-X-N;TZ53F=P>CN> MSD[./VZ^%R[./\[O5S?361$NI.7][>UX\?-+<3/__NE$/GG\1CR]NEZMOW%Z M_O%N?%4DQ2J["Q?E5Z=/RN7TMI@MI_.9M"B^?3KY+'_(1\/U@,TS\FGQ?;GS M6%J_E*_S^=_K+ZS+3R>=]1(5-\5DM2;&Y?\]%!?%SN#N MXT==W[SX\L5\'2^+B_G-7]/+U?6GD]&)=%E\&]_?K.+Y=[.H7E!_[4WF-\O- M_TK?J^=V3J3)_7(UOZT&ETMP.YUM_W_\HWHC=@;(O3T#E&J ^B M7C6@=^B ?C6@?^B 035@<.B 835@>.B 435@=.B LVK V:$#Y,[CFNL\']+= M-^1I9;]8V_U]0QY7MWSP^I8?5[A\\!J7'U>Y?/ ZEQ]7NGSP6I5[Q\\)J7'U>]?/"ZEQ]7OOQB[>];+\KCVE=>K/W!OB&/:U\Y_-_ZTS_V MS=H_W6Y6-MLD=;P:GW]8$O)6EPX4A!F%J!G[R3_OHIIE9/RWRK_-$? M:K$:3V^6DC]>+,;K+>F?TC^D+%&E/_[]SX^GJW+AUE.<3JH%<;<+HNQ9$%GR MYK/5]5+29I?%9"]UY'>2 MTE&4E@6Z$ \/)JOW4G?_<%4\W+Z_$0[7#AC>&>X=KK\V?"9\[89XN#=>E,.[ M>X>;XN%Z\54XW!(/3XJ[]Y+[=\"R=SM[A_L'K#?![,'AO_)MKST\?.';AD>OO_&"R>/#7WK;\.2591^O M?VG.]@Y/#_B557I[AV>_]UN3'SY<%FPYNT^AU-UXW7VOYGJ\*/[QI?S3^E*Z MF-^6^QO+\>8O]L]ETLRNBG(?8"5]_2GM/B\<_]Q\^_/W\>)2^B^W)"5K5=PN M_[OE]7S9SM]KGW^]W_-A>3>>%)].RAV;9;%X*$[._^/?Y$'G/]NVXR2FDIA& M8CJ)&21FDIA%8C:).23FDIA'8CZ)!206DEA$8C&))226DEA&8CF$-1*N]Y1P M/9%^GJSFD[^E^=TFU8H?Q6(R71;+=])RG6C+ML02>L4ZE;>10LZJDYA! M8B:)62_?W.J]??;FVN2L#HFY).:1F$]B 8F%)!:16$QB"8FE)):16 YAC5P9 M/N7*4)@K?ZVO2YBM6C-%./+83"$Q=?@R95LW>QHYJTYB!HF9)&:1F$UB#HFY M).:1F$]B 8F%)!:16$QB"8FE)):16 YAC=P9/>7.2'QN9[TG(]TMII.B+7J$ M@X^-'A)3M]AH)WHZ[SNC9[%SR)-TR?DA Z)N23FD9A/ M8@&)A206D5A,8@F)I226D5@.88V4.'M*B;,#S[QLCWQ)T^7ROKA\)SV,;^Y; M@T/H'1L<6ZS_\NA*<_.EOGR>K+3MC9 +IY.806(FB5D'K@.;G-0A,9?$/!+S M22P@L9#$(A*+22PAL93$L@,W:7G+\T:"4^YRYVG+O[X1[( #4])X=BDMUC<) M+J7Y_6JY*K^>SJ[:MOUB\=B-/ZJIE;;[1BDM"7'8TW1TV0Q4,U'-0C4;U1Q4 M'#ZFIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J M :J%J!:A6HQJ":JEJ)956N.*I>[H;/ABWZ?MB0.YMW_G1ZD#2/FE %I*/XN5 MM)I+7PMI44SF5[/I_[1?ABR>X.@X(C45U314TU'-0#43U2Q4LU'-0347U3Q4 M\U$M0+40U2)4BU$M0;44U;)*:Z1,I]_OO8PC:-IF9M5U!++P7M"7F;7>61*> MJQV<4VC" :AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J* M:EFE-4X#M>\RM3Q1N,M4=P6LV]X.BY]M;T VFZZ6TA]QDBW_E/[+*]97$K36 MW(CAHV.(U%14TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4 MRU MI[1FH-6E _+V7M&WZW>3T:X"5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U M']4"5 M1+4*U&-425$M1+4.UG-*:P53U4\U$M0+40 MU2)4BU$M0;44U3)4RRFM&5=U@8(L;E#XA?->:+$"JJFHIJ&:CFH&JIFH9J&: MC6H.JKFHYJ&:CVH!JH65UCB1TAF]_$LA0J>-42U!M135,E3+*:V94779@BQN M6SCLY)CT+TF[O;N95\<0KQ;%]B"C\.09VM2 :BJJ::BFHYJ!:B:J6:AFHYJ# M:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B64UHS\.K>"/GLK4^>H4T3J*:BFH9J M.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:4U/TVUKLU0 MQ+49OW/R3$P?&VFHIJ*:AFHZJAFH9J*:A6HVJCF5MGORK-M:"NRB\WJHYJ-: M@&HAJD6H%J-:@FHIJF6HEE-:,Z[JI@WER*:-QY-G^S_I0BP>G5)HT0:J::BF MHYJ!:B:J6:AFHYJCM'0&M!8:NNB\'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEE-9, M*:5.J8/K.'[C]%GY\];#C?41R7=26CZ>7!=2,"N$I]W$"WQT"*+U'JBFH9J. M:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5I.:WCY0/_\].NPGIHR.-U%14TU!-1S4#U4Q4LU#-1C6GTEH^@OCY M\4QR6@_5?%0+4"U$M0C58E1+4"U%M0S5Y^'@F M6D6":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6 M4UHS*.LJ$F7PUL7FBCB4I/?.IZ)UIN@FHIJ&JKIJ&:@FHEJ%JK9 MJ.94V@'',]'F$E3S42U M1#5(E2+42U!M135,E3+*:V95G6]B?+_46]2_CR8 M2>EU(1GK<)/4\>J5BS#1[A-44U%-0S4=U0Q4,U'-0C4;U1Q4?*&_=?:*@W2>HIJ*:AFHZJAFH9J*:A6HV MJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI36"KUMWGW3%W2?Q\3>3B\5C MDPS55%334$U'-0/53%2S4,U&-:?[LO*D_5@E.JV':CZJ!:@6HEJ$:C&J):B6 MHEJ&:CFE-4.J;CSIBAM/[/MRUTKI*'WAH44Q'DM/(Z(UI*@FHIJ6J6]7F"HH_,:J&:BFH5J-JHYJ.:BFH=J M/JH%J!:B6H1J,:HEJ):B6H9J.:4U(ZFN'"D?BB)ILX\EW2VFD]8/&16//CJ1 M2$U%-:W21CN)U'G?&3U/(W). ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U M!-525,M0+:>T9AK5E2)=<:6(6DPV9[/6I[84\:DMM.H#U514TU!-1S4#U4Q4 MLU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU MI[1F@-55']VWKOKHHE4? MJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:4U M@Z^N^NB*JSY>/;6%UGF@FHIJ6O? Z@<=G=9 -1/5+%2S41JA M=1JH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI373J*[3Z KO M6CZ_F-_>SF=5L93PQ!;:BH%J*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J M(:I%J!:C6H)J*:IEJ)936B._>G4K1J_SQB>V>FB)!JJIJ*:AFHYJ!JJ9J&:A MFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6DYIS>"KFS9ZXJ:-[1[;_&X3 M=L6/8C&9+HNEZ%27&#PZR-#6#5334$U'-0/53%2S4,VNM-T3CDJ_Y82C@T[K MHIJ':CZJ!6UO<*?3'YQUFV]PB$X;H5J,:@FJI2UO\*@[DL_ZS?C&$>/C1"8'64Z":5FD'W.>+SFN@FHEJ%JK9J.:@ MFHMJ'JKY+;^9RME9?SAL_EX&;<]KW_BC?1&H%K>]B-:_$9*69W9'PTY/>78G M9-KRQ/9M]J%;@/R0A6QND.OBA9ZX>.&O\?HHU:I]8XR6+J":BFI:[V7I@M)I MWQBCI0NH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&IQR[]H65:ZP_[+[3I:J(!J M&:KEE-:,FKI0H7PH/%XDONQ,//KHM"$U%=6T2GNE4 &=TT U$]4L5+-1S4$U M%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,LIK9E&=:%"3URH4'\";_6QN]/E\G[] M818/XYO[]H!"BQ50344UK=+ZNW\\*:U[0VAG JJ9J&:AFHUJ#JJYJ.:AFH]J M :J%J!:A6HQJ":JEJ):U;;KZ+4?47CYMU -5"5(M0+4:U!-525,M^19-: M]XQ^'VK&5]U5T!-W%51G@X2WX8B)HP,+[2M -0W5=%0S4,U$-0O5;%1S4,U% M-0_5?%0+4"U$M0C58E1+4"U%M0S5^'AWZ&5;0(FU M8P,*U514TU!-1S4#U4Q4LU#-1C4'U=Q*:]QDLOWO64"AT_HMTXZ4EZ?-@[;% M:[M9)D07+T*U&-62EK>DW^N^?$O2EB?*HY;W+D.7+Z>T9A;4)0%]<4F Z/XB M\="C-_QH'0"J:?W6^Z3;KJA#YS50S40U"]5L5'-0S44U#]5\5 M0+42U"-7B MEG_1>^XO0N=-42U#M9S2FE&CU%$C[A8(%_-)45PNI6^+^>WF MAQ0Y:8IJ&:KEE-8,J;IOH7]8WX(TGEU*B^G5=?EP?K]:KLJOI[,K:54L;EMS M"NUB0#45U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU_9;"K2SV*\ M:#N*E*#+D:):AFHYI36CJ^YO*!\>%%V/9W/V=SF(I:/3BM145--034U -5"5(M0+:ZT9H.+_'R?BIPR1;4,U7)*:P937>70 M%UKGU*P_0@?4>F#&#HZF=#2!U334$U'-0/53%2S4,U&-0?5 M7%3S4,U'M0#50E2+4"U&M0354E3+4"VGM&: U:4/_;BCI0^HIJ*:AFHZ MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI36#KRY]Z(M+ M'[:?O?IU$VB3G>!KC3"T +55%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5 M0E2+4"U&M0354E3+*FWWK,GS8G/A4QIA,ZC[' ;B/H>+ZVGQ3=)^%)/[U?2A MD()OWZ:38B$\8"@FCPT=5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1 M+4*U&-425$M1+4.UG-*:45;740SD-SY@.$!++5!-134-U714,U#-1#4+U6Q4 M?N!QC>\!POKW2X_$& MKJ6H-U8,'AUD:#,&JFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-: M@FHIJF6HEE=:H\ON60=D,Z/J;HR!^";OG8_DW4VKLW>XF2YU?47Y\+!TV>:*\'9AL75TK)":BFH: MJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN65UOA38?_G MQ@_J"HN!N,+BM4LLI'])=ELNEI*?\1)MOQ3?"T&VGV!:BJJ::BF MHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B64UHS\^J"C,'@ MK:_%0/LT4$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U% MM0S5'/R_OQY&-_OEZ_+7T.>YZ%+IV-:@ZJ MN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5I.:N29_L7-,=UT,U']4"5 M1+4*U&-425$M1+4.UG-*:<:74<24NT3C@V&6Y^W9;[KAM MCUN*#D6*ISHZOM!Z#5334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U& MM0354E3+4"VGM&;$U1TIJDI'P#O#SB_'R6G01I'CXL;&%:BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CF MHUJ :F&E-3]4J_7S-]%Y8U1+4"U%M0S5(7#CW^2GFD>+&.CCJT< 35-%334T(C)@&D7?2P_CFOFA-H^T,_9UM M;U?NOPPCM"$$U314TUO>D)'R,HK0Y@]4LU#-1C4'U5Q4\U#-1[4 U4)4BU M M1K4$U5)4RU MI[1M%)TNKXMBI8Y7X_./M\7BJK@H;FZ6TF1^/UNMCP?N?+?, MGF]E5,D?/BLGIR^^[\H?$KGE^YG\(=]\_[3FSS_>C:\*;[RXFLZ6TDWQK9RJ M\WY=3[F87ET_?;&:WWTZD4^DK_/5:GZ[>7A=C"^+Q?H)Y<^_S>>KQR_6$WR? M+_[>O)SS_P502P,$% @ *V-A5J+M&V)E P ! @ !D !X;"]W;W)K M&ULC551;]LV$'[/KSBHP] "F27+<;MEMH DSM"T M$$K,G4=@]+K#,Y32 M Q&-?WO,: CI'9^N']#_"-I)RX99/-/R;U$XOHQ^C:# DK72?=7;C]CK"01S M+6UXPK:W32+(6^MTW3L3@UJH[LWN^SS\'X>T=T@#[RY08+EBCF4+H[=@O#6A M^460&KR)G%"^*-?.T%]!?BX[NURO+V[6YU]NX.T*'1/2PA=F#//)>@>_P'G= M2+VC,C@XJ0QB6'U?8[U!\P_]7YD)K$7.&4KX/('/VJ"ZU8/%(G;$TL>*\Y[1 M:<E:<"=O:942\DVNE,& M)R1159T:IHIG^TO'T8#C3,%SI^]_$B9<.*SMJ+".P-$X =]>Q[9A.2XCZA^+ MY@ZC[.ZK?@+C^G! ME@N)-.$45MH).FJJ"ARM5\Q T6@;YW*I8,UV,.MP#@/K!VX^>6'/!99P?H]Y M&XIQ698B]XH]3&<28AWLC;6OJDRU-,ZA5^/[Q@&GA++NX&A?'8()M;+/ROYC M*F9[^N!HZ(.CO6?7ZZ<[@W4SO]:M&ULK55= M;YLP%/TK5VR:.FDM! *K,H+4 E4G=5T5VFZO+MPD5@UFMI.T_WXV4)2H)*VT M\0#^N.?<)1+1 5/):ODU%HJ54]L6^9++(D\X356>F;.14F4[HJ% M+6N!I&A );-=QPGLDM#*BL)F[$9$(5\I1BN\$2!794G$\SDROIE:(^ME8$87 M2V4&["BLR0(S5'?UC= ]NVS&U'",(&>;*,!#]66.,C!DB+>-/QVGU*0UPN_W"?M%XUUX>B,28LU^T M4,NI=6I!@7.R8FK&-Y?8^?$-7\Z9;-ZP:6/]P()\)14O.[!64-*J_9*G;AVV M */Q'H#; =SW KP.X#5&6V6-K80H$H6";T"8:,UF&LW:-&CMAE;F+V9*Z%FJ M<2K*XLLTN;M*X><%7*>WD*07Z6R6)G![]AO.LBR]S> H044HDY_A&.ZR!(X^ M?@YMI9,;"COO$IVWB=P]B1+,3\ ;?0'7<=T!>/Q^^&@7;FO+O6^W]^TV?-Y> MOCD*@04H\@1$2E1R,F2J91D/LY@C-I$UR7%JZ3,D4:S1BCY]& 7.MR&+_XEL MQ[#7&_8.L4?7NB+HLR^(HM4"&)<2LOD-FRD%ZRCP'?.$]GK; MTT"<>[H3MR-WW,L='Y0;DYHJPN#*"(T/"6UY@BT!WOB5RC>"=B3ZO43_H,1[ MPE:DK45,%T-2Y3BDSW^5^EBOY(#&H4#W=+_.H-<9O/GGBU?;?4CJ09[A_0E# M^_S?>5JC]E9=,W?*#R(6M)+ <*Z9G9.O>LE$6Z?;CN)U4^H>N-*%LVDN]=6& MP@3H^3GGZJ5CJF=_649_ 5!+ P04 " K8V%6;>KE^UX# "R"@ &0 M 'AL+W=O!KJQ3RMS \SIN M2A/N1 .[=R>C@<@T2SC<2:*R-*7RQQB8V \=WWG9F">;K38;;C38T0TL0#_L M[B2NW!)EE:3 52(XD; >.B/_SN%X-'<\P @:Q M-A 4'T\P <8,$O+XKP!URIC&\?#]!?W*BD!J M#&X@W+@(-,X#!2<"^0&Y$5QO%9GQ%:R. 5QD75(/7JB/@T;$*<07)/3_)H$7 M!#6$)K_N[C?0"UN]U*C@%54@G\")_GKG=[Q_ZN3^(; C\:U2?*L)/1KC/25)GH$S ME*YJ3TB.T;88IKX\1>=MO]?UO('[=*BDSB[T>@=V1R3;)Q$>8W,MRMJNBT3JGHE2IZ MC2H66L2/!!LD,:&3&%2=A%XE=-#W>Y4\5\W"L'_R#/1+BOU&BK=Z"Y)PP<^Q MDF;8")<,"#QC:U?U;/L5&K[7KI"M6@7MDUQ][[7#>(UL/U.6T;QG,YP:*(^A MMGUXU?!^M\JRSL[#,G:*YT$G]!MY%@5<8P$O(SMNO-D?FX',3A6O,/DT=T.QUSMN/++M MSM@-/XD*NH4EF%6Q4&CYK4K&.N+W*4,VIH$BE9$66]4,HPSR?U\^NWA MCCR-?]XMRU8GA!<09IA_2Z'T@8A"%9 M+6?DYNTK&1\A6]*P)0V=;N\2J4AE#N2)'LB,Z91+72H@O\9K;11^V]_G2&O% M_GE%V^\C7= 48@\;6H/:@Y>\>].]#3Y?X>VUO+UKZLD<)PIGQ]91; GB:I)B M65]PD"JJ,GV.MU8<.$4[3OND%WP:#(9!$/G[,RS]EJ5_E64E%*1R*]A?R(C! M"A92,SL5&LQ6&# M,4%GB,&JGI;:,+)P';J6!OO=+7?X@P%E'?!\(Z4Y&K;IVU]6\@]02P,$% M @ *V-A5@;"5V=+ P U!0 T !X;"]S='EL97,N>&ULW5AM3]LP$/XK MD1D32!-I&TB;T5;:*B%-VB8D^+!OR&V_YPK<_TN3#RG4 Z46KA1,#B)''AY'O MX\:HN]O4U?)32^0<3S&WGL>M3N_/Z20'UFI_L3#Z;LNO[713FTLLK!MFV,^4 M7/=-1)S!LM.6-H)$^(.'O0?V1;W(MO8MVK79#.T@NJAHW$3X-]D<]R;M)F39\LFGYI6EQSQ9FU4Z+#-?<>8.:_VV=ITPR3<6F:-O[ MQUSE%RNNWXROH;GZ6ME5[!49=8]?8WT:.':1\5L0^2:VNW?\(J/D^#76)\,C M%]E]M6_VO2+#^B2T<=S:.FPUU@ .M0/R'8[(8ATT&,^Y,%S6LQE/4R:?G;DL MO:%C^R?;%K]=G[*,SH6Y;\ !68^_L93/\Z19=0N%J%>MQU\AO7;B5BF>*T!\=<-/)+$O]M8'/# =@'K'8CO MCP,]Y?>)(MA53!OV!.-(DF (]**_1^,8J4X,'__^8$])%"6)'P',KR"*, 2> M1AS!%( &#(FBZCVX\SX*5^^I-8?20$3;8T.P6BP^0"X99K>]9!:G[+ON<#69V&HO6FY_TP>AW,A.FY9WKFD>)_9@ M!*_M7HBN;2;1='HY:;E4P9?/QWMMS 0V=">J3FKE.ON..RE>[=MXWR0OTLH' MV3 -B]_KU5AOY7:N.-T5E=-/,@W 7$[=#7?2V&ZX8K@_=XPOPET\MIX[O91-)\R"=^+& MZ.>#5(_];=Q;3,!K#'$X_HY!O#+_)8QZMY.56.CJN16J&^-H1-,#*KN7!QL0 MQ5LQ#Q+](DS_/NX!K![?K7-0(%+F2KH!P^H!SR>*JH6RHB;7O.&J$F2(GP5T M$4(7_3]TY&S#C5 / MPA*I2-'IZFFO >0% GGQL_)\&LR$VSU9-@#R$H&\] MY'1>L(-F2;'):T+2, M2Y:E)$X7I& W*0.0'Q#(#WXA<[J*2[H@FS@O[TF9QVD1)SUH ?@^(GP?/61;!#$Q>82>[8%CSB FIH_0MS^PI7$:34P@H6># MP(E(SEQAV@C["X3#Q!%Z-D>1W-+%UFW++ML+ZO*=L#';M"C9.H:8F#]"SP(Y MP62K;"3V+!%\XY["\QIP2>7;*^^4".5N(#F)B3HF\ M.^6=JF&@Y! 3/:UX%LV_50\CH6PL22$FYI[(]X$%+*'D-DYO7#S9V^X),3'W M1+Y/+ACF5[@A19A[(L_N@9AQ46S7HW[(MG#KBITD'7-/Y-D][T33[4YESA)8 MJT68A2+/%L)-#@N."+-0Y/T8!N+D*/Y]@$IIYEA#$7%*W><8K\E8JP8/-#)/0S+.$3JNW'[(.,3$) MS08)38Y?&6NQDTK4J7N$=?T5;ZJ-(?W/>&XZO^CKF-USTR2N+U,KS>OC1\OC M!]=]_:.WR MRC:96W6];<<[137F>HX^%U9G1^]/8_$[NBN.;V ML\N_&]OZ/P;KGVZXNE"JW&RBDZ75 VG"RD=.H@A MB,,'&0@RX8/6$+0.'[2!H$WXH 2"DO!!6PC:A@_:0= N?- >@O;A@RA&&6,! M20NL!6A-R#4)\)H0;!(@-B'9),!L0K1)@-J$;), MPGA)@%R$])- NPFQ)L$ MZ,VH-PO0FU%O%J W+SZV!>C-J#<+T)M1;Q:@-Z/>+$!O1KU9@-Z,>K, O1GU M9@%Z,^K- O0VJ+<1H+=!O8T O0WJ;=ZIM_./VKJYY[G&\]])M1^?M?/QT_*Y MN7@O$\X:_M,=?P%02P,$% @ *V-A5E4IDH^) 0 7A0 !, !;0V]N M=&5N=%]4>7!E&ULS9C-;L(P$(1?)^@)MLB$42 M6[:A\/9UPH_4BD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z]-X^,N:RD6KI$ M&VK"3J%M+7UXM0MF9+:4"V)B-!JS3#>>&C_TK48\FSQ3(5>5CUXVX;-3NIG& MEBH71T^[PM9K&DMC*I5)'_;9NLE_N SW#DGH[&I] MKK0DCAC2>:N)/)UE>Q$ M!_W./MPP[9[\:O].IL\P5,ZM-BY,S-+E=H>1M-U#$X3(>M5_Q*-CD+[Z?-1. M.Z?\3.]PO9_:+KMY.-8MU]_Q]QD?]2_,(4!RI" Y;D!RW(+D&(/DN /)<0^2 MXP$D!Q^A!$$A*D=!*D=A*D>!*D>A*D?!*D?A*D&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( "MC85;!2'2"^ 8 @M 8 M " @0X( !X;"]W;W)K&PO=V]R M:W-H965T&UL4$L! A0#% @ *V-A5K4,ECN2 P &A$ M !@ ("! 14 'AL+W=O@ & @(%!'@ >&PO=V]R:W-H965T&UL4$L! A0#% @ *V-A5O0*\TEA!P WB$ !@ ("! M'BH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*V-A5O?ZVV4Q @ !04 !@ ("!4%H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *V-A5IX[)+OD P % D !D M ("!O:@ 'AL+W=O.T<# 8$ &0 @('8K >&PO M=V]R:W-H965T&UL4$L! A0#% @ *V-A5A:GI>N-" D38 !D ("! M0[0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *V-A5MJ$"J^6+0 8[$# !D ("!%\H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *V-A5MUCPBM% M P +0T !D ("!%P0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *V-A5J+M&V)E P ! @ !D M ("!#"@! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *V-A5JO_-B-$ @ O@0 !D ("!_3$! M 'AL+W=O&POXW 0!?&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " K8V%652F2CXD! !>% $P M@ $U/@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 * H ,\* #O/P$ " ! end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 184 262 1 false 42 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://radiogel.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://radiogel.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://radiogel.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://radiogel.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statement of Changes in Stockholders' Equity Sheet http://radiogel.com/role/StatementOfChangesInStockholdersEquity Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://radiogel.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://radiogel.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 8 false false R9.htm 00000009 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://radiogel.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 9 false false R10.htm 00000010 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://radiogel.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 10 false false R11.htm 00000011 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Notes 11 false false R12.htm 00000012 - Disclosure - COMMITMENT Sheet http://radiogel.com/role/Commitment COMMITMENT Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://radiogel.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables) Tables http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits 16 false false R17.htm 00000017 - Disclosure - INCOME TAXES (Tables) Sheet http://radiogel.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://radiogel.com/role/IncomeTaxes 17 false false R18.htm 00000018 - Disclosure - SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details) Sheet http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details) Details 18 false false R19.htm 00000019 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) Sheet http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) Details 19 false false R20.htm 00000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://radiogel.com/role/RelatedPartyTransactions 21 false false R22.htm 00000022 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://radiogel.com/role/ConvertibleNotesPayable 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://radiogel.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://radiogel.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails SCHEDULE OF CHANGES IN STOCK OPTION (Details) Details 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) Details 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) Sheet http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details) Details 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) Sheet http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) Details 27 false false R28.htm 00000028 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) Sheet http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) Details http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables 28 false false R29.htm 00000029 - Disclosure - COMMITMENT (Details Narrative) Sheet http://radiogel.com/role/CommitmentDetailsNarrative COMMITMENT (Details Narrative) Details http://radiogel.com/role/Commitment 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details) Sheet http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails SCHEDULE OF NET DEFERRED TAX ASSETS (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE (Details) Sheet http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails SCHEDULE OF FEDERAL INCOME TAX RATE (Details) Details 31 false false R32.htm 00000032 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://radiogel.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://radiogel.com/role/IncomeTaxesTables 32 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:WarrantsAndRightsOutstandingTerm - form10-k.htm 216 form10-k.htm ex23.htm ex31-1.htm ex31-2.htm ex32-1.htm rdgl-20221231.xsd rdgl-20221231_cal.xml rdgl-20221231_def.xml rdgl-20221231_lab.xml rdgl-20221231_pre.xml ex23_002.jpg form10-k_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 708, "http://xbrl.sec.gov/dei/2022": 33 }, "contextCount": 184, "dts": { "calculationLink": { "local": [ "rdgl-20221231_cal.xml" ] }, "definitionLink": { "local": [ "rdgl-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "rdgl-20221231_lab.xml" ] }, "presentationLink": { "local": [ "rdgl-20221231_pre.xml" ] }, "schema": { "local": [ "rdgl-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 401, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 152, "http://radiogel.com/20221231": 50, "http://xbrl.sec.gov/dei/2022": 3, "total": 205 }, "keyCustom": 52, "keyStandard": 210, "memberCustom": 19, "memberStandard": 19, "nsprefix": "RDGL", "nsuri": "http://radiogel.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://radiogel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "10", "role": "http://radiogel.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS", "menuCat": "Notes", "order": "11", "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMITMENT", "menuCat": "Notes", "order": "12", "role": "http://radiogel.com/role/Commitment", "shortName": "COMMITMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "13", "role": "http://radiogel.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:BusinessOverviewPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "14", "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:BusinessOverviewPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "15", "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)", "menuCat": "Tables", "order": "16", "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "17", "role": "http://radiogel.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_srt_MinimumMember_custom_ProductionEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details)", "menuCat": "Details", "order": "18", "role": "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails", "shortName": "SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_srt_MinimumMember_custom_ProductionEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details)", "menuCat": "Details", "order": "19", "role": "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "shortName": "SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://radiogel.com/role/BalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:DescriptionOfCreditRiskExposure", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://radiogel.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-06-022022-06-30", "decimals": "INF", "lang": null, "name": "RDGL:FunctionalAdjustmentShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SCHEDULE OF CHANGES IN STOCK OPTION (Details)", "menuCat": "Details", "order": "24", "role": "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "shortName": "SCHEDULE OF CHANGES IN STOCK OPTION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF CHANGES IN STOCK WARRANTS (Details)", "menuCat": "Details", "order": "25", "role": "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "shortName": "SCHEDULE OF CHANGES IN STOCK WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)", "menuCat": "Details", "order": "26", "role": "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "shortName": "SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_RestrictedStockUnitsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details)", "menuCat": "Details", "order": "27", "role": "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "shortName": "SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_custom_RestrictedStockUnitsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "shortName": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:RestrictedStockExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:AgreementTermDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - COMMITMENT (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://radiogel.com/role/CommitmentDetailsNarrative", "shortName": "COMMITMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember", "decimals": null, "first": true, "lang": "en-US", "name": "RDGL:AgreementTermDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://radiogel.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)", "menuCat": "Details", "order": "30", "role": "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF NET DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE (Details)", "menuCat": "Details", "order": "31", "role": "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails", "shortName": "SCHEDULE OF FEDERAL INCOME TAX RATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FederalIncomeTaxNoteTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://radiogel.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://radiogel.com/role/StatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statement of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "shortName": "Statement of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://radiogel.com/role/StatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "8", "role": "http://radiogel.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - CONVERTIBLE NOTES PAYABLE", "menuCat": "Notes", "order": "9", "role": "http://radiogel.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "RDGL_AccountsPayableConvertedIntoSharesOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable converted into shares of common stock.", "label": "Accounts payable converted into shares of common stock" } } }, "localname": "AccountsPayableConvertedIntoSharesOfCommonStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_AdditionalPaidInCapitalSeriesAPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Paid-In Capital - Series A Preferred [Member]", "label": "Additional Paid-In Capital - Series A Preferred [Member]" } } }, "localname": "AdditionalPaidInCapitalSeriesAPreferredMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "RDGL_AdditionalPaidInCapitalSeriesBPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Paid-In Capital - Series B Preferred [Member]", "label": "Additional Paid-In Capital - Series B Preferred [Member]" } } }, "localname": "AdditionalPaidInCapitalSeriesBPreferredMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "RDGL_AdditionalPaidInCapitalSeriesCPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Paid-In Capital - Series C Preferred [Member]", "label": "Additional Paid-In Capital - Series C Preferred [Member]" } } }, "localname": "AdditionalPaidInCapitalSeriesCPreferredMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "RDGL_AgreementTermDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement term description.", "label": "Agreement term description" } } }, "localname": "AgreementTermDescription", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "RDGL_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board of Directors [Member]", "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_BusinessOverviewPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Overview [Policy Text Block]", "label": "Business Overview" } } }, "localname": "BusinessOverviewPolicyTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "RDGL_CommonStockIssuedInSettlementOfAccountsPayableRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in settlement of accounts payable related parties.", "label": "Common stock issued in settlement of accounts payable - related parties" } } }, "localname": "CommonStockIssuedInSettlementOfAccountsPayableRelatedParties", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "RDGL_CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Options, Warrants and Restricted Stock Units [Text Block]", "label": "COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS" } } }, "localname": "CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnits" ], "xbrltype": "textBlockItemType" }, "RDGL_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "RDGL_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants [Member]", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_ConversionOfNotesPayableAndAccruedInterestForCommonAndCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of notes payable and accrued interest for common and common stock.", "label": "Conversion of notes payable and accrued interest for common and common stock" } } }, "localname": "ConversionOfNotesPayableAndAccruedInterestForCommonAndCommonStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of notes payable related parties and accrued interest into common stock.", "label": "Conversion of notes payable and accrued interest into common stock" } } }, "localname": "ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_DecemberTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2022 [Member]", "label": "December 2022 [Member]" } } }, "localname": "DecemberTwoThousandTwentyTwoMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_DisclosureCommonStockOptionsWarrantsAndRestrictedStockUnitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Options Warrants And Restricted Stock Units" } } }, "localname": "DisclosureCommonStockOptionsWarrantsAndRestrictedStockUnitsAbstract", "nsuri": "http://radiogel.com/20221231", "xbrltype": "stringItemType" }, "RDGL_DiscretionaryBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Discretionary bonus.", "label": "Discretionary bonus" } } }, "localname": "DiscretionaryBonus", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RDGL_DrMichaelKKorenkoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Michael K. Korenko [Member]", "label": "Dr. Michael K. Korenko [Member]" } } }, "localname": "DrMichaelKKorenkoMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_EmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Agreement [Member]", "label": "Employment Agreement [Member]" } } }, "localname": "EmploymentAgreementMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_ExcercisePriceWarrantsGrantedMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Per Share Exercise Price Warrants Granted.", "label": "Weighted Average Exercise Price Per Share Exercise Price Warrants granted" } } }, "localname": "ExcercisePriceWarrantsGrantedMinimum", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ExercisePriceMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Ending.", "label": "ExercisePriceMinimum", "periodEndLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Ending", "periodStartLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning" } } }, "localname": "ExercisePriceMinimum", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ForgivenessOfDebt": { "auth_ref": [], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forgiveness of debt", "label": "Forgiveness of debt", "negatedLabel": "Forgiveness of debt" } } }, "localname": "ForgivenessOfDebt", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows", "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RDGL_FunctionalAdjustmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Functional adjustment shares.", "label": "Functional adjustment, shares" } } }, "localname": "FunctionalAdjustmentShares", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RDGL_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern [Policy Text Block]", "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "RDGL_IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt": { "auth_ref": [], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "effective income tax rate reconciliation, nondeductible expense, amount, forgiveness of debt.", "label": "IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt", "verboseLabel": "Forgiveness of debt" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "RDGL_IncomeTaxReconciliationRelatedPartyAccrual": { "auth_ref": [], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation Related Party Accrual.", "label": "Related party accrual" } } }, "localname": "IncomeTaxReconciliationRelatedPartyAccrual", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "RDGL_IntellectualPropertyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intellectual Property [Policy Text Block]", "label": "Intellectual Property" } } }, "localname": "IntellectualPropertyPolicyTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "RDGL_JuneTwoThousandTwentyFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2025 [Member]", "label": "June 2025 [Member]" } } }, "localname": "JuneTwoThousandTwentyFiveMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_LicenseFeesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Fees [Policy Text Block]", "label": "License Fees" } } }, "localname": "LicenseFeesPolicyTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "RDGL_OfferingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering term.", "label": "Offering term" } } }, "localname": "OfferingTerm", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "RDGL_OnTheGrantDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "On The Grant Date [Member]", "label": "On The Grant Date [Member]" } } }, "localname": "OnTheGrantDateMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_OneConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Consultants [Member]", "label": "One Consultants [Member]" } } }, "localname": "OneConsultantsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_ProductionEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Production Equipment [Member]", "label": "Production Equipment [Member]" } } }, "localname": "ProductionEquipmentMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "RDGL_RepaymentsOfRelatedPartyNotes": { "auth_ref": [], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repayments of related party notes.", "label": "Payments of related party notes" } } }, "localname": "RepaymentsOfRelatedPartyNotes", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_RestrictedStockExpensesYetToBeRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Stock Expenses Yet To Be Recognized.", "label": "Restricted stock expenses yet to be recognized" } } }, "localname": "RestrictedStockExpensesYetToBeRecognized", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RDGL_RestrictedStockUnitsIssuedForServices": { "auth_ref": [], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted stock units issued for services.", "label": "RSUs issued for services" } } }, "localname": "RestrictedStockUnitsIssuedForServices", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units [Member]", "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "RDGL_RestrictedStockUnitsVestedIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units Vested into Common Stock.", "label": "RestrictedStockUnitsVestedIntoCommonStock", "verboseLabel": "RSUs vested into common stock" } } }, "localname": "RestrictedStockUnitsVestedIntoCommonStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_RsusVestedIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Rsus vested into common stock.", "label": "RSUs vested into common stock" } } }, "localname": "RsusVestedIntoCommonStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Depreciation Estimated Useful Life [TableText Block]", "label": "SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE" } } }, "localname": "ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "RDGL_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "periodEndLabel": "Number of Shares, Warrants Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice", "periodEndLabel": "Exercise Price Per Share Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which non-option equity holders acquired shares when converting their non-option equity into shares.", "label": "Exercise Price Per Share Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.", "label": "Exercise Price Per Share Warrants expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.", "label": "Exercise Price Per Share Warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life Warrants Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "durationItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Exercise Price Per Share Warrants Outstanding Ending", "periodStartLabel": "Exercise Price Per Share Warrants Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "durationItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life Warrants Outstanding Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "durationItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "durationItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "periodEndLabel": "Aggregate Intrinsic Value Outstanding Ending", "periodStartLabel": "Aggregate Intrinsic Value Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "RDGL_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercisable Weighted Average Exercise Price Per Shares.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares", "periodEndLabel": "Weighted Average Exercise Price Per Share Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "RDGL_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1", "periodEndLabel": "Aggregate Intrinsic Value Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "RDGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of restricted shares unit granted, value.", "label": "Number of restricted shares unit granted, value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RDGL_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option Plans Exercise Price.", "label": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price Per Share Outstanding Ending", "periodStartLabel": "Weighted Average Exercise Price Per Share Outstanding Beginning" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "RDGL_StockIssuedDuringPeriodSharesFractionalAdjustment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares fractional adjustment", "label": "Fractional adjustment, shares" } } }, "localname": "StockIssuedDuringPeriodSharesFractionalAdjustment", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "RDGL_StockIssuedDuringPeriodSharesStockOptionsRescinded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Rescinded.", "label": "Rescinded shares", "verboseLabel": "Number of stock option rescinded" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsRescinded", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RDGL_StockIssuedDuringPeriodSharesWarrantExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares warrant exercises.", "label": "Warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantExercises", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "RDGL_StockIssuedDuringPeriodValueFractionalAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value fractional adjustment", "label": "Fractional adjustment" } } }, "localname": "StockIssuedDuringPeriodValueFractionalAdjustment", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "RDGL_StockIssuedDuringPeriodValueRemainingNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued remaining value.", "label": "Shares issued remaining value" } } }, "localname": "StockIssuedDuringPeriodValueRemainingNewIssues", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RDGL_StockIssuedDuringPeriodValueWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value warrant exercises.", "label": "Warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueWarrantExercises", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "RDGL_StockOptionsExercisedForRecissionOfCommonAndPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recission of common and preferred stock.", "label": "Stock options exercised for recission of common and preferred stock" } } }, "localname": "StockOptionsExercisedForRecissionOfCommonAndPreferredStock", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RDGL_WarrantPurchase": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Purchase.", "label": "Warrant purchase" } } }, "localname": "WarrantPurchase", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RDGL_WarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expired.", "label": "Warrants expired" } } }, "localname": "WarrantsExpired", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RDGL_WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Warrant Exercisable.", "label": "WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable", "periodEndLabel": "Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable" } } }, "localname": "WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "RDGL_WeightedAverageExercisePricePerShareOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Per Share Options Exercised.", "label": "Weighted Average Exercise Price Per Share Options exercised" } } }, "localname": "WeightedAverageExercisePricePerShareOptionsExercised", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "RDGL_WeightedAverageExercisePricePerShareOptionsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price per share option expired.", "label": "Weighted Average Exercise Price Per Share Options expired/cancelled" } } }, "localname": "WeightedAverageExercisePricePerShareOptionsExpired", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "RDGL_WeightedAverageExercisePricePerShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Per Share Options granted.", "label": "Weighted Average Exercise Price Per Share Options granted" } } }, "localname": "WeightedAverageExercisePricePerShareOptionsGranted", "nsuri": "http://radiogel.com/20221231", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r423", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r423", "r425", "r426" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r423", "r425", "r426" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r423", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://radiogel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r281", "r365", "r383", "r392", "r393", "r408", "r409", "r411", "r454", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r281", "r365", "r383", "r392", "r393", "r408", "r409", "r411", "r454", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r211", "r212", "r213", "r214", "r279", "r281", "r310", "r311", "r312", "r364", "r365", "r383", "r392", "r393", "r408", "r409", "r411", "r451", "r454", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r211", "r212", "r213", "r214", "r279", "r281", "r310", "r311", "r312", "r364", "r365", "r383", "r392", "r393", "r408", "r409", "r411", "r451", "r454", "r495", "r496", "r497", "r498", "r499" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r172", "r282", "r433", "r447" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r172", "r282", "r433", "r434", "r447" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r449", "r490" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r104", "r112", "r123", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts payable, related parties, current" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r6" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid in capital - common stock" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r314", "r315", "r316", "r444", "r445", "r446", "r487" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalPreferredStock": { "auth_ref": [ "r6" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholder in nonredeemable preferred stock-related transaction in excess of par value, value contributed to entity and value received from other stock-related transaction. Includes, but is not limited to, preferred stock redeemable solely at option of issuer. Excludes common stock.", "label": "Additional paid in capital - Convertible preferred stock" } } }, "localname": "AdditionalPaidInCapitalPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r51", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants purchased for cash" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r31" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potential dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r119", "r135", "r155", "r193", "r196", "r200", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r340", "r342", "r348", "r410", "r452", "r453", "r492" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r132", "r140", "r155", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r340", "r342", "r348", "r410", "r452", "r453", "r492" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r310", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r32", "r134", "r395" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "verboseLabel": "Cash on hand" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r27", "r32", "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH - END OF PERIOD", "periodStartLabel": "CASH - BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r27", "r100" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r136", "r137", "r138", "r155", "r174", "r175", "r177", "r179", "r183", "r184", "r207", "r215", "r217", "r218", "r219", "r222", "r223", "r250", "r251", "r254", "r258", "r265", "r348", "r394", "r432", "r440", "r448" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrants exercised shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrant sold during period", "terseLabel": "Warrants", "verboseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r113", "r122" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r50", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "COMMITMENT" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/Commitment" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r444", "r445", "r487" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r410" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value, $0.001, 950,000,000 shares authorized, 362,541,528 and 343,530,678 issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of preferred stock for common stock" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r1", "r109", "r118", "r126" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r22", "r366" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedLabel": "Cost of Goods Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r35", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Related party payable conversion" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r35", "r37" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Conversion of common stock, shares", "verboseLabel": "Converted shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r56", "r153", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r240", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r109", "r110", "r118", "r158", "r224", "r225", "r226", "r227", "r228", "r230", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r356", "r403", "r404", "r405", "r406", "r407", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r52", "r226" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r101", "r103", "r224", "r356", "r404", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Outstanding balances" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt instrument, increase, accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r15", "r158", "r224", "r225", "r226", "r227", "r228", "r230", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r356", "r403", "r404", "r405", "r406", "r407", "r441" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Redemption percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r87", "r485" ], "calculation": { "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Capital Loss Carryover" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r484" ], "calculation": { "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r87", "r485" ], "calculation": { "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryover" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r327" ], "calculation": { "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfNetDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r93", "r94", "r95", "r96", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DescriptionOfCreditRiskExposure": { "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r97" ], "lang": { "en-us": { "role": { "documentation": "Description of the sources of credit risk exposure faced by the entity.", "label": "Description of risk exposure" } } }, "localname": "DescriptionOfCreditRiskExposure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r148", "r164", "r165", "r166", "r167", "r168", "r173", "r174", "r177", "r178", "r179", "r181", "r346", "r347", "r379", "r381", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r40", "r41" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r60", "r130", "r144", "r145", "r146", "r159", "r160", "r161", "r163", "r169", "r171", "r182", "r208", "r267", "r314", "r315", "r316", "r331", "r332", "r345", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalIncomeTaxNoteTextBlock": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book.", "label": "SCHEDULE OF FEDERAL INCOME TAX RATE" } } }, "localname": "FederalIncomeTaxNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Economic life of the patent" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r30", "r53", "r54" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://radiogel.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (loss) on debt extinguishment", "negatedLabel": "(Gain) loss on conversion of debt", "negatedTerseLabel": "Gain (loss) on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows", "http://radiogel.com/role/StatementsOfOperations", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents and Intellectual Property" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r21", "r155", "r193", "r195", "r199", "r201", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r348", "r402", "r452" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r19", "r107", "r114", "r125", "r193", "r195", "r199", "r201", "r380", "r402" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "NET LOSS BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r156", "r323", "r325", "r329", "r333", "r335", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r157", "r170", "r171", "r192", "r322", "r334", "r336", "r382" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails", "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r143", "r320", "r321", "r325", "r326", "r328", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r483" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r483" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Book income (loss)" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciation": { "auth_ref": [ "r483" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depreciation.", "label": "Depreciation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r483" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Other non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r483" ], "calculation": { "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock for services" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfFederalIncomeTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r29" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r29" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r29" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Payroll liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r29" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r29" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r102", "r116", "r147", "r191", "r355" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r149", "r151", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r30" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Common stock, stock options and warrants for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r439" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Payroll expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r155", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r341", "r342", "r343", "r348", "r401", "r452", "r492", "r493" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r111", "r121", "r410", "r442", "r450", "r489" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r133", "r155", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r341", "r342", "r343", "r348", "r410", "r452", "r492", "r493" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r150" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r27", "r28", "r31" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOW FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r27", "r28", "r31" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Current operation activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r31", "r115", "r124", "r131", "r141", "r142", "r146", "r155", "r162", "r164", "r165", "r166", "r167", "r170", "r171", "r176", "r193", "r195", "r199", "r201", "r207", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r347", "r348", "r402", "r452" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://radiogel.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss for the year", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StatementsOfCashFlows", "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Non-Operating Income (Expenses)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-OPERATING INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r104", "r123", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes payable related party, outstanding balance" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Compensation amount" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r193", "r195", "r199", "r201", "r402" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING LOSS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r4", "r61", "r62", "r440", "r455" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred stock, liquidation preference per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r250" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r250" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r410" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r4", "r61" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Voting percentage" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r139", "r209", "r210", "r396" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Financial Statement Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from stock offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Gross proceeds from preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from issuance of warrant" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r25" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionCosts": { "auth_ref": [ "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to operate and maintain wells and related equipment and facilities, including depreciation and applicable operating costs of support equipment and facilities and other costs of operating and maintaining those wells and related equipment and facilities. They become part of the cost of oil and gas produced. Examples of production costs (sometimes called lifting costs) are: costs of labor to operate the wells and related equipment and facilities; repairs and maintenance; materials, supplies, and fuel consumed and supplies utilized in operating the wells and related equipment and facilities; property taxes and insurance applicable to proved properties and wells and related equipment and facilities; severance taxes; some support equipment or facilities may serve two or more oil and gas producing activities and may also serve transportation, refining, and marketing activities. To the extent that the support equipment and facilities are used in oil and gas producing activities, their depreciation and applicable operating costs become exploration, development or production costs, as appropriate. Depreciation, depletion, and amortization of capitalized acquisition, exploration, and development costs are not production costs but also become part of the cost of oil and gas produced along with production (lifting) costs identified above.", "label": "Production costs" } } }, "localname": "ProductionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r127", "r128" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees, including stock-based compensation" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Other fixed assets cost" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r48", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life of asset" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r280", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r280", "r360", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r358", "r359", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r26" ], "calculation": { "http://radiogel.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Payments of convertible debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r83", "r129", "r500" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockExpense": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "label": "Restricted stock expense vesting" } } }, "localname": "RestrictedStockExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r67", "r120", "r387", "r388", "r410" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r130", "r159", "r160", "r161", "r163", "r169", "r171", "r208", "r314", "r315", "r316", "r331", "r332", "r345", "r384", "r386" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r189", "r190", "r194", "r197", "r198", "r202", "r203", "r204", "r276", "r277", "r366" ], "calculation": { "http://radiogel.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "IsoPet Solutions" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfDilutiveEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF DILUTIVE EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF NET DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/ScheduleOfDepreciationEstimatedUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r310", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r71", "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF CHANGES IN STOCK OPTION" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r57", "r58", "r59", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r136", "r137", "r138", "r183", "r250", "r251", "r252", "r254", "r258", "r263", "r265", "r408", "r432", "r440" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r68", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF CHANGES IN STOCK WARRANTS" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r436", "r437", "r456" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r436", "r437", "r456" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r436", "r437", "r456" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Number of Shares, RSU's forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant Date Fair Value, RSU's forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Shares, RSU's granted", "verboseLabel": "Number of restricted shares unit granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value, RSU's granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, RSU's Ending balance", "periodStartLabel": "Number of Shares, RSU's Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, RSU's Ending balance", "periodStartLabel": "Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Restricted stock vested, shares", "negatedLabel": "Number of Shares, RSU's vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value, RSU's vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of warrant exeercised", "negatedLabel": "Number of Shares, Warrants exercised", "verboseLabel": "Number of warrant exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Number of Shares, Warrants expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Shares, Warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Shares, Warrants Outstanding Ending", "periodStartLabel": "Number of Shares, Warrants Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercise Price Per Share Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of options expired", "negatedLabel": "Number of Options expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Cancelation shares", "verboseLabel": "Cancelation of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value Outstanding Ending", "periodStartLabel": "Aggregate Intrinsic Value Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options Outstanding Ending Balance", "periodStartLabel": "Number of Options Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share Outstanding Ending", "periodStartLabel": "Exercise Price Per Share Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r310", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInRestrictedStockUnitsDetails", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercise Price Per Share exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Exercise Price Per Share expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Exercise Price Per Share granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r288", "r307", "r308", "r309", "r310", "r313", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life (in years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "RSUs granted to consultants that have vested", "terseLabel": "Restricted stock vested, value", "verboseLabel": "Fair value of vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Number of shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life (in years) Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "A statement that a range of reasonably possible change cannot be made for a tax position taken for which it is reasonably possible that the total amount of unrecognized tax benefit will significantly increase or decrease within 12 months of the balance sheet date.", "label": "Significant change in unrecognized tax benefits" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r136", "r137", "r138", "r155", "r174", "r175", "r177", "r179", "r183", "r184", "r207", "r215", "r217", "r218", "r219", "r222", "r223", "r250", "r251", "r254", "r258", "r265", "r348", "r394", "r432", "r440", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r60", "r130", "r144", "r145", "r146", "r159", "r160", "r161", "r163", "r169", "r171", "r182", "r208", "r267", "r314", "r315", "r316", "r331", "r332", "r345", "r349", "r350", "r351", "r352", "r353", "r354", "r357", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r159", "r160", "r161", "r182", "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/BalanceSheetsParenthetical", "http://radiogel.com/role/ScheduleOfAssumptionsUsedInFairValueMeasurementDetails", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Common stock issued in cashless exercise of warrants" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r17", "r60", "r61", "r67", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of preferred stock into common stock,shares", "verboseLabel": "Conversion of convertible securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r4", "r5", "r60", "r61", "r67" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Note conversions/settlements, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Services, shares", "terseLabel": "Shares issued for services, shares", "verboseLabel": "Stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r5", "r60", "r67" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Cash, shares", "terseLabel": "Shares, new issues", "verboseLabel": "Stock issued during period shares new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Accounts payable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r60", "r67" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "RSUs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r60", "r67", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock option exercises, shares", "negatedLabel": "Number of Options exercised", "terseLabel": "Number of share exercised", "verboseLabel": "Stock options exercised shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockOptionDetails", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r18", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of preferred shares to common shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r18", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Note conversions/settlements" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Services", "terseLabel": "Shares issued for services", "verboseLabel": "Stock issued for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r5", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Number of shares issued, value", "terseLabel": "Value, new issues", "verboseLabel": "Cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Accounts payable" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r5", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "RSUs" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r60", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock option exercises", "verboseLabel": "Stock options exercised value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/RelatedPartyTransactionsDetailsNarrative", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r45", "r410", "r442", "r450", "r489" ], "calculation": { "http://radiogel.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance - December 31, 2022", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets", "http://radiogel.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r154", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r267", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH PAID DURING THE PERIOD FOR:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommitmentDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized tax positions accrued interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r42", "r43", "r44", "r185", "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/ScheduleOfChangesInStockWarrantsDetails", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants outstanding", "verboseLabel": "Warrants and rights outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative", "http://radiogel.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and rights outstanding term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/CommonStockOptionsWarrantsAndRestrictedStockUnitsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r173", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://radiogel.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=126898976&loc=d3e600178-122990", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 53 0001493152-23-006366-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-006366-xbrl.zip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

E,YB\M)=H.RMID\@O\,Z.:0FI\)GH MSL8@-W'OL,<+AB[H_");#) AM#$83_E70+B*T37_P*2<'HO<"Y4]/&/$S4&YI#1<= M6R&,W\6P8LKN0C_[ VR&8P44;4QJ]@#]=#!(&(?6E$'?P+'S2RB3A)SQH. " ML%+Z-+P!E.@[UEH XA:K++9(47$IG=/:V,)%Y8$0@Q4>ADR_21%/-@GMJ:'D M),G.P1JV161B3#:\(E0^?'Q .1R@VD'=$G%F="O:5M47'%$1!>8]K@N&E,(\ MT"A!6Q3J4 &)=#5.4&IP>"GT^&GVA$<3-1D\@,2"Y,\A<$RL0T)2(]E]=ZF^ M0I]C!;7!%=_4]=%:@JH-8I[]M!W?=9GK18DE$]_F2^V.,FAD&#L/3#P.J%\. M^:6)3L$90M\*CXRE'O31->$A:IE_9,^_Q2&"N*LJ/ M28K'V-M!IC,Q0\VQ#'?8'Z QSQ8$710^ Q/^Q!,+Q-ODH$5](A]Z/H=^HN4S M#FAZ">NCO%6\A"(U;8'Z'LIQF)89#(GR9YXDQ4=,/(.=DH]#";/OH;D3IB!# M>#LT,A,%0Q5*#+P%,_D\)2[RR71@+SVAN/W;7>/JB05K VOWNJ&B2FB0#7 Z MR&3),])#:RMN@">L.[68'9HC!D:HU66S,G 0"AMMD\H:F%*MQ(5@7=P#$NRF M;,V3LU,^2<[>LD%9I:#;C[X94+AQI)Q5::NNP+KHIC4DAY7TIP!9)'<*2MD4 M=0S[Z(A 1:=@6#,FIFBH%Q)QSJ:B$P/3<01PGJ37[SWK6GBZ,(< >"+R\1C/ MSA5%($=#O0Q+2ADL-O=EZHZ6$F1"-Y_-CUAI&S8S\9[^II+DABSQ2C8E/!*K M24:!@U^KU&J[QHD*54=Q'U,%!&6Z&4-A72"^^%,2+2R3X(@SZ<#A@IKD;"H$.*6A38[U=DBS MJ^X;5*(XH&(D7R?!8G*D.$I(R0M\,E.Q%JS,,/0XE;G#\M=Y)JP!BWUSB@9) MW=<@'.D4'F2YYS>75Z>W)(O6K\G0.(_ : M103>7"/P&D4$7A&!MSX4(^-6U)9RI)]7S+N/?5T3A&/#ACH:[.KX5L?190GV M#<>3)06U2&K@!\J$-E;>+OS=ZD&UNEL]K+[=W=ZZ04>",J:"KN7T96A.VL+# M::R@ODBEUO/O0?\9EJC>D$=:%5%]]A[:<4@:CTZDB"K9Q#>!/@[7)N&)WHMIVNRMQ"P&Q^/ 6)A]&0>3/G>A M7'W#BRD%H;J_WZ@T&]KW?M-"D8EE.XZO7+XOKK_[K!1+]6KU;>3 MXF+HLH/#]\"3WWV^J=7>->K[#5492*;9N:CX"XR)PW38/HRKQ[;,M">3'*> MNZL>ODD**BR.G&P+3DM7YL+0*6I&Y MS!\5I$-K[H.NQ=*-'9LRWI;D.40 MS69"?@0B E.R)*L MHM5C[RH&'9' NKUUJW*Z924+CNP;!()32;E (86G P?Z9 Y]F4,1IDH(:2] M&,4V5=.*])QD+J^..4V\_:P<%Z;Z5L1P2-11>G%!BP$U2XU6R'AE12F"4@J O0_=5U3)=OP2C[I2_*%2U*62J M MHP2FA&3L0IESE7HA*-O"NVJR5JO7]M[N&KE7+<^&8:S1[>Z"D ME;&RE@K446R/I;J43J;+$K"]$,8FZPLITV%;A!'%2QBB[T1D%^JI K8/S'0" M+-G'-&(:#Q^)5N*UHW)ZG,O"JRBK)2%?C3U;AK0!74"J@Z65Y#:DA'>INTK. M"TJLV>^;' =CNB 3)\LJ1Q\6DN#J8R5^:A\Q@06U7E%829\WV_R\GE-!TBH# M*]PA"Z$86IKBCI*BRKCU]QLQZ\D;F!B:TX;E4;L3M/M4_OS+73U7=T ML=(#KNS6%KOLW]?[:8&C/-S;/YS7,!=,;K]@?"(/+U6^[Q=5'H9":JH?C%^% MYXD'Q[HK&5];"^VQEI/^:;GMT[=&V$J2^'B,Z21G!:QCWP7AU3%+QJ?+ E<% MKF89[+_]'E8[P^']X@_NL)],*E]4(>NCB46I2*OZ=%) JX#6+(.%*WEPIZ#M MHZ9X2K6IC"LL=H4^&(6N*Y,T1JQ9>?''2MHY%DK*2X6<20).JNH-794I>D,9 M=I3?P8YTLMD[KA^-U+)C$X83.5QK/Y,I&3Y526U[ZYSR=KI8\@%FHDKW#13< M\,$8FZU+2[K"#&2PF*G'0IGH!L?!9"M*)(GQTL1I6H$OFS"QOW2(IB):'LP? M\BU5?@.ON V<\C%W$T@5RS/A^4D(F>5C- '&HY-)AMPMIJP#0IZ\.S'$#$8X M*IYT0201VQR^S=.@U!M*327;;.1O!/0*3;'0%#>#-5Y3?2\>'Q[A3P*$*R!) M,34[^8S!])CJIBB/+ =FNJY,#,$$9L'T 7.XX4V!K^KEN ['&R&E466(B2J1 M 5M%5XP4$"WQ6++5NYB6J!+DE&"&@Y&5CSDWM&<&G#N(I,D,L=X[46DY5LP" M%Z$.0U"T:K&MQ0L9SU%'&$5/5%Q),F:+ M8ZA:IB@;UZM,Q..TLZ[ >X'WV1Q.?G#'H],,.JL&H?N=%]=D*3-&ZB:P)D<8%7@J\/0JV1&S^E/=HZC4 M/J8Y%7@J\#3+8$\?!ZX?2$ EW32FBW,.!2?[ Q;*C )G! 12O@8(59RB*GYC?*7A*E8<@PA5V5I!B(R M_ ?LHEQ@KL#<3(,]X5P?'B :+6)/&>NT)DFAQ-IX/4S,S*KM7PIW>'&!O0)[ MLPSVC#.X>( !.U*H)* JP(F-U9R_8B'#X%6G!]GW=GCY"G\AS-HCS' M7,MS-(OR'$5YCO4)LW@BP@?+D=K8S((R7'VN3FO&-N9"R;*Q8YT@3["NO>ZN M_8LPW:@W4E&?VU52KJ+KAUB((,E;G^EY+*IV5"MTU1@K6R!UW&4SWC833@VU M%>""3:J#)W6HD$TH=0879[5Y\%;="F$T0HBJ^ZI"X26J\6_YZ18$U'73#%,U MQI6/?Q (;/-.RY^N:D[%"60RG71[8L'R%MU&A![#NV8?%BIZ&G2HC3=RFA";?(PU0S5 M'VV&"F/APK*8\CC2HPI@3B%G?=02,PU5X5JL*F*&%(O2\66LB&QDA\AOBVY, M99HYU&[7^ W/*'J.NNHZKFA*E4S0&.)8L8/BL\ MHUIM8N(PMC:DF$EJ/@9PPM1:YXF6QE(5X$C0)*ASI),@]KN@LN1F&ZOA5"O_ ME!&86"V31J)Z24HT#3DEG\JFI_2*4,C&3)@)C4%JAK2 * &6=&,LF!O^Z'2QU&A2SJA6,63RLHYH2RT"/8P..1,Q(A<==\CU M<>0X9+3R#;9R.P8P^ZK5?<]W;=HB+!&?%(BF629@4YO='HY'!OO4IT>DPI5P MH;#_%Q+B[G#BY/NX]M2L1>F>HU(2]:2SU>/@/U3#GJL^6Y.'IV +XT&"SB5, MAEC3VJ5B$/JELAT@"3HAEKJGB[N!ZT!^P+/F M*&36S"*/ 1YE% JZ5)4523D\@71E*@U&!?(F U;/\C#(ALLF=R0$RLS.%2J M:'L+@N%'JLL]O<&D>*NDX9&B Z2R-"H5X^>A MIDEMQQ^$0]5+D@O-2IHM)XY/X(/)R@*1[)!*$G*QI/3%@0 UPTMR"IB2RF(. M*1JLAB3[9*CF3ER,U M'B=50\IV3B3U"RO\DSH7DQ:"I*+G])G#R-(Q($Y1=1E9HB)%!JGN4I9G5M-%R7*H>I2FLB?O)F7G@)2:7OKC_@.>V*99(.&$R2R MC;)P]Y@-4@Z#]'&XE/YX,G))AS8I!*5H), +H /X.BX*E@86Q864:'7I%H[ M2!!3H!CO.J7(%!6Z\S<5ZD"SO35-=$0P >=_\"1)R>A\6;U1J:ZD>F6: 1-E MDFU$9$4=+I;%#DJ5A)#8YTF(ZPEWH,4]$.S]H$U_>@!GK.RH^I_H]G,9"\RT M"2',9::4U"K-E#@F.S5]I6[L*.ZK/E0LNML">[$.9=WJ7M2(09EI4*VZX0<_BR[N!9'*F=3R90,1V^@.FY ;U?3M6W3QCV53*C[BDX00[/M=!E#=M;]$A M%@AGZN3DR]ZAP^D>!SA"-K%%Z7I00-::+7PFH=?*&%$+(.9L*K)>QH1:&5^. M;R]*:4/\L3)JW#*YN1 1(K>$6XTT M.=(]B2N+Y1]]XK('D5JHI$:HZ+HN"4DMOI'B]YR!DM6J56UX() MU=3D.JMDG*7>I9PC3H4!T:[$QI0P<:'I*O& OY0#0-F,,H*5!A(;5E$A(;U+ M]]:E=K2JK2[;S^ 7V8W)4NX.8+W8+1AOO8F$H*Y?W"40.UM0365;H#F'*N][ MJ3;$2*A8/I6R[D:@X!4Q5WM%S-5<8Z[VBIBK(N8JMU5YKW46&HB23H@?EE:0 MM]B!HY^"#B)#*V.SQ44FR MU<^PUA=*)2=!W 4EB=T?LG-8JAS9V4DK78P,K<(.-R_(E&@PPKA-YJ7:J+Q-6>ZPL4='"+N-O#AQB6%I$A^MR;*B QOP\&)4ID08 MI6,WU*NI6:2IKB!YS!:4HDJ320(B+[FY$&Q0$9%QF'-H:K MU_7C4$:"W#OB07JBT'G7E[W4>$,Y=(*6@(MKX*-/9*<)O(4&)EN6JSC/U)X> MGUS_DME4]B>J]41O6F8_F]7*F[NWZ")5,QN=^9M?J_5Z?>] +QQ:Z2F>!KM& M&32-[I$EM? 9S>[3V:1;B^2 M(]S>FC)$ADLT',C.]&W!-K%[Q@>>FL1S.^100-(VT&.N)J\?%@@\MK@IKO^ M'G.<9.JMVUOJ2C)J)XO';>VY_7M'T*W)!.7$0MGRA;09#MZB#89GQ 'I[=)X M+5^H;?]ZMHEW-30[(N) 6WL0TL!.:SH?688E=0 DRG@#7K3R/DD^D*Y]E-S M3D\/WW]^7AK?9!A&=I?1<15-FOD&ZV7K.946ZM6BG' H,HJA2@V,JE%I'.YQ MRR/ I?@FG"2[]=^P)H[I?,FK T4I OTAC9YJG+L,P M:K,;!XX$!1VDCI3D(=G0VA3@8 GJP5([5".P-)4&O6WS)&3N_%>0]^,ZV9C'4[-H3+K1H-J MEK*KRF2!C(]>W!6F+K[,&ZQ*: @R@SR>;T279\K/Y4C@?&R(X[ M'AI[3>V'X_V7$@2:A5/C U0TJ\V]P[?2T*JNCGP?"*1KLF'F KM6X:CTH##F MA7&!GC;U--EZ!X>7&"VSY4@34D>EJ3"BQ0_A&1%0%789RBXTKAE0$H-Z>$(U MXT@70=2KA\3)Y Z((_N+83*X4"IP0,\%)S+MM&17':Y!1RDN.AFFLK?(-$R8G>+WZ#;[/KC@^2.\\N:F= NT\ &42\FY+)R3+LHZ1E0MK EU"69 FRJMF:2!U%* MVC+=.Z'E"XRF=BQZ&=IL\&$J*HM3B\(IAT:/#ULLD6]!3KK@PSF;2L8Q+5MZ M2;\2)L4E!RM,GR$5R,.-)C4J5?*7/OD:#PF5N9 M T!QH#UIELC2N!Z=:Y)A;6XLB^5=B:!BF2VX!S^2SPQ/ECXH,L5-';X)-">A M4(C:8>KXIJCW*(4C1X)MAMV&@6HE4'2H/'7;.]DJ)ZCQ&$?J^K[11B Y#$>=F4E ?(EC; ,FVR8VKK/3H_\9TJ>]-G;JPTRE'](C\O.CIOYH6<5'O6)M&'7:-E ),D"RJZB ME&K_J?4Q4SN>NU-VL?T=UH6(T#E%+E($+U>4[\D0\Q#$%9_/E9!U=&P50FT[ M=.A&UXL;UH+6KI(BK< A]_9[XTWU;2HL!"=.;$1*J[(VG85Q()U8M^>"81\V M0-RLD;&!-42,9*;8+CJ_*NQ1#T'>0E[T-_6W"(=VBKL_P&$M2^]>2N"2L.O+ M!2V\PGF=RKFWO9421VN5J;)^VOQG&A_1 24;L$O3&/RCC8*[QF=M52MQL&BB MNB095 19Z\[S'UQAPQ$J;6_)HZ9H@.U3?B;WHYRH[:'P%JJ# 0?E?VIP.N2( MM,T%GI$>,,E0%+"P:_R!C$HJA$AA?;1-41@'#5L_F"35MN#T(B=B8R008Y&I M<$L%QN%EIM4;*L.D?#@J#6B>D7(5IH8$NRJQZQ-JH#K$A.UA26 BG3!ACV1.D>%;E (K[:RXB[83R#!G=:L,_T3U$B:K!.3SDU.F M(D"P6 [6L.C'2NMRE#BLQD);--ZELSCW.9O*1\U89.R#CNLA(7!$*I,UN(@. M7('";=HV#4E1:"[2UY8$\? M19^+$AIO (#A6R(WIY2K?88Y)Y+S*$XM;]/Q;#<<15;"A@*R7< QZ#>D$5.& M"GP@_YKQYNS\E[?J>B!7(2M7K':F3QT%FU!H,9\[+>^RG6B@0JTHQP1/S09C M_>E D?TB4&2N@2+[1:!($2BR/A2#[ W(/5#2(VU0:>WW0N>WAC'EBI#F Z3V M/VE6,C C3J-F0HL)I69 /DYR+8&>XW?9//[)'/J2Z!N#WC!T+$HK 2T*F8MX M1.3")+>W_O3;2ME6<@W:YA)5N2M<&>-,TJ3*,E&Y5JK$!@J#0\J!4KECTN[I MA>C72L7O)@8%Q5&WM]!BRPHMB4F1,/N)XUU;//K$;84[0(5-KA/7BL@$"$LW MA7R^:Z)P+'OQ:&N@-"K0,L'S(Q^.Z/86]648,4PD9C^]+B$6\$DEI^@P;&7H MXS#L9"=!I:4$')DZ27MJ7/-<.0%8Q8)2[CXZ.I6-/O']ITV.$RR?Z)W8B%.R M00<>=4> F(P-KF6E1G3N*41(D5'+BFGWCT03.AHX59I^))TL@7-2"%$YPQEY M6.^K3][BE"U:9EIA6GMB./JC?%A!P^4P5&F?2;HG)H"2L4\6SDJ9O,:&GI)H MB8!YA''];@JP^/)[N98*5 ;NWD;K$KPWDQV1RM"@M[/%5;\ID;DSWC)XX*45 M^2AF)]X>=E*D_#U89248'1PZTSPR [)M!@-&^B,VV%3!L\C7&1/:_,O[J1,O M)CD_2CK?KNWX^ XO2RU;V^ETN#-()7 H0JI:ANDH@2;+4ZOYU2^8F&C68\W M,B^%5W;K(Z'0P%5E[*;[*O$PO;NF(V2T&,NWB.4K%X,D)1MFW-"-UQAB\BGI ML7DM4 1A=GO]Z1H&;;K#OZ5'HS<WJ2!? K4[!W5$L)2DI$Y%3H4!-SJ9"ZLNGUL>D%3!6]HK0CY[N M8#;)RU8RL+(8N4,XS)2MQXF[!N-EX7.;R]/<"QGIPN5*"T M)'YOXFUA65G'+G&)0)EOKI0G:7QM8U8\6K&Z@?\P4M94 SUMN :4D^HPB8\/W8BRO@6I$"XI<"0"X38 S<]U*7-9ZUN!Y7BP@TSL$X7LB4N+LY6SJ7PE"5UG#$JIG%@I!;MG@,B% MV$P+48]7T]D"#A^2 2S*7,MUT1-5=;(WN*6J&X$$RJ6)G"RLXY!KXGER M]7_)]$C)]9U4B.P-\HRD,O'IH]4C8QH\7YD>583'S>FQ#NV04;7;6W526RI M1U1ELUE>>GJ,3TBB:3%D53G%*-8(^!67'D1JTJR4*A7Z?VY<3>8"DSIUD=7O M'Y7=:H5->%C_Z5$E6_^CJ>[+5K,T914XHK(X:\KE0"N_?OT_JJ6:?*6#4P7> M3-H9O!C>5CG D@VRB_:;JGZ-&M];/C! S6RX30_^P0P"DXN]!L8_:G)D+4\/ M:'SI.J0 INP:2D?D86;#+?]1+QW(5[$\M+V56H*-P/ZF'^,, O2W,OR.>.:C MRL>"K540U?[IT'39#BZ/"5=UY!I0TG)@"6&',K>(@E="/#D8@1V^WXAUW2"( MG&'F4Y24GU-!,YQ^L;\<%.]=7NY*4IE1YP9;>VV&7_ MOEY0"QSE6K6L2G>AY\@QZ2B0G=.88RN/%YD49<:PRI74D:0/3Q4:L$T7!80+" X4Y'B MN!TZMFYE2A$53U,2=(EU&<4K!T67TH\R"SK^54M(K%]5(*S:K0 MK/)#A0O-B@=[ZO5,ZFR@E*N!L!VJAR[]OO^1-6-3L2TWW,:HX/L%WY]-,>)H MOA3&DFY#JMW@Q'H&E$^6:%(ZTQK[I2C#7=^WA:LKG],LTM&<^*90I+VH/ SI M2MV5@5K2W,^)-Z.E'287RBCP7^!_IL%^#E/0UP&'TK$ &E8JQA<3(85.@WPS MDJYFC&:KZ;)L3I@$M5*];0QOB$9#Q9;6NCT/PMA:3N5:A,(,K!X[.677!A7Q M-*DJ2C;C5Y7&<['- _>2%9[1BZG&_%H('VD!M44;.ZXI[_5(&<&^ MJ?LOIXDSOD66P1AQIM6,/C9 (JKMQ12,A6VP9#4MG?J/%6%,)OM8^XU?;5RJ MZAX>+/SV5I4\M+6&; 67#2+7Q48<;G/)G2-&1G.H1Q/Y7,X 1YZDA:O@&96- MR5']M*RLQXPV32E170-US14L.YS>DC%P7#\JC9Y N+C^EB>(YW-J"72J'*): METD;CBJ4G[1CI:Y(P]+VUIO&6UE['#DCPG,@"*,*$CA?3A D'#C99E.IBZ@K M%ZO"(EV^%@!U3>>VP?E1RV M#?;G/YU)>U!DTLXUD_:@R*0M,FG7AV)0V$S2$A.8B.L/T]+'1&E#ELK%% ?7 M?N!"L./T7OIL97&I,>D!^Q;&@:J["Y) Z'N><*7HD21&8(\>!$JH&[XZ?:TI M]I$=4HP.HE@AF6-DPJ],+;1 MTJ"A\09;K.)M#\#DN,X3%YZB)>O+AN8!<-E4^+%T+,HL )#/!B A.&T0=QS. M)AIS0A)C!-D82?,='M+KS;%1.'X5'!K=M@5( M8)+T+O_&$@@"RDN6SP6!ADIH!#:7>Q,H# MR6;HF/,,\PM-+J*H$QN3D=(A@:EZ<%"P&Q1U,.350&R0:/1ZJ$,XBXY+AJ139.G^J95(P3Q]S>/ [++^8P)[/D\[8V-[" M8]5U_;8L_28";$SN_,V@EH>KJ 67MZE@WB15)O-AKX,RMF,HC1;;3PHP O:Y M[(,-V">]E T/I8EBQZ3:E%2,GS*()S-IJ<)&FD$"^:0WRC#VI+ZA.\S@C M# M3GGH--"K4N%D?>XSTU1&(%4BC4PWLK(CG5(:?99+J=)R#O%MV9]LLXER(,G56.0"#8SB<<"5>JF0JVH&8MA^W(Y09,D> MWT1^D[FE:6L,];?I^M08D\M_9V6H'DE ?;(.!>)>P#TEP_/[5/_,,L->2?7< M1-G*BONRI0IZF"RJ/)Q=@EWC/"-<(OH]/U)9=&&,764K2297XP)X M08_:D7P%M,,YB0!-/?]!2!,Y]FGQK3BD8C!34QN2X>$E],P'K&H38$-.+"3\ MA"%6GQ0)R5 &:VEY3YUW?C.Q]?2K29N-T*(^?*KR9N!= M.F!6GGPB1M3TP"T$NKQ-I<40U%U+ZE4NP#)>=OT?U=)^9:]4V6L2!4?//K8% ME]8) K[T44A1RXE8&0"0 YL*GOMCXA"H0C8E@+ZA(7N&!O-2&F[/Y,ZW MEA7=E*]$MWNB :?HM?"XQB^^2#FM.LZC[/:EC"K8"]>5'MW17@<%D',V%4(A MJ)78G=SH CD&\4;H.@+C D VT77$.4I-KZA=M0M[NB/HN"]$@^R 2JUL<*7FA(W>S"#7^ MGE#CO,83+_L\S3'(> E#7Z.PN(\B,GETW*,'C<>^A\%!@4G=#;"A7A"1PX:: M>X2J:"N=?^R SHVEK*D5IS =&V'-6RIA%"I&[:=821-G^P2H6Y,Z@DS:*/T M%I"J0@%Z5$F*.TZJ'B)HC@RYCF<;1FP(ZDP1&-R/E]XLT%)@6D,#-90/>0T+ M7:^#4XSUB;$6L,KM6->* %.R/+?WHYAX'1-*A'< OZO.X8H(EU31/S*,(@WN M^D8/\TR=/E),#K(DF@LJ$TAB9$Y*VW9XM$!>T300ZCK@:.(*56Y@%YT2KFJW M9:=(.W?RE8R ^EY1>20RL6*=8>HN&,6HBW$)=YK.$/V5,/:NZ]]+%Z7L-MS% M R9SXJ9KJC:\2A2(=6[QB5Y0[IFOR\90$K>U-=Q?QK*Z,::G%SEN3BWZW 4 MUGNL!:QR.]8U8@=3MEU^EPQ7;9P)/D\^8_E=TR19>I4AK0 M42YY*8!CF,-0UINE@INZA;LBWZ QPR2"89E:&F._0Z*ODOH&R;,EG56Y+E+P MUL.#L53WZ77%H5@'G*WW6 M8Y7:L:T1KR=!))5I(TDZ(F>F&?IK@4L*5M$0\ M /$4JO,O1G7H#A9. *(L4D DK"2LRSXBH31OZ&:P_) "T>L DO4>:P&KW(YU MC0CEB/.'!RI)8)(@J;);PS[J\" W]K&(&K460ZORF]I^N6O&7?%6VI#)V) 8 MA:P&KW(YUC<@P=;*0UMFV'V.V7$4+G$97< )?T ZQ#+VI:&C;4?U7 M#&MHN:)$?1@%&V5_#01:17Y89)$76>3YI X_M8]N(C$(9& MP@RF)P6^( U7-BE/$G%WC5:H"O6HD,A[$'/Z0B=<8(KC6/PR_A)24CN\I6_> MB7([QOI\ED-5[U!&&GLOW2A;F\J*1&'T3E;AI^1^8H/8$W.('?5EOS39JX9(EV:>?B*NUHI=*'3EFY3.I2 M'#B@9@1#7:>,VY+=PQ@=SGM$PY@#XES/]ZD[6!(HC;0"B,+/^,-OH,\%G#1] M%6#!"2I"(MN2 7!^_NT* :*ZDVUOT?MLC*_>-FE0'3ZEX:KCD(AD@K;-UX0W8RM@%,E7& M8J38&2SB/N>R$#X_L2!9JR99?T2 W+B/L;A76O>_4KI_00+Z,D,AN-47TJ=RR[-=I<;4AW:=9?4V3C1J!BG0F0*']R'DEVIVRDZ@?C M^O9SR;A6[.ES* JBLUIX?7'N_1#[A5N&YS]0J6X\_JHY.9]%?=)U0:^>%'ZY MDI9K6O(.V%]9;16/OXY,PS!$BJ5S$ MBW2P=+L4K%(K+>I(OCPQUG5E2=4DUA2_G%;':!VPW* Y0#@Z05,A5 MA_-414M9LH8C9#KH#HZD$3&MZKMF6[@+/D'LABMV)WO"5IWA]WO:5<\7.N29D>2 M"M>;0Z,,]Q+Z?"5"DF MJM1*(M$#J!]#3P18+!!(2%+5CFJ)P<-5]#H50=*];4N&,*T>GDX.DR0A+.[# MG.']6"0:1*Y"M%J>:/6)=VE[ZX;VK9"NH]1F9PUKHF=NC3)4]1&L2>9=0G+XI, M5QO*J &!G00]4$$ [@8!LVL[H$;WL:" *@G+3V:S.B;T)S&A:%CCBI9P35+' MTA8A-_U30V^+;JQT#X?JT6)@)Z7L8SG NXYF\J2J=U856%"42C$'3XH\PQT M-(_6'T.DFVX?3;X=YUXPJ+&/I"5;:76Q(G(:GJXYQ#K$W''*-"C<%#,E"H5Z;PN$B''I<3CAJW+&(\K22Z:;0#W\3"&J3Y=%)Z M7:@4NY(\NQ3K PJ4YWL8, WR =>Q9,T+$UU X<*8\%3%9-@Y[*J)M]IF9&[P MB7LZ%+I:*6*AYQH+7:T4P=!%,'0^]0]0H[YH!;?0I/)!M&4)7ZKOE&D$6FU6 M="?0@8@,V^^R\ ML,&GLE*V!?@&L'F[U/5'&E'UDG/HV_))[4%%MZ(AMX++9 MAC1+*J:)_MP0BV8-?,>+Y,N'QO^:?2 *OX!$ M'/$7Q]S4D\O#/YCN70D$ L]#4Z<51R@A#:B%"(D+_':*18E202N>;+=%_0WB MD 0"6YA1#Q_KNQA7R!/"2&.8;RG3"H*\RK0NL*(#$+5D26U:5'Q*R+8>E)-X M8BT0R(#0@5Z1FJ*T0!BM,/0M754F-7BUXAP@ ZN.56:D1A'(85(\LNT(D+ST M3'C2_.8+4Q9D/N9]./< A%&,O8,R[^(DM]!YU!#A?1[;465_UC/\_^R]:7/< MV+$M^KTBZC\@_/K]R2"L >7*6%IWH9&6T.$S'QB]M(BVG\5; M6UOPRY(>2+@N<4WK5@OJ0UT0--I53]JU):9K5*#PW&4AM3D1%]6DO]%S*@T/ M-J/7X*=#0ZOH;R1(25Z>E3@^] JQ^8<#(<(S@NT="!71$SH-J39F9G-_DF3\ MC$R2H4$+ H8R%>[^&,.8%6&!K1 ^\O3"4)^+0C-,I#<70&0J0)DLUB60S M8.K3<(7_66I22K%&%BY374-$J,T@&:@#V+*7YE0J 7+E+ET7]AXJ<*]%.*[? M@X43^PU&R#C(36;39C\UK>V"3I!A-,X"(H2$0##WB!A4MGGB)AQRC3AH2[QV MJ.[T723*11IY\NMK5YQ,$H7^2C(6183B&WK50YJ[3J,'VG_UMW<^:)_YC/\G M*>;X_<[6]@L-"7:];SBP+U0 MC0I=0U/?ZW*^4S>D H*N9Z8OJ)FA<)XY&)>TJ@(VR! M0]\X3P7[FU2D1!)C\A6"!SYOE/C#_OLC#ET\S*DIY+SV1\NK4DW!X7&!T7/71MD6DQBS+L MX6R"C2Y2*38SN2-T56+HIB&SVN;=)]O\*.A-N')"I[I3S+2#7CQZ4:=BOM!8 MYLVDK!A["[)XTVE9<2+^N@:SM]3$?@F6=N-JJS9Z3HHBK8QYU4R@&HZYF:/@ M@V,%$:(D$HMK# S;]EFX)H#I92--!IKGYH["1_/D2E27NWAZ5;5N4PGP$RZ+ MX=7YSIN,^X;>QH(U=YC7N2IFF[L0J>M\L$3%"\+Q]$]B; #NCGO[?)Z[1[)$ M,W]H#XZJEICS%"A^<94M>I!]_<4PNF/A2?Q0K&!?='_X,84_) M)B0=;:>*^.]4T:QQ-$A0$IXK(6D2NQ3#B=*X")A8C MIH8:,+V+-<.OAQ_Y>;Y7T3- 1:3'G:S?5%@H9K3OTV24SAN+VSO+2KOY"T/< M[6#>V/PT7[BMO13SU^OAC6C+>$D60HDB@6/(;72@EPX[ZHP.*I3@@]BOZ4:$)8HQMA+1D N[J(8=9E MK-29]!!'QZ90'64A+9MA.&3&JG:VCNB2U-L(UUS<^P#,"MMM4Q"A&-H"F4JN M60.*0',8[/4G8]A+)'3#@:ZQYU4$4[3)%=/ D\7"+)0A2NG /XAGT=ZSSF7E M,0T'GFC;YB5NFW1B,8]H7A7153@3*RST@.O?SO0/,5GM8=_:M9GH0/<8N.+$:IQA'YU*;H1'S,]*ADX49N)NT+L;" M;PR<>*Y)^)QZ^+0RRWIH]<*?&,K*3!IQO;._O1DR/\SU-1'?1K^M%\ MNK&]M1L]^3C&_S[UKC(E"@B&).)RE=)<08>4%K1GFD"5@P'WH< E11(C&A:!;'B>O-E& M[ YSVMPJ&]F>Q%$0<(M>;1YO1K]P8@F6XC]QR>EH=.B!-E\"&W+5*-5^*5E>.&KWR.\PO!E&R)9 ".#=#'6&]N[VZUONZNH MXLIP7INCNCQ.%IN ;0C! Q-9V#R1'!%.HSF ( _'"/G)T?'&R0S2R22H)UE% M:B@6$CSY>_SU+P[NBLS I[^P3/U_Z248*?@Y>,C5?#H^N\^\;&K?= M0^.^+S1NNX?&]="X_WCS[QZC7\?)%6H7)1#:!\#6>RHK@O/U_$QHOB5HX"=_ MNJIN;,Z*/%,R(83REJ]LLCX^(N8.GWMG:V<[C@Y'GTF-R86?I1'9>I\:P\4>ED!^3S_(SI?9T^*";LUQ=/ Y*Y(X.BI&FPS'*,B")Y58(-?C2RIH M9BT-TZS,%U/U': M+_:"M&93.=*R0@W 7:466I"7Y6<%S_YK3H,Z7_A"Q($WR^O5[^Z#LY)>T0A* M.IJ]@;3>4PD,)/#\H"JQ,3@J%T$?F?VT0%[W;RL"+WGVF=N$E M<7Z:8*M,9MQ %J>T8X(,%-"U2V6\2YUZ;@= $T=Y27T0O!1):0.QM'G-)V9/6= VYA)RQA4 MQO?%4F\,;361W3F15Z\6OM7^;P4W#.Y:SQ?'.Z8E(B]\D>,\H0 1F #L25' M(*EP]&M3R:''$6>X1J0WJR<*^C@WI50IN H V-!> EXZE%U/FWGR%((,X5R/ MFL EX6MV@7']_"<^_6$TFL\232V>N''\EI)C,\'Y%' F?GM87&9562@PXF,% M\ TGNNA7O1ROV53X>EM6O_&2_O60+T:$(#YSDUSWA">Z8$.'$43%>2YY'(7K M,[PN-M5(_G4(D+E(>"S T[B()D:(W!HRH;E=V/.OM16 M\U;EM#1Y5ZX:< ?G/0QM UPW9([NPM ;18 1H-O7\@/@W>G*STFKT_%H.))( MPTWR',?HG_-"X3>@W\_^#6,!Z"E[O5?I^;QFMA9I1VFM1+VOD*H=#NAIUA2N M[,O4-'BU7S6OAH0=+-$E!RJ!]R\KQ74!*P9,$/W)4B()85)V8=[CB%M0$\DO MX50?FR&,>/ &RH&,161#S\*J,JZ2*YD77@9\5K[P "7!L!G"5@%Y)F"J.AW- M>Y#E&DYEQ<5G>!*-K8<+R"ML4X@,.N>X6+F/$4)IB]A/Y@I-)"AONGXQ)A^& M--M)3MO\D:QS?"J*],_!$-,O(!T2\;8U-RC#<>=G M?WOKR>>GM/3>.]Q+5"?X!3N=3S-\RG_#-:^P1WOS.HZT@%JJ74/(7QD.W&?Z M<[1F4SG0/6:4,.Q!)QCML\1(ISPM+IK)PO6-,:6?49-\#N%DPBHAE[*(%E>[ M?@$5,#F=%(&.WZ:@$S27_Y!"6J56,KA%&:*-\T!JMMWH7(F3T9K='' M6D_6>;;H.3D@KF7.%;Y_AKR(8J>ELXU!5RE4>-77+%$((O$T_BNN9C]CQQAH M,T478UEH[?6.%:N&2S!]K)V^LC\Y:S:5(++K5:,E;(,(/]R?LC^/D7N[+!%7 M4Y![X<6!Q^WS\-/VUJ:CU.'[J#$=+\\1%E:B/*:%])X=#F VH7[,>/YU\!DT M5ZE181,_B:*C-!G\Y/M-:P/P9K-I6#&CH2W7#0WX\$*U2%0=FO M"[>1+H^1K6P%"UT8RNL;V"[B]6E<33D"0F) #77'Q-C9^/7=1P/9]IU$=S>1 MQKY*E:MB82H@C"_1*E\6MM3 ;Y101EI)XV#G5PEBG10$+HQQ.9J+X\9%8E[3 M,GI3859(2SQ#E F?0GL<0V_3NJZM2;\B.I_;@!'+S3@X._+SAXIP<']^#@ MAW,WLXEJ* '5,#LV,4GO%G2L2>865(:N+CXNN&&@\A-20HXF2M$C8HQ2SYJ3 M$R,9+W)YG,VIH>"$_5>2Y^4C%R5DBVQB4[.'/(-@[0(;X9MF4QF9>QS2]$S7)C( MK)2CK**['MX>S\[\3(/6IU4R%O]AFM7UX[F1'N9!$2/V&LO5&JOM;%97UBI* MQB#H4GN8-MZ%J)-#/Z M &O9HIBZUFJYT+-S]9SQ"6(J:V\RN:I:V:-R9JS$K**']=%)-M/:Z7D?+UFW MJ:R(V(O8^DXB\ ?M,'YAXV#*]L,7F,><<[9P=X:4CG3YEQ8,P2R=YO:C$PHJ M JX>,$G%X,@:[BM.J7&R3I$8JO2C-P<'0DO&(D_ODZ/BCO+*U^&DN?=Y!U$. MY^L4*%W#S2!I[MCSC?EA/Y, K\RDYL4I8]["]HLE'.K>SN%?\WH:?W)1I>P+ M.I?=K,S[N20 CYT><+>8SY_X_OB5SY\8.S2"Q&++ND[Y(4?>',XX'6C[\*^1S3*;5[00/R@9^$ %]OL#A - 5 C]_8&8WP>Z M'7>M/\AZ]CB[+0NGB7W.^=;R0:M<+/:EJ9(2I.#@_4L#P%MP7<$VO^;*\F@V MO5MT#( -W%N!X_ MTJPPIBM#2&P89,E$0F-QA@EINFTL#DT]\6HBR0)!,$#];%>B8+V>^0S^307" MQ+MNE_SX[L_OKXY^FT_1O.)5P@25?=W!>DX%D1$R%%ZG(^FPL+L=HQ![)ZQ: MG23;K&YMK*21#HY![4Z(!G8XY3! MBS6:_]*0LSCAZ'>J;@,MH+0];+LTFN-#_:P=J]#T&:9K_),-+7C#\'Y> 2=9 MCGMM=9SO]5S-F&D6Y"=&^_ MH2VEAS?^$J.<&7@P)@=<^O>_QA83T/[7%QO"$V5<+\9;P<9Q*0Y7#N0'J6@: M]$X-VM(+#K]H[MJ/>^ I%_LX.7P5]HZ OJ*_M$B 6L SJ,9.T2,)OI+:0OKO M.GSF.?^B_'/>4-F_FBK+M,7$^[]P#6.X&4.ED56L<)0R05G)$!R_#(J&2)XC M:=*FF?WQO__[ZNIJLTY'FQ?E)2 #ZN(&JM^;$'F'9YA)%+[ &)Z;([;G_#EF M4\PQ*<+&+]PW*BCN\NM SK+RHDIF$^7T^YPN/$?;Z?(@G[3T]B[&#MN-QC;= MM0]QLZ_9_"S/1@!!&%VCT7*R+,=L!XO-71D>/$R3(W<%WS9F=:KT/*TJ0\,@ M'O&!"+PDY[0?0MAE^&PA#Z9<$Z! YO:3<30O'1/20B/74#[ ,^679F#8SN_S? MK:W=/QA;\.CT\-UPL'VP&1T?G?PE>G/PZO3#\[7\N0;">%%$N!EX(P MIU,V>4K2Q4IB"GMCDET@^P7'CE,^6?UY,_I'.3==K48)BMJ$Q[L [:Z J?$[ MAG J])(\OO(J;N>3E@PJ'D[7G>MLDY!UVIEHM@D.^Y/T2;K>U9A4F_&=-6&L M.?(ZJT=SL2[QPX,BR1=U)O[X&_N15X9PG7]T+-366(T/UEN.U0PUS=S'Z4@Z M&%Y-4JD'+K7N+M(%KZW!*Y9,.1*C>I1*"Q-;\"M1/([N>?0"2XNK$3YPL?+[ MC:45>ZMEF>/C9:IN,7$OJO*JX4))AAW4R&R:_*G&$V./Y1>]44:I _)Z,B3# MH74 Q8"\?$%B [;T'/PI2&;0E) =Y4H6O$!62(G ".1D.#DY./KPZ.C@]?!W]_>CTM^CTM\/HU8=W'P_>_T//]$GTRZ>3 MH_>')R?]-?.C T2<8/&CC5[)@GAV03_FK)K6NFM^( $QP4X%CSZ7!KZT[%F2 M[#F_;+ M+"=SA:$_=$4F'([A203-^UQR ,/C:NNQP&PY>9(LW$NFK0)';Z29H;2';B^(H6AD?Q:%GTP RVN4 MC3+.9RX/T=^L8$AJ7):T+#E-%4CK0 +PX]ON^-%Y,%##3.L-1X66.3%@>)W/ M4?8(.P7VSAG4FHV.8;F2R[*2>:9T,@01Y_/6(4F0=Z?SRA'H:=ET;+$8F+)^, X7;J F'$A2F^D8QME8L_V6R*-S M/2!\X3HZ NK+F/-MSIBOYU2K)6K>9S)JI1G3Q[#& MFG0K4M2 TG^:!CQ%>T55S'G;@&BFT]@LZ/#8A9%*N<5R,Q^\2 QW-ND?2:1R M_8>MJ364[TW/#&[#^%.J9SL<..OM^I6:IF^UZBQ4:2B:7),4[.!T,U!6259S MV8;Z1BK9M6JX6VJW/AFXGE,)DH%\-\I58N_':S;5Y#NZ;BVK6#8!=%8()(. M\.MD"NW&O8]2[MDW)LT&T9:KT1\_?]?P M)?FL%29%IK LIEF2^-.*$^$74O?J\(>JPT!<8=M><-,G1/4\FY.-6S)K80#B M_R@7@G +">6/=/'U!40B49,D8!MB<]CG_+(4E(T8.6?H?&PDM*;OU^<+I4KH M/ F@5LZ) GB@^TD5$CPB9J7#L!S^]/QYO/5B/W[Q[#DT;Q<*S/JAL>$L( W(S;E-1-P; M(#ZQ$^\]WXJWGVU+Q)3^O+_S/'[^[%GH^$8W^;V;T6\92 \$O] &HS%N"R14 MK.TE<$NOMPK9TC&T8&6FS@AQ[);A[V]#D:;R'K9+NIPUAJZ:[XJ*ORJKSW*< MY2=>ML%\A=Q]=&B0DABUH5;YD]Y'6_.SWJ7OAZGW-8)P&%41X"O FX#RI7QS M.&AY@0 X6/WB_DO-^2[?D- 8+L=L?*J2#P$)TLY>-*613$+902M= M"]N4(P#&([&VOC O$DG63R_M..CS&.D?HR?;3_F_?,*_T$#S@@$38);;W$5Q M]&3GJ?D)=QP$Q5$.7F9CM2(P%F$[P? M,5P)T^?7D>W=I--9SK8MJQO+.%Z)6Y?D;;X:+J5[LO^4?D6[V2H?;J\T[HAY MP^U1M38I@.'U"F#-IL(*8$8;#9*QG.NZ$V[(J1+52 =O+FBTWE9M/#%SX:_P MWHI%I[?C\/"9!QY#YQ'AE M5W3M/[5,40$?+\V*CIV[$[6CM]^/6]N0&RLI=1I"?ZR!Y.2\,6#+:Q;9K6S' M5(<#N]P,56P\KS@%2>J&J@([5]Y*" 5(@J\;2<"@5 MV7)(PT$OI=K-2!$R'R1M:Y6;BS] J+Y- @ZD&V5)X\%EK_^ MPUX1W4U(,*99&-V=<.QIX1MU4[!?9PW3RFK1 65 M%L2"?AB'&H<8U%@8HFO#H&1D,Q,2')-&\(:4U89KA&QD1"#&E:;7ZG0EU+65 M#T-[K7&I*)D\+Z]HI?[X*&2B6[R=">2;/&V3Z*NG&Y@M,$P\(^CV;^DPE_Y@ MS!QG(GWUJ+8V=VAM?_150D;; QKZRV?/7WZOL=_Q8-5EYEH)&:7)@C"5F!HG M'*TQFD+=X44P0S:IUT96'Y)P]F.]9JR]6*WM6!^0DD.&ND0<$ -4-J447*R7 M@9U5D7OP>P(X^[+'V8K6V8WU 6BUIF#,IEA$BEW%1,<%KE0H^@SN^:;99 MH>#IV.-GZA9)#8L^+D_M04Z%7R@3WF6F[Z=&EL%-G$$+OSQO)5S&R6%@GP-&P\/ M)HA%& _#IGM#+T6O;.4BS,".CNL;\9E54_-?X,;T$DXM$U2@7PAJ^@ 5;#9##$_?*3&P;+FT-O#% MLQX.N.R//Z^%+^/-Z$/A(-L[NX!L;^^%R0%<^\@=C,U]CW3#-&M8];7;97H- MAP0R!/&5;N$ZH^' 3 E=+OGROW$V8!^OYXGT7#W1;H/[V[M/SI\"QVF0AU"@ MKA']M=T%]_:S39_]#L)LJ[$<>=5:[E4D/_9E+606>&+3SP)6Z\;V M&>IJVDOSW:4R9DYJ&=.,L_O>6TVA[76 P=;>>#U*M7^)IY7)(K.P/9VCM=88 MU!:AK@=;PW27"<-[9^A7Y32TN<0#]&OT6WF5&OI%L@X$L4=JQV$A T2?X0M/ M-7+?V>O5]).4T=#/M'E5)] 9FP-!D&>D?E,2AGJ"N:>EKA2WD76-Q&U35_[Z MN98BH ^M61]\?#BX*-TZ:$IT)GT\&8CAUM8:]MXRH#"#BZ!0'Y-:*+H(\W2: M5FQA!_A$I43R=(M6'^#WI&&L,+5D(*L-?=#83*FS!E&'(&V4:)F@\OR20&?4 MMZ9%\^%ZD!S#(R&984>ODFILA=?"IPV25L6M^Q":ZSOZE:N0;-5,DPE;FVOJ)\):O>*]SQQADAM07$./MAQ5=])AS]TN"/S@->4'Z\7O'PD;V^ M.J79NI5%"M5 >C58&WE&?WH>X(&-Z4Y+@FYT9!5 * $A*DFN*K#3.UG'1//, M+04@K$&C\KZ_]WI.!:+6+3C8=2LT5AV;LBL/WLL5*-"K$'[NW9(P7&C)CN'R M*Q7B3=+[[9KFX< H%(\D1'5+;"M>@D)0B\"@NZELE]0(48GVI^\.*YF+U;-HH;_ M)*X.(E*J=%$EKL_A9E$H]])=B0/9U?9IA&0 M/DM?>=ZKCWL/\[3OIL#LA*!Z1=ULK=,;++E1=9$4V;_5IFS3"P#%564,X0XP M7/3.*7@C\48A1^S#/&LZE\T L*_$[* M+\5?UB=80X(TODX#RC#Z!'.+(<%?9V-;&726'?2W-T_FTH@ZOJ MS>'@M./CN@SNFS08)J;E+5[&DPNV(75=('.]7J08E+L4HT8I-N1TWK,R%&6M M"I;?>]LC"0/>4)BTWQDLE98(Y",U4 M4BJ\(I#X:I*EY]$AXVEAY'^ ,8?@P;ML-$G2//H+R73QN=R,3B82APKX,7#M ML>7H?>9UM6F>BJ^_M_R(AW#UV1(F3A/W32#7R4B\K?"QJ=> AT9=B=O+F"E$B"VTTXLZ3%PB6)1[+#M=_5) M&J'W"?L69X^(H!YMFYPE7 7&2I M[E><.HU *PVFXV\7)(;:3&Z_KFDZ1*87F8,7"0?LD1C)ZL]Q]#JYS,;1R552 MD"%[@<2;IOW(*"NG"#]+!F)&MH>L*IG$XPS1^> 92+W1!N>/ MQ,\XJLOC9&%9R/@SB;4?O33C<."O@+ZI %0%YK@)2.<@?VFN2@F)/!*3>C/P;V&A%V&9I)I2,T@M5TTJ .G'8?E=ROV ME^-O0K;?AX+7="K7JD,&=PJ(FY6-:@[3^BA/"N,%=#"LVW@C1"L&3Y&&'%7" MT"^+]*R5+A+.=#3AC%=LE.0Y:#5\E"&3LG-P$I)F-6:\I'-)=65U"3O\E:FL M4L[Z#G$&;Q5IYAE:0I'=.F\$*,3M'+*2AU7FY<5""^(YVU$+55.M/+ELRGNS MUTJ(L.+!.U0Z^_HS>1G!4&RP6NU6/S:^BN/*)E/CR!B[GOW#H6OY@*4-N=GN M"='AJM>YW=>Z*/9'=,I_4.BH0N9[GJI!,?%(:\6[(L<+V$EAC&46-!K[F.\' MDR)R:: 1#9UM%^2(-B8SAGTAOG]'[=.B56U+O!(%5X1'P7D M9I6'ILO^K>1\#,(U-0VEI@1=AFU9 H##'4TD'_&+%\^Y;:'7,U!&'3/Y-'V2S\9\J;O2*I)IN84Z6*U-41,?97,J MQBK[$CT)25H%=]RKYGM7S>\$0]5]EYLZ<#!U\]8:\")M/JD\4W+C17"%G2=W#*:NO0X'F,:0-4[HZ[0"WL>:@HN^9LFT58A&!ZB=Y5/$JW M!!S[9=BC$_^EP0+.QK9!38IT-(&FO;*(08]+(?0D3,V:HLT=#I(5/K3HC9-@ M_]9PT]B:$'?Q"#<^3>@R2Z^D-L%=.*2_>;(6QL!]5N2OE'D0R8_69)(!KL5/FT%]_Z;5VG=ZILEQ9\W9$U659?V M,:+[=QMLFS4UP-3EYW"@=G'09LQ^ST-/=MH\VLIAB3\*[1NK&97(/E2TIE/Y M:ME@]/"LU=:JDW/?L&=[$%7'_!\[Y1P[[6QO5I"0 P*=U65#>B-LOS7-+B9- MJY+):Y 9"?(-W-Y0XP+,DRJA0*X9*F_S2$:61D6DQ:[Q+)*7&MKF7QLI) MDYDF.*3_9Y-%G='5IAZK5--ZL$ \,4F3O)F@73S;]8 A+LSAJI/SM)$X6(I4 M>C)B3X#C4I7B!EGU:^Q']3."6SKHGR698;#EY;P!*8(-%B&;(15;;$Z,Y>?V MDI"&WV8LN5JC[O*D'YH.K>- M\5_M5I)7QI(S8!3WXLW^(@E;W7FA%%*TAMD]E#C8H,W<8#2<9 MVJ5'@IB Z+KZ#O2_S96J4PLNU&56?@_WH?"=K:BP_$/JO7HX^!<*8!4DNS0D MU0S>J+PS)"^D(T9FQKRA7_P[_+R$A2[+#!X3- NV5UKPXDU5,LX2;>Y*+K^* MO@!^ET*CP3HS.%K]<;/8?AS"Y@1= -8,J=,X,OK3&*.P:N=U@/T-F_>50 W/ M*]/.*E1M#\[X^!8X[+,>#OM]X;#/>CAL#X==3_W0 2+2FY;;7N=:7Y&@[^!% MGIK;JN(;EDD8!*S!?5WD2DD:]ZM,C,:R0$;._F5GW?N!E^=C:POMHG#KA5\1 M=QOYQ.MQ=GV<;BW\&B6]80$ 5,8* =W@K8WM-FPE:\L]?:49(^YV9+ -]I0Q ME/:U(C>H-.67A9\8#I#N$B/.F$N='"),CS/QHXC >H&_N?S/Z=%Z?F;1 M9"WO0=-JW9M.XG)4EZ=,X,/8"5*3'U/ CJQ.*N.55 % M;ZUW/E0K#I3MNKUTEJZ6>?9^Z&EZ1*&R.[9-M'8>^Z-H4C9.3,L.EW\V$NR2 MP3"7!\/7<>IG)33U$8AO:1/=_0Q-LP_,S(P"ODAN!+X]G9*V&^4 M3'_DD-&UDA.;KJT\%-?2/>R$:G^^&;VA#\!@=:;"F SH2^01Z\B$J%#2K/FV MWP&4)R7F=9[BG,YC"4ZL_[ []!*L,0D;V7W4^)$A!ZI- 0]2<1QLTSQJGIFM M'.5)-M7DIIIW9\QDTIC\890UO6.S!@HJV'M0"=<"4]4.==:P0&D79SF^S,I: M5MZE,E,S9<.^[362Z^LO $1%P$-F-&8#:F@OBHR)ZPS-1H I]> M&/"?_ .-X*P<9]RS]I]S,&59@@8=(X=8\]H\PKP\HJ^& YM', W31+^-DREB M-EW.>I7.YDUB,CAHCPJ+S[+MD,]4SB6]W96=::/1Y*1Q.2VKZ'/A:VJD]Y7F M3WSZO<9/]A]TI,C:>V2/80#V+S0";@9D+QJ,PZ &1B#4P#H ,X?^A7E63X3, M(JTN-;/_==AA&G/>3"S3T;+;84HBZ;9P$W%#PMY-!3"7P475QNHF.R8!=[;0 MD[ID4SN61-;2XK2);(PF7/#*I$);83^,FAA9C-ZZ7J];S+6%,YD75F"LBQR! MN]_CF7LBDB33VH_^+?:B7Y:<[R!%' +-!8@TK >8(L[ 5 C( !#2T5+*P/=J9T+7E,_4NP;HHTZ"3)D &";,JM. ,@O%< MP@_TNG--I_);67.#%$47G%M3M2=4F(%X7 N<$;IAOX\* MXU!3IGD3"DG6; ;+,QPLRY,#U43S>@G:HV&)-@[&:?$ 13.KI-Q.@%2>+F: 08(@V#&P5N^(!K#ZRC!+H6/7T- M--?>3[H6W30G'F*X,= 5GW>5*>?%7U!J$8>9<@@M04#IXR;6N-((8MHW._)Y MD;'7-BO)<>*K--P^*9[LVIV;UV"U4 GGM ]XD<+-!0^_)4 <)!<_8=M/&.\7YLA0G=5LC;TOO_+3Y#EH?Y$L01JLLRYWN9ID73K+AQ1C$FBP\70,"H%0JP#"8H O 2$T@8+D6G[1J,;;1Q_;;&ARH!C64VN6!OO\DH_?Z MG:/M!1D6K1AGCGY/#Z3%Q+8\6J6TAX,S;JDFBU>4EP(;/D_9R]%= 3VL M;UJA@.R[SQ)DYW$3A1MD%@(\3G0LKBGZ"9:_K#/;G4"3[))#$PHWDQWW^75M M*1A/($3FTEVM$=0Q'';OQ[+*BNNVY+_N*RMERY$@V((X&,LP&W)0#ZN_':;S M@>%I:>W2QY/CS#2D%%!Y3Q:G,U.X@6&C-, KJ1N#,C)M\1V"=++' M;_B M([;2;D!L/^\1V]\7L?V\1VSWB.V'X@[Q9=(9C)?DKJDQIXLE+X64)B@7#6JS ME]*JW-'"1[R8.T[YZ*'F69=KT;8AK=+J-C896D7(8I$%(^T]J#6=RG5^MV$S MDKG8U$?-.Z666'!@B":W^@W18#Z@/S4.<@O-D';:.-$<84.'F^7,SVB&V9 MASF5,+<#@KIQK8'\>IZV9#CH/>B2/;=4N3]'$],#4AN]A#4$Y(H9!$G0OUUY M(U8-Q&LO!?B/:R!6KZ"4]R6Z]L?A,6M8A\+.B,2YG65@ZC&^#T!0O=Q3>E02A9?'?LJX[5$]2:BE;Q:%+_M,7$$DBMM^O6 MYCM,.U(%<3VN*K)?4NA\Y^MCVW@RT(2F-80=((>BIG*]%*UQLZ[RWBGA7]/$ MR]S>.HFQET/P!KWH[NE7!(&Q%@G7RGN%092T*!Q7#>XG09,K5UU1I]=35;%I MV;TKFB5W2%Y+HFOO ?"+8@3#@7O'65JDY]DU44Z/J9MR]%EB MK7ZK;GS"US]T@_RSI%V)@)+FG( 9X4K9, :Z FOLARP$(_RBHI:S?&X[:HO[ M8.TTCA5DS(?,X)L*1CL3]P6A)PUCK)'I;#0YNV27BS\^7H([-:CWG&$ M!XZ+7,*V -<6B:4LT0ZI:M1L&)"U8S;VZ')"R?0[X4E+[MI@V!CDEGQ.V3Z% M4V;[50X'+:'P"V>]GKEJ8W'\5NX;+ROG]0CTLUTNN>!+1&OA[5K12,+%HN%D MW?+JU]+(4-7!]4;L7H8)FB8I.H]XA='8DMP+Z3L-7MY9R01)5GAI$=#N4,4U M"?@ L1RF$4)"UN1Y7EXQ15+$#$F._&9U2R@%(8T95].8-HC&+YXE"W%5Q$X] M@RK2O].^Q\A[IEJ1*70HL#%=297:VK8N86E>O5%WST63ANA9VA%T]2!(1DR? MRR?-DJ8S3FC. M/$#BTJ\TYIPT;'1QI ,A, E,PW:#E@3?+@,/LTE9*B6.IS+1P!Z\"?Y&)$4Q M!VE@)=HGF_J-A\V/0USEC(UTOLP9'MMPV1]-.:PS#3<^"&1Q1X$43,-D>8UM M+$D\B2X=KT@!#)@SR#"GR3_B/I-EP772X[DQ*F/W\ZQ>?EDP$C /DHSH(&*5 MHR7.]LA1MG<9/$8N7$/!E8)Z!:!%8<6?HTV\>_^=:B#S!ZVZ[3C1L3 MNGP"M5FV.IB9\/9F1\U!A^ZIAQ_DN7^-%2%FP>W-B.A65L1UPKE":4&?^&;% MK4R*1W#_/AHSVV4+DX;5LG/N DR6..[G0%:EKL9-'@H<;"X:3[4& 4&?'.5W MW#GTA[<\?$12<.?UE V3'M'>U1F[QBL+,KY.3E1"W*\K<*#0GZ\*2=/PW[8K M&6VD'A'8G)-H+69?O8\P)?+Y2<)&Z"&+. >W_R++)^5HI(Q$;AB-'\)>TF(> M"961Y9F-E4R6;TT9,Z<)4?\IY ,CYO3U(U!Y4UZD/*DS=]7)PW::YQV9?PY, MX '6FDZ]SPO+@N"BI>,T3Q:U$CG;)=J,/LIWW-&"]:/GS2;X)%C31ACEX6KW$ZRD%XC> B=G,YE(EB-OGA.' T%U/"C;)E1R^X>C8"-$N[JE3:OS4%JRH8]4;JVLZE2!/0)8D M7Y 39BHS=@?("Y!Y%RZ\Z-/FR:9TH"$=1$.U=BD[IV)*)6"K&B6:?VVJ9)SB M1C<43;.%V'2=@4V)[BW+F9J!:@]8LY/#BVRH)&I*&\M'\4F,7PKL1JGKUA M15EL\!JSW50):"I/KFJMC1&#I^L;0E9L2NC%*,HJ?S,L!8F#[80U-_4(Y*L\ M<8:A>;TAFM6NKI]"OF[S))EMF[UP])(%3BL;;>J=[&S%-G;U:J#E*/4O_9H@ MFA"9EK \$>XL1QD+A.#H;JO-8A?I#S/8_YR/+Q1$.4O)PX D2>C(-VL]%X+= M#FD:G$Z1[*V8K+1"C(L.IA1WC;.ZFL^:E3U?3&R8-R@=APU93.?,!W?;/.A+ M<@DMMTSOC4N4MY05'VW4J$J#,S(OK.OO:PX?1N13!5T(JL/5VLGI%6'O;]8U MG4H@*-I(00"SWRH5RVBJENS1>_^%Q%^^\,5P.-"K4\'1 *-K/<+D-J+H.C19 M&#@63?D5GT8.L@**?_&FZEQFC[*; _"=V#G6:?J[]4[.\-OZH/A?E59Z. M+U);94+JD0E2$9XYETKWA"^LY*)*;^J>TZ$\,3>LN2WPN)4G7>Q(\X>O(@ M[ZL0R< 5!-RWZP*IJ$+C8-S^3"EZ_CFOLGJ<:;@WJ3C*"+FX*JM\[+I,DCW- M@4L'_#RV[ZD1F$4#4P@8$QI95K_B M#=XC*K2OXZ)\?HE&8)]]W-8#@U_XT\ MB/ -",:1G0JOE9^QA.AX)E_4ANI(O)K ;5DS8-(-#]9P4+ANZ*J,C5E+>_$2 M)IGC+-"9TX&;5\+,4' >_-+EA3T$7ARV'P9P0,Z;1?3UQ,YK<-;;9)A\8BPM M, -X^;(34*G?Q&.4S-1;BEN:6BJ#ON+@<5=I3A=#C3,[GE7_:-(MHPPC]GB^LL?,DAK!280A(;XF5_+8,X+*J@ J/B&3 ER>':A7 M'SN,=1%'B$6=L5!\X;MNCNX<\D!LUUK'9\Q#3?F<@OR#FPT"$1.=SZOFVE&8 M<\S+T1J2%*1*I%2IT,:>]B%?U::3<@NR128(#BC^HS,QHHALWASM],,,&I*\ M,;ZY=8&[UGHS>J,[ZN%WDRJ0(!#&-88=!M $"!X'-WPMB:B# '49$'_. .[K ME"IO$N_,:$$Z:0[G6'/-O4KZ07?V\=')7TZ&@^/#MP>GAZ^CTP_1Z6^'T:L/ M[SX>O/^'VF$G^/.[#^^CD],/K_YR]W>&)$'Z_;D.]8'P7EEH=4E6>Q0^_YJ7 M36HI$3Z8"!KNS-ZP\WU@)^SM(B!MEF<8*U+WE7*9E9B7<+%L$"%> *-O#V#"XVMOZ- M*2*Q]2,60P-B6F@%57$<,GKX&A_=% M;,K#A:AM.+CI\!7=!R_Z;N<.1V X6'GNY@5,+ZWBNI8UN'WXEHY=Y$@-RX)S MMCABG-W S[\@.U$+C?"JRKYP^%]SBE?6_%UWLAE1',Q+C"5N(*%=U2N#H:PBNB+:0V03=B5ONS''D5 ?1*":D8U.F7K!;$ MK W):1C+F-HKON!94>IF[+P:RVSX(N+"' M W<<@&).LCHHO-+CJMZ52" -HD&4>[SW;B_;WM>'_GQ0K[(Q!\^DLR M]LBGE3MJMP.OCK>V'A&B4PBC"-^E+[42OE8Y9'!;2KX=,'NJEXU79_X&1..< MC9QYCMX54Z>0(_P$(6]S(\:F*(<.]2N9TPF_XM#&\VN(JI;H/$6X!.=5B>HQ ME;,T+X;3]&PO M?D[[L/O\95!5L,(>Y"7W7Z*_D=DV>56BFM.Q2B%85$ M*R7"]0A^HNVW+U.O\H'9B348(^M@J/WMC.@FOVE*IHK?JZE_%!KD05_L;^;" MA6R)JCKM..]"=<5^ALXHS\LK_-D)5:4*H=8J.]KK3*F>_5>IU^IH_=*OD4U:BWB=;ZFN:QGL#JSZ KX;;@>B!=?LN[H4-> MHQO$M1.#I?ZE%=\; RT"JP)N/RM2.\EK'@]/A$7IM\]"B$+A6)73\J3-Z4H MNQ@.'*>4O_+#C\1#NP%&_[*'T7]?&/W+'D;?P^C74S]<$PH152NZ,?/[@)VE M"'F2[9/W4+YUG?EP@/1[Z_7ZY/;.,^]9SB5'-PQ]^UN'WLKWF+$_>W'=X*/58]_9 M?[GCC_W44%$H;Q:=&!]MK>3?1/(;TZ5.8=F\'/(0 !:%4JM*Y)[)"]R( M.0I_F519.:\-$%[:[%[?X270(T@-2IN72S:533H"2<&"5LQT<='WBZ%+6T*C MXN]SHQ5=EZ;\HX=&@4F--E=DVC*FX'Q.%J&P./)?IW& W+!A7"T,_MEF)[TN M(X[A5KL=K; 1'0NR7Y%;F)Y*/NABQ8DR;9=^]EO'"+_D.*MG!,.1E:3&( M.$<,6H+7L53_T7D2:-3GI!YB&[]JUYBX*/\-KS+KX=W)C^ ">WSV5!MMT2+H MTACVQ[0@86!/W5!*57,OCG5R^,K>3ZWTKIXL[X+(2(.HMG0L'9_3.J14U>>" M\8VXA1N'74VBR.N,9-/%3 QN6W.MZ%70 QS6>2HLJY J+J$1/_-H7O"7: #361/+>F[O7VR\]/O:,<7:655^1K-$T*'1 M!5H9X0) Y2; M"6]G#$/B5R@;BL#$Q;1;0MQQ:CAI1!HH<0 @>L[[F'V/_AU4D\>>8XN]+-.Y MSB*8N?)2ZT%@#+YD!Y0$TY(95%G]62E?5H^ZM_;6;"I\GW8? D9.C-,\XSXY M=">5@+F+D*U^30)(KO=:V MGZK"M?=HX14T+,\CT:H^.2<2& @.6]QU^RC=IW_],&,X;0R;INU;I^-NLLO5 M.L?] 5BSJ?QJ(E^Q.0>6 H-M(@\;FG)#CV6U[+DPW5Z2)].!EV0Y45?CVH1I MS$!5 :'-ZEE9WR[Q:'PA<,@V##TQ=9C78(8]9W*9,R]'H%#43"40;:FC# M\HAHGE=^+BSE(_8^3-S868O6F_0^.4ESB[PSYJHLOGM.D_TF>NR")KTYM2:> ME03/A-W>D8&'M:W266D)/NJ),2+9BG&^K4J_J02BE372VZP-A6%GM@]RK>-4 M.@.ROY2@%0$U>$;:ALT!<,@[\@F+W!_ES$:O'$::>EN2042=H-(9)#WR=8Y7 M\='NP'3:(9\= W-W%%Y77L&!,-_S0;LF!19+;8IZO:#KDG"M-F;2";%9?LV, M',[LLI3>$7S$8E+4H/? ?>&N#GD:_FXM/.'F:G/9UE:K2_,6&8=%-DN^4YT) MNA+J4F'*'-ECY/#&?&;L*\=NX'AIE)_,1ZUC[7@SQ^UIVB@C1]SL)&XY!]G> MA>F+8*<4F1G=;C:*;Z>7#+\?L<%*#8DLR_@3('\68Y-F[.9GH"E##\*N)IB@Z%ZT/?,2UINLS6,V,6 MC)U9P(H_M^V-R^X,K-?@N)O>Q^$<8FG=D3#)I->ED?\I8.K@8EF)/894+/Y- M;&@R5W84D$F-TW3JTH*/V F['GJ]L]5#K[\K]'IGJX=>]]#K=3:_/I*N3*?9 MB$FDC;?UZL/?CEYO;+_LKKB!#7\_O04XH]]XMB^0RJ^9U].3DX/ADXU7YMXV=I[&X M3"A@]D#&PX$ .6,/V^A!&H7FS]7_2S\5E%!MP(3AO\]++O#P#!%.%W-*6"949\XZ)F\[\D;\>OC\\/G@['(!E+GIS\.KTP_%)?^/]:#OE;V'E2I5<1;:O M)6OM(JTN%H8ZDYE T2= \2SLP",!:MJ+<3$T>8T+ X"G7WEZP- E,0QD7KC M@D>0R>/0SW+JTA^2\&4*(-^17^3@Q=7(0*7_:HES0S[=9B6-;A_46M.IO#,% M/!!'-7V\R(;7C,1LKI@7GMS0V^>-)28-95KSR57BBF;\%M:&\ERCH:B88:#7 M8E46TG;&X"HC)83F4I>S=%&NZ+2K?54UZ"2].#29,$D,P\N,R6=1W#\<5'2- MTG+4Y"@F%E^C,QJ%U]]U15S>V70H*,)BWDN ,XH MM^2IQ!;%+J:3FTTYHJCTU.?!MGA\N0AC2 M'Y.?T.N!?AW;7L?IN6N?_7,T*:]21NVI!S9G7(!SY+*X8Q@./WP5T?#_K64RS;<-"E3]!$W1BG10<+=$ OSU62*L-2 M/C'5CE2=DG!1HMVCKQDV403+XCN&;KGVZ6[5G[NMUUKUD M5I->=DJ [4$2:[Z@-@F#=C7D==>FMOC2^Y!K)C.UQFXX W1K,0L+=Q^ \=9] MJ!+]R$):HVE59CN#P+-2?IIE#^X61VSU$O'XECHCK*J[]2G/?;7-R1.D73:C M-T)!$_OEM]]VA!/H'-BI8J%ZEZ)=R\6([=O.&V8X,'L!A?(I,*Q-WB?R,ED< M/3+[(SL)? TN\7+$LMA_R[/&J:V]/&MBJ; MQ[1.=/Y'DICCAB/M$=:KS*Y@>-IIP[LPKK'(M+AFA# 7\]@FC>RDQ3GW08QO MO':R\?_]PV5V^;];6WM_L!?>]S0RCDX/WPT'V[_0:7Q_?'CRX>W?#E]')Z<' M;]XP8?[A^].3S?ZRO>_X/@JILR:=VF;D+N$=MF:WS>!#U"IJ7:9)+N4OVMQ' M20X6J'[E8EH)^TNIZ,[9QHX2!G-ACT>D>FATT8%H_NV7NWO]^?[=YWO_+L_W MSF;T\?C#Q\/CTZ/#_CS?MYR=MAJ,3=)D_*\YV<5<2T$WZ3&9L3G=OW'T=[)' MZ*PV9;$9?9A7T:M)EIY'AURW!._I Z($:)-C6V?0K?]96T^@%&G"S+7\*[SY M,JNX>ROP2/-">]RB55$S"5E5-J-7R9B9@-Z:UGZ9XS?,;"0H%ZWQ*JER\X34 M"PI$J!5\BDV8JC9C CA!>PD7R866?)?21*#>*-(4]$M2&4@V>99+:J7)0 Q1 M!UHNE]"*;18;?&$S>F??3SHRS]++]!I4$!E[; *AAXAI%\C]'V?< HAK8OQ8 M25"UJZ4PEF[ $3IISUSCO2!ZQT0['O24E]RT4NC+T[]2B3Z[2R6ZNQF]/?SU MX"U4Z:O#P]='[W_]@;KT$5U^/U2_DG\>MB+C_XW;G<<,L5A.[F4>]"$C!X[) M)>BOU=;2YG ,9_0SM=%O&;P=@*)R:6E'JFS>2#^&]/PWH7N/2!#SKM[Q"?I!B3R=H]$_KY(Y.T>B;PN2.2N#?:7D5ZQ)+TR MYP>E,K]_"TPD15L7Y0M[47X\.#X=#HZ.ONL5=NV&]!T_;[M++^TNB06R3Q;( MP?%?#D^C-Q^.H^/#7X].3H\/WI^VF[4>_O73T>D_XLBT=N7FK;]]>/OZ\)A> M<'IZ>'P2';Q_'1V=G'RBO_KXZ?C5;PF4"S--2R2Q+AQU6,R9?^[P/H;I4&E! W.F2S%!BYM= MN&BXWY@I T<[FG%211J%93YL!$=!#I;4CHA=RR*6)A+CE4IWEM3D"E\A-0Q\ MEG1?W8Q.X/@O+X!'D%.EY[G-PQJN'4/+;K@6D,-%M3[^%U &P9%:^AY,. :' MCT>_;C)"[=)[;W\ *V2#L&&B'!28EDTD?>.3"CUF+<%/))69(6464W=***%% M"GQ7#LP/5JU?9=+>?F:W,W[_P#;H-?:NF"1_,*9JMR-Y]C4:-Y?J_?]AIF_77>&<=W^RRIGZC'[2'VSFVCC<^ MP.F^+:^^SVSAR-Q*;$@*:; 754FZ&))85G^,JHNS)SM;>_'.[HMX9W__:8=H MW3 ?D38T^3#3Z5[+KQ14_W?,^G&;'W:]<)U&\[NVZN^3K$EO6^YNTAZY/K3S7RO.0LN?_J\N*?AIQ4NW=UH_US5$/Y27^ZL>ZOQ$][+? MT^#WOGGH=WUHE[\>"L)).FM4$K:^\:0LK5?W&KW8>GG'1_:6 ]E[MB3S:W!: MVQOS/_,BO>L]01ND]=B3_?VET[_>YT;:,COM>4=GYFN7Y<[.S-:/W)_;GYGU MO>+7:S3K8AM^ZWGIM^IN;YL.>_".;IR=]5!HS]?K_*R-F;:]NQ[[\^+%5PK* M(S;2=KY26._LS#RP0_-#;+3M[>=KXM>\V/_*LVOW1[/??4)E?3)AOPGAY'UD MOQY1*O.NIP+B^/)<%8WT"=Z-04X%".?NLYUX?V\[WM]Y(0W?:NTS:O,QW#57 MZ8G1$WAKV^\.I]S13#DU;^HF85BFP>-? ;K)30B$#;,JOS!K 2I2=W9VY24> M.3+X3:JQE!1P)N</=_9C_Z6)=$!%C3Z M^/EJ0:LQI]N2KKVM.'J;U-'?THN$UNC]WZ(7+[>W7_;X]?74*'Y!UX%CG$=B M],CP=W_BY.RA]$1$ICAS\6NC>3@7OSI%'C:[8P6PU(N]DUB^ MG=[7_I@C7Q9FD 74O%P"/\\E\#.E,CG3KB9&\9B:E^Y7*'^?OB9:]98'R,3^ MP++'=YPUW5X"?_[^M.DJ)14%V*$?FE?M<%&^8;I_^#-/XQ7=Y1=EM;C5'+YG MVKH3X/@ 8*+ON7\TT[RY?E/2Z4DM*29!L@UZN93'FE6M^RQZ"#,N9TJ!<954 M%7A='^(D$MO2I37ZKQ?\_I3>[<ZS>&MO*6'^8W#!MX@OX3J%#3G*.LVA^-EKX9 M2^\(_.4_RXP>1B]:[M:55$V!K7ABFV(X9A/7+3-6YF8PN82MYNT+T,TD+<^? MWCB6S>'@U.=375YPYH &Y8D'#;&L-+QW]$-:=(1 R.1*(4!7-"'FRH9@1.08 M_Y<=23=.=SA8L;V&Z1H+C(N$&X!E4^R")1_:O5J(5TJ@,S>.P6PSK3R.9K/D)6QB&[IPEL9=:&W0<" [%.RK8>VEC7)! M1$^6;R/!WHA"C82F$.-I5F2UT,X+M=$RI5. J7L%JJ&F25, STO^*'\Q2FCI MQG7;\5 9G]E&-O]=H@$%.C9Q@E WG)_=C Y-XV6[:L.!6[9 ;38(*^$+>WOQ M'I#U6UO+[YT7Z"CVQ*GJXY-/M:^DNY9)H/3.[6)I(X7&N]F"]F^_B+=>[,=; M]'% _)F_73:@A[VO)^S].!UQ@X$3Z<%Z'GTJ2*+,$7#W?H]M7QN#[Q=$688# M[F$S3NM1E5G##3? W-_ 906MA&VV'9QT[I:6#6>U<)X9Y?VO54703G-SKT[A M>4.+4+GT,T,01RK,(Y4S5AN-!4N3G6ESJ='--*7%9L9ZF9H& M=7A)_\S"+"/PS%37BF>7">O(_<8DF$^^2O.,K4=ZQTG*7XEVGR1/G[Q\:E3R MWI.=I\:F=^-G^5KSS?'>EK:H&=3IYM1B>';P]?@3O\S='[@_>OC@[>1J\/3@_Z3B?W?A[7O:FE;TGW!_UW M'_3MNSSHS]%0X/W!KX?H6&N["*"ST:>3DZ,/[[E+ /W@[3].CK@[@-,&KSZ\ M?WUT:GYS?'CRZ>TI_P3],@_P#WU;I/L6W#]E[1KW<5:/YDQZ+L'H(LD7B)?C M_Q6-N/ XOA$JRND[B$9F:%Q.&H8LM'/-983-Y=NQSXYF:A&WO>_NIV9ZJ=/? M9.78(Y&7V*LWY'K"/;C/4AI>PC$ ^L _YX5XYUR*?_UXZH;>RT@22;;@UZ1# MT]ITGZ3IP[#)BLWHJ C0+!/;I,[G!8@U<&O6]YUMEVF__CI<\@.SY+0(;US3 M^5?^2D7';J$^N(5"-BG)9,40_-W(R_(SONJF)5%M[="G7=7Q0EHC :Y ;W>V M&>K=)TN]\G)V#Y,03@GRA?0$G98WT@6M%+SY8G5XW/A4N?,)$?#!**UEU MV@C[ FW067G)D)TCW';;!UYZP?Q:9<-\FU;UH"B (#J6R))$(A\:\<':JT@) M'ZN0CIQ:%]L%.\_TF1EO(P/7?MOM_M _]K<\5]#8L-Z M&\ /3R%WW\7Q@H^9?>9>2K\]??*GLRKZ[S]WA?4>6CW[ MS9-:8L2_ZT+7V]?G/4/]UG%ZF1;S]$YJ[%96I^VOJ.YZ%N^]7)?ZM*\=_/9> M_.+%FI>EK629>E76C4.WD\"/?\_Q^J8C==U^?MV;=$.>[+R(GR]3R*Z@JEH> MRM-'L 3;.T#4_-XE^/%TP[]690WWNSS/FKLNY'H>/]]96J+[JD/Q_LOEC;CUF?H]WL[Z[$,3TBCOGSV[>MP3[ID66QW5&S3)E NJR:T\XT[ MP\]%XW)^EJ>W\D^^\BU.7>P]WXJWEUNW=4[DF^ZZ]5^"_1U2W\^>_=XE^'%] M']:QT'>W+_3]OH6^NWVA;U_HNYZYDJ^N%9$HHR383;3I5XXVG7"TZ<>GCAX1 M0.BNIZ+;-QQ<)77TDX1I.=_SDT0]@PS1C0FBV+1&R"[3?+$9'>0YD"7X C=3 MN2B8HT/!VUU))U?+9E^*T@RI9C.UMYXWT=6/X:@N/Z8-TZK03CW?^UF851C# MFLP B'@46_>(I-#!:(:#<9DJT-%"303EXL,:KS*2K(NT@&^91O4<7IG3/XPF44,C CK%?RL71M'7IY"Q69X"',.OV]!/<564 MST_3%K_C9)R5OZ;Y__E_7NR]V/G95 YQT?4YIV(%T')6):/)0@1R08L[FA3D MQUSTLOF@[CX;BP(RUH1(^^MNC:?B[9@):G\E!B*\XH11JFXLW8-%9O18B;7! M2JQVY1X8XJ"'4?QP&$67Z_JQ*L]31O@F>72>0H(M4TO$=4\;9PE JB'E_AH M&>+G^_OQ[O92-.RA #'B%[1GNSM+/5O7"XM!$I(L0$:SE#B]L]SR\_UX9V]] M4MW/GL=[Z]_Y^#BM4ZYRQ-T^)DL_+V7;W=N,76W?=U/WVN_7B64S> MRD.")OS*[E@N-2U*SP.[[C)]1%B%[?WM>'O[=M?C8TXO;@/JM+ND3;YI'=8F MQW@JU$Q?#;%9\X3;K>$U*_-MMY/:]5^&V^%K;K4,CSSW^#"G\OLC"1&'W.V) MD:B[E9QV*!TE?.1E5"EY%I&+:GJJ8SC@>@]^=5/*MT8TV[,T2IJFRL[F*-K3 M&/DX=:^:M?V9Z,E/UE6X70( K(5SFHVUT%VUT37/;3]M1V#G399SBF!:5JDC MXAY+1)>KS+4*-:NBX_3"< >_+^1J>_D"=!*S4%#X8;ATW:FQ45R(7D(7JV; MO;>?A:O*6_^+&TT0K*)6;7"K!T.GORDIN?7;:H: MB+<;3WM'JX16$7UD5>R\X4C(+ -K2#F>CTPXG6M$F8&.'LYJ;O9X3I(\R^C* MC+6..9CQK.5NT&'6DEGISX9;-0D7!6; M.D>875HWQH)8AV#W4A>J!Q*D!QI\]_F2YWOM-WY4M8+= M\#YWC1",5>ELV2AW'KTSTJKERP@P &;7DCP M[3KX)/P,)O8_23%'^QV)BG.S1_FNQ&@3KL;#9>_UQY$A6$AY$ETD64$C*3"Y MMFV'9\M\;(97:Y!R$2&Z6W/+@>2B2GU0+[U@#,HY6C!ZBM[/U*FN%9:^R@]9 M3FD$C!">TB72<-"7!X(YD":8R/PTR+#3 WT?4' PI>U\RR6A?1APC:?R85X- M!X66[WY3.LX5S3Z5A)PK(7W:2LD]BA7[EFK0O;X:]/M6@^[UU:!]->BCN"C? M9O^:9V3V+;0<5)*VX#C:=T^CJ[*BC/:FI.'2?S3 M=OSLV7:\M2?] +B_0"6Y\>Y?[SU['N^^V(V29ME+V0PZ/%WGI(1C@UM$[A;I MSG%4H 4BT!AH$12=HY^8T*&Z:D 9R/;.5KRU_T(=BD3@)_3W._C[K2UV;NP[ M:GF),HS#UHIUF=C'HZ.$BL1' M;&L\S*F\(H$8#N;*1.Y"?$X<+$!%G?^?7C[;C5]LO[R]F^Y$\X9'A@/V)R,, M*KIV3#!Q79"A39HA' V26?+0?H<7@NEEZ@QC7X6&*^6_9_PZ:V(K[S9T$ MT2XH6H96H8TQ6.#/%EV>N\X*/:FSL5G+KN-G(R7RF^& -=(SI!N^9LGUU-\J M0L)1#L$+A(BGK!85\F)[&]]78%YMNFDN]0BV#77=4KCHBHN]2'M=";1 =^W+ M4$5Q"10)K9\7WD_(BL)O,%*1DHZA!M.^W4![?;1F4SGU>A+3U5+;VO@Q#8Z\ ME"P F^.HTNOK#%X&_@_W"@W:1/ ]GT36EX8P6=?XNM,1-B/N>(=ZT[+!'$NTSQ6WJT&/,@$.]CA@$T4/;L"@]WV=TL^FQ.2T]*+IR>XSNH+?#1 MQ%#16T7M @0V7P:JY84-8=GDQR] MY2\F89PV*8S61;.WI*[G%?='92Z&SG'E.6.-+Y,LYS5&(Y6TFJ+5"$1,6U9) M+TC]3!QEYS !:?E)1X5=ZC/P-9@^5^49K[3W77<)8"M2VGEL0WON%3G3626! M7?J8= "'[47#(#&:HTE*SD_:E8$-QB%W-,YUV_K==5ZORFY69;I]-1\Z10*3 MN.2T/PU=@!%](H<-0;LDBL0_E@P!+YI.4V@S^G"I#<[X%.WLZ0D*E,!P< 8- M< ESKA$)'X'A*)G1T?B20;62'?732SL.^CQ&^L?HR?93_B]^VYO7!_+()4DD M_<\(8B9:#+CG:#*GA8E&Y$)SOZ$&ZIH&@G;#^I/AX.,$(GD41[,L+YNXX]>[ M3V5^S(A"8ZY8_"_TE/+/^:NNG_TR4TXD5#G)B%F:!3<_+QHZIT_V:#!D8#4I M7'LT;4KAGV!]%;Z-^4M,S-=19A.\']69LOGPZ^B&:(":QG^>LWJ%9I9D5Y'H M8:?UF:,)$'N%L727>K+_E'Y%NXDG*ZD%**O%TDK#EIDW-129&KJ?Z"DT,D=7 MC-Z66;>IL (@+Z7 99AS!E62=BI1338UWN&-:V\H= M.NTX^2N6=XEW"89$5HG/DZF9U](3[,G$:!LF]4\F<9S3PA>FLD0:F[G]TM&8 MO] !P/MEO:T+]&GS9%/T4)K7Z156-C3GI+]>;:X$7B7/76VDT6[$54.DI4=A M?WOK:]N18ER8*MGU]22;^0GKEG!8VP?>W0_2;[TNZPZHJFD=&+VP;,D/^:RV MJSCA'?N''8<7XI6K%?-I2G)3>UT2%:\@[@D7'ITEQ>>T$DDV7@OL&C*]QR1K MRVX.XI&HN,HN$3W)JNE24%( #GRPQ\86VXQ^X7"+>$=-,*;P&[YG _=A.,B6 M3/V6H<_^FMI\]L-8K+3)H"/H0F\2^6>$B6(&:Q3ATTY9L0CHY M]E#&CFA.'9>Z+D<9N]&\R'PJS;#XNM (&KW=^MGC+)^;+I+I%U(]7%B(Z->D MS,>T,?V)O%?"RQ$7'UZDY:S,,TY.1F#Y:P(:'RFJA%8OL+LD;&<9_7K!$G59 MHNR4_XA*T+P\\TXM3?%SBI>IVVT*(CD)3M=-;E)D$?!*;"*WGY16G!F=C5'3 M?1?J8-QY\4*BYJYQOTF_I*,YH%:^FTL6=]%+XGV#55Y-LO0\.N0-0K;J Y@L MR8-2/47F'"(:&FY'P],)0(@E_PK"=YE5:./*"GM>& N5E=7G= &_N"Z+(LT1 M1Q^S.+Y-SI"Y+2MG/Y(^EFZSJ**55N"ODBHWC\3 (9+610_6EG46FQA1;<8$ M'$$J;KCA](S8ZJ)SL%&D*>)\9TF==9%QAK&RH?^LXZNP['GLW M;Y]F?_!*Y6#$D4FVX#^2(3?*[@==]$!W[JZ%D';S4YTR>.:0/@CGJ.[W9 TT M^0S(@LH&,ITF]7I$(]%&QZL:LU9G8U+I;H :X60>*B;L"32!1'C<-F/CV7]L M#7XFK6XD0="!R"E.9Q+ODGM"M+X$&U!OD9H0+^MR^GVJ ;H\$_0.*?;]'L7]?%/M^CV+O4>P/ MYS8D"^5-]@44<0>L$WOKY'[W0S?#7-85XJ(5%\]J2)[NM+22J[UF7Q%H+T%L MLS[ _9=N1A\=T "F"'/-B0V3Z),"0]O:PCLN&(-0\04JK5G.@W&T']Q>>K"R M 5P@QS>C=\D_Z9_/T@8I!.<#T]JE:DO,Z_1\GI,M%_!5W@(S_K#-MI5L*\ M*,]CA7W4 MLE*V\^G3.ZE.R#E,Q')$38RF"O?EI>^O7-:A367AK;=&RZX&8\ ME6 !L[K5$.H.@5;]*;S]5%Y[.ZQAX>F,B4/GM3%KD;(&_<$&//%HFI*E2()C MX%26'.^/4OPS-W@%.[KI(1+YZV#O? M==0M>?HN(Z2%[>0L^7ZCWI5!TK7S7(JL_0ET4>_II'VB.S-MTCR Q=% MQN846 (O[FI2=+E48WA>TA1A53@.UNJL)PC/6GA"GIU;(*D\KB V9Y/Z/^%W M]W['FG2 #2$F"+-GZ56MN.V&PP(+^!?L\+,#G7-5.>!-SN4WH!,MJ-3_8.3) M%?G#*)!0W!>G@R?(67/J8Y15Y/("7CA"IH*F#%B-%CXQAM ,0$'20%\C)WXF M38Y1><$<6*>3M$[M\$V,W\ZC';K %-*$8;\T5,:/34ETY]S&H",E(R#E=)0R M8 U)G8LJF4T ](S&*:(/<,]HKAS6 )HLXX $PX;X@\!^EB.)$L0.AIW"H=>N MM;)L[N'AX J9B8UQ>=6CQ^XY?/F6L>%D0;Q)?V!RM;_<;G^YF0WBGB0<>6OX M[DD:#K#%=#?5M1]B,U=;(@6Y!]Z?!#LZ$MX_[G'R=<$927:Z^X\T55%.LY$+ MSO3WX?J(#AWOC[1-S*X(Q0R&\CQ/)6O[L4*TM%GT*8O[W:2_3S(TB9_)1O$! M/TNE)(&KOU..LFNI5"R,D_B1& MJ08@EB[R!Q4O@7K8W^-@5)=@CZY_5F1$3 MNO91:)462GBG!7)6@<1B+0O@-BTVN%Y6@ F2_@#39J@^U%R2NK@+1.FE MQ^ M51!\9RE(+NMZSHD3-2.,^<8/UMK9*?$+Z,P[3"F45R+*A"%2O.42"-S;2" 7 MO6ZZ;QR1)640V(DB6JS]*[4',,H+,J0OF+E$/#B_RL*>'*Y4\C3<3#6<"*6R M/=#?LT!NTLBXO)DNU@2@=#EZS'R#%)B.R/NT_]$X.ILW? 3S;)I)_Z;80RO9 M(@L42-1^2;*/)=4&55X9D8'2<)U>5?Z39I*.+32(_X#"H9KS8UQ%Q2]UU%*] M3-_O?7LLNF4X.);$I'3M[F_8^]P6T!:]2\ ,O;TGB>DW%J7G$,"HY"_&236N MHU]*^I_H"0[Q#JU!]N_ !#,?[/]\U.]I[J>CC[-& OH/7UP\LE_&-GX M31[,QM;+.%*)D>SWJU+:O2EFX!4M4#D%I._):3FC._O9UK.GB F@^--\T!;/ M)"#CNNV9E+EDM^2^9ZVG? V(@]!6S%'MG!J6;H5C M>O6E#BBI##1SGO>8OYH()U##=S&/[#R[3#?J)IU%TY(&Q102HPE8,1 - 7BQ M\DO)]7(G>< -8)+\4L%X%$)G^I>YX _2+Q("TG)78!^71M/B MZQF7C(-MW H.!W8)I8(!)5V&W9PYC;9?>+X:N5V 8-):&UIA==@>'MCR8:J7 M3Z@G& X.3E[A>,:,0ZDX1E(J1V["F.;-09S8Z,HR01LP"RLP&C-75#I"L M$?R::K#*5T Y3CU.Z>&@/*/I&Q/#OI*S)+4-#PK'FR'#<*0!X$ AI<)0&Y9< M=0CT?'&,S[Y3*>P%GLVUSJ;,FY^E\^0_=HGU6SA'Q$YL(ER?=#H%.#T_D[BI M )*]IX!)2$?&^M??-9D@RIE6QS^Z&6@*RS,.HPX'.'1\V/1IW:XVE:8IF.TN M&@J(/ZL?;G;U4;-O)8"R(#%S?9C>#4^RIT:>,U7#H_ .YN-BKH^?Z8'E)T@H M< I99MWIXPLA06&L>2,_38\';GEX_.@*E)I<^:SWX.73Z"I%WDHY#H#/UY1" MURNTGZPWM$ SF*/OOH##]N3R:==B,3D#QP43=+I(1H$#WCGY3;*#[$/*!.D1 MH@AQ&FU/GNH,F&=I#'/"G+VDR*9,2A7F<;JWDK3#5>+R(]=NS",^K#>4*SSK MRQ6^;[G"L[Y#@ZXT]GK@M-])%,U!,PRO3QB36R52SV':8T@ *,= 0K&[?0RL =7 A]$/)S285N4O(">9*-&H1 1\(QV_KE<&!_ MRMQ,2!28$<@+_)3A&3YUF8T-(;!'W"H7O*5^5MJBZ FC \! !?J0IW@#_N8J MA7^2CC<2!&4O:$'H-V>F5,--O Y8F_AEM"LE&5/R.N. >"D)2S=@RB*9ED?- M?*&1FY4((8LC(0U.6KPJJS[HKG[WJ%P>\9N>VH&F 3)-G+F M$B%]JO0IRUE'?V=8@1$CH>-KR]D9B*F>)E)A*5[0*CISH17F&'>%9Z>FD@RQ M*XO,,RTJ[#!:8P\Z5G $%V&F)%="X$L.>@O^Q57*0<4@,B:5_$$I82%AHH8K M]OB'B2V=-\ZTN71&$M+;C/Q"*+[)O$^UIH)@GGBK*Z+_J\(B;P X'I\F7GL_DOO?C&N-;>O4VV"4A#8J0!^3(L63CGN]M M;6QO;>SLA]F^5^X?_+S?9L29@BCX06R9-88#1ZVQ3#-2I7[HRS:CD/0_'D3D M2\,/R'$)5;$QQ(620_[M+&VN4K79.MA*AH,6,EER!H:"]'KZE*SR,A$\+/"- MU%"$2_0AG7-T6&5)<*5%PJ '/%8Q0,3B(! "GJ6^8I/0YTF@P> M\G&@B2\K>$O^HN#;_IL="AMCX>Q=@R1?KSK7(]'FG1_G$JS@J5D2-/A)BM5G M4;&RM51/'LJ37N]*/BS^E[HD$%.^=Y'![1.O]Z"ZSS,AGC56$5.OG MZ9@[6OQS7F7U.!L]\FS PYS*D>U0S]Z'8.'HA.5\>$V3,@F!V M:>@"!2]8T M8 @-9=/VWG%;T%N5CTQ KJ'KHHZ/WZLYY@*:KJQP%^G79O3FJSI'=S=X=/@! MTPU 5D80P;0D"SNA%0L3PDUL)QJM0S+A&(]84UM I-;(\,R >>'I1WH]6ML4 MZ7DF8(2:I(0;7##EL(GP(%%NVNHM]9W:WM&^&?TI7+.I@-DHR>BZ_9LI*W.@ MN:."SLE<>7=[]V5M[D #)G,>RHN=K0#'2#LJ&>#HG5C:NHD>M#'ADQ[@S;:D M^Z531'LKJ"11W M=%XETQ3LY=*9A;_%'7K-=> W@ZW95$1]J8S4*FMCDT50E(Q+BXC+)^U+<)EQUP53^XO[-LGX M'RS4-+%.!0/I$H7]P2/UT#CJ;@\'TIA!&@T!Y,HE"Y+H\<1('(C6,0F/1#.I MTG2#C*'*%\4)_1F1P(5ZNS2_LLI0%E1K'XK9'!!7$S?M.DIB*[@W7627^O0D MNYC >M*WLM,]+Y(QMI+>]Z]YR8UC*X;;\H$4(*HTHY!P"F.F1MQ*$FX9&S&^ M6_8D1_PRV@Y.U5-;40SFMJ41E&> U:KOCPF:M^R&;S%UU%@URX]ZQR12]WIB M[XA%*D"/K$29K!\_U-;F#BW[CS8LO@L#TP\:^L8=,+/?G/EA"M/VL/0(@?]EA[L5K3L3X\%;X;J/ N]]9FL\EI;G(.KA>EJD+$ M#A))U0OPDHL#3<]5:>MH:EBY?);A0@PR+J\*OY-*+,,Q^MTV!4$4I>B,L"Q[>%$/P4@/V9JJ"OY4HQAAO-U0,WO0WNP_<'5,P?M=X M>KM0I\\,WVGRXH3;W7!S80F0FWXW?<9BC3(6-IU8ASV))//;#;K:?A%'_H9& MG(?=_CGB+0__"<'#@Y-/7#._L?5\4Q.A"C<"WXJKOM: H99%+@T&%U M4 JZ%;DP#''^M)0>PN,?.)$*DJ5I# ?!/$R%@=0_E#-+6@-F" 9*27D#4]S$?JVE M+E%R!3:-6'^&@G:+A=5J=$ZTZ,C-V^;5:)* [X[?NQD=2"0G7MX31/5-]LFL MM^G#Q>NN\?6L"F+<)W.NK/6W3S+<#D,0\,,.!W;E/7 ;.J*[IERVOE4+S/GS MCS@C=$.=Z?.^SO3[UID^[^M,^SK31SK":XVG;$P2DEW^[];VCK.AORL8__3P MW7#P_& S^NNG@_>G1Z<'IT=_.XP.WK_&7[PU?WY]=/+J[8>33\>')]'!+Q\^ MG4;O#H[_\AE>0HF==IFX[V?[D@S3>:$!FX.9%Y-D#W0GRI7 M$U@T7^@?%H2"BBMU,=&%XMC93%-V@:KS"M/\<;'T@G6!IV( Q5TR@-J1^Z@4G%VF.=-2%T%?6]]RH&U'2PW$;7R#A,5)VD=R4:D7]HE MZ1\?*?,#XWF6%R#5.V4"-^T,-$QK:00#'JB2V7"U&X<)C*#$0]$1DK*[ "]" M#2+Q!P$FG?IIA0$JI"SEJ&8S1(07^90P%H3#-3\>(.,1O$I8#S7- MQ!".J##W317N>HB4 OI%AHVAP:Z5Y@\VX+V1^ A1/G2<2B:-$: ,/12HF?*A M@6UAVTV:)1 &5$(F^TQ;.$I(@LXP/L^G>LC>+/*[6>""*AG>YP6PEG>3"=IZ MJKQ?26"<1=PDW*E2U [S96H[)LTT''KN@[N;@Q%6(;Y+];U#\@SXON!KV>5& MN0>)CL?$_&C=+$!4ILE;<-%1\,B=;ZUBU%%XF.(W%'.82O0L>2=88!A^?_ MX];%,FK!RBP1\L1JT#@CFO=""(Y!=.L*FGV)N!BNZ :MRZ)5V9CJ,>F/##^D MBX_(Z\]F\/Y%Z3VH-KK*-PHG#'^ZDQ&0.>_-PP?6XXA&/5Q(Z@&-^F$XC,_Q MHE\!:;?9\ _6F9BBN@MWFL[*>-89\2%!MPC+M5D*X-FLH2?\W$_.K,3LEDV1 MFB.2GY40X(M :\1B/L>'/VPFW*-M4 M1L0]+^2&,B,VLAGQ0U5VX+ZG:\.>A7!=+J7(!1WT_8/18[P]^TR\KT,7OY@; MYP2RRJ(14E>$PJBBM*2P%]JZTD%A'R@:5U+6IVI[8M#W(C0GF#BV.\:^\;+I MA5]N*]VV(PVG@!D6_5L'HA:#P99I>:$P8BA\"!QQD=I[# M6OZW"E*!F*$4:)0D6DGU[N)]V#RZTG%N-$L,_?/WV7.8IM]K4_XS%QEON,]! MH]/M1%NOG01ZO4&Y;1BAL<)"$-._UE;<_7'-8YI"X/$F)QXVH4)P0EU@ZJ9K MJW*6F]Q":.:=N-'H;8)P$:W=I%Y+?HH:O8E86'U"( M]5H3V151C3S-9T72F$=[XE WQG"R,-[AC(<%5/O@]W' C"("(^3+ M6,SA8Q1>;&VUKN2XI^I"GV$= V-I=]CE'%804VVH)]=X;!N8QAMT-0>&9G*S"#BC:UL6GR6'2_9I:A^U8L=2 M1=N1K<,0;(YT7.D?VR[G>[(7R-QA!-L>,9S?29K^D=*SR9\7[[61@T##1R9O MF5JN4UH2+L2BLVT!_*$A\LY#._7WE\U8#.U(;,<3.N$%")$RWM282/[AO2!A MRW,/A23C7')^Y 0*25!N74]Z3/B-QSO309(8KD#>!-R M[4-)HT@)VPH5M:,/21%.Z+6O4KBH9SJ4:C)X' 2V^]Q5%X1+WYI6?!V )%PGW"',/A"LKNVG\DVC%=#VQ!L)U M3#7<@@JDI1 'QKQ[)N*&"X7WI>-##2OX/F$Q:E3BD%ZP M>1B9MW]E8RW(:8IU.U(LZ(>X1[!DQK9(^@G:#7._>$Q?X?@&Q%0=(@9'8(@% M!Y)(A_ILO!ZYS=-T*$V[D3Y5=3=/0\T-[N1P.D2SAES; X@+ZK&SFH MQ2=W7XND&CFVP IS YW!CTU*%G%X&1?EQ6@&=F)VV+5)#HWHC'17C#YU U>P MC$B(WL0(BO@H8&9IVZ]]0*=7WJ'MH+\O9,\E.PK.AB\&&85V"(B18'XCQ/D MAWH\ 8C/49+4S<2X6*Z&8/85'Y@4J";SU!W85-3DE@^Y$WE _H#O4.9%,!UO M46^QW;57Y"YN>'PNLD"?S7OM]]3!,%_=5]EI==_)D=+I?6Q>*:WV6>?JHMYK M==K;K>M[+3>W:]<0UIIOSU^7O%M9'I(LYM*0Y%9#DL5<&I),2D@R[H+7(--] M8Y3;9R08'YP1EU5?7%[6KWK93*O52L59 L*X,]=4\Z^)*R+YW)%RVKIJ-GJ= MJZZJ-/]J-CY3P[S.V5FKT;SBO0<:G:O+SE6]UU0^=+XTK[#/5C/55I*HK?3B MZB I]HJSZ2*)M4$T24:->-]<5_31"L:]L^ZOJ']*1C]U#>^E%?=KHMM.9GSSM) M?L&M%F,:@Z$F!Z!\.E(^@4UBW=I;0;6$>I6W"5:UDCB0$GI2EPYS::Z8F&ZS MH"> *EH[+ M;)>+(Z6AZ?=@-23NOA**1M5:XD!*Z$DUAIJ!\W@BR4PGE(6)$J[+!@[S-&?Z M+*/5TMSB36R"'G. <<(5LX2>$UU;$D?W\Y/>LV&MJD+9YF"*44FD:0% M8,E2@Q%CE&DDJ)5&;^&OT+E&R=_B1P;V(AM@[A.N:[@*,YEH%:-3\0,ODC]2 M>C$ +7+<\6K[N29__N\6%-C'[LIPJ,L!7(#&$QNP0\2=9N* 2\T;XF: ^\ Z MF'^0UJP_+WLY 87_QK$GENBS=H(]@+#XH/D#^\]@?#$ML4J 7[XO[X7Y]Q(N MB!KS BB@ZRG3>%H@TW 0ZZ*>K2N\^8:[96=^>ON/JJ<\=;!!&#?6(YXRX[VJ M(('Z'@ZZT44]#Z/HH !* 1KY;6(*N7R%NT TD$;T441UQ)8R$G&R&?[C^N0& MS@%_6E65?VS11R=X!18T64I=OS-&IRPS9M M1].QTP-@X>!VJIR9&E8]X8ORQ\WL[/> M6;CS&Q=HFHE-AH"(&7.H[;(+1^%AI8AF3EU#I'.+)FVN#Y-$#]?804.SE-7% M;H68G$0V@[P#9GZBS TH&BUT& W5%ZQ:';$!4CP2]^+XGF%*LO/-GE[91=,\ME:KB@VPY\ M#TI#&\-I&!;P=MA?6M>FI$ MX/^$JR!:5 6)JD"D0X@F 'I _%1YPW1T)@,_LCU[G#992X R[+O1PRYTT0H$ M]&'\6Y$>T"7.SWCU=X$.ZYM,B":HS''4$Z\'^XP3"-%$,1>RP@)B@!_Z5MPH MU+X<*SL\=F,,:)RZ14H*58N/QB8]0A+J2/F(#=X/KQ'Q 4#Q9N5S5I%X8UTCLVY^F"M MDY M@8G*6]&2#"/9ZTLF?$G'83>VQ3=:J0B;Q1=KBW]+4O2K1OV=/;E -:YMSQ1FMR%92"- @2)+\SDIB!!3]H?I,4Q!?3[1\I9UP+KA:Y M%ER#UT1P9NQ@;>, 6YOP)1PJ"1P[QAVVP91?E* \FZR#E*)M%(#ML6;B( >-3V<\?,$'(;043B'KR=H M]WB@>X%P!))4L0NN0I"02;G8H@\#*5Q65<5*=GX6-K8 MT11!^DJ\\#*6_PQY3E@(UHX40EP)!C(=TJ@T!=5[B_]"4P:(.;P?;WRK2FD6 M".Z2>+T%5(3Q7M\O9 5<)P:F,0 M13^,$>\&L5@0ST/,AXQ8V$5:6"I$Q/V:8^,P<8&GU+SBW)9N [- %UWLU'B#. $GC#P":"3,3__T-;(47+,%6U,KETUJY M[=;*Y=-:N:34RKT$W^1TKW7R/FI*A='W2-5N3S"RCA^=R29Y0.D241<"S&^-FR- MI>F&#?)^1+J]:"-(_H09+Q9^AP.&,#TCF[$F Q,616>OQR*N"=E' JQ.[E-& M9^X-SF7#B)EVC:VVHA&4T,^/YO= ;G-RXNFDM&##B]"(GVS&T3!4<\--=Z[T MD;U[.!F'#%U4)X!4QH):7*[LC%!U.^P;IHD.?1WYJA/T\;QCUH1)HYR":#S& M52/;/_"0^"&U;&8^RM61PU"Y!JO-:TSSD5)2@UNN?06JW86X!O*F7,]"PL\. MMZ]K4Y PASK&-_T!K'#05_^KC<:_GP9*TR6_QW#$8N;8N>O?=QP1H (:7,04 MYH)A@2:*K7?=PWPQ#\8JZ(U3[,FHC:=P.JCK"9P).TA5Y>RTKI3SN8/;MWQ" M(G5M_XWP22-\(4BO&D 4&KZK2\$7O \#P.>C0GAS$^Y]BL N@4.\YF$:'33F M$?,<.)=@B!+A Z9/!?IJW77M@?@-;/AR.'6- ;R&]%^Z!4 EY68"-XM,5K1G MI),2!8\SBG#]\F(&.$)Z#26Q,>8J.2PMG3(#;6QX07M-' A(#FN %#ZF-"\D MYU^*N:.<,N(H.[M^*&8-=P@[ OB1X7_@C:ID8"ATH>?G#6$8A*+%1>%-M$(3 M1GCOJ5L6[IL/$%*?2E>N1MVWZ =,Q-N#U^#:49P6+L+P%K(9S _#0SVIX_L: MR)G(RT6KG3 X63-LOQQ7\BTIAZ19Y77 KNY?2()*>+(9@+$%AG]<:5_N0D>YOX"! M00O[FE)>17Y3-+K3Q0DGSJW2T\;8,1Y9K5"66R,N41OD"Q71?1FE5D/)4L%( M$BDTVAC(()7*M&^XM/S(-%W(7K"^KX+O/&7]CO=,!P7NL N8;/C'T""[5Z " MJ&1\$A9Q[7,;F+]UPZCU8 .S>VW',K24-3UW;#R,GAIW9./0=&@O:-2AO&,H/H*\5$&Y.1[0&".7%._SH[R7*--!$P14/L%D1PU LEVN.P/O.[%=#RL(AMS';C)* M0U*"Z+(2H*>@B0%Q8P!H,NH;VB$>27]*5BPF#$38K?1$H^=9A)!G4/Z:\ILD M\!\86*LL'#X.Z:X2;)S:*-*R#5?,<*4-W#LVMZ[1IH.]&A0X1X'%340,V$P0 MJIX]LN'HQT-0B!N]MRFC3X9>4S>!77JH:IRRMN%Y<+NHV%QT0;EI7%Z"H*=)VJ^#H>9P$:HA;\)< M=\R81--;E"VU6Q]I5YC2XB=^"@!\\/RMPOG ,B/EH(U-JMXBW!<::ESH&P!5 MS_2&/,M'7I7TNOFAK(C[3_5KIV_HT MY-J0SI:#[LE5[RV?2&T1:QG9.KK&P&0/ M=1P^@4E'RL''TZNW46^/J@P8UVTXW"]X0S)#*-=3 MP/=;R[A^H@R#U!V]F\<4I&J^,E>>*TWZ+ZRQ.AA,;T= M'^9HZMGD6Z(I[^1Q"Q.15$[(*T12%^1RETH1)MX-2L.05.52^>(TR.6ZLHF! M?L5!TW_80\NUK3GMQ8L+C$NG'S^(OHHH M\.HF"5)TE:DO]B8PP)R MR!3!$84B#C3Q(&)JA@ 5HMFW4NN8+EGPTUSP%Y\;"D;,8.V8/;$'&.A;0'Q+=]0HPFR/+I4*0TB=FW04:0"@J\ M(3.%LADLB>!ZOL@.!=%IZ*# W3CV/<^ $J=U%VPW\EYFT==@MS,ZRA="R/[(M5JIQ![_T:391A?$FP91PX69$43,KY# RZ V- M ;SQVEL!*/E"X\P\/X6+AA$Z#,$X;Z;QP&3!0/&\JX=J',LSU ]L >AWA,()F5 M+XVZ6$6 '_B>NMR[&ZV<])5YBE93'('[G61D6!9<#=%W-S U$'^#0&YAN V1 MHF_;MQB!L*06?4:Q<^4#.M?0]^LKN.\ (LOVFQ/061^&CIK#B8*7BU$XE7O; M,?5[/L[=EY.JZ&?"-7B4E-QE/J0%N;(!BK"EQPI4^K!OV(P0A+]35L]<:O=P M9#P_8?Z'4E6@P2J@N\!%HF%_BU3AJ#@IRJ/T7@<[SEAL 1#C9#-RP],%0 M7B\_"-^\D!EAA.M=45" ?AVPF2@W^".\)QQ+XNJ_>!U:)PLQ#)?Y"-#:+EAM M)]AB(A*3"H"DO!-9.(J55?)G"OT*8 F%[ZBD]66H/WO,E0-^+/U;8_EA:C MOV_6KDA=2 G;2LA2O<+J%4=7OF(5O"/LU--ZXTOK0CGP)[M+R_1WGUN]!58V MONB"-;O:@(7/T9!$*Y9&"*"_F)?T#FG^MFPJ1:E8P'1*O.".@R0RX;K,PM]( MWZ],HA)67."L.1%.DP\@.<=^=E\HLLH3(I$3BT',P#Q1/FY:UL*(ID!8ABWC":X':@*B@P?V O=O!16K(X9C MWPUWY'(7 ; #R\:9BM1C(^21[OO!;_3F>U3]:"*T4\6=NAX;\7 8IK':G#VP M"?J;R=6&AW 8^12%,;P 5CT$>J"F#-2FS&6:*](/B8\(02Q5B]\CY7#+RG;% M/%3Y+'1B:=9C!+/)B/JUA;#U%3.\V@#0J75QF,_ M.2V5B\\M%P7I2)_KX6*?:RC)(\3,YI@?HL'\AP=8(F2(8D>)I3A)/WPOEG2Y05V7'N.L9SD:X3M%+-\X$1F1&=^OLFF6UYD MGL6\8),C%1'])2^(G$&P8>Z@A!T[:&M=K.>?%%98)%V\A_V*P()Q.!6#GBN* MOT5DT^*F$"X6A&/%BR)%=7'2#_#DT]2X4Y7/MQA\8$=A<18QG\B*H&?T;.8N M8L@&EI7T=G++$ ,]Z+L]#/Z)7!#K&@,[,4B8Y4U:!;)>"F.ZDR3C[?>L;"(9'+F,WD*P?:6\RR8:"<4.7OO067AVDM M5WYO'M35P9REAH]/7T:4_(M\%@$T#S7=[5&?Z07(9 )QC:"L8" +5A09R(QBY7Q?9=F@$VA;O6XLJ M^;41-AZ[S89?8R)8"2[4#W#2]G$25CFSG9%25!6^.>(IP:/9S/RS)546#HB* M'W_"[+.A"Z53%,*SM+%/,JV.2%@D@C SCIP"2@M)!GX,#L%,F368C8L(OJ!S3FDBK+J[K/;JX0.&UITRRS7M[8NK() =H"'$V22Q* MG)),?UWPPN ,.F$]Q@]RF9Z$3XOJT7%*PUXJX$N*+R/^=O@:?CP$)PBVIE" MH]M@8]0YJH\R))L)RC]C04WI-Y%,MXY]D(BXA7<'KY0^#'E\@IY.U+;?2QM! M)'HK==?OYJL+#[['(QBH"ZD1W5"R;.9B]@I8$(Q;.80!?NZMWU_8H20>-991 M74^P#=W<)(]L1O!;SEU\3LM9U ".!#;EP$8##DGXZ6FWC)+DYL&)'SX2,T3$ M;_I>*/ B7_@K3^$0]),[!F:JXNGB;!YO=8RZ*3KWL:)>QP)B*4W:]>YI_<]L!DZ:A)70GT M,BKJP!+(4EE% M$92PD!BUY4 LKO]+LX3L(=OE6>C^#[C?SV+8:PFC-[(7#4^,X4V*F"B8H8;^ M89&"39YME^]("TILW,#!RX2#%R2\"6^?W S)(""E .=L!>X=2HT73D7A6@F] M*!@Z)@^$LK-X+@]CMXJ4>!B97@I)FH7S[-8#D2/ID#X]_J[4/41P0C&L9.3C MY-SGM %*90)Y'^]LQSLA)LN9*C6'M6PY_T\4SPS$,+Z)A6DBF$*"Y2?8*AI+ M4I"OHD[LT6O7=+P2=T3]6E7ND359F'%'CA)[7C5_.#@8H.81"UB7IIB8RACT MPH%@35@IBHWBA'=)\[&6\)F?B909VNQT1-XC>P@<5P9=^A.PC:R!/7%0-T#7 MMV$-T$$",$6=U_[6L/FMQ;B#B[^>N\'YJ[!AO3^),?RJE.\]D.\9.FB*QMWW M7/[XC<^'MLD16[WF13:3SQ\IS;^:C<^]UI>FTNA<7#;;W7JOU6D?I?[IQ/JW MJ+,(]O-#M819+L^^[*$=D 88$L,U2%[Q<9 D:LC0=!D?F":BG(/P!8XU0Y^9 MM>,;$XNF$W(7%O8FB/%K\UH,*AVG]%[01K%2 GCT+V!,JMCO<-T Y %:NIA8 M<<=,T80IF"*'YKL^#YP;GBSW4@9B;N0O6']KZWD6WO!AXXN="=Q]]&9^HOHJ M!]0V#P[1@9?'^*&L2]&U7_F/.QF_/\B_A6.%/R*SU -@QA=RMCZ M3]]1?GO/9Q#NZ4:VS(:W/_*^0R.V0EQ823S('!\$6S3P,X]%K_5 Q%BORH^>S]@G$[6_Q4@]=>0THTZ6?<.FUL>]WG*]W M>T,]R%$OLYUWBG/3/RCD2FJA6%,+Y?+;& P5VEH)PT"QL&$Y0MQ4\B@=B64* MORZ@Z)G0T*_QY!K/.<2/*@M^A/K^@I_,OH>'JI:^Y8$[X"O_LB;H-/,;("_F MU$JAO)_ %\D@VT_8#_<3;/Z>^?_>T^T4*H]#_T>Q1AIQO:[$;C0[:JCNC-K+ M"4_S<@&PMNA>]B3Z\Y<]%W>M:X.SX.;BKJM0CJ/X9X DGO4\ R!K$^0SP)8$ M&$#GV/RF?+(6F2)[D@@2.-K"CK59Q]O&NXCDZ2STNLTYVM9_04Q^3PQ;W!C@ MW%&A;%A/[?2,0]VD@LZ]BMN >\> ^D-K$4 Y291/TG;%^&PMO@YQQ3#;N:FT M)%GO:02"00'S2+R!!W=Q1BL"8O! -]84\,@W#BAUD-#0X2]Z3V%6+<-;&^#Y'H4<>C&Z!//1T;[1# $J!601.&V%]E>OS ML %.P+""LE*> T]=\ZGF $JH1B 3?YIWE4?WCG@$RET.9W;X*/5N0^G98V.@5/.U!?S25]3V-4B:>+ W3+AHXY1Q/N#RU' ')O;P M9QBJ%YD82IJ(D>!$#-EN;=[KRKM[=RRE,_!L4II**BE.*DU$%$\IY#<@FL;L M-TO4"E*C! TG!-%?%;93'!8/;$DDM,IK!P^ M(\7@R>O!T1NB01OJH^.)XTZ08\.A84H] N<>*9]ICBO^C#Y ()#CQ^XZVB=@ MA&,]_1V>!L<:= <)%F$&UI-Q7+#Y_]H33^'%MV/9>0^7G]VA2EF9HH\=3M[U M*+=3\]^-#T;64\/ B*OH,[QRE!O9UB$_$28W?8O)3T+5*>)(W?8 !6L M8T()^6M*A0N_AA. JOQ2X3EQ2';\:P31QTV=73-'-@X#W#'_\]F^";L 57]Z#/&>R%WM(K9! QP[-AWABXKY+'9 MVI W-!$4%-55N49+DV;T;&;B<\;9'0"G+RN=D67T)VZX?Q+NOV6A-QT7OS0Q M7=FBNR-]6EP$3E+.RSG-DATHF/ZN:U-9IQ_SVFPF?PB\Z+!& \AQWKD[-@TO M+!EIPL1H)*=]X@ =+I^X+.Q1ZW#^/GX0E%JOT:1BZY#R')$OJ"&^\P-[\;J$ M2IA C[Q:9-?_DCO*%4K(&'EF.^=> 3=#7PW/\G3?*65L]A)\Y6.EM#3$%!O1 M/9LRZ.%[1S8O)_ET;\O/Q"EE,X$- C*U''G%9,PG6_GRZMJ@6=F"G=-,9K_2 M&8YT)";R+%J&SP$)NA,C=3 Q+_N2>:!&M6;P=$97XB>)':S5;, 2LU'-GO![6+^,X5%I-J-"U$U:W^:EPB7$^PN%>[TPR3O/U-R507&-!)!4&J$/T%$2WC>_,D-8AG@<6 MP?$3$3WF@:4].&/-$\5"PC$0MV"D<4R\"\;WCI";.[ ;P'"FZOC97^3).#%17[38 MC>UA'WJL$I*N$^XRB@>F8RD78#8555$W.]NT,1C5&U/-A,OH@9M&N$ 6O6S9 MS6I@P#E31>Q'&$8TS8"0AU12]!IP_U/XYF;VKQ7DO:0 * Y>6&,)-M[G'P6X4(N1O3Q&"FI]\K;!>>M&A1 M)W"#9C/-?RB#RK+RI4?6 M9?$J.<%EGK@F:W5I,2)^(LK7VGX76%["%G)J\P](VS"G2-?R@\"AR3_A1^T> M_,];\4$S\!WO7T'?%D]$"8[$?V8_#T50DZC@%/?+Y+\O,32PG]6^"S;&(^R[ M8QJ[*J5K=]K-7=3=+*WHR<_^9D7M0OB_$U)7E.XOW=^V=K:3ZI*79*\\Z_") MP,,1=1JDS K>@A\NW2'"2ZR&/# O(UQF\7\=N>>A#4/6K9!^Y_U M'",QZZZ-),G9=,CWM9U=/Y%3I5):Y%1I:([I@0"_.%(:FH[3WI_>A)T%;D_Z MM21D4T]GDJ?J_,8FG_:*+/'J_KJP7R=O&85': MXHK87XHEM5K-RU1]F?1.ZC_PK\'$U.9*8P$.3.)94!:[SS?^@I"W[H]!-*^Q1-;RHJA:44N%,F!K,82M\H>SLZ^EW)&H3_THL(4%YFS!;R>F)RW= M2\T;9C-GMH,:1Y#^PZW3@6UAV8C(J:%\-_T.,YB1EL.24UYWG=R5.MIWX&@/9HQ2OQX3&)PLFL.&=P[P+T<,M0VW-DY3OYZ; ML;1MB]?\V1,GF*(@AK*94^XV=6GL\I"RL\->5"13RMNBF6*,3S>F5#_TX*NB MV$9CZ$.DAI8B:0(G8T M_X+]2Q9=45-73FOJMEM35TYKZM*:NF0*'I31M)@_*ZN0\V=EB?%6A2.<_?.J>5[O-4^5;J_3^/2QCUX/!V3E5RM[(19#*2B@4G4G7L+ MI./0&"^*EC:X.2JB!:E*EA"5;&44G(>2+S0'C"]1K\4]:Z&X=+RGK.^C!ZAV M]GVHRB9XGQAC^TXY,-Z"Q8GU1'*P;<@'QC_&E5$L1?)'N\/#RY^.F0W&2QD/C+NW5- @'XQ.?XP9*49J M)08=QJE;)&%;J7-[89X4',9=L,5*02V7\FJY4%M$$Y$D#<" R1C1NE)2J_#; M8O58_@Z;QQ I4C&;[VWVE\MF^'I8''.GF>@R05)U)R,JF9'/S_KK9"L<61"C MR:8GO)N)1]-GX)M2H:H6H5V=BC2D,2G.YP"8R;\PX\E)AD@4)%/Q-W0IJ4G,&-JY,*L\ MP1BYM:'9ME?F_Y0%/H =7GQ*BGM(BNMZM;#79D/XW4\C?O?X%D'"[ZX<%!7# MTHT[0Y]HIOMVUT=2__=\Y< MFBL!Z^5_?2$!UG1B903@)QK[..NK#V3T/DP@"V(0X5+N^2"RUK?OJ OEX#=; M^6+FWQN64K]CUH2IRA5H?2:($57Y6E>.CXO%BDKS)\8> MCZA1^;;_7@X'!8]7.$%G!QK)YX6'-#R@QU6.<\=*F_KE?8)G[)L;I>LYC'DJ M_-NRV+V!46X)7SHV?;BREL5ADXUD,?@^QUN6)$5%*\M$ MZ^<;4$PM$9>/3;1QA["PG!#KBD\Y(+/Y!KQ0#$=L]8$I#?Z=4 '.7%*!2)P. M?A?**Y!#H"HY/E@FG#A K7S#F_9/CF$N;%SOG&!.M_%JVVR.E.^G_(ZI^\*&)A1<\=FPX>OC#U.X%PMX/Q?@#TR!1 M&*W:[#/38'<22I+@SP#03?!DZ)Q[ \?'D5P@7K!F^F+ M\F%N25D*(%'VATO" M(W7ETA%SZWXGGE-2:_F*6JB6-UBD$2P2DA,%M0@KU8H+2]'YA#GD>/6+5D/Y M8%P#ESH_;R#WQ_^518XF%WTR)HMK8]'DO7&=#I3?"S1-.6/W<%826M(-QN!6$EK2!,*PB3Z<;?93V9KW\U M2*/R#,1-7XU*Z\P2%EQ;63Q34'-5'-Y<#6F[\SJVU'E1APTY0%2A5W,LH!E[ M!;5;F6[Y8DQ^+1)D6(V@XZY946*UB.+%.M8XEJ K;]=',-5]_KCM: Y"45A(*S3,7FHC@PU9MN8>6K!2B)2LSJ1AS M1O7.*M347+FJ%O*)J;8NYX]RY93$$W$7>TCB@834_K$=I8N>Y"$\Q9P#]^V[ M)!Y8LJ!)"2IIT#R+?GE^I)PXDP%3_K!-T[B^WKD8.JXFJ>7'\5%YSJ>1RJ"4 M9)9=3M>SP2"[ H7/W3FU%(MJL;A&\XNGN:)*,JN/T_+6M+PU*"HH\C;*S,9R$%&5S)BEV#1+35>N'7L$#V#- M.C+/%U^R5$U+EH(LKVV4+%73DJ6T9"F9KIDG*%DZ24N6]J+V9'7)$ACWQ4IQ MOL#DY($%2[G24;DX4[ 44_:1%BPE=RL[*5@Z27K!TDE:L)06+*4%2_M2I_$4 M]4=QA[>J,B9Z@ ^K%MF+"]C_0IEU"73+3;AG0'GZ$INY?.%]*JY)9T.E"2EI M4N1S0Y,25-*@V?.A3G]HV,VVKC,3GGZ6,6L%WMPL*3AP_( *N!>00/98L/E_ M/TW:53J@(LW@>\49?&W;$I'5!8ZUE6*N?8$3&+1+O/\O'&$ORSE ME";Z'RL5;XAI>RJ=\#?;N86_OB%!5,II.LH^X'N:CI+FTFTWERZE^WU HI3N M]RX-[8J-@;QPB@>'L1!M7!T?E1PRD^*0$6%.Q]Z45!><>) &M8_X(C*W M'HLG"6AOO*AGZK-G6PG[9)]SKO+S8?%GR[IZEJS:+64 *L_6U' !$CY7UC]'[-C,POL!.9.5M,!<;@^"L\JAT-!V:SA,7& M;%.:C?,3T\2#O>B@T1AJU@TF?H**VX"U'-M\CAX8:8!X,^M&JC:^"H&Q6 JY MPH>:X^"EHMX ZQC6P)R@$4S?C4VFWRPF?Q?8D&-XAE261MI4 6XQ,3U81]&4 M :$+_CW@R$(9#J&57DA@=$5+JEK:DFJ[+:EJ:4NJM"75]OF#H5;W= MK3?H2Y6^.6U=-1N]SI72:I\V+YOP7^U&\R@5NGNE0;7@SSYHP!95U)$:?,5, M#77B2\U!49HJ5(G>2L?*9O[0K(GF3)5""3/J\L=1!Q*).4S%Q#1+#?4M!O)E M2I+D'@P^^,PCCXXC+AX>NPAY@T!=HK;M/#4&%*9?*I34S8NX:#F#\ONR&4VQ M+78X99J#*7>&K<,!>:"2@?H6A;&0([NL#T^Z"!@ " !HF'D#_X$G3060E?K MU(YRO^*K#)>_ZUYS9?:HW%1@%/+DT&R&LD,1\E,V8)18"._,;UV]2W%R(4[R M%,]"E6/DCA&R5-L<(<, /A(='3;6#'WWZ);RRL?C97WL&*92.'X:3@GOV1@Q MPQ"FB/EJ$/-" ^&8$^P2+YT^*$H\13P3KEA%T^\T,#!UP"]>7H6&'1N@!]:< M(E*&71J17W+D0$<(;ODF0"F;4-=E@)F$O6[P$M^!BN$==V@[WB&&A>0#L"U] MPG !G<%>]2.E<\U=J8(.?BD3C"%\%"LJ?HL.1S56)J O4(H1C H ?76$C M .@L#OMW CA 5^YVHFM.3IQ_2#KW^8I:7WZ"H'!U(T@&#P@<#'V>S_$]\3" M24%A!)&+.,F?,'\.<-70N8S4='O,9U6& 46O(G A>+O_SK;FZMJ_BFFXE/3F M3$Q&#$EG:"$9%GYX/V28=+*J49<3?AF ]X%9S,%$.-5/Q\-=T2O0?2!_&ISO MOR!: 3>H#,(*+Q8\:W"P_7^38!\Q67D=_LZ'T1B-F&Z@Q.;81(=KH$6\ M\(2SF?!E"?2@.^.)2-H &"+&;?%>[^V)J?.T)$I&"EXP=^.(E2YS[LC.UN@( MF.7220:DP*_3LF$+&N(C5YGH*U5>?8#QN@)Z&:B*ACN$-[H3(-5YHEI]4 M.3KC7XB>3C83("N8X[ 5U/C8:&S:4TH/E4F> C9^O',5["]9PB]+USA.TS6V MFZYQG*9K)#)=XR5I:/,Y'(6=YG"4CI3+JU:[T;JLGROU1J/SN=VKMWO*6;/) M\SBZS:LOK4:S^W0)&GM^<\]@%]51V\2,,2+K)K/Q$>E#1/9,-F M,PZ[,QBERL8](+)E>2 #%\=9\R T34R#'=N.QTNGN1I-^R ]%VT/RW9&5'8S M=NP[LH/$SD+P\[Q9"P--F&-!NC:^? *:W50X:&XFH//C/U'3MVY([6?6C282 M>OTSX)9"O.>G0&NA5X\W&ONE5% +9>Y6_*580?^1BGF]8QGR0D.9.!H?RO-@)!6'==>X"FC*NT6JIR&6DQF%)6 EFAS$5+66+B66+? M,$VLI $"!QYR#=8XW"FR)S!;C4&8UX#J[,)7?6)+?F""7 G,N49&)(+"(6;I M* 'KBVVN%LL/^Q/)W3S! >%=^)M"[G?",$(L^B#_^Z:\*1(](8OYEQR/R/U" M_"K*HXX4[&7A'X;8Z6()'=RXG8*4/E#KGQ.A3.C.W3?+GGYH,][4>J$+X$[N<@/Q$:XV+M4/M!OCW30!:H MTK\U'1?@.3/PS[$)&B+R )VBK]P%NY$V50PI4_-\2E4>H$IQ?I/J4LGD(2!X MLID.*?TI)TD4)^GP MON>]XOT[Z?[AYK53.W5/)O2819RD=* M\Z^/K9-6CT=5SEKM>KO1JI\KW5X='FFV>TJW\;%Y^OD\#;4\*=@'VMMLYM0> M3(2?V3!YHL98<2N*SD'HQ*6A0WP&N2NL*5@,^]!YZ[F$1;M._VVR*&/FC9H[ M5,YPDN6&CF8 W[[A.81^>ANFR[N\F14:6OR%' X9Z8-7KK+5J"*+DB_)JFP! MM$I-I"*& XG .0FB.H]- M-:PKGO"$G*E[^.FEM@W=3Z-R]>2U?OSDM0>SDY#96>76?I(2)H T!=;/^:7H MF!*/G#CAC(@R;F[2(UCB\IO,/X$#80VQO$O4E<. =G]_I\P=.,88&>;<$)[$ M"O?M>\B+1_G]$.?[I"_^1U.&(.'_^V;H>6/WW6^_W=_?'[EL<'1CW_U6=P9# MXXZYOS']1G-^TS5/^RU?*AT72\>_Y7*Y?/[XN%8LYVKP=^6X^IO0-;X7#_-' M0V_D"[=#6.\0MN%H ]BT>.K-^P9BWS7@'^]KT/+U#E0,<)"M=H>QMPL*RZ/+ MB;MH&L%3JJ*3EN+WJB$O4"ZG'"Q48E!1D6H,(-1,WY^91$(!2V#LA;PW^<(' MY> ,-"FE;1\I\-+#,AQ+]:W0KN!)O\5#OD!@U=Z"JJ.]8O(M[ =)I.1;6(=\ M3Z:'YSB(95U:*Z2T]H2T5MP/_$UIK?P 45D' M$YD5PK2\4H->^7R6P6#KZ. ME@(@3=9ES[H+IB.**RW7!O1F<9(V:*^7JZQ-^>64\I^0\DO[04TIY5=V2OE MFU@R1$- )M[0=F _NC+0QH8'),ZIN&4WG M\_!WL5IZI.$;T+0DJ0?0=;C-%/7,$=_A$V\ M'SXT39ZA@'5N"+RB,Q?NCH"&QVD^*?ZOSRI12IC$"M83GJO$E0(4P!N(#.(R)9U*+,9&T,'.47SM[J^X'RW@U[ W^RI<+L-E&KJ?-]A'UQ.N032G@^:'Y=>R:?>QSE\_[WG/0KKYWT:_M! M3J^&]"OETG&YE*^!CE,HYX#TG\),>;Q.<_( G6:>*;PHG:8S\&QRBW"UIO8T M5IO_5L[?ECICMI>U]=PUR?FT)GF[-,5,FC+/[\.TJ MTAY%A48V&$H?/WY4FHAXF%:)*ZN\YAB?:&J.-Y2IEI>BI9+X_O&^E#0XO N" M3_,J]X7@UTJLC"?X"^;<\($SR\AW_9QISBIDYG1EH\1IQ+GMD[B:TOAB&D_S M.?>%QDL/I_'ZX-^)X1I$.D)B]YEWCP7B;38Y_(A)F3TV&%JV:=\83,AE5?G< M:WX*TSC]+)'G<[(+KY[@TIS,Y!)<,1XQ;O35?M*XE0E'6-C3'])!^@EFGZQ/L0HI=TBENAF*+*<$2P:99ALDB M6#_+,)\K'.=YEF%^+:<79>EV1I;1G[@ VV#B@/(KDF_ R 7DP>P;4H_7I[2% M3JK%E!:D$4Z50CE-Z",R2S/Z$DEF8'*62N6*(+/B.F3V57.'AG7C23M-^6S! MBQRP-$$3G?0/Z_@,/RPSQRA0*GW@WD+$+W;\I]6Z8MI';#Y)X M->0[EP6UJ:,GI,9>3N!EFLN>W,.39D?-DEF:'I4L,A-2\AC)K%( ,JL<@@1: M@\R:H[%I3XF6 JJ:"9:$)BK@QQ<&4"$SE4\@,*U;6PW'0TI$(,=KTF7E*%]; M1)>=:_@!5J3$A$(.ZS/UHH5C_M[739B%-+]A=U3)?A2X-$-7-(]I63H; M,YJSLWIL\FM&S6+^*/]_^W'C>XJ=Q;S0JT(EAZ(':&-HL&M@NJ!)D0,06*LQ M '5F/''O')4+ M*2KO&)4+2U'9GR.2HO+C4+F0-PU M8^)I\RS%Q&?!1!P;:QDI(@I$/*^?I(CX+(AXKO69F>(@X.#E53/%P6?!P4N' MH8<^EJA;>F#K"H%.>8RY$6 MG3P#F\K+>?.Z(%4A__:%SO),/-C_E\V<45@99[GBP/NC;6_AN?OQ%=)^?-OM MQU=(^_$EI1]?W 6'CQ&6F,->ON>]XGO;5Q!P<#8M9NAPZ\;=]URA['F5['K#3RB>Q(<&I8A@-[TM-P&\% &A;$:D43G @@R' M\J5%!QSTCN'^TOK2Z7)06^W&47(-5H%P M9<2W?3(*)=S["7;I6>!.%N;M>/M@NK-W'#S1U0'SBO MN$O,5OYCO/_-_4WDLY8=PTKV\GZ *K", QA&M13- M$G]W/<,S)=_>#X@IP8^#-Y%5U M+3U\+,\@\=LYN'0,:V",-7/!GMZ&-I628Y+)<;]A?55HE7J-$[*5.(7W$DVT MP6VJ[>X)+]E7;=?'LQ3'$G]QKU+5I11E8\3WN*# _ 6HO,&>:)Y'T((GU8#W MC$KW&]97A59[KP&O(0OV5 ^>G[*0JL)[PE1(%=ZKJ#;'-<$(0@B7(EOB[V[_ M-TDSG!&?_H;Q[Q-;<_0=Y%,DM=9D1?E7,2W_VF[Y5S$M M_TK+OUY>^5?%+_^BUL_9#/9^WFK]U]/M#5OT_J#TK< SX+>4=O=Q4VG^TTM1 MZ?S#'?]( N [2'.BY+\GH'*4'E%B3FV-5PCKSIGM+K *^"H0VHUC3RP=>:OM MO%.A MX;$DDUW*\%.&_TP,O__>MZ4XE(%!]6Y6"4ON-E*D3'G@2X#UQ:#;7O% 7^GE M+K/JF_L>8>[983'E MDBF73+ED,FYSEDO6WKP/5$5DCYTQKE38T=ZB<85^>E'D^.T*?'592YIDRSY1Y M)N,V9YEG_LW[MHU=QA9FV*4\<0<\L?HRNP2N2& OI0GLVTU@+Z4)[&D"^_83 MV,-[<8R;H??D6_F/,;I17&> RSBC?.[P%C/3COX9W[Q1--/[[YLWRF_;R/Q^ M2;<6X?_R_Y^T_,!/(!2[N6I>=JYZV4SG3&FU3YN73?BO=D^Y:GYH=7O-J^:I MG[0XUAPE_)7Y+=2:JPNM,]G3+3TF'N\GJZHP-R\#Z7=$^^*DJ9IYR MCR^ MKZR;&:HW3%%PYQDFL0$?P\&]@C>,,5DZKY(17%Y*DJ4P)0#C! 4W*[-65/J+=\(VL:=T-N-&?&>V']%5E4$0H'!C A2, A1\Q0&Z MW*Y-^YX'@IDV&,HB7NY[$WVNO7O[$#_ !MF&K<^XY+(9"? +V$EC&%-&/(93;G!>\?/\-J/ ME+JKZ(8[F+@N)U?T]&4S>44,0X@#08V\ J<=N)/K:RKZ<7!.@H,O,&U8$1[% MKR>>8>+D/QJ(8%P#X5L>9U3PPK TB3 QR2VS&<-%UDYO,08&AL8!.G#XE3SM)/[Z=1O/ L[$&I@3'99 ^:$C.O+O"05&:) +::%< M._:(M@?;!.1B7!S F4X0>IQ/[4U31OQ\K.M$\ MH]FNP%?(X,]F#B):W5M1U?F6F#B^5\S1T<7D6"-4)DJO$UJRE#3RE:A,PUL= MG7]XS$-5TY:!-HZW!LPEM;BHAL\A'57T,'70V9@N. 3(#_7#L "=<)!)7X.E&8 MR% S5.%3!S8$+X-=,>L&> ]]*?:%.I;8ES B#?1N6AI7$QW;5&P@]- 6^% K MX "D*X+"2;\,;D+-9N[9','S$\.7\:'0>/#(1?"EZ[Y05?IPL+A+F:,SGCAC MO$=817!,7#-@FKY;BX$^2AX "[GJ LZ\R!/-/?Q8 6_ME /10N;OS]E M$\\$/@A6T,PE9R#-V"=E[J:P!TR?.#R)04/3A/N"',.]=1>2I,2<>"LHCEP! M P6]JF%V,@L#=S49 O\ M0#0Y'M\7LO:R&8#5&)'[9Z2!V=*?AA0C%2U3;".)_SOS#J1)=*X)IYL6]I_% M0_\5S6/38'>"NP>L*IN!8\6#@L,+L7(Z0N(Q(?]?2LK/9S\T4#4;8.4YM>0 M\YI,YKTV*%Z,603ZF+@>H4=(A\8 =.>)Q<=0BIF7J!4$_@Z#I+7OCD!/$?)8 MX8#VE9*%&I30U6#-\*N(X\[8&A%0A'W!U\=O# "("?U>@^,^R+\5(002#IRI MN:AXA3DFO5ULB$N*61=9)$Z"RQ\4W@+OO+/-.Z&[DL5CH(\< R>F"?H9L7-W MTO^'ZRLJOA9=@";[ 1>HWPBFAKI?L"O! ^,O(IO1;<:U0\V$#TA51E^@-@TS M.&E@+O#P:;?,X@[#^Z%M,B[-A*('2ZO(P4, "6X=A2B;D9=/Z* JG/WBPRZZ M+O'$!32N!&8 ;G/&3YP:F;.:!F67&>UX%F M$#8)(G,N]FVC>TY[9 K,NM2D\2[T4] /X2\7,P%=Q7#="3I,754X%% /!-V4 M2><[6N"41 2JJ@.T3+X],SNW[&<$B=,QZC/5W F%DOSFCD0$4*?NAT9K@@SL8"'!3Y1 M4BM 9[7OX0?OGO@(Y;W-=8A?0_->'Z*((AXI?9@O?(@HYNN_8D$K[FT5$8:Z ME1> #[X1-L_.5M\B81Y7JL?1>M4$%E9BF%;9X/\D-?I1>\<&\H4/+)X%@0+? M7AFCFI'S!O:.G^:,N#&(A5V$T F(3:.$13/E_-J6,BK\#8-_4PB M7!&)IG N >#J?JHRO_U 898;S $N3N@XF\(:UJ7EM93,P MXO(R0.J-." \$YBV26'7(-?"3_U5_,S?..WK*(+&O*(UB=QBR^PA1,4OA'P= MILWEVV@W#@OYOBF-U1$$?LNF H\ J6)(&3XQIY0%MPD4PC(,Z=(I@KT@!%,# M*2%*/9@K)480O94)'BO4.IF"O!D80C#H#)'7L)88M@ACP(>7F+2O%D53G6C% M_P4ZD4PL"7!:&0+##:E)&$ 4HACKG@ F@TIT.(92J!+$KQG)P3"GF\$C4!@) M(*3\1,-NBXAA*2ULJ),(PN$\(*HXAN-_L@ALL:=7,4 D#3R9#[:AAA;RV*0T MG-)P_/\Y[,Y@]^BO%,D-I,!/^BZ%VX)3$9^ MPI-G;RBXN"DS!:."OX#%NA[G$3EH+[--UV-I@>M1?&A05O@[Y1#LYVV;S[OT M:VV\+[]C!?M1*'[/Y0ISW2J>&\+MN5+]C@]\JE,A.M4)H]/Q,YUJ_<')A?OI MR_FDZ+NJ@,^/30V@L&R+O=G:I"<$XLW[,V^>=\=V[>:Q51^9%\U=P@$[&%)X2HFMJ5)IYQX]ZE=XR-:,6YS MIQ>:,QAR2'COA6D[?7\465B%U]:7SK=;*;5;NPB*? )MM;H8$/ ;O,TFSFIG]?;C:;2 M_=AL]KI[NI_39J-Y<=*\"OI8*?7V*6_SM*4M)9:2UN.+4K$NYHZ_Y_.@,G]Q MQ]?MNEL>Z1IPS'YT3-\#$E[6X\DKK5Q^N#'Z M91R6A1GN*"0>8Z>PQP.]TQWG<,=YON.S^L!I?&B4/YY5GGG',6;,<^'/ M[XJ@1Y\=D!ZYQB&OK8NN><:(FNML(1;>;2-9HHXEO[MC>0@FSISKRB-9\OQC M?QX&WR?Z7/D[F[B'-YHV/CRLNR[(@7K?]1QMX'TW3K[_/+;_J3GC,_/N3_W- M\DT_<)H#78^.L1?RS+P3Z5V&Q=:^]7JW2WK.LC.*00:NZZ_&>^K:O=.3 )WF>RH(DGN\8Z*]J_G7VT^E:M:ZV0_J+ "\ M43A8[Y)XILF")OZ&2Z$;QBE:=4O'_\$BO#O-Q/R_NM?0' <36:F$%VZ\T/H^ MTNJ-G_\TJ]]_7GFWE]UZ\[@R*CS@ZA?-;9*B#[?!E7Q?5Z\40%5'&&>W+[XO M_+I I,_$O'Z-\ZG\LF#1?'GF<7$1PN5_YO 0O/#EBQ-]M]:!OHD$"NINYSH< M'.!I0/]]8_SPWEF3D6Y[((6,D6:^4<0?+IE9$\O@"WSNGKYYGU>KN8J:JY1E MH$ ".)>;L?0TXM'L)9US_K'G7(%SSJ-S?UOG'$^FN3 C%BT3KMB P5[!"&\S M3[##6>J\^_:Q\L6Z-N[ 0PL&#_ZCIG+E8MOWA\NR/)Z"%H70VA] MB?V/#;WY8XQNGP7XW*W?&I?3X9=_]=J.IZWFD["O4U'QUM8+QH.MY ME VX1&HE6#U/%C0;FH/(IGO ISW!IX%A_SQK%[___"M_]7?M_/,5R_5WQJ\+ MF_'KGNUIIA(U'U\Z4XA]LT\WD0I B\\KJ6<^L5SZM1= M^KSR\7A./J)_E M&+@^OSF_^N3F[LJ:UP6[L\17!B'C)6!"2L=.KGRO1.,4B MYE!X(-^EW]&H%I.MY1C:<)4-F&ZRY&#A<7+PI=['LTF_M>XC9;[)8;YAX^3< MX,.>#.;6+;T;&F7(NPN&@L>)C1>?M^HGK?-6K]7L4DY9M]=I?/K8.3]M7G7E M0,;FGY];O6])O*-D09/2Z7.?>D"G9POH-!I1OLK?__VQV>C];5:?2%&*4%P2 MCS-9T,1?;BW^S!@IPQ[V_.F/S;T^K-!Z2-;#(.;0X52 $4)HOL T7H BB M76I3C*"!I(5/G G3YV\>;KR(<9SSQD^W\_G[SV;>.O^[=O?W^2?S^>*2"UV$ M?KARS'?&FY+QO3UWG&<]A?R13JGU+W871E0-M/;CP@OQ).[#?3W6R*I4U.-\ M$D-!J>JV5>9_LE2Z(X\G7Y=@\L#M?PYOQ]]__N5>CQK#WNCN[Z?@]8\*!X5V M]=(C#RDOW_N[2?GV\W/*9$&S$=_VH_:<3P._KG>;/W_<#[[_+'[ZQ_VK'\4OI5R?QB=71;"1;UK 7RRU7L X:Z/?-W$Y5KAH8G+"8!] M*TG7*4D_+TD70B2]+""9R^\H)+F&=O7F?1IDW&5$Y-)AUPS,.1Z1#I73C<>Y M<>[[,(0@HA%& \<_=*[I^?H/P_W^?3!Q 0?@$>9@U SD 6%)WV31U2_8J,\< M$ X@&J[^U+[__/>OK_JW\T\EYCTD]6C]T@FJB." *-0@6@6=W5&PTS-3E5]F MV^U5%I[/I>9T'#H)G8[JDCE=[$K]W6CQ9GR\!\3(ZO *OR]]< 80LJ?ZM]%M4O+VEE=X< M;J;^+@8P=Y3+Q16&S'T0[HJH*K,W?[+PYOF+ZA-O:#LX9V &Y=RK;U^'=^Y7 M^[R_^,9%!W7-7V0>]8KK Q#@VUC7-WOI!K6Q68^/W'4B-GT;_MG1Z/ZT6K?*C M,/ST(1B^BQTEA6H$W-_7 SN1-/:$6RAODR!C>I@OQ82,GI' MNV,?/S]YS?SMX/A;8_+@*SK>X(J>GQE&KV5C5L(O9F\Y8>@N]G8/2Z[@Z3GY M]J_@Z?=04'-5[.-074<:;2:OXJ67F+Y$DZ>#TU#E3$?CCIG3G7LI-[BXE?UL M=G)9V'QYH"'X\S7J>&/)[;JQE:/=)1WL^&C7Z'6CZS2Q53,O-4-O60UM;'CP MC\B6GLZ'=C7NG_6JGR9WDQUEI:_93L<_%85:C^ H5WXPRF&\W3F.2OGGQ>RU M+C5);*2FUDH%M51>74663%;R\ -_)N:RK0-?G<.^?9?\R?KLY/[V2_W;16G" MCJ^?N)O1F_>"39RLZYYZJ+/T ?;+RA/\V2S]++D-V[;[U4>YIYI/Y)Y:N:-D MNJ=6@;T'[JF=;F&G[JG%@;&MNJ=6$UO_SW^-3Y4/X_P5>[#O8S'+W;Y[:O6. M3FJYOZZ_GN5J5TLB=NNXIQ8'=[?JGEJ](]:];-;T3_]X=_D'W]$J9AAS1SO< MD=.LZ#V[=%'^4DF:KRIA;/%!OJJ$[6%37U7"P'^0KVJG>RB 8"I6XOK2IIZJ MS3U56[JJ9>Z4)'>'W9V?:A\.=G4;@Z?P4FU@5GZJ#D;-+W_FIJ?/V_1Y#2_5 MR:OQ4CT!IA_GU./RZLY3R60C6_91[? M?RX/56-=#]6J?(XM>JA6GN#/3\TS=E'[='JLKS::EWFHSI[(0[5R1\GT4*T" M>P\\5#O=PDX]5/FG\5"M)K:I^;EOYSYYYW_5'NS]6+69;7JH5N\H]S5_?57Y MX\OUA])>)%"MWM%IX;CV\_B?RNGE:I_;HCM:Y1+=IH=J]8Z^?)SFJM;??T[' MJX,03^RA2AA;?)"'*F%[V-1#E3#P'^2AVND>BK6R6LS%E9BG'JK-/51;NJHE M]@[-Y.9=3R[$Y\_O 1+;LEMZ7XUX]+#AAS.6B72LVVMJ4G5:9;*/^!5P]>B%9IK_&2RIT)PW!R4>=:UE&-% MFL?L&R6EC"ME7(_1B0HSW;1L:]8*"@6\"A?G?W]@I8^7MT\>\.*PK=,T9;8_ MF-C1FAU3^G_N\.KYQQ>+7+1_TO?J%S]@9Y:'0 M):PM2C'^AE?T1+G[V!CEO!_G96NPX);7B';6UWSU.DBU<4QRR0N?J0_*IA!M MHPG*<7FK75"6%<'/;2\N8/CSY.YV6IZ.K-J_I>4WO2AJM!2I%H;U?C9^W.JG MQ]76Q^/;Y>_=(+:S8,=)0:\UXS2/<_M7"FJYE%?+A;CBKN7XA<[[994%*Q!* M].OJE/ZYG]R?Z9VSXL,0:H$(7-;%826;VA$2;8,C;!F)M@%2L514R\6<6JEN MCD3)#P3-ZJB[Z.\LR'!/C9NU3NB1S98YCNVFQ/UXM2,EM,59&^6K-?EZ=M7] MH^XDUY$Z"#&Y1!K"H?/=!7U5\VHA7U6/RZ4]);$''MLCB:Y24\O5HIHOK6X] M_]C*[ROF:8;%]*;F6(#L;GTPF(PF)IILI^S:&!C>+-W]<3O^\\?7RG!T\I#N M#X_Q#2R;5":!AF,EJ&?/:?]Z[!\LQ\S5%[<=@G8!IO^^.9RC[&.U7*ZHN5C] M=8VCCSN\M^FE;6G"S:)+JZJY6EFM55;[%S>]M$YW;7+WM;8F_#^_*[MM,_]YRO+ MVF;[.&S;A>OLNF,K=A[W;4 J)8*:K6XNNXS M]M ?+@!>WYUM4194BL!MCS;A]&7X.YOYSSA,]]RL7Y7S,]*< M&P/>@(_FMID[)($5;O Q00@P_K_#0^7,8*;^3KG4;N!>N^S?";,&\,,2\)+. M&,_(?8=OZC(ZL-\5^4XK*X:%$0-VX6U]QX)OTGZ@@?/^AP"+/*OWY5[0_>&N.O_8X-GTK7AH-&."J M$WG=F_=GA^'SE"?YN]*;C@&"N@,$,/A=:0-9\--NVWB$Q?"/?I._PF\"W))X M]9_?X*3C#MUAVNUAGP&9P-ICNDEQS+"O/3KCR'G.4ECL*80/#P^58^7#R"_N MAL/'2+;:#/KR/>^64!_-2N*VMDVH_],/14COC+OON4+MC0RW?6E]Z72SF5:[ M\9_?^N_W<&O=7KW7O&BV>["+SIG2N6Q>U7NM3KNK[.F&SCI7V4SO8U/YUJQ? M=95F^[1YJIPV&\V+D^:54LRK"NI+I&&B$-[2+A-+7>OQ16EB%'/5[_E\\?O/ MV^&)\>7;^.>7T3_ -2^(6[E\+O_]>Y!I<_9O2_MW7"W^ M?=N?E4!+-(D5!I6D'7S-FB;_W(J+=/.=G$T33R3OGXU(5KFK_C$N#O\ZN1Q5 M=G(V^>V,,&Y4@S MI_EC8$[PW.JNR^ _>D_[\7VD-7Y6&N[WG]-KT[)SC?._]1U-Y14,H%+Z=2UW M\IOW8CO 72PV%S$4JQ5^76YN2J[SZUIFI7RZ].L#[,<'G'[4I,1?DAL@EX?_ M>/8V$FC4TO'Q2HMRZ2'%7>_QY?OQ;&(1>4FNUU:&\M0]_]>C6ANUZG>L/ MMJV3!X,Y=\: N5T@K^]&^[MN?!^Y@MA+7\[K_XZ.A=;8^)%!8DN:?Y "\P-!1NI/?! ML5WWTK&O,<>K]WWD<=9-^MK'"VQ8<7PRNO*N[\QA0E@X0:R,">3]9PC+^4'H M=G;-K*MJM;!%#O Z0OFK[F=K#+JPEI*7QN]?#I,.EVH)9YEUT_PQ9A88%O6^ M2Z;'=^,$:U@_&W?E[K?[EO&T+/K->^$";G]0FG]=-MO=9C>)!YPL:.*O.SIQ MQ+X&XY$RSL\8U#_E:Y[4]&T2M 4X6 M"ZO3U!ZK\YYKH J ?77%*.E:,-4HE7W[G!]__.OCW4VE\N3-#RZUJ6.;IL($ MMW]>+(@_K9W[#JIE%2YB3REG@S/;GHI8J:JEZFZZ'>4B[G^7:7%DZ3GNW&5?*JJUV(ZS M^T!>FQ_=]JBL5E%KI=T,8PTWY_G +-#Y3=AA71\9EH'Z/A9DQ]-9_^MG^^1+ M_J_J4PNKQ5X:#C^1G!;9P9Q8>['.@>57N'/MLYQ7\_G51=NI2^?1M[8]'1@= M\<74T?-:+?\Y1P]59I!7'AD]!5;1*Z^Y]7\[WQAK.[NNR-NP_,[?@-)\)5Q^ M[LIV;AFIY4)9+56V&%A]'9Q]O9O:HLN^#/RRLD9KZY2;OQQN?A;'S5O6P!ZQ M<]MU_1@K<'%4WS]5O.\_NW]:QW\Z?>VO_#;5]\?$6 .__GFGV]U_QK B[2+F MHK;/Q1>T8P VD:^JU5*:)[.#"WL$,U]\7;F\6GU 5V:++.7##U<1]VV+3N* M>4*5B,1C\]I5_M;[6KW[7'[J>&R[TSX,>'>KW>A<-)4#$9M]F\1#3Q8TJUO4 MM;!<@+EA?[>?\SK.=;__+-3O\Q=5[V.CMJ,$]_5\WA).Z6W;N<,V7)MTZ++! MH?'C<&CH.H-GX!@+QH^^8V+%RYOWAS--^)\;4U8(FYDKW['54%:+U8=,PXF1 M(I'R#3E.XLQV;HP[9C$<-W'*^I[O2B;T_5GXVSW_V6K9?SP$?==W);]Y'P($ M,[)U "4Q2%I,'I+&X^C5Z8?S=W-7NF,G)=9[E'8SJ"W,:C]HAN6B:L?B%4:JJY=H6]?B7XD5;(0X?=H./L<3\^UM@ MD^6+53573)A%-BL*$ZSU)@N:U>FP"\VP(%J"LL#WK]V>5OJU4:=7+CZD6>W_ M9^_=FQ)GMK[A_ZWR.^29Y]YOS=03YR*F1;CJ:@DK@64K@:>>U 3=<0:X44>+OLL0_GO&Z^&Y>O_#:L,;T M8,,N(H>LYQ/_W*5Z3UQJF3@J1;YAJWNKFIQ,75O'GU2Q9_D0[KQZV+NG1^T;INM!NMID3_Z7OW M+JL_-U]U\:B'9&/'\XIQF'PI(RO%YTRYV+AG-6'TWTA8)5N22\7GE$J@[$Z< M[%869#<%G; 0#HE%H-H8/.9,V!;)GY_CHQO[(E_>C+!=V10_=^Q; ^I= ,Y0 MS@1&N ?LDGZ#;E7?9ZZPW/?YYJS@E8E67#/14)@E1Y@=15T/Q%M,YF%2K&5? M7GX_;!S_+&Y(BKVD:[9O23Z&S81W5G[L4AH]G 0:CBNW5'[4W;/KY[1- _.I MIX2B.CFB.EJGZ(]7\N=-'ZJNH76FSG6VT,W]^7N5?4Y#FTW+:>)))FMO0QP^ M#E4ZH*N@"^>UBX8Y]LBC+Y10_P'$[!$K]+3@!$"XV&7.*W>PMQE(?4OAR?79N][8WCYG)S,YTG] M)2SNKUQ2^=*#^; +TZ^W)3.><(%^X3"4)YWB)G3 XCCM@B+G(;JD/%XIA\7#I =9I@=:R6QH1M%&YMUL>O"!OX&GS, IXY";M0RYR>.0FY#& M..0FCA,3+S]BAMQ4=G#(#9MQ4_M2;9[4VU*C^<",P33XVSNZQ=EI?DW4.U0&ZA6GR[9L&8G%JLCV_4'%L\-QBEO;"[. MRL_7#7=DJI3>U)"BSWQTK,D37[#,5'W.U\,U1$?,;&\]&]E.<#4^+'0B$[X% MSCB*:O9P1$_+\MSJO>&&'SMW2(\X#N$C*,\(F.HQ#ZF9*E25L _-/@ 62=QJ M['.F33VG=W]76G?-/XFB.MS,UTSZW*N1WB_AJE+AY+&NG.>JH3>LFCHR/-6< M/Q#_+.[O&Z;R]??1W4W6O;8O=:/+M/^R>7OXZ; MQ,GO/+LG3+O7%MG]^Y^_]\WZZ.OU_%D@NZ>4W8M/QER-A9!F>/3&&?R\=H;C M_CB?*%)M@$*IA$=W/!?")^?OK MT2 _T.M?M'*B@+A>>BF=Z56-7)3/EGO6[=-;AM"O'^.R> M2:@-+F<]6NKMT"MAR\'C>^%R5E5BVSW#EZCPM:T\M#^23M&$@0Z9--7+P>-# M&8LR-N&@0R9-]7+P^%#&HHQ-..B025.]'#P^E+&O)6/30-[ MXG(PYH- 30.]$K8,@T^2@826=G E#'')HJI>#QX<"%@5LDA&' M')KJY>#QH8!% 9MDQ,6<[C.J9MX.O9((J;1P*,9C48V^Q>7@\3UQ.6\W7I MV?>@1?!X2[4$Z1OX-7'Y?JI24)N:] -(XIK28F*(4DF^W .)(T"J)IV\25S3 M;LJ!0Y0#;U<.'":=O$E4FG=Q+7M#L80)<$P@#5 6( U0%B -4! MP@#5 6( U0%B -4!P@#5 6( U0%B8"Z*G71Z)W%-NX.!(](S- ,%P9L&P:7M MI:"BZNV&2A.,\R0L,&'T2MAR\/A2O1P\OE0O!X\OU/+]7+P>-+]7+P^%*]'#R^5"\'CR_5R\'C2_5R\/B>N)QH;"48^IXK=K1L M)JMDZ/]U.O"3DLTI'3)V#_JJ.CHX8*7/ ]O4B>/6_XX-;](QVIUIJUD:7G_I M3;O=_E.)OBQ2\Z_45;6;OF./+?V GJGM?)*N;#5^:I.=MG+E\$%?*F2A@6>93:^RYGFKIAM4'O(X,/1;GG0C.58\,B>5Q MD-?LX>L^'\V=.2OS'P+"CT)W)>)\-Y5 M^T@P'C(=,ATRW1S3:6.76LN=L$\V-*]I6*)KS3PKOHP+RW*Y4))SA3)RXIOG MQ,>,\$(*C?##>"-_#Y1 M3J=.]O[XKE1!\_NI)D L35]D?H,,RF6R*(/>O Q"6V!SO!>G^I'ED.60Y9YA M?M?69'X7,AFY@,%?Y,-'S>_:ZYG?O*?'C,4\;6ONT!P9P^D +>89$;) K)>E M@U2RS:RV01EI_U[JX6J@? \,CV,YNL\(B\:;,)F7#^E>8 M0!(B\!!X"+S44 V!A\!+P+$B\!!X"+RTD!"!A\!#X*6&:@@\!%X"CA6!A\!# MX*6%A @\!!X"+S540^ A\!)PK @\!!X"+RTD1. A\-*3H+/.9L4;I _+\>(K M,UQW3'3(XOJ$C+IM-D!&1> A\-)"0@0> @^!EQJJ(? 0> DX5@0> @^!EQ82 M(O 0> B\U% -@8? 2\"Q(O 0> B\M) 0@8? 0^"EAFH(/ 1> HX5@8? 0^ E M()LG&&2>*C^CP MN7QA2&>C0Q:_'%Y_(:._SOT@&PQ9A.C)\^S80Z#H00;^ MPW[:Z*S%K SC5S.9S-HGA: HV$&J)9"=9@/.K\1-BP,6&2,A$R$3O3TFVLA4 M144NE4K(4\A3B>"I5:]2>;Q*(4QW7_0_7ZB7=^*V$9\=65TQ.[)F6[?$<>FV M6[TK2A^W,SWMEWZ?_V@=>7EUDUF2Z^R>MI@PN=%3:-H>X8O5 O*Y_[C$\TSF M:G!1G.V:.,/8#F(NL98>AKT1ILF':1E#D A3U."(N211+2&B$"-,4P#2+ M,$68H@9'S"6(:@D1C3D4C0C3Y,,4@X)O#:9A?J6R:G[E8E!HLWF6OZ[.*F;[ MM'Q7"/(L(<2R++JR<_F7"_3>:AYF3BZ4BG*FG/; *$J,75!LSTXCV!93+20: M,'Y"7D)>>KN\M)&LS'RF+.=S!>0LY*RM<]:JUR]L,8,P?4,*X-FB7E>JGIP5"BGK6;E1&DS#M,NC5=,N><1GHZF65\/K_,4T1Y1II[E,&I=.N22<,T2#F M$FNX8?0:89H"F&(D$6&*&APQER2J)40T8O0:89H"F.*0>H0I:G#$7)*HEA#1 MB!,B$*;)AZF",;ZW!M,P33*[:IKD8J1GHRF3I5[;5,_5;.:Z'Z1,^F_>N53) M!=IN-6VR5))+1H5"[O!($S?D/A_OF O%=+>M#L^H3*S8D(E^UMK!/MVZ_?$T0R7Z)VI6FR= MG)5ZA?M>&?M11G(K@5I\M3:CF40$S3#=7N8*F^?'=;%B7JX@-R(W8G86.KL2 M1K5D^&2SF/:",$T!3!6$*<(4-3AB+D%42XAHQ%$P"-,4P!2#_V\-IF'8;(6X M[^N$S6)RK&]^_39N3KX?FDT]E9&N+0>ZUIMUG965;"%MH2N4&3NJVK;J1%]; M\C7C*>0GY*>WS4\;:F8KETO(7,AN5>]AV&L*89H"F*:V[T]\YG-NQB>JVA/"+:4I0^Z:%]A?O/."0@,M2#F MDJJ4[=EHRF-7&YC54?%WI5@.4AXAFK)S M"8Y+Z;O5)$X;-7+6!ZKQQ&F*8!I:BMYXW,>RQW"FSX]G/+X0W4O.R@L,OR#F$JNC,#*-,$T!3#%* MB#!%#8Z82Q+5$B(:,3*-,$T!3'%L-,(4-3AB+DE42X9H+&#/9H1I"F"*4;>W M!M,P!?+QV _/AEL(_FPT\;&=K1]=*S=??N35(/%1K""=;1XOCDY.'TZ!G"?P M5C,?BW))RW3+5% [((>>S)'Q8:KMY7LR'@)^0CY:-M\M"37<=.,M-G\ MQM1Q%Z8W[AQCK7S1RN-%"V&:?)BFMO=&?'IC=L66CC7;NB6.2_5'J\=_]HRN M2=KT@NQ0#08)CZV3Z8FF7_T>>UEL[4@?%)),C+7O22-_,JBXG4N>3>T%L*7% M+U"P[)I@P1@,8BZQR@S#TPC3Y,.TB*'"MP;3, 937[4-Q>,6ZOJB,K&SX6,> M4S-5UVWU> WL[". ',0]C'W2]-MU]?;/'W,R."P%(9YP?RM9DLD*_#ROE'C% M@WVBSRV6Y/X?'SB6IP2-%AURP7"P7%'.5K#H^.W)M/3SXVJ>@&2QXW+O..5$ MY$+D0N3"I5S(DU^6!:GF>7--;%G)R]E2!3D3.1.]=GC/3!35$N(.P0$N"-,4 MP!0#^F\-IH]YJMA >L.*N*K@-[+OL'I&[]G7=/K%I&*W,D[1Z*N_?]7T9/G; M$N1N6V_R=5:N%')R$6>!OU49DWHNV\CU?6T)VWR"7"5:*P950EW([H(J M+F*Y*FRS"F3NLQ*OPTGXD7-U K^JWJF.WAK!!]UKXGJ$'A#/)C]6#8=EE"N= M:68ZN+N^M4\K7_MI:6ZZP<.Y:%^)=+H^()CHO/V4Y8Y-#U+M)&^@>M) O25T M[T!2%'^[)O[0.X"82ZQEB,E+"-,4P!0321"FJ,$1^0J2KFL[.G&"%1R:],3X.B37-@V=/S2! -_X%A+G M=HA%2PI4$*+\#:%\9=-UC7E8R!C(&+O#&&O,PD'&0,9(/&.@780HWWV4KRS^ MUYC=AHR!C+$[C+'&W"9D#&2,Q#,&VD6(\MU'^8KB/Y]98\X@,@8RQNXPQAHS MQI QD#$2SQAH%R'*=Q_E*XO_-39D0\9 QM@=QEAC;B0R!C)&XAGC_76+O(K,N)09HZG0FTML7E\7T829$5AYD;S*B_6O,($D1. A\!!XJ:$: @^! MEX!C1> A\!!X:2$A @^!A\!+#=40> B\!!PK @^!A\!+"PD1> @\!%YJJ(; M0^ EX%@1> @\!%Y:2(C 0^!MK&UA+MO1(-,I0_^OTX&?E&Q.B8X@]FSM9F"; M.G'<^M^QX4TZ1KTSS9B5<;%9^%D\TA/=TG ^02J[YM2_0]54+8WP!1Y(1T1C M^9M23I$EH.:Z$[S6O?[GIBZR=4BZ/>Z:),FYBS[0*^7"_%QMMS7V7$^U@+Z MZ9&AQ_)")\(+JL?:JW)&@-ZKM@4CT:OWAAOYW+E#>L1QB,Z8AV?TQCVF9JJN MV^JQ3\T] C9)W&KLDZ:D6Q\VOM;)SYN;=Y)G>$"Z.ML'92&&1UERV1;?;?H0 MM]#W-GINLPF<54K,F!3K6"+Z?WR T"OF?3::QY&$3[Y$R/G,E!0YDREM/.9%Y-\2\VMBEI%@V MI5_&S66YG,_*^4(9.1HY>LTWBWP*;Q:'\3<+YT(_\J;?II4BP9O%6FR26$*_ M[&:1RY5[Q$AY>O%=L8/X-LBZR+K+NZK>*PS7=*K*5C%PI M;+ZL&_EYU_CYL3O%<0KO%+7X.X56^U7Z<58L_/Q=QCO%6NR16$*_Z$Z1*Q?D M7":+@@P%&1HFKW*G> D/+]@AE'V1=9%UD76W>*>HK>E.4:?WZY99[> -X7 0M4/!EIGT^)Q=R&;E8PM@G MRA2T$=9@(SR701?M=L:;F&6$?(E\N0:^7&*?OXQ'BV6Y4,K)2AZ]8\BF;XU- M'VFF_$P^W5#/\U))SI0+%L_5@0> @^!EQ82(O 0> B\U% -@8? 2\"Q(O 0> B\ MM) 0@8? 0^"EAFH(/ 1> HX5@8? 0^"EA80(/ 0> B\U5$/@(? 2<*P(O-?* MU7EA9_)PY<_DE@]4646&$3R20M$@X)A\R\ M(Z1%PB'AD)EWA+1(."0<,O..D!8)AX1#PB'AUK!$[EB:'9]WS+KF9(.N.=D5 MQN>U.].3IM:\OOO]XZN63?#XO-3,R4/7\7S#I^K##9_:0<.G>>@F;]I=L_S] M=^^V\>OFF_+N=2RE1'>'VK%I=@D/K[P]R;*L&CX-#/66)\LA(R6,:LA(.S3E M#;DK%50+#>!<"@W@)4/97.]/L=OX=MG^7D8#>,>&KJ%<21C54&NG<0 :LE'" MJ(9LM#/#R)"W4D&U=)N^2V:'%53UR#F9Y.Z_#M#TW;'98"A7$D8UU-EIG-.% M;)0PJB$;[VQ]O1;KFZX(U.EFZ+$)*DN=D%ALU[GCI+"N.:2 MFI;&W]+UW_%MUKC'FA:L:4&['\T8K&E!1D)&2@DC84T+4*ZFRL:4$V0C9*/AMA30ORUBY[?6-J6KZZ7[6SC&F. MSXMHK6)-"_(YZE"L:4$>01[!FA9DF210+=$L@S4M6-."#(,U+5NL:=GL&&"G MWWV?S>3E;*XL9PN%#XFH/T%%FHQ9USB-&X&'P$L+"1%X"#P$7FJHAL!#X"7@ M6!%X"#P$7EI(B,!#X"'P4D,U!!X"+P''BL!#X"'PTD)"!!X"#X&7&JHA\!!X M"3A6!!X"#X&WU4P=WGUV<[DZ+VP0NU&BL,PNOC+#=<=$A]RM3\B=V\8^Y;/WXQ^YXM/;R6ZC<<^_TDC5H8'L 5#Y MDZ1D1NND=4UU!\CBVV:@=;/X0;JX&S&W YB;>="!2[0#X_Y@8.@ZH2^C\CIK MW'<=,Y,OYJ/X1)@B3),)TP+"%&&*&APQER"J)40T%E$T(DR3#],2PA1ABAH< M,9<@JB5$-)91-"),DP_3"L+TC<$T'$RX0G"'#[H+HSL;'57X[>0IY*ED\-2*5ZE2%J]2"--= M%?V>'0K_YXOU[$[<-^)3)8]73)5L>0.X[%J7YL]OT];E'VV369(O;IFVF!JY M46I7-8TNWW/Y@D?J1.V:!(75K@DKC-P@YA)KQV%0&V&: IAB@!%ABAH<,9VLP#;,GJZMF M3_* ST8S)W][V=HO\_*D6\P%F9-^*,6/HNQ<%B6CZU8S*"OEO%S.ISVY![WA;W;"1G,@]ML,K(3,A,6V>F56]/V/\%8;J3 M,G\=R9+YBIS-9U,NSY=F2FICU[.'#R=*^GM6S:K^AWX>KL:=:2MG7];'IM-&TRN^]FSNUDOMV=ID-TBK#540"*\G,K7P?'^*\.#HY?3BS,H[2 MKYEHZ5)R4'D1EW&9JF3+#R@JWJQ&PPD>"-,4P!2;G2!,4P!3;':",$T!3%/; M>"(^42^_8DM#_NMCVZ$OO#4TF *MG/7K5J74Z#KEE/4W7".A?7*@1-@UB8 ^ M?\1<0K50(8/A4(1I"F"*H2F$*6IPQ%R2J)80T8CA4(1I"F"*,0Z$*6IPQ%R2 MJ)80T8AQ-81I"F"*<;6W!M,P[ZZ^:@/#Q?#.1K/N^I7?AS?Z[21C%X*L.__- MR4RT>T$3PP7:;K6A8:DH9PNI2K%#T;"C&NS9W7FVQ5$+'7Q*160D9*2WRTB; M:7,HES/8,A3Y:OM\M>(52\'V(@C3G1?_:^EX*)?+:;][Q.=1UE=K>/A#=1R5 MWICOB:,9+F11MG.#8O%*N\AV#6QV&'L&@F9\O<2G',JQ79-C&.Q!S"76Q,,X M.,(T!3#%F"3"%#4X8BY)5$N(:,0X.,(T!3!-;7TIPG0'8(H:'#&75-&8Q6$# M"-,4P!2C@6\-ID]O=+@0!]IHNF7FCS:JE'YEKNXJ0;JE6$$84$E3WN7C_0WG M";S5G,NL7,E7Y#*F7;Y5 9%NCHJ-7&\KY9+R$O(1\M'V^>@9K7?7P4AK2KE< M[+^;3N["_KL[QU@K7[3R>-%"F"8?IJGM]!&?Z9B+U!2&O>/=2WN)9A+ZCFO# MSO3J_L=AA>C=WTXQT5TC-Y_0Z/+%C<:.-E!=HH/NEC35':"LV#59@6$5Q%QB M]1-&G!&FR8=I#J-_"%/4X(BY)%$M(:(1(\X(TQ3 %$>-(TQ1@R/FDD2UA(A& MG.> ,$T!3#'BAC!%#8Z82Q+5$B(:4QOE19CN DP?[ 'UY#!]$MH 9C-R)I.J M7#1DKAUEKE5U ';?0)B^"1VPCEZ .R'?XU/D*M&V^U #U(7\+JC8(I:KPC:K M0.@^*^KHK1%\T+TFKD?H$?$,\F/5<%@6N=*9_CF=3 >3 M4>[HZ"8MG0,W>#@7[2N14-<'#!-=\FQ L#LV/4BVD[R!ZDD#]9;0O0-)40#N MF@!$_P!B+JFV81[3EQ"F*8 III(@3%&#(^:21+6$B$9,7T*8I@"FF$J",$4- MCIA+$M42(AHQ?0EAF@*88BH)PA0U.&(N251+B&C$,3P(TRW"].%)BQN*]"^($Q16ZPW;6]7-$%\YEXYDKG7)%[#TNPA M.;5=MS,]/W9OM9[]0,B M38CJO!01FU[Y"J*N:SLZ<8(5')KTQ/@Z)-ZC?&7QO\:D060,9(S=88PUIHPA8R!C))XQ MT"Y"E.\^RE<6_VOLR8:,@8RQ.XRQQN1(9 QDC,0SQI)Y[7X^YDRVWQ-3[B^( MIQH6T>NJ8U$\N6L;QIXO962EJ*P]U?+U&?:%<]J15Y%7G\&KSTMX?G/L&,V% MWEQJ\_H:B2;,D,#BB^057ZQ_A0DD(0(/@8? 2PW5$'@(O 0<*P(/@8? 2PL) M$7@(/ 1>:JB&P$/@)>!8$7@(/ 1>6DB(P$/@(?!20S4$'@(O <>*P$/@(?#2 M0D($'@)O8WT+<]6.!IE.&26C=#KPDY+-*=$IQ)ZMW0QL4R>.6_\[-KQ)QZAW MILK13]L^.C_/#'I/;VJH&^[(5.FF+-LBK]KC<#Y?*KOF7,!#U50MC:P[K6O= MRWQNRB);AZ3;XZY)DIRSZ,.[4E;F!VJ[K;'G>JH%] 4DCPP]E@,Z$0Y0/=97 ME<,?FJY2V%J>6[TWW,CGSAW2(XY#=,8R/),W[C$U4W7=5H]]:NX1L$GB5F.? M-#TZ:B@_\IKM?*V\DSS# ]+5V3XHIS#8R9++MOANTX>XA8:WT7.;3=RL4F+& MI%;'$M'_XP.$7C';L]$\CJ1Y\B5"IF>FI,B93&GCF9[9E%9*H"A;MI/_>4KF M=?J8>,&.2 (7+S2I9@R,S(O,B\R[(>;5QBXEQ;)A(_,L_3)N+LOE?%;.%\K( MT+-P#^-O%KWZB684?RF9; EO%FNQ26()_;*;128CYXHY%&0HR- T>95[ MQ4MX>/%>L8&Q-\BZR+K(NJO?*@[7=*O(5C)RI5!$?D9^7O.=HIK".T4M_DYQ M?%;^\OLRJQQG5;Q3K,4>B27TB^X4N7)!SF6R*,A0D*%A\BIWBI?P\((=0MD7 M61=9%UEWBW>*VIKN%(5,1BY@V@#R\]KO%-G7NU/0/PQM:^8:<%MLNNWJ:/+] M").65I!#"Q1\F7U?S,J%O"(7LA@ 1<&"AL(:#(7G,NBB\\=S M9-)=9=)U\NASM:0B%XN*G,GOJ)+D99.S19.'SRN:_#VZN#[N&G_<4O[I19.[ M5R7)%W@@'1&-:0$II\@24!/E7U*1>9%Y=YQYL7P2.3H-'/W8S:*4PIO%DO+)B_,OVI'C7(R. M\&:Q_=(K+)]$08:FR?;O%5@^B:R+K)L2UL7R2>3GY//S8W>*PQ3>*9:43]K] MXF4C\_/;20[O%-LOO<+R211D:)AL_TZ!Y9/(NLBZ*6%=+)]$?DX^/S]VIRAO MM7SR2S/35+X6R"\UC]> Q^40ED^B8$F*8$%# ._V)_CR:W8F2>7PK0]7I&W2]\-',>A8, MKUU8\6@]*YPELD8H9IQUKOIR0/;W5$VSA_2)$_ &6;9'GZ Z1**O,.C[^HYJ M4@0XGF3W)&] 7"+U#$NU-(/^WO4]4N['-6Q]<:\^.0X\>\1($OS"QV)F71+U M@6.DN_D_!P?2L4%,_9-TKO:IV&F3OV-B:?2+^8IT<.!+7MVX?5!V*4QVN;9I MZ M;*;*M,'S3[9NF8#O&ZO!ONB;-__?L.S3;--612Q?C__2O=&?HW@"VE?E/ MS#ZA#%D\8[X>F)(ZEK=#P1%W3I'7O?M\?! EF$^J?Z7+R8BNH.JH74/[5VI2 M(Y9>Z]*M>O6A+=;KG(^FH7JN?'=8O@HX!4K5Y!#\HF]CE MYAEI-<'F!Z5RF7I'4;*=Z=?)^33;K)D#YP\5>^,A7?6$?80*;U_#2P=2S;9T M8KE$#W_K@E504]V!=&S:=R[%B:6.=<,C^H=W3Z?6:J+V73!]?(ETY0HUTKAB M1H#.&L '=P3N O E4U\T=15^98M\/[QBT<4!]?_W738D:;Y2[\3$\*8_QL-? MVM7HZGS>XO=2,P3W[TF;12@B!+01N&TN?GC-LW* MC=$8*1NAC;(>VL2.O<_4(F'=)O& %WLXYQV)G>G4__UKL_BZ6>\>YA2,5[[QE86-:PQP<\+)A+XD"@%O/_643#4EZGJY=,NO!YJHB'9?_S-"FQ M,K/[TC]FKU M5E7_,W8]9LQ=VA>$;ETS3#)#D$O[R7HMHU#-9E=;/ZK&8' R^+,9S18GV!9) M$=DAO7E+CK]'R1+B#'X+/VM@R([!P#4LR?:W)ZG!_I*H'FY7(ZKOTT&W#=-R!=HD+F<);D46_;X;7UP<$&H M*#-^:?TL^;BN.6!J\A\I=QZD7[RI4,MMP$,./% MT^WOR-^]< M%U]=2;Z'E7_@=A4]/WH:],TN'*7=HZ3M>IM&T".F_J.$W<"-CI*=Q.G#DEPH MQZ7*/ :E#]O5A<\CX4MN4 $!E]REE%Q)SN2>0\K'N3(3*D4J9_K&+;$(U&*' M3#C/?KD?9]6F4\___F.^EA)\]SFRMM?BM)EPQH%+M /C_F!@Z#JAGZ'$RQKW M77 XY=\>I=WB.J2 M(\+_-W)[%RFZD:M[EE[=-;5W4\N<5*YO;C;LB(P)@W<_UP:JU2]/4'07_N MD)%JZ$>BB+A^/X) -[WDM[P!<:I,!,6S0:M^]G=ZT6]?3JRN*L:=_NM>,[XD0X^-^.H9+ZM\_0&#)PUTJU#\%51= M,;9C0SKY^-DD79][69'S+W;3Q_-O_D'^K0]'ICTAY(*8JK?(M=S5-<.[[>9] MIN!8Y\.O_==7ONK$L4US]E*2#-LIETO-?7LY(RQ'PZM[EXI%6])3^:^XG/]63N"(7W?ZB/9DQE]$_FLEY!3D7*7R*)NO)P5'V5 * M#DB)R\[0"\7$3(+AC^-VK5_M_;*RSXG/OD1C+I43E[:GFI(:TB#]F'\8\NL\ M[E<(&!8TR[4,S)E?SC=ZAG'7%4_+U.#F"2/?+)6LWC MKM+5:QH@YY,J'K56JU_4IM>&1Y501/%XO=-J_EOK^^'5<]PL&U$\_^VRA/85 MLCZ[J[%"HL75XQG06U,YRX+Z,I5N?DHZRME.1K:(]F^G=^7J:&35 MLUNL#UQZ/?1W)/7HEN@YA;5?,\5>Z;]1/"R;'S_8S?L@L]G5\(L^R'4*^\4#I%/5G3X>'7G*7T1T[].1G]&_=>C<0&I>[$ M[\ZW@QZL9SD^8LX:Y=5N'N$ZJ_R*Q=>16^BY2HQ_HA11' !#^'_0DK=47[+D M?;_Z%/Y0M?397T0^>4X :_7I9_=YD64 MSJG6O+^]O;XZ-I77]H,UZY=2HUF[J%?;=?H#:P6XW4S)USV1UZL!K53D2CYN M]FH(C^@WZ M;\"I88V)+L)NMD4O&&TAXZ<_B=J^K55JX]OL9N7Z$ON0!3D.I,/Z2:/9A-A& MZU@ZKU\T6D>[;F"^YH'']OA?FXR"HH>BK&0Q+RMM$,BLS7+(Y.32"A5L>$?9 M'>V5V9KVJG>FW=*Q>]L]^CT:/<==_P*]E9W16_7FT>H:*_M,<34[9&;QJ%;K M4+G\*>F052]VA)6HDLH4'V]ML?*(F=64%)[ZJQHIZS)-5CIUU$R)U$S16'![ M/!J9;#Z :@(^839 P^)HHCB82?;ZT=>/A^=>OW^]X$O MV:^Z3[NR63&OII1=O6CQ+:OG.41O-A)5R,BE4A(5Z;S@3;"02M9J'H\]\0*Q M2_6>N#-2<_KGN&E_&_W*'VN)E)JP:LF#9:>=_U>5F ^TJ'IC$G-5BCVA,!YE M6&)7\[AOJFE;D)C4L&ZIIH3,#4L/LC@:'AG.%GQT+[_\^:6U2K_:SRGX6-<$ MI/;5^?DIFWY7/94:37H#.*M>-EI-Z4!JMIH'[+;0:%[7VWPL4O,HMCH$;PV; MC8PBTZZ5::-%.;6@5;<_Y& (K:AXBW6%&R$GSOFOW'?[_O?OYPRH6H%55S8X M:C.-Q4>.:'PG\0QM:/H?3=E^(PJV_$!QQ!LS21[VL3X(]Z2IYN:!LR"4> MS^3%L!XING%6@;+09\Z_WQ[;#I]W0__$?V"$XF+@Z\#^79\V\@UKG5Z[9_(^ MGUD>US?1;ST5%0?P=_XC?_^;$@]Y% ^/CAEY,8ML.#FY7)!S^T&*F+7QJ=;\V^S;E409$RL(%/J#_28-C!)*D&=+D"DB-1WBLEAAL7*JTP8 MJ4+NB:,9+@'YL&KI9RH1[)O(T1/:=,545JX4-@3%MWHZ:Y,31;FD/#W)\ 5B M(A?IGN".W6LJ&)F(7+0?3K2^WB1MY;2Y;?N!S1N\92M]LZ9!Y8&NT\BZ?C>( M98C>\*4A^ZQZU/5P\5Q+>]'@A5.@/5"IY0-=7^9X^RS_Z];MWM[^.#:V80XL MC&/0_%5S_G;9NGD;H-WA].6X?>(9;GR2<$7.KE UAV)GC<>W/@?H\XKC7R", MCD)AQ/;7XD.[Z\*FA_FQ%W2]+K^R!3Z=)FG&G&YKMN+*( M:L_,'_?O)WS>L>/O)B*AP(\Q%R9).^!7M4PJ:)D\*B*>SQ@;OG^\NK0H1]V= M@4SDEZV&U2:>QY.;6[TYL3KKW^'R8GS1S6J5K^7,UW5VCGFI6\,--@$"0ITW M=@YF&L 9;R6CJY3!'-A5O)O/YXD-3Z[*RHJRK5M.W'3Z!WP7?^V!<7CT[=YX M5G,/]%VLF?$QE7,%W\6J"-\!7\8_'@@O^O/^WG]'T31"GA@M71I#>OUODCOI MPAZJELQ_(4MMXAB]?Z6AZO0-^@;X:&;VI1J!:,\<-%F"8D\=&N;DTV//9I]U MC2F9GW8AT#MBJZ;K_C\'!]*Q04S]DW2N]NEQM\G?,;$T^L5"1CHX\(&G&[K(I8OQ?_I7NC-T M;P#;ROPG9I\/Y MZ]BAVDGB\..1',/.Z=Y^/#Z($\TGUKW0Y&=$55!VU:VC_ M2DW*#IR<31M(6(Q^Z1__6_"7$% ^F/[[#Z5T'-$=HMX<= EE!_KL$3LJ06:Z MKQ31>(:>\VP52X4H\8"H')5KX+F-\U?BI<)_N^)A8*W<&K>=#!6YG\4NKHU; MV]W?:UC:1]X;,G5[8W'U_3UJKHC$3I$E M<),RKPWHS#3N*)YQN-YNCH?T6]K*?F+B:NH(Y+@S)N_F@J&'JFNXK=ZY0URH M.68UQI;>IKLR>E2"69ZXDU A>4ZUF$8O(I?TG8<$<\6,WF3=_-2ZK._O*9^D4&@PBF2A/N/KX&?[ MA_'[MYY_]_FPVFZT60..BWH;BB58C0240[0;)\W&<:-6;5Y*U5JM==5DE1+G MK=-&C^W&Z5%8BOWN M[_D[?FV\I!.GS)M*=ZDJ&I=G.R':8+W%,.=&1O &13/6. MQ4Z/"/U)=8A$+YJ^[I.R.5E2*I6\1+_?5F_!*CP#,:L:EM2FS_)"A?4 M]__?_RUGLY18QN?V6;M&[X6?V6^4?S]\I&"@WR$CCS^Y"#HU0_\;UN ODW>9 MU"5ZF66,1^U67@9GJ^49I_?)7W5 MVM^+#)9S)69^26!]29>1CP[HG]2Q-[ =2E-=HB+!@-&HE%"SZ*_,J*G(Q9N' M\JK!(SI&HZ.!G%&R.0,EE+U\[1:_:1^<^53,?,QEE M*3V#;4@4QYRZG 'FZ5F^Z%GCLTOG\E#U!W9:RNMH1DP?5CZK1I M2HV UIC>7T<.5?W&B&JOD:EJ+&NZ*RPTR7 E:H(RDT#UI))2D;ZJ^AW5[M5; M8HVI7+DPM(%)A8LL_:A*E4JND/THT:?2A9MD-+ M(E' @,:E3WI?R%0^2*5< M\2!/N8U_+K Y]O?N2-M&.E.=&^+Q388&CCL9=FU3$J8) M6/(?A5&2NN-,*0IG3%%ZD*H$A\U-1MN",%I_(@V%>:>36T.#'#_^<6+UU3X/ ME,-ATK\2TQ[YT7(P%">>YQCCX4$E(W552+KI4@DTF-!/.^IH(IY'@0SX.B'F M?]WQ"*S2?#D+E*3_D/?W($\''N\Y1/7\AU-A=@#^!HV[>[WQT';Q_D%K+]#VJ:4JW!DMBHN='K?*^ M:7?I+^GY#$?V'>6TT6#B&IJAPDO]HP3BJ0XEBR.62%?%IMIU)V),#FR0KF[( M*6%11!G"NO>(-K &; _;Z!Z="&]'B@0M>.;5MG"SIRQGWZ8BI1 M#"8*YB[2QT?5Z#WZ$6KO[U'^M&Q/,HVA 3H2<@CXCN%=$%)*-0 M@OU(%$'$TODW56DXU@94H-HJ:-.1/1J;8C\]Z39\.^>XJ-BBIT-%!EWCT'9% MO%((4)#D_*0HO7\0UME/XZ2C\F)L,M'KPFOG2 CKIS*0^"=!909]!5TQ([UE M@UTA#H]^H@\KM9T)7<@(9 U]G03>#8MHU/: 1?LR?\P+R1JN?4X\@3VEE/]7 MXMB+50U+-P02E)Z8I-N$G\- I0**7BJ&S#:AJ^$7'H_BD\I5@1:7RS]UAJ8S MN^<7/%@'Y=-QCYK88X>)58>1;42%/1M^R_B @MKADE5@('P ME.&/U#"GHIP1E^C"F0*8N(,B.ZB\HW W#3ADL5!*>$I6DRX.7LI<2/ E0790 M/6CBO]*R#\'FHX&*=PA8T)29!8*66T !*W&4PF7 ]0WF!;[@7Q'R MB $..(BJ] "\8 6P<*!Z:QL@Y"9P^^R-F?W0)=X=(3[+,-@,QG2COMR>=<.I M)F4[G;OCJ'#4&1\!9#W"+\,^>ZZTVOT]N#M_7,KKL)@'J 3,-@8+TYU0VW R MM,$^17@ZS7Z./ 5_: :I<8B9<1Y.*26 MF9E:_Y0'=:8_?XS-]M4OY?I7*8TAME)G>N:JA7KM1+FX+5%+G&%S?R_ (D;8 MMNK6"&0Q/QAI44:P&!QQP9=@N /NT3A3V3VJ"'*-"SBAQB-V8.@@84).9@QE M^HX189#N[P7^@%D]+ ULET>NZ"N$V!0BE%Y(^-V+7Y=&,*!8'X,;'*0L6+N! MN.1V+DA::I_37WFP &$W,]O8OZQ3 4ZW%;@BZ&7#T-S%P-J=3;>BV<*4%]GHP1JMT-#'II 1LA&FEE!+''#K>N&2F8-03W)/_F M&S71 24Q+@[ZD!MJH\'>^&6+9QM^I&0UZ8MT>W%GU%:B^//$*IB&NV1//:]? M'M ?Z3GV0Y491T[P=6E"N/*%45;RSRWR)OJ$,WJ3IKLT0NSX]^SHW9O\';,[ M*ONEH=,'>E"+0!=!]]>D%R(>N\THI5W1J(E?-A-BNMVG^*7\%[(#]Z,M\91\ ME"[XG9->WR&TP^U.C5YKZ5M45M04O2!'O!D7]5JC?3GCT& .89L_OP_H'&> UX3$ 2"9X#\+7 M,.GFZ9_H_J@4B*]@8(U&X1'KG 24-_IC M2QMQ\(*S-'#CPBKJ8[AJTZ^TG#ZEK:L&-Y@+X2EE7'+IOYU1I,:WZ=.PWKJX MK/FTDZ6F_U[QL0;E>,,;>X%HALH NE0F'=S0B_#@]^CO5%V5:DQ\J^;^WB7= M/!6\S&7W.IRYE80QGC)&[IEL_OQ@SKZ".?MKR=DO8<[^NG/VV2W.!S%&/M:H M)@/KTO-%:YP%-*3F/W@N[.X?/SYE1XTQH9!ZA']OJ>UUY3+#"&*(?@H<-^#V M]Z@%QVPI[@$QN''&@Y3SK_*C$K8+YJVI^?Y9KLM431NS#W*](#YL6'^X=\V% ME(T>/FYVURBRIQ0TWYH]XE%[+'+%PK^,L?HLAL44\'T0SR%T0TSOB5W!+Y!H.&O M@TJ&*LNQYQHZI^_(-L F@!"QOYD(87R%'-C7+!=":$Q69JV9(JP*O^D3=GV" M1 FP'GBL(HA@\]"E+9;#[0=.JJX),1ZJWIDSG?Y M3Y$!1QX&I@:1&)W#8B5 MPJ4*M*P@$OA+#6@M\!5\T(.+=W?,W\(@ZDK@5?/&+++O$)9P0[63 2K9"[@0%J9" MVH)-V2AT6X#5ZC,6)[>X^8=RDAFT@:!D*;;4\N:WZBYA0VM4""()4YI'.B&. M(**C8*@NN_D+-P;P+(MF1"[A7*CQZP'S.=,;Z+C?YV76W8EP87#9SBX#ZG"' MK=R4L$\0 ;*H-#9&<'WAPK WAM@G'%3/@/"!T8,(DQS$L*CA9MSZD7;=<""Z M[*HF3^]\(+#R/DP98[GG2Y#V@2L\ORD'N(5 #?*K%7NG2?]M,>5-H>O[POR< M&/C43)27NZ-"$LB8:A:) M62>0CB52%AQR8&LB-9/:0%26B6M6X#UE+AM0$?#5GJH1X551(3N"]<&Z-7@H ME:Z?,-X%3>B #NA"@ET0K@-E9=EW7&##4^DJ*'+[CGT'8*4?,G1@EB]<4?5! M^=(E#JA*Y(8EW7L^DSF9< 0/B'H["36'-Z^ZF'EE$F;1?S,SZ<\ . M=WRUPD5(M5V3BIDB,!53X-2&A@1KX!R[2R$B[$;FZ?4,%[*99AFT@\R@ ,;3#'(\"E; 0TQ:IGDO2:>&M#VA(/[6-*BB# M+II$TU1Y@AN['8M\JU /A5ELL+X@$XH%5:B<>"CC M022QR4&HVY%.&/CV1) M,-?L'S][U[_5'G%3&2ZFH>-Y1.R1/XO S_MZ>"G MSPYK" @=OJ3!1'<@U9UYH:G:'7?IM9F^1V010DZ^0:4*2\EW;" B&3*-#':/ MN)1:<"MUN4^<+EB# !>]9NN3V0^S#,;P"LQN\4(B?Y0:5G"]A;"52[=B0LJP MR_,9Z5_OZ'$9FL-2B2-YUB,(Q@T O^%E.>+DA^OX3.V?U +9QY M?RE,(]=MN@8(UO,K#4OC!V47W.FY'A'V.B.?3DRX6C#44EJ8>L?]_ M!1:'H00=01R69:D& 1!X4]\&;PK<=H!9>*"V9YLF5Y AM.%MMKCZ463>^$GL M?&'D?F2[@!^(2S.I1WD/8G,4Z6V#(17.F-_@%LK.HN/'CXBK.0;K9-CJU>AM MTO NZ.OJX@6\+"JC9)1.)RR0(FKO_$_!)A>V$A1(11[$U@IK]I?Y[KF9*K.Y M*8^L]=WG@6KV#MA-G:X@^[$$[A:1O\0* *#PZ9:%7AU[Q$1]X3]^E8+M&%3E MT*/EI5"<,:D9SY[Q<2'SQM=Q*5-U*=70,Q?.H:VS!'-V; U+]_./06E<4;9D M:LV]\2.0IDBQ]M4$#Y2"0RX: J5,.F#5#!KSK5"%9FL&NT ROJ<2R_;]'E & M,J)W6;@>>H.) RF4&C6E#&0N$Y_)/#M1;X'DJEC2PI<,2EH6W4_M6 M=:&IAB:9D^$(O)DZ.';I)BC='97^$V0256 JSP<.1,[=P.99U>#Z'3ML>Z%] MX+(H*_T(2X+6"5QVP::E'Z2RFFF_F2<)6UJB_$;/1SR.JF8RM,#?2[<@LN-[ M;&4J&,E^EC[5K[;#3"MN.G..-.A96L2WCJ@B.G^ 8%UJ"EG](,D0/-(.; ?, M#^:Y&H"[&0[ (MJ-3\P>VR.D?OC4Y7YUJD591G:7W=<=5=RI@1#<)V%1)6-& MG.VQY3=!U7M5IS=UEL]^:*L.R^3W_.AXU*U-#3SZ>6W"(N0B@$OE/HO?PHV# M)?33'+G>FWVY.SNO'#O;S+IC%I,=.96MTS^_*[X?1__H'RH7#/^WO^KC%S<3LW MTL BX?Y*X=4[5#UV2&&&R*E?=\AJ-]E=0RA'8K$+#;.(J+@!IODH'?FU)W Y M@-H?PNH'I0E1>850Z-$U8.XCB[H9$(_D:H(:=2JK/X++*-2F. 953_3E-Y9] M1^_'D)8.?PJK 41I(=.'06' KLBPQ"^;82FHW8NMT3#8M5DI2:Q%%]2OLLJO MQ>..K_ >RM\@/\$CN>Z]B8R>4KMCP: MI(]=9L0%97>&22^:PDD-?FY7&G/4=J%3'@7L_AZOY&3X'@)=F 06@GE.6K(/ MS0O<7P\[?,8>RZ5DSIIE#DJ6K7(A.CL(MQA*YE?U._.C9HT*>BSAGX.8GZ*/ M!'J$+!.'>_V(Y?_>AMN$'WB%'#B>@V!"B (<6L5<* =G"^$(N*]-G4EF]M[] M/>$I^@R&MV'QI&$JR0Y@,5%^\FM9_,XB2JF4SQ3R08RT705YS!4'3TGB+,89 ME'=1B&SNHWCMI7@L>X0O%_@&FN4_8KX6/-,(OS'T:,(TLUA(NH!J1(VV6 43?2T^P>) O5.1\L2A63<4* M_RJE)[W+V>(P(2H$E7_,J0 MQXZNVG7Q8RX_4\A5ZHH'W?*Q_6$U.$LI@ZO)76XC*G#F#J< GGQ@XI4 M(:R#R!\WGJ@1&NI?7[6]5XJY3.634OJGDL_).47Y$)<0Q#Y6KGRBQNL_5^UL M]I]\KI3_(!H@B2)"$Z[?!-(!H=Y^2-89?G$%([ MFV6!F2)+!'IQ],>&SNKY7JDI!=[1'N4#UOW)Y;N'&WW%7#Y7+!2S M'W@2';NH,&P:%KTI<4=Z-*53$F66[L 8C5B9I,W:U!*'NXMN6?[3 2>#*GB M]),3<%01_Y>\ZPG]_3F]AH%W7!L8U-YU>"^Z(/W6KY.S!2ZC+V2]OW3" $]B MPJFRZ 8VX&%B2+1BMS@_OAPV@^&9C+P7)5P&&E2 ML7LITGP$0EC&="AA*48H2]B.IX8J163+,N")&Y,MZA'\5FM!NQ_(MO!C0*[? MV4747X"%)(.3-KQWF%PCA3Z!>:WFL[1_CRO_HQ2RLI(K??@8MEWF>^%IY*SO M,U&= _KDH9^LY*LS?OV)."6"M$#NM:-K$^VX? =>EU %"%D>$AD:'K,[!_8= M^._83DSFR>NS[CE1I3>WB[F,+4X[U@*0%^AP*HKF8J OQY8N4O:H# ) YW( MQ#%$;KG">2,TJDNOGL.ARM.B5)->'D.RBM6[NW5EVG1X[L2FQU.#4B3'6CDL M]\"7.M/L8>7OJ4+^UNY(6L-Q7Y6S2J5\>O17?_>9[17%C'F&(U-438"] M#J5KJI\^!=FFHCDI3T'F/9O9[< TN'<93 BA1"Q(7V8A#\>=Z1_\4:I"NR;[ MSO(_^NAV9C/66;NG,>O]X>>U,%":MNL*F+UAESWP^B"G\NHC?ON M;']:O_$':S@"Y& GW1NSH!ASRK$>(P3J/8*,6C^1'Q)FO(EX<1>"K92"8N]: ?TZ(ZM@%>,3 8_:7_Z.]-N3/Y5LV-)? MI#Z%\9SPN!_KE?ZRE<:.4HS522OU4S\H4"5"[76ZON+\7,7LQ\+2?NI#Z ,# MO*I:%J_48TG5!I_*H\@D.OMZ%AT4:8T M8H_T)XWP]N#PU,?D_&IK6S8:MW*@Y(.?"B^:/;+Z=!QPUD 2*P\X/C@:ASW\ M'#[J#Q819/VM?=-/OCO3(T,+R0H?Y@]^E&K!L$X;#G["+>'M;LP3]1;)._1@XPNB%?[42P. M>OG,1-D GS^-!@].!2HO'PKDCP*2WC\T7^D)2F8!8=WI=_NG^L5I_/F3-"7S M7,#%*QGE4:X7FQ.M"US;7)P5%I6JK."RU?NA.G!9;#D7$$/DS-GJA79+C5X^ MX!(E/N>*#[IS8/TUNE9S^JWUMU8*SD%\A2]EYAP>'%!?"Y7R.NJ.O[BK?[7'J/K M0Z]< ]$61&7V$355M0+MM&C7\A@$E:4MS;-YRU J3@.=Q1U>0U&/'&=+^>[> MAW3&A?^$.3FC9'(9X:3(P DXMVK=Z7V??OFISTIC7W]%UO*@(F->ZZ>M:(ET M43('N4SPT[//*">7'X&T+9H,+="X]CPK89ZV/[/J<>[OR??,46F3ZG]-]'K< M^DK=E7>7;NHSJ, MV^'Q(9$K+ODA'V?HX80U=V:6_'R6>5@D:+8S"6_[L2O'$*:$1E- YU-$G[RUF0S1I9FD M[U@.9R1?=/47Q&26OO,S0L-LTB_*H*5O"T6:_X" M,>&/4;*PE.7$ #Q-B$8(1QOF61!6YPN,-$Y;R)*$8:;"8. U4*P=ES]6+ [! M"-84G'^JP-H>=UU#I[_@2W3MN/:C8OH8MZ?8#&"C%XZSE%E-G,6[-D$"J6K" MR%YNIH0-6=1PQ@<*W31 (U4XKKI03[F6 %04,Z7W[I#X90=7.%Y8@#,#VQ/7(T,T!])POJD"8TUD/D;0&/;ZYD/=6/OO@[!1 M73B_,7II\W_-IL#[CL6AK4.%JFF[X+%GN_ SIJ&L6V .WE.>ZY1Q.M9VN"($:RIF"T+6!4=282*N5F$ 16U!C$M<.W$^W\:/,E\09QA_= MJ:%>=4]^_#F]*@:!;_];$E0%O[#7-\NQB2[CW>?6K3_UASY&4E@>4;XL^F7, M5JN)^F*7C=RC)-K?@Z+_>=!7_!(=^J1/TGOE V.0P+((YB,PAG1='EAAWNKY M2GXNDF7I??9#\)'S 307:,C2R#!M3PX^#%-KQ:=S'WC1#XAWOUWA@BMFM;%: MJN;8+B\A9(V^)O3Q>;H8YD+D(Q9T,B*LH#_2_X,2A@_O LDC*@.#GM5AEQ"7 MJ3([>)SD%RWR(=R\9GIVOBZESQBJ%5F*#V^H\+[P(51G#D_R@&ZE/J'W]P2E M"<^(@T+ZN.FXCW1AE]::GA*IZN.-2T0>2B"<>4NR2 G'7!JF/8E: MT+$6,\\D4WF[RCM#CU4A?@X$D[HQ%K!#8*2E)M+2J%WDVI9%3&$^CZBN@MXN M,/S#82&YH++>,X:!OV,("I9EN(%"9?7S(@J]9.%^=7YHMV3SPFX)](.P.L() M4&R<01AL>VSJ/DG%N=EL]F0 D[#?@,7G+RVA+LNU[_O/I282A%L,1^!H.#9I M4B/9+\0")'?,YE/,3YW!9EE($Q MXE-@.34 &\P&"JZKSS&/=L382?ZRC_W94C"F12/&B/%9X&B*$:4]E ;N 0^]?#1V M8*1/!+Y1]J4/_L=VHG#F?$+M%=. >\7^'K!+W[2[K(6*/XS3[\8BF.:5YG4C M9#\W+!['ZA*#-:>7=4IIMG-E#N[Y%@S >3V0^,, M_4YK\],'?0$M^R);Z#8J^=C+14FND-N]L6E.9J!$F$B.5]I+<%JUL_#F1S'-(?SL2Q FZGT44#-$&%IMMQ52N)TJ*;6E S)'?HY%/Q#/4 MOF6[HM8X9L[B3"LZT[38G1T9XY66?0C-8_?W1+N]>9LE[.4TH.(54,_GPL-_ MC;BDC?M:U#_DL+$;K-73B%6=L&Y18\OCO:*<(7-OPY1V-AD3RE0D MW1YW/392UXZWJ?A(A!E?".M]--,F:]:N&3"K9,A\0&*XKRQ9]I"-Q8$643(W MB]B<0TT;#\=\Z#?$+C7@N#D2?)0:,P8?P!H:2_'1)-'^4M&,5-YP8Y9-??,] M$K*A>HV8*N_C84!@%7@G,.(9_XNN7(%.$5IOPKI;T:?YK@FE(N MF^D-% 1JZ(&J,!LU-'!YOQ]FW]1:UXVC Z42/R$.IM)1U>1 ATB6WTF1UK2A M=S+T?_Y!44SQ[\'X;=[[DJL7WG%3C%]:4JP3+H^/0Z#/O"/ P# %)VS=/.]& MG1MES:'FBK2_P ;S^9B_F:GDZ*O9S=$#?[#?@9-WU66DB8PGY4_UHU_PK2"; MVQ_7S0?7L_ZHB/)76G:50^N(VD^LIT=.87V&LHO=_Q9BA-'QL1";JUHZ_$^= M"D)J8H'-7?5JU 2'#H.LNC>HB!=-XV[&]_=GA]>7W\VP:1RT^P,6H !YM,/ M*N]<4A+_E&A?3/>04J8H9XK+6[]ID6T(%PCC>!%:$4:AX?&;">4.R@"Z/Z1R MQFASB<,=-O1RHT%$20=?532,L#@=/$[KSAJ9?H@G:-/.%AQ10,1BC@*F@ORP M6\^X)WRLIN^YH="AU@%/:7#GWHP<_'IZRH&[*[3&E/I4OU [C(C:@CA+9;9M MT%QV )L$2_^HVS =FS4FIQ^YI8]4^P3&YK+&-7BVKVF#Q/::U6W&JK[?E3DW M=5@!_[-#3#6JO.G]&/C8M[U9+O^"?SG:4)9G,T&#$/FO[A++=@%_M[(U.U MF AW";F)2[:)9F1$VM_"$GQ_+$OF89W?>8)/Z-@6?>#]RWG8+)3^P)077&O$ M8V!P%V_/'GJKZ-5M1IWXYIG.YP]34FFB?7!P)PEC\.P+T=$- DPLEX*^8 R> M/+_O/._-"PV+QP[/;%XJ@4+OB"1HXGLQXL02##YA>!#]#J'OG#9@[>/]9IJ&5;X\]UL3?GX(Z!G#"F7H[H^DVU^;=M]BN7-+J MU5W.8>Y<<_=ZQ)R<_6!G^L,[+U^7L]-CI9S&ANZUSK1)QMZQ5?MM_+H16:04 M2<$.L:?[=E0K[],>*,!830L)YNQBRF0M\[.*B?.0S:Z!1PG,XM!!)B*<$,P( M&G8/PRH.I@]NJ(GM'[X8)4$%)\\$%G)(97X%H;TA Y[XH6=WKC-\5&_[D43= M<"'C7L0VN8[M,X?6DN^)_NFZF+P;2PK_X7'K$9=XUY]@ C6#KM\R+OQ2V$#N M8PC_J)9@F0',W>V&465(I:97#G8]8@UU#O@ +6C93%^D^M-[X*6RN**8ODGA MSX1D>E&'23W,3Z?>"UI\E*ILTGE07:"!A0/1*4@_]%4 Q&N#(T.1OZK(/Z=' M[? .7Q=DUN2L!IKWB#[!,1CXYY2",M/.Z6F/ZDRI?5#^>GP][CK=-*J-H\[4 MZ9]HOT_N:N:Q\N[S<6C3M'VFE.9)@:KDU9==XY8@'Q$"&2Q=U>0"1R1(&.#5 M8<"-#@EQ@I/C/1(]-ELL5O#"7=P/!8+9SW[TTW39@^>N<[LBH9Z019K'+-*U M9)$J&4PCQ332U[ -XAWX#X\ .WHTZ+ P#XXW1V!G9K%Z%!S\"G1T$5< '.9?:$UYPH/?/ MP.@/Z$W2-.B)BKH^PP+O&E?]0=R'7SWI!FS'Z!N\Q 8RZ;R)" Y#\P"15$SM M#5-4+'4)7P<) ;,CMD'RESV30F!K]!S\J="^1U@,. L,1@.NL2SE5P#J^*A1 M SR,X<[*4F!FP_:Z3?A,M"!)C+DG'<.]$:?O)V*N_=1W004=JX;#XL2M7G"[ M:H3G^/[1MP&NQ=[^DW>&H$ M2Q>\&Q"634JU"D@:B"7V+?I>_];JBR_)'1#BL<^SB+0',:$1RXW0_/"@[T+C M/D[V,C:;,BX'A3GR8-:.''V+&[H?P1W(L_^8(]<('8]R:-:E37 M+S32!,R"BB .!9[U[+*AFQ9W DNL,L!@?V U,>#Y50,/^81% <#THAH60L-A MV0S,K;XCQ-K?$PEQ?!JT,6*#/40$=$A48#1F&(*''5S.0;R@#=,[5$=WJ5+7 MPX"\/U3NO\;G:KM&=>'G8+;(34;G%'%(4JE/A>3>LT=AS>86R88G%LE3?X!G*A+&P^MGA4%5*#_XYMCW4/,H1]H_+AB)Q:/./)@-@^*QL3T0FP7R/!B?<\ M3TF)TM']$(0CJ(6]N *["ZE33.SP_>WOBY.I.@\C!)[\$+R6/V=AS6 E M\8?_"T(J=6>8;NCE9J 7HPG@S+@FI/K%@^0A,&S]A';65IS<&ZY(EG68$UO8 MS3PG2P),<$4C4F]Y9M>=%0WCRU 7PS$91*/!2G&8!<)"0V&4FA5G&7_')+(Z MVV)+8\W.HW/5?6YR9G[+=;T.3Q?U!=&MHU&Z#9^/,#1<222++;F3<:.#E8:+ M#! ^XU-,AYL=@\B;A;*8'Q4W$3./)30ZT!*,?8[E-.[*L;]&H@*D$'J3,R7B2 M@\2$>S#UJ\QX1\?/ZU^$.?W]U"XH-*&R ](*Q/T3;D@.3P1SV5W7(N#'8<7M MH!?%'>\\[/A%?.R*L(/X9LR8Y]D4'?\!-?IQ-[YUW,VW+^-FYNAF,.U&9Z;Y M;X87/3K3=>Y%:^[OMS@$4RX\-%S1D?JL,5JD+II7RP1G\A@1CU81(RUX\%P1 MU<;94/PW',[?"!?@7:GCQ"C1]X+V;*:1:E:Q.,.\>_(X?I3/UCPU% M]QYT!0ASM^GRB' *C%T"">8F\U8?TF#\L0BSDSX2B9 M5U%84]J \C1W'0D_(;_9L#P:=S+5\I7>=H^5 !P@74R5/I_R WGWN5W[4C^Z M.JU+K6/IJ'Y^4:\UJI>-5E.JMR\;9]7+^I%TU:X?7YU*IXWC^EQ_VE<=Q5%Z MK4D MZ=D*2PL,M) UUC*L([O656]BG$@6\!+E7@?DRN8X;G;D^U(K*13E'=W[]921 MPH85&2G<>?Q-AQ/(X.1/\/5,"(_@8_Z,XNSA]$O^Z$2],Y3 1*PO2MD>":FS_6F;V\[K&6EARK!$]THZ)EO2,^EFN+'P/# M(R]0$>L452THXR4;40F)U0.O*OM7NIEO1_8'G^8@6) 0)WWO].3F&SFN9%]9 M\(N5=6(7ME[QD'VJU#].KM1_[$!/O[:]YN_)7?^R],HB_Q4/M) X>;_&V\%: MO;YCQS*@ X.8GTT<='D^'Y2WI@]M0>Y< M,17#8^%J:-DH!<4+4!DGNN6&H6@Q5I0E;'')4=H M!#++I](,1QL/H44QRPD4HT9%=CB\(UB F$$1:848M$XSB9\J["\_4G-%8D/J M;&B?RG+ 7*B,4%T_)0@88;&Q#,];)QIAR4#0FJ;OJ*.!S#/-(-8)P1._'@-Z MT1HL_ E[%+G>D#ZK\9ADT*2ASG$+PW6 MTPWF0Q<,*TFM! K82F ]K004;"6 K00VF;W'@O:G;. '.2;DD>8!2AB77_Z= MSM2K_,I_MZM>^8>:>'LP)CLOWYE>G30F]=)9P;M2J.W%M[J_!YO%[+S7MWU] M^O<($:E!'C--58]E ,F\5C\ZMT!8OBJ?55"-_(OW:64/E-CSGIAMP=L6A.8Q M-6Y@CH(V?UL,S&713_,0>KR;5,32VYWM^+6^].KG10?N "M#&I>_*A@JKV/A M>4RZ\8EMZ] /E5YX&Q:U2_L&E?X\@7;^W[%%Z-F(Z^+)S^I,!\WR-[UXDOOQ MJY=&$4L1#L^P 1C<@HU/'/,M8*C<%K[ MF_MR>TL*;2L?>NR6K_L)[KJE:>OG/N2@\I;5P=%$.N+Q0A?.Q;,-QOO0*F7L&69$#4:?X7?2CLRL9M,3 M^"S&,#W6L()&I>@'VD9%%.$E;Z)X?*XM/3A\ A@*\T..5$<%HH1U,H](^9&0 M\AR ?D=Y4]1 T96QV>I0% _3<$1UG!C([:\H\NKH2V6I._:83/('4'FV'.GG M&T[88(W@(_/0PV1KV9^"&?1O9Q/<6+-9-F+3L6&HG9BN =GE[!_00-YEF=[@ MO>$/#7M*(7Y?=\!&**8LFZN)2 D!KUKQ^Z%P#YL(DLT,]_>D!_-+@!<-W65,JNDCX)^S*&$(+%RA;A4X22U[G3U9@[;(; MKGU./#&K42GEQ:A&:!?MCU>$?MRWJF'RQBZ\AM;P)-U@.P+O9]>FO,SH6.%T MA'7"Y(=PW( @/=V'1[@B8;J+*C5B];U!_%K9*D:$*G0H*!_9KB&FS+&;4/RX M/7@-J_R%6;T.<^@&Y2O0-V=A':QG"1-DT@V!+G)4,#AL'K-!OP&*E:(4H,?\ MS".PCSPA1L!9#%X]2YW=I:G>168\[E#OFLU?X"ZX&7'!ZVN K _[GO(1&_+1 M[W:F_S][;[:@[?_K'=VQL1<2\^KU=02CC0>P 8\G#B$)D"TD M+($Q7/U?D^8! 1*#FX/W76X;I*JLG"OSR1GW((Y:Q7>I)>UC@)9_G;]WII0;./+AB-U;]@95'UIW()F8K=Y(A*5%/ ? XJHAK"( M2C8L(M*<[O%MZGZ$I@G8@(SNK5^&?7=G:#&G2:"0"9/@/KR@Z0,'59,9 M]0 1>84LI\+V.7@'*.SI&<0E: M60^8B%-M+(RHH0(6A<8,D7DV:+ 1!^$>R P)5M(#'8(XH;?SX:'W>!?H;A"0 M!$?!!GH5W+:BX(E>FCY%#N&&ZY0DX[WPC2<*HU6A!UUJ#6<)]>M-5C<_V*1: MEH-=51UG%/U2PIV&PA>^?D7TQM,37*NQ(UFRO((F:8Q-"AX?&23$4S:A=;T$ M_@;P0(@GE+&X9; %0&O=K2*9S^]BU79^V??0U3@^*K;+4#[1R'ATU88& M.^F=J.8$7ZOG*1K0A'CB%<+=Z,) M$^8C4BS:!XI85V20B("AB[8C6?B9,0,3W@!KI=& M&)^P/1 HZ]<^(?UF9NK*V!C,;9D.+47F*I-N9.NWX(TE\0O!/BSSEZ$3+$D. MV44XC$H7U3 <'T&I0])&ODV."SG*,-!%D0ZKS[KUBP8L<\P(#.,A+MU>7L72 MYVV,T]5P3O6G^$OG4Y'H5\YN7)$8Z';A-_B"^QO6>7.F5"%-#[Z,AO:@)Z)O M@Z_;$K1VL<+ C.2;E/6+G[^H*1J52L!" 2,KG [!Z7X$B5TM2[,/)"4B;;X! M"M%/\!(/8J'!@NCF#'Q9Z[&<+ MX0&1[^&9R@YX<+^C9'%"0)?LP(,Y".&FYB=+$LSEV?Q)"S)NN$P0'M>IC\\T M<]5HXB"24&+4=)9W)4-@R O_-4;#N0^!_!*!?)5594!N[590VP-6%1:6D!AA M_()OOL[G*>8^=]F3WA[$?0SB2Z_S4?7R[CJM=N6GWLF?:Q 4'1^!W5)HNX?X M?;LFWT"!03B5X+\(\P78 ^1!PAFP W3G"BW*2$)%<-!P#F'PA)J%)M!9Y$4) MU8X(A)G1 _ WD>:!5R@<^KSSD\='QD?/J!+ZF+$"_ !K;4H7O@I$YW 5Z&-& MJA:K/;QB.-L/EHFC0!]5KD))9\>*^@L^ ?YF*D#W7>!/69@+[0."@,]T=7@K M<^,:G-F*4@/PE>AAP*51@$^"'Z?[Y_CZ$M?*&M,4],F#"!Z9N,$]5#T[4E#B MEC5H!\-,_%XX:A:LWSIJ ^8A.-MC#"QJZ*Z?ZD_ H3 FEG'!&7 T,.M!P$AA M5(*([W$N"31-8C0V(PT+">!#S'G ,.:R;-JDJ27382>O!5K;O!NQT/SX2.P% MD4M_SH#EK=>_9U1-CYS0U8 ^. T6/@&^25B<,O1[;%P#[.WQD2^@O)5L%NJ" M P1>&9FCZ7<&W\3"+E$6G3V414=3%LTTY7U0S:S-L]'_[+7>;'Y-GVIOLUNZF\[[S$C9\P$ M+E,A")H&\W]69\;F#)#,'7$ #'-(;!>I\& #AJ$X?TN3:V[83&3:;F--!]0T M$S6M_#I_'[S17U\I0,%4*-2T^O5]I_Y0I:K%5J/>.&]3M]46U;XHMD+#I850 MNN%/(IQZ=N&E>>,<6# ,;$K7U,MD[8;51A;=IJ'-#GZP$DB"_SUA3@R2IPN9 M5Z\22";W\MZO?+0+/<%I>0)<"+!NZ2-_=)XO\./^?ES MF1]=]/F(]TNOL%\K9(:Q\F3.HM;75.9%=)WX.HCJ>:69]P,<;?*W*AGLWH9: M5V^0_\B*?'DV;";[)\'BL"+L!Y&[+//#R\DQUH1-@?.T+(![GDSF\(\\7^'- MROI7,CY >8$PP)&PX/S5GFE?55Y>@=C2X!U*;!0&-'^'E#2 ;A[X9O M6OTKG9YS*R@^/WP[-YG--1!O%YZGII]4H'2$%8D=$@.W_B)(B/Y'L98L,)E$ M/NL'/>]/)2]J?K>C<&NDV(^"B>0HO)51L- M^/SO\;A@;G*7K>$W&:CS7>7 5R7Y'F*73>12N5!.@.<9AC^% PM$J7@C9($4'=HE7XD%O#5R.G*-/,^/RZ6F M6'[JIMXVXY>Y=2*#F;JC0/ _HT[ O!;1C-TM(BVSHGB@[U&\,NE*PIKRX?^H MW="1*TQ!\Y: ;#J1 Q*0RBUV/CR/:74E>#CE)=3@>F=<2##Y7'QG[(9H70#2 M6GJ=:Y?WZI?P*)=&PL[?#&^O)U436)4;%&6^@C%68#]*%4^K\X01JMFZ4A=^ M^W5>R>=O9.7EKE[<^5/PKFC-)A^O:]>?G;MI'^4OT98QY(AEUQ0:*WFH<-WX MLNTGPILG@F=8VN! -%9B86YO@!$_+D,>./K41-H\9N+2H:11!RY!E.-:.A\$C94]Z M*&&?%RN1COQ/U':*H=PLD!*PB9]5T:OLPT3ATV&1*FK:QQ^$,\G)4$I23:*C M\G"XI^Z,L@[I0[6REE^6\)@_">)(H!XA5O/?O6-E"#1(KPO^ M)E64N[]L6^FXSM#N0;2%L ;A=31*CI+>*%>CE#(3QKFOF9HR4*Y:?MP1:MYO MX%*BG_X+;"Q\Q@%),/IO(I_.^E K2EAA+1Z_/7P5,)P%T)080Q^H6=17"[BS54BONT] * M9Y#JM@)H61,.!Z%V8E,$'FQI?[5W$J"Z<1DO^+MHM_A=UR*/L@^PEQ^Y7N&[ ML!9\\W5^4U3*Q:^Q.._N91=6^77>*G;JM/;2Y_C1#(TCP;H,-95@I<);IX;K[3FZ!M%=2^"<\H(V4*:ZOP@?P.O59!!G M1=)[HO'G,.:_!KP\!,.%\3O":DX;#(.^,MPF) $WVM@;Y;&U@X8+J^'*)EP% ML,QEA%'8%V1.7(1:;O4?PC_D=H39@@PM*B",/:&$,A<=6 /8==0(\BA?02-1YX/8W83/Q9! M4\$P7"5HG<='$]GX-UX)Q?994=;@8)D$FDL#00@M""RX#82ES!W ; #N@-2U MKXZ 2\"9]!%'L&\6 >6PFB*#9\T(DKN)ZZ+OB(!2";Y[FA(H0]Q,RIK/1/B% MFDB69C2.0@+ [ I>!,)$A,:+H% 8OK6Q*; >B[(B1]WF;\'TR/@H!.B+?V[@_PH$&0>,05?X4 MX?L<'Z'#88VA4X!Y";8]P@T2$A3A/[)$.)T'T)$TY>C9%$@M&7Y%'@/B3V0. M'#PX;#LWP>-$)?N(\<<*8D)E AE#%7 $ 44)X6UA.H =#%'6A07LC!^)T?U- M1 A]Y?\ 5P&+AZ#WX)K=M[BEF^4X=:(/_ GH)H+6_V"_P]KO.H+CZ+!?P=;: M.BO>[RNO\ZO1O) M/07$'3RODCDB.A(C5 "&CB(89^R7@4_KL-<5&GA\,]LW@M*C'H@7"U9?T7,+\!46-]&QB?ID\PT%4D@3+3\60,FP%T M*L+/2>BC0!R7A[K&-?@;/A4$+4@,42AGO\XEE\&.I+]/9M_;<-26O& 8.P0( M7L&:H*8X>:93!@^V 229&1OR((S)(\+B,XW;I\+YN&$;A; M):PWM+K6,H+"6Q2_28(1?Z')U UEK/_!^]:N=B<]EP>Y:I9CC%L[RP+(/%6H M)R>6-2"I)MH+Z %J1<_;@6,1S[Z1*;!,E9$@ZK*F3X&%+@D^4R.Z'I$O&MH6 MQ^,HIG(2X?A(IP)"ZC=W(,T,F"6H]'B!_$Q@^_%\UB\0QDX%"4(6 XH--)^) M.]\D7%L"="AW !V*!G0H=0 =.H .;2)1@CMU(*@5HH]&_4D9IL%/8QO5)ZG7?9BTRV_IR\G_$G?U 7 MPRDB @YD=#(<4BT[@KJ-@2[U8R&WOGCP3JW8+B&(=3RW(D?G$Y3U#"GDIM+ MZ*&N,-N?H/-9;-^C00>GR=P9\5W0- HXD\J>04$)#7*/[%H,1(F'HG2*1SS9 M/H'Z8_JDML4V JH/&V=.T1B/'BNJ9,@\GH1!MJ[/BK#,O_+RM_%X14ME(H\' M1N'[;3.CS:)*'7-;))MC&1K1QK"FKFT<']GVH2-BV?J 4<1@0!:@!Z$Q4PDK MCC8A$3N%(U 2Y&-P"(%1/DDF")A758*@/VVB C\93OM%SSVCBAH:%I9PGPGT M-\FA&?1&E(:3.R#=*7SU LANTAYL'XT>LQT?=DK-$ NM5Y^="8(1G?)FM$1] MPHLC" AKHFNBRST\% "]_IOXFANP>&"%YOR;6U61%9AU16R(+5+PE8&U"'_9 M1[W./WJCVM=%I77_TMU36\<5\T^/U]/!NP;KOSE476R9)V2GPL'D;>7FOSCI M3V ^?/F94<#\A1@6I3FG10&S9WP-3XEBDJ?);.+XJ")TR028LB(#U:;IEK*) M+OA)FSWULSWICI')3>>2ITSR%T%05,5/E$+"ZOM"X/NP?\D<-P5L6!5--S+2 M1\TI^!6P2..9^=#CHSR=.4TG?R6LNX%I KRH,4H;P!GIZF1H#"W5WV(9 PA+ M]WW?A[.VT /01&!G\.V,_68&C=XP7BA:7HB OX<**K 8LF]H\-*()1-AT.PI MRQ4,]E50]0$P/.?%XBUT-F0-A8EC"1B5(;R:L;Z+A^=@>>'QD9[:4P4XW9%T M)NBCN,S,K_D=?(QPGB9>F>O:"2;C>!Z/_M&/NB>P8W/8%B0.VB;TP?!-U_&1 M)HS'DD"*B66,7TWR/#;_ KT"GZPY$@4X'1#_&8[:T=,^O,$UE,8I(X'4[:&[ M(E)A#+>.9RYB2N''FH-17,\5QYZG:P6=EH6QGBLTP:E!G,M-<$T,9!^]7("% M227SB<"W,$=F(39A95DOKW'<6^'YRC*ZRNN!OWC!C")7AU6EF3DY2+0.F41S M;T58#4[RJ7[//#ZB,^BAR83G6HRL&!P99GVBN\;"/00<5]F8UL($=,>W$49_ MT/&1.=P(9NP\,\1[IZCWU+[80BKCQ.!=ZD33]-')MG.UR#+\*(32A]/R2'K= M/;\*WC7!D<^R-0EO.W9#323,TZ5QJF=]YCVUXK*SJH6UB[U3$G/VD5@^P^WK0-2VN)I[S.W]/GE\4,CYE_*X5$S@,-ZXZ?KG,0IM7= G5;UNMBI5JC;8JOS3'5: MQ4:[6.[4FXWVIGWIPX6JWV$21CT^0JP*'-XQ>,(M.X-YZ$.HLV%3Y.K@RUH# M='@TY&0LZ@6X;F7L/!=EOJ'(Q)-^%>O6KCY\T?IT+C?FU6GFLBD:%ZWXQ$?X MN<9=,2I=3=@&V9 RB45-@,LMT]X56-2:O4A[ 5.Y1-(3,YEHQ\Y#=Y?/VZI(]U00.GOD4EL<+B[Z$*0U:447NTC^QMRNLX&$%?5\28*($[Z0EB+A8Y"DL]S-XU>SV1 M@U-"T:6.J JH9_#@L&S68;FA1U2^!PXB>Y- HX4M0.1'6 M6 3Y,4A-XQ/'J :WZ(H LX(54;NJ/X[8NJQNZY+95-)BP_RR@:69]2_8\&GJ M&!@]N'YC^63UNOFK=:\>A]KH)=GLF>72UEH3RS;#F;[E-^QG_K*Z^0,_ 1* MS;P&[&5-+/),,AD8WML*<'!3*JDC KK6YES08?.T[;(! [$48MJC+I#TBQ&,QHD"M,P -!7I!W M^6?1+/0JS!7V(1&ACW-(?1]@H8[!1!D;:R(YTX*$W>W69%S]% M?L)*86T,WYFVKQY2P]:-%4@1OV\!W[0JY]?A70KCJ7X\D3%X(@,CZCA=BGP" MO"E!9_QQ%NTN!2XCH0QGU#QAER8I1W# #CVQW@%/)H6'%XE]S_+2MD]X.:\A MG<^GTVDFF5I/]+-0\L.[CV=4'02#PFCLRI,N"C4\A=TTYEBUDTD13;4%"[P; M$_@2H/ -J/8R*TD"7YI566Y@_RQ,OF#V**S/%,.OSUFJ^,%F(.]J@,\',HL_40865J&)'@I@8.GV\DZNT M#6!-3ST20X_?;.0A]7QJP5 "ZY]W)+YG._=1KUUFOG)EGV2L+0MKWB@<-?W*B9Y M6BKUF>>7BAFGZ$-RELY:Q*-,F--D*FX_(S@N.3Y:29FDEU8FX$CU1OP(#C<2 M9?*2T3)\^7S6ZN>"M$D\N@,=/9GJ%8H)8M(=0/*9;'9)W8&+FF':@_0Z./DC M&3;#B7\/HK8VZ7S;56816ID+KO?2JGPPCCP8(4$/M1[@382]!ER.-#O-1[EL M@LD$^+>>?(0SACQL 72E2-,A4Z0A.2@"'EC3'M5*6OWSK2,W>3X,!ZV=3-U5 M_G&E6-.)?-Z?/3MH# ,W6$B&22Q@@;NW_C MM*U:=%B2L+CN/.THT?"L,;\LSX2'$7]S7^7WI\8\Y:XQ3[[.Y^\YFBLPT^[] MX.1/N=EXJ+8Z]=)UE8)?:E.WQ>A77/S:/3:\5$@YFN"X/[B>@@MT(6% MG&S6WM183I\@">(16YG)J\]77+;#2.%:2U9U2Y L5+FWQVE1S)B.9]-=#6O@ MTGG7:(=8M+,.:IU%IUIBE6EIY;N;PJ)%+RQ]\EIV4,6,Q>8$K'&)NAJ[ 8IP MP>Y:K#@6[%G^XVT_O4J2]:/2D2RL_:ZV N4SJ@@;/H%+H7I\:,#R$ X,CH$) MK$K_1@C,2T!ZY0^07M% >J4/D%X'2*^-0'K!4 9".0NJAH-#J+(7^\1E9Z0: MYAFO\^YH)CV>WWUT/[C]\9+3;B^9?IU/VO=OSQ_WW3'-G/QI=YKEJXOF=:7: M:I,B.:IZ=U_O/!\Z,7?E,''L?GR$V/40MFP)!0#".S@]?,8Q!XED6'":K3@9 M#Q05XET9-R6X^EWIET=IK3*KW_3Y>%,K:95$J MG^>6>/6"C+KORT/7U2^;OXQV15',)R_@6V"?VYM@;]\GW6H>00*#TK"P-R"@ M3K7@S1*WK-I442(5IQKUV>T.KF2>)L.+R_33/$$N(,G.\ U?- N*NWV(%A=X:2\FR_IH%=:$B*.]]Z6'XK/ MI4;J*L<&O]<2J"^ME?".=T5'6H@1VY)262:12=.)#.,UA3=827H5X2[!4$33 M2(UI0[F[&0Q?N-48*KTD0^D:[KVJ5=1Z+GWCIUSC9:@H3%S$#!7%DN#PZTPJ MFU!\KMT]/1;7UOM3[ Y5B\ JV9/I7 M6%04NIJ)(D!RGHAY%,N'2'8ZA(R2/MA:2;@8:1=LWX]- @.EY,H+('SZT-=& M;U^J5AGEPBU@"5[8P8AIC05N-6BR08/JWS"G&F+!D]"#XMR0.Q3%+9MBJ!EZ]:,RT%2P+$UAN8+S>G)"+ M063AQB!2/WF1_HOC(XBT"Q$>S(I._3.?"H+>U?\)\57A:\#.A2%!?35>HHGR M.\+IG<@\IJ.F0^P;GQZ!I2,ZH1_0[C[@5$:,UV^AAS'Q6#;['(Q*=6![QY,Q MGD _(]O%HY1,\J)O3 QJ( T%AP/W)BJZ@04[0PLAC-^=F90DEQ)D@K*5 YSG M/F1G&%T4?A?CZ\*/\8+$SI CBV?=P96B/0N? L8R9BW3LQ BL"*AF<>LS.+F M/>=ZCX_\%XIH!9?"\O#\! C*B]<"/TF.$/G8^.X9#RL@O*,_PPN5Q'OOQT=X M\TCG6Y[N8I^%:QHI4WRT 0MQLC$:-PT^@Q]!\)0!]8#LHNT=8'HWM>PFD-@F M4*-0//,)-)/$#E&E"@A3!7*Q2U&95K/ML)K!]:U+F6TZ3R>3^7"MNT8;(%(7 M)4LUBG<3;_8B??-<%,>U47JKK@"=/Z63IV"7> .OX=8?FUW&/J.!3I[03YXP M10)!P)L6%X*S%^'-/@3'?W!\V,0-@3M!)A%I(C@O51TI&(@Y 1'EB05PL97K M[4!+= 5$>YXB@P4PP8!WX--.C/F3S!Y UD?$HU+ LVNP\^=&E"1XHC^#0+I" MA4-Q\FNOS8'?:I-N2?#GUPW$6!OD5YU7,XMZ2G_I/>-[IX/WV'20AKH6%DOB8FLZGTVE3X'O;M1P%V,8 =FF3Q$7K/U@.E^4H1VXY MJDM;CACY]:952;(9?JP@2',H(OP]1G)&S2,MFPD-!V;5L<:&6I6?)_)TZ&8X^!]N\ M J$S!.[%IF07+3^DDCW-&#BM6:]+BK.,KU\P)*;2\ ./CY2)ZDK( 1X)%O@S MJFJ,P<(>*+YGH[/VZS5 1H2X@W[GRY0PB7OK2%JVC/3: IPJXF&TA#YP"R"P M0$*?"Z_GNH;LESB<#-TY4)^'ZXM!H\Q49>@%=[2D7Y'UZPE>F^-Q'W +9D$M M?<$WH@RWK$M%.3DKU6_.U?-U0&^9=3Y$D98IN9"9#8-K1.&K4O$:F M.5JF%5MO7(@^6J!8_MT[?V-/W23;D]"[ )N0T/5?/)]3$F7AY,^U]0K-M$:V MN] %IFB !G-:[N(LC.%YE>]?:6)9C;D6Y$6)?-P^%%/-3._SP^Q[4([39Y=& MXF$Y'>*YW8T[5O[9ELQ9@-8P]GP(7W=-J"OD B)BTJ(>(I1.D M3@0R5 A^$C7;4.D$Q>);?#+WUW9_G\ H: CLVRMLL379_(3?(WD:([%C+ -5 M$F"FA^D9/55S?"3 $AD*O47P4^<(T4+IZ54N/*R;L#SV%M6A_ 1F#]6(H+H6 M$4X0[J'QP>%)^0M$@,2ODF;!%Q!V= 0+JHZ5L/;U-Y,[[8VLJ M>@&ZH>J<1'B;&'IK.V09TP&6\: 9-Y@+1+53L##*,>!L.)*$,4JJZ#/9C>GL MIUT(:DZ-)EU)Y(!$ NX@?0,PEP)1K\PD8;M:1@T%$PG=O0#1[JNPAFBD*IP@ M\!I1)&:OZ5@9@PW#HJ8Q)0FLYH&X5K.YO_@YL)>^3NJEFCT[RQ9EWO0.T6_L M244,P!:GP-_EW]Y3S[67CFQ6>)_;Z8 R1HZ$VF)G>)7->\&K82T X=6VD8)$ M6#' 5UZ4?P2V3Y)\VE86).1Z--"(UQ<7Z93OS8.C#I@7-$X5 MT3Y/%N.+K"_:01&XE6@G?SR\9; @7ES'62:?Q38*_)&ERKAX%_Q<)N6G/^VN M(W#;0UQIL3@OA]0 '(XS$($OBE(QXX&H6@;APMI941)148QAV'1[!8N884.0 M63]K[LS_EA0H*Z!W<(S( :.JPDYWLX[=6AJA#\<;6T8D)72;;$&?MY=,0(PK MH*-PP?/Q$2J,!UI/IGIB#\[8$U0(?41EDC_T+UIU*6$XWZ?_2MC+,P#Y1'CK M,L)'AI2J49F-V!:P!)SSQPO"$"EQM,D18 9+#&-=P:*@2$8(T/#%+"EK-]SE MQ2; $L0$=+/, MJC!K_8WU+1<^^&YSBVX#"B.(WW#*6!P'2'$TL<;/&_1X+UE#GAO![RW/7"?]W39H;W^!]*+A)U0X^+MPO3(%@6$P&> MCM)8PEV(N#E-1GX*,$Y 8<#F.Z4OH 8NPP/T:YG"HW+-QC1@>#Z!Z<+>:P^6 MOOS,_$(OP?,W@6>KSOSC3-P&!E<\&2FRM<]+[['#"S&J;BUNU/%1V*@8TFL* M5^(L"7-&O<"[&P@R"<*MKAZD%JH5!WK2'K$ @FBD^\TG=K?EI5V5Q^##,G*, M>Z8_&7AA;MG6WK']=Y=6BR-F!NGWD+-AU&*Y3X"7!QIP/2;X'PJ4/,0MIY.1 MBT< 3Y*^4FDBXU)$.&;0_.=/UG+585N#>;>1P-G006C%@:.XKEU[J (G0"&W MM$\ 5U\8:^8J.78DCED4!&D3=21--&>]/=0A%(O@FZDP%RZAA('"?@8B- ^K MWL3N!,=?*@121HVOQI:&+ _B:/)6"TG@E]^ XYF0.CA(192T;I;9SPJ0A1G M;0(G-(@HVZS =\) KCY88 @Z M&)L$_ DTZ\SV1+ (4@"H/Q0.'.( ,_,POWI\9!@ $R='7SD9LZM,)$AL'9T: MVA+<#$UP=WI(6>K?T3^%+\UD:@K1X!% -2'.08GMFA(KX^06+/B!J0?(_-A6 M%WFX+"A)VN$R:_O M^PO&!C_P3T)1E$'/B_T.S2$!5UPGU%UN\+Z*?Z"H@GS M@=@O,>HW@.I#WLP4CAT;LN_PELRE4*W_!AZ0+N2B['<=K_C_!:<8L0=E^XOI M6VJ_P8+!BK5)%Z]3\[@<01!'M@>@*PZ6DL!)@6<[2P;0,\%#P5>Z@.\U\$\# M#: [HZ;L#"=D(;*""FA!ZN0A37_YW,UP!-#7]GIM",?1>;T?;/VG^/D+^XV: M5S(8F%N82C,P.^P%#WAJ@'T@V,Q:QJZ;8F_7T[!#G.-VWC0A+))X:#>0B0"[ M/8"F;57FNUCF;P3$TH"!6H*B]EE9G!L.GTO6D7,"G,5/G%K&^7/KM^ =-F$5 MZV]LG(<@7%"NC%2#0D :O KP3'R]0%X*^1$K(-$R_!.+ XP(OS ^B3YJRW2S M4-);US_P\G@DP$L*E-GWKBJR=B483&N=D4$JA@3J791Q9$;\3MMPVZ!7PQP\ M]I5T ?*H/8+7JE;%$Q#4PE@O;'44GOD!M0B4:^AD#8V#MQ\A=LL@/"OPU_ T M$ ^O?311X3TZ\D]Q<9)Y[;(9L3Z P2_J6X-@?,Y[FY)UM@'DG1*L48'R+8#C M@Z=7A.-#,;Q/:69^Y!8'/L4IJ_)D-G=-47N".)Y 7%$9#ZJ+8=AX+)="*9H; MY+C;NV;)'&!>AF&+)#FLX\*)?=$3,9I1YQLH5-.+U.AP'3^+M10*Z3AT#@+" MDX9WRR)P._2P6P<\,Z;9ZD-=]5'K!'GJ^,AG\O'^75GMOLJQ=#L'PM,XNYU] M/GSH=MZ.U=!1LB#ZC2V[7=I4P[,_$$IPPW.>3J[6!;@8D.@V76TF<^WD?$3.!K^(\(@6-#R'*#BTQLW!#<\^,A]E3V )%LEZO&,S/8$'MW1C?8)^ MQF83?8(QJYW/WEV^,'U4VV^^4-?;ZQ&,4Q?Y=T+0AQ[!75IVI#V"?I)\Z!'< ML65OHTI.*L8PO3?Y\+TW$(L7E]#'*&-\_UE*-MZF MF:P)753B;K$)MC7KM-@$)E$VT6+C9Q,/+3;A6FQ\ M?8IP+38^7P]HL:E&T6*S$?W0NY$NVXVR]%#@M]=BL[9NV6Z+S9E/C\W>6<+O M;L!#E]'[*8Q-EM&/IPKUD_&MHG<'*!%7T?NF>[VJZ#W"I4,5_1:$-7R37#9Y M:)*+IDDN>VB2.S3)[8'"^-;]*\$ATN[UK_BM]V_K7UEX;H?^E8.O?^A?^;ZU M[(?^E4/_RJ%_Y>^2^4/_BBV][%/TMNE>%J1Z?/3;LKTL?FY=^%X6X,0A'^W0 MR[*7?AJL2JZ 0QKBLF2O?A;:VL\"N:R.T4.)-HIA:;/0M;M0UN MQZTK\/X MZ[03%S7)1>/%V_]Z]98?,EXE2PH7I/;X36F1986=J6L10J?!A2: MT1M0P$\;*7,PALJDL@FFX%_^MS@.A/H(=Y?8M;"3G[(;YZMB(U_*B]\5;CXG(UR@[WF'_*R5]<6UQQ 5,BD$EG&?TJ7MWDZ.'.; M;Q<*G$GJ;!?R^?"A76@[AIE,1D[2!=LE7GE3S4+^1?O!S4*%54>&+9Y!.TSU MOWKSR]%]C=UJLU#!:QI81"-H(VL6"C$=T4?BHVP6LKWB,$!LAW.Q2S0&^9F5 MI1N#_ <2!C8&Q:ABE/Q-J7M[?5FF \:R;ZLQ*$Z]PVAY^C3(\> MUM^WWABT'<-X: S:@65W+#T@?MH'E;4J,I NQST-O&:!L[Y07T@/B#"261[% MQ@/6/HK,VL=!QL+#1@B+7*.[F;H,U/*(:&:H8<@T=\$/D,RNS\RX%=U9B62: M%E9&2,VCBRTTO=[[QABMPMECX?,VH-%8RE),1&ZI8$T14&?BV'EGJ^"*FT7* M7H8=('X*VU369I2M5WV,1JKRR4I674W]1.H5G@G.@YC?KP.AA.!%QBI$"3;* M5,!''>5H2]DJ_QL]L#21EV9&N30L*IKA$B-2UGP*"ZPT#=W"F00HD\OZMEZ@ M@)J1 (5Q]!RB;RHPZX/9 G$N-#[H418R692R7E-O$.>@IG;-?PO3O^@?-KOZ M%X$#0/J38G0%KE/%JX=4;4K7=^7V.WU+ZZM6_Z. M$6$[WQ)%'UJBHFF)RAU:H@XM47N@,*+O'/8SU1OM' :.VWAVBAJ(4_X=Q.Y, MYK(=Q/ 2.& ZM>\=L%<'L4=>=9D.8N!6D3OCV#N(_;:U=]S_W85V'_L8%V:. M=JR/T6^]?UL?X\)S._0Q'I38H8_Q^_8T'?H8#WV,AS[&OTOF#WV,MC3S-^QC M]'/K#GV,.RSVD?IIW3_HGAN;$LBFSE:7.JFCT*A3V.C(X&:6[J&A90L-+0R3 M<"A;E -R7F\Q83L%P2K0GW!'(*-?:,&?HNH(O'[1,A\/%Y6VTK/4NCE4%DQ_ MA9QI%FH[GEU^C'Z+A7^*K\NO4$AD_QT?PS: TG0--L<,>3FH52N!3%@E@']?4U2@@3Z!0QZ?,EAOVN)V^8JS]^&(P^6W.QW0_!7 E, MFQ5YS)LR.\)B27O)]LF?="*?]V4N$/_)E#[4%7LG(,"8H@*K'ODL*Y'0'J7% M59@'Y D]/=A*KY"I363R;3,3B ^$L% 6^#F8A> DU[G:?[L:W.G7$Q&D$8^4YAAOV;1=TOH3\A4Y>+_6VSGX-?1-07I$2)'-2\FL^=??&-6 M%P2[[< 9SE ^+'JN5X>.3K98>VZ0,G9M/D0BBYMFW>-$>[;"Z=8()Y&;O^S@,K6PZ,U)Z2J*2IHM(>3+)FSP3$*A8L-;7(9D)*=[ M>>F6Z]S>7B\,4.)5^04C75@X!7O3G5O/9:^7I@RAB-T9W4+"2;-^!X>+*X3QH 00[T\C+QI1"J% M_K/#\]O6S23--!M.@X^^,FBWJ*/'E(@>DBGET7"1R7E"SS3H(BC MNE+$$<>)EY7JI:PFZZJ\_0NM>,[=%7)D@G,ML)+DAK7(+ZRW#Q3@W*H"G#&. M,Q/1<=Z^/:N2EE7O"H/M"G#&.,A,O *A<$.(9S=^<,#LG275CV2LY.V0%Y9:)1E/6F*3,,LA;!T@M,X!H% M 5R'G_::3^K'%6^($%R;I7$I$1X#-_R.EC2"$=]9AQG#K![6\"> ;LMX)]=G+?K4DKOAAH=0*[6L0/JY-GQ<<'4J-_WRGW MWL;UGIT/1&--"=?6E@,\\]G3ACC!RQ5*Y?PUZ?%1Q]XI"]8ZD<:DI9*2%$VC M7/U]@>GUA%OKJ],4P'>FR,!0QU@6"+4NRG* @689SS0CH\P!K)Y MX95*HO)2^F!"M]%4%\Z %E<--E*&,$765/?^D:2[4GK09+8<;:0,.8RSH8Y) M9,)5]KH@P24(0(-09H*2/Q&52D9XP)7TVP-W>W&IWO@GRL.>. U\ MI%0.'OKBTDF_8FZH=U%O_4A5.$'@<7B)UNW.Q"!_Q0 M^$OCB# *TP1H6W@/XUUVE#$;?P@#WI(OV*5K?BE6L[WAN3@1LLY"(^,=@9T] MCL<'L??*A(/\^]WG6RR!.\L<<&>CP9W-'W!G#[BS>Z P2L)X*@B6-%4>QS?( M-ABIJT(BO/==6OVN+J^G*YA"-,Y92YJ,,_WB]?E5>NN7=7G])["Y>)RQ5"*? M2R;2C'^!?@1U+:5-UK6LSQ1.0(MTE2]]?"7[7YG@NI8=+6OQ9Z7HREHRB70J M7#?4-_&/=G_9N+D9]M3DE]#$Y;":&/T1\Z-+ +-,C@A@ELE'HY7I]_*$?N#. MZ_>^%^I+B.#2&_,3K.PIDS-^RL>5(5DU0:('<$&Z.320S&8/?$V\CX'\F/WD M%,Z77*WG'_U]HN6$$NV(-^TOVWI*.&OM*0K<['I)?"8L'HN7 M4X()2(&E:/C^AJ5ZK*CB0BK/V^[HN4E7ES7P8E2$1QY_76=2LYMI,;*Z2;.)R"#HVM$Z"@Z:3N-=')J,ID.L6ZFNV,Z^,OWYN8+2AH.JE[1."G M^*JB@%QE$ME"K/W&S$95]-HLXE#1']7,@LZNJ%\&I /X91T:,Q ;TQNFC:JOFD:5GU?UL;/7'=:>KAR(,SY(&*'C$[7 MAUT'LF#4?X.?U@1;SN42N>S2E]LVP/38<-)=9]*MU=X&^:N1/'H+<2;QPY.O M>A2NP#Z5R&6RAZ!^!Q2/%6LFG.))K5B;8\"+T YXD=6;,N?ESXGXR3RE%LB8HP#0JR-@@E#=N''P@%ME,@E@'OQ. M_W<8S+Q5&D%]SVN-.*Y_W2U,F'2IJYIB2QG+6:ZD+I)64+\#C#J$2]'91#ZU M?BNH75BM;:&:=U]H@,N26ZTQU,$7\[8TN>MWAIE^PS&ZS M\IUUXJ4YU7(M^[IPOUL6V4(FE<@RJR3&[2*[?88@C6'H978(93P=M&1YN@%X M96,0I?-1NND/FY6&L'\,0M"9P^UU/:9)P?9B?RU/AK&6?(:Q(@;Z+C$0H4$# MJ&U5Y'0^(/_TP4.%(>9880S4O1-*T#AV!!MM@+8_L79W6:2=9&NMB-(>5](= M\+J2A)OQ1H8XYJ$XZM*P^C-?YV^7\EWQLU?D:]+)KA_8?]T_C6:G>GR4^=>A MG?),Y74NYM6/]GFVVJM+)W_*S9N;9H-J=YKE*ZIYVZDW&^T$]5ALM8J-3ILJ M-BI4J]KNM.KE3K5"/G;?J'?:!C]L"!SO,/?7[ZQU/$.,8$@X^W NVSV7CA7V M#([*Z\O@KYH>?_=$F94Y6 2IZ58<3CTW+R.,2 #&\)*$;<2*1JP MFN4+PM<(HV;TS%I4,KK4V"-?Z\X0!<&:!)S*@,]!7_TV%QO1V5+#$>,& C^!%?;>=U]6HU@$ M3LTGB# Z,.ST,:L%6\W'V@]_G=^S[T^7,^:9ONKMO'U%LMU3)$F9(N$CVZ>T MR1 L!(DYNI@=P.M$S82802+U?_^_/$/G?FMVF?WWFW#NSB_;X0^5TJ_S)-=_ MES*E[&TO;; >+VHCB07/!W(HD,>L^LIV^:):N;\&_EBS1I4OBHWS:INJVWTN M@XYVY.'ZO$]0NW5 :S=NYS_1N[+'O*U[V_Y/XS/P77"3_WN2/0GX M_.*O,\;&W5WZ)W\>!0AZ(O"K/GM;2X,][VN27?\>81D#=0$A,IPL/)3PJ Y> MFR-JGK*,^UE^7>MNPJ2_Y]>]5UX$=&;[PC96N_+3]HQ0$3#W6I*':X;BD&F] M_">.9[>$(2O*%D&*\N'%?E\5^L"[WSA5MLT,S5X<6T;#Y.)X+LB9RFR7*MLT=LZ:YPYGA;2KNU=9]*Z@46OO^+?U:[.WAJE&YP?XM M>QT^"2W;(" !B^FKRD3F85"BJ/]2:K_[DTFF(?Y:@LED?EGDWX$;ET$]L5W].SG5;9<+,][(Z\>%@^?G"H)(.B6T4^8=">.?1<<^U9AT!)WC[MK MQYZH?LFEKOM]KO+RB7P^DTAGO<:M>O)+*$:(D,7^Q^>A?@<3868GSZ0*OX-P MQB,\9ST:)E&%[C*2H<'>_(YA05KP91:8D!O@) \G0_U.^SXS&16'%]?M@7FG MK3^=0H^G#.VV0#0VQ_5!U B2!00C8B- %*.(F;3?5?=I+ TFL7('^V7ECL[G M<_'FXN&NV>#OSQE&RL 2-78$ M=N343U&F M9@*K:K^LXI(PY>4D1(U(TI@(X&7C3S6!^Y>?J/ UK@NNS=/RY$_F+)-S%<*0 M6B!$B]V2A/_Q\%=CTMM&.@'%/;JF=C'=?6TTT4;,6Y(VP96,C!1E/(1"3_%6 MP[OFM]IW[J65Z<*:Y:J);)9.I)G"[GNN)I_5S#(L;U'%AJ4X&0\4>(7*WT,\ M>,O-\2TPMIK-XB$+;Z&\7M.U@LLP[R?Z],A4#\G-D MLYY7*5Z!"?2'3\6OTX'(\P+X#-@;(WYU58E.9O(G($;W]CXCYCP?:Q^>OMI2 M! XT[Y[$YSKRE)[.WRXOWA>'^A&>03:YL3,(+?VGN[*0C2A%+]9,6@;4!+ 2 MX C$$%8>%'RD>Z)QJ4HC.7Q+IOQ#9__D4O32GV56Y;Q(/:'%ZMW ](E5P2\/ M=.0Y0Q$?=O?K\R8_Y*2YG U0Y2984UT5F#4,3+?>M[&AN+Z@0OD:B&KW-R4085%3A$M%WS,@BP"C5;F@A,[OM MLBFOF1F.??^#0?JE]8Q3]!O7@Y MN;MZ_Y">^# &; E."JM*+/:S?U3]B5S/UYNMEW/R5ZAJRG:G<%MA M)]5"+O>-Z^7H':FFW'WNL%=3%MO7X]2=RK/7F;^%.S983;D;1O_[UT2Z I7J M[55)KH^T.R8@WQ9W361P!F3G:B)S9[GD*C61&PAEHTS0+:QU=#%3YU:XE]^K MI8::6;O6<;<+')>L\G(5..93B4)AE0Q=Y!Q3WJFJ15=@\/;V,OT8<^GJ-+M* M(B4:%MO).L-UXHD0AOF0&-KU=,-A-?NRFF]77)B-M[C0906TV_YGA::GR9N@ M]%"$Y47YO[>XT$7\[&.M7/^\8*=*;Z/%A85#<>$.7I95UBXN=#'8XWOUD>Y< MRE<\OQO%A86_OKBP%E5QH>NP>X_"YZ#!%>G28-WBPM#'N?*-9R02$W$AQ+)U M?*X3>*]UJ]Q+_N)S+FVXCJ]PJ./;08U>B*".S\5D3.9&X0?";>VMMRMU?(6] MJ>/[3?E@#WD7AICJ7W_@,D!*Y"O+@2=ML/DHN$[0Q7@WE>I8>RE\/>6\YNPN MKJQ9C@[+L2"=#'!I0\!3!FF4#1VYCTNXW4H_%Q.4U5GIMJ[=?F9"F;CM\$* MD[D?O.#]\I6(YK+"?QT%EMC'SI'!2RG0:Q=5NJ3Z_D62!L7>.?.\TEW EE5_ M0!"RTBD?DNZ'U1Q6LSVGW2FT#-:M ;6:S"*Y9U94S^A[%*],NI*PE)]>C+?8 ML^JMQPO]#_IB^#R^ML 6!A=[5LD5KJ/2;\ 4X8U5&GJS?J@Z5+Z14@=?%Q-6DM8L>LLB5Y&CS$=:2V!L?D&.LO3OM5;GV?4A*;CDI&67[L^5T8TM*SE\N&V*O=%E]#M$<;Q6+S7'VWB8?EP)Z MW HOV)./S53GHUCJ<(7AX'ORPB')^!V2C*XBQ*C"-PN?>8=O*R0>NS+[^/(P MN6N,UTX\>DG<1A..&R?K7YF$=%UKKI'XM9#>GG6C?1WDNUI=*:855GA["Y&% MW*BC' LA#OG'59BTX,@_QF_=]8)"S9=SE:?F8Z-9''>Y[@I)Q[@YV+K22_"(R^1.KVX&]B$5.QY!5^R)8 M"_QHTKZ\-\#G8F\6[9A:O%=BND9X@Z-=7S;N$CP^&@\$9'PI 3@ O!NZ,$'! M3T .9^49',E+YWYK5+G:-/M^J,!8:?G&1/]AJAVH")J]NLR+GR(// M+_%,> MB$(//(2;C,5/\*$>D!U5CX:TF5;H,8-TY8GVR!1I:#&61J9%!BRFB0@HL G8 M1VP3$[ /IL&54PI>>H)B99X"W^1$Q!@>CKMA-,*2HZ4_+8XC_GJ;"*-2F9D7 MO+#'K7LS=Q6LWY?>UBZ<)<>+^_]>><4[W6A\KP*6_7M/,4 @S'6LDH?7U^[2)!&L77VJ/315 M;= 7NF'6OH(V\50(C*$0]+0G>_$TOG/B8@*!(+(\FQ@N3G4P"B+/>A>1#'FL- [IT6\51^8.& 5L(7 M)TUXX<]__^?TE*J)@L3_2]V"B/,W>-C'1) Y\)!LBCH]U=,-P/:&[[S#VS0^ MD44)7Q3U4;"+CX2/Z&CAO\'Z./W?]G=PBB2Q(PTL1O_I-Z5/T4TF?WCEE?TO MZ,?*R"M&]:D!X(!>$%3;ZT[^U$ZM!--)]9OJS$9@!465[8K<;ZH!I >3LZ% M$M(%Z[?^T;\&_V2&QGI8_-\_@-1>5%<%]OVT*P"A 0\?H;,B= 8;VR,BVPCJ M3!!X4L%*/$A53#@+%Z\JCE[G;:5I$F8U',QLN;WXBQV4_[I_@"T8*O+Q$3:! MCZR*D,O^^Z?[)[+=!)Z"U_'%?S*KW=" P) =006CPMI8AW7E!@(_@1$.HN1 MD8!0:M6/B3B>-92QH%.VJ;9@6)/#)$UNZK& KTU_UF:]SIO<&,$;3*%'VS&%A*S\E M)/EW[V0Q8A6R5:&S>_SY4N%U/AP.I&*MVK/F\'E1&TDL>#Z01>'D3[M\4:W< M7U>I9HTJ7Q0;Y]4V56]0[4ZS?$4]%ENM8J/3MKN$<9-_*4,<_HC"F>R3<+6* M"\"-]-,-4Y4)E@'W_[\GV14!&O27Z9K)6B_N]>K%*V$\8:B,]Y";EO^Z*O7/ M'_TF*8XW^3]J@WL(7;\:!T\P:_($R=DU>Q3>*4Y>K4O1U=9B7#7BI9@7CI:E M;6=EWO4F>%FPZF0[JS*K#/!*S%H#_&]T7[]G1QEW,3C1Y*G,CT"$BJ3S6I9\ MC_D17"^@&XH?2U5VEZ+(_S<4&:> L"MJ9N#\IX_Y9_+0$V'D[4C=$1.BI^U8 MD2\5L[?T2]?KR@_KD@3E97<\IA 0VA5^K%KN$C/5@L9?&*DX&X'6NCY(,8ED M-IU(Y3(+:P:6X;H(^=E5$;[@!!T9YTP$)3&ACB_,O(UU12%4[?B0JZE-N9CN MY^G%]<(+I":6JIFUR;F\C,13=!Z^YKSZ%W"AO6I]TAZ,U/K]RT4K!(S]7\6% MD9:[YP$;^M[^[H@&#WQRH!J/HT[=V:.]*=[Q*Z';2M7M7N*X[HRY$+Z+5^G[YF5\X3F=_*'/LIE5RM^W[D&9P4 R2BE8?G;= MTBQ=R%SW>\,DS7Z*:\^Z6R4$B(@/5QM[MY;?[RZ#3V3I="*3S>V^QV_R:\KD M5YL1)CY=9'QV/4OE.@/^Z>.36;U:7?^#H4DT MX[F^IHA<]:6KE&G ?CF?2N58Y=*5/@R1,TS%&B(N.2!P;?;]2&FU3C5_<_G8 M72(3HW/QAG,OX8FS<5ZVNS]TZ*S+M@S-8=16U1HTT;FE06[^ MT3KOA_%"0LUR^[EQ1V39/LH87)%D(I?R:Y]<) V_(M1.E5B]C.4G5Z[-H?E> MNUH^+WU<];-+.!I1#AVDLRN/DCW8X0WZVSL=_/J.@[2PK&.FE7-#VQX(Z0)\ MCUJW&)VP45JX]OM\7/QH\V_S7C@+%^EDL6W80H.,6[.&N60A5/%/Z)EIO[8D M"S[ \;%:6,1_F[.O]SVNW4Z]:Z76,H'\E@;P90.&3^_'F,4E8/<.\S;_CGF; M:PE.%'L_7)0=5G-8S?9BA>6G4-*+Y'[C"._5+?4!^*.1A/1_QK3T\EF?#F]H M:?T^@)W"C5^W/R"^^ !P<3[K!S$4@K%W&3=S/4YPCS33TZ4]AUY@&!!Z=\NW/QX,5AV@QGMN=':>%RI/);O7GCAP(PQ MID:3^5WO!=J5VRJ_;)7N9D264\R^%^CJ>?5J5'[_._-_NJ/R!\2-?K,Z=X4[ MM]8@5EBA06QMUGS.O_-W3[7AK1"0[HZE02PH,;)X]QOW>9TI$V9Q\N[0OQ97 M_]K:;%^Y$:O%Z^N/*X;_MOUKFX@ TPDZDT^D4JDMMZ\5=ZQ];6T&O9/IJO1V M7^Q=<-MJ7RO0A_:U7?$2#NUK6VM?BQD]G!%K>17:Z#;6T1R7!J?W23JYZ+>]#!5L@<.M@.'6R'#K9# M!]O^WWL?5K,OJ]F]#C9F1PJTMSG)IAJ-_W-Y(6:%F_?)C'Y?MH.MBO[S/=O7 M8HP/LHE<2-S)O:O[C+1]+5XPJM"-0]'(6:A*C>>*DLLHU^SD?)ETGX=([E'7 MT!;J-'ROQEV]:SLRJ2E6%K379^2OOY+=Y[NA^IX_L."A<>U[-:X5=JS$!(M* M=!4F;>'BXYE]KU4^TY%UK3GE^:^J6-'W3I]E_K9VM?2FVM4BBF/23*>>NY+N M'LN])=O5H@ECPF5PF>02&=P]XI;S+:K:4025ZAP4J:S^RJ/$ZZ!9R1)Q$[=ZUJZW+3JWW M(81)HEK/)6[;LPDZ'C*HNYE!C11R(H@-=B:#*C:NJI)09L..P>+/(FAJS:%\%:X$>3]N6] 5X7>[,H715]KT0SC/ &P]K M[0DE:!P[@DD[%:+].2K.N(' 3R2AV?,VG^VQPKT3?0V5)-;RFC89XM]U(/4[ M8!4E"7SPQ$;S@FT(5J0O>IUGGI.*QKUEWU+LSA]F>0"-HG9\-%:H\4 *D24 M1\#[ ";@B@17 +[#F@5!@20(U <<(M01ZU @UL6C@4^0K MVK].#A[M^EEY"][.+SNN("E?JKW.[^^^1KEY::Z^9 Q9XT5M)+'@^4 A@7"@ M7;ZH5NZOJU2S1A7;[?N;VTZ]V6A3]^UJA:HWJ%JQWJ(>BM?W5>JF6FS?MZHW MU4;'(+/]/X3H2+-3L.&(F B$*0K_#3['Z?]>^F"(;>8 A[(C#>Q;_^DW-17Y M\>!?*I_\<1+N F-!-R@'Y!.841\/#9%^B@P[?)[$^WAG8'V0,/][PISX?M7. M8/I[GT$8 E/N[@;3X'?OQR)#7S.M=4K+- AY$&&Y/A]]*1$K'..QT6F)[A_K M_=I__W2MXDOMP_KQE:!MW5Q%,-N,@HSV.)*G3Z+$BYAKF+:W<+[$VKV$M/LJME1X/OLKPR MH[:VH5A(2SOY&'9K[%>+H7:975TD\L-UC@LWUN@;1U6:I5\ M]+8JB^)3%]G-*K_U?7*;&@ )+8/9O^X9-L,4[H4Y$ M?21Q/',NFSR#^1%\3T(^1O]8JMJO%D7/=-"!/1C[:K%CX74D\J_\Z'5R.U&] MP6/F]6G^[I-+9<%3W7QL4NG$N6\GB>/M;0Z_Y2 0)'M*//R]A@:8$M[A,98K M#DC1DS_9[,*KC4!&^;$![@MY<+%9XLRV>7XEVUR^$_J?M_2$4X/E8DR28. MVTV:\.*GR LR3\U$08H<0IB.6QXJ9/E(&CP= +KST&.>J_G[^ZZ;N>V[CP!< ME4D%= /&&X7:)K1MF.I.M3,76'EVD;J970R8C5 ]H,9H"WZZI\BU1.W]M*<* M\&8Y6+CY:(X%)KN0JW>2=S?F0"?/&-_* M?P\/.C:/(5)>L/O/K5R_=2,6&]JG^*V8(7H/.GF6"9AB%-)\._WFL.61Z=?Y M9^LJ,VMWQ(QAXU0%+*.OHV^Q:\EIMN:E$/I=,I!E?F=5W#/;.H3<#%@*O!CH/ M'2S':@-)T,SY%?"#L>1,PHR9B88IG'.66L_MB_=[YF[D-7!&+TPUYW=L'ATS M>)B,/RM%U]V=2:13?M-$,1L1.FEG>Z?N]E1+UX&"OF%5;H!ULU4+:XKDUL'6 M*\NRQ&I:LT?XHZFV8'R >;[9:PL<4&9C4=#*+$31+\WT)A+R0>U5K!-13-D: M7%84P(^;IU://2_F5"^-K#-62)V\YM9\IKPG4_&@)M!T@O%%3; +%JI?_Y\@ MRWJK*IP@\!K4"]#T0*!F@Q*Z14WISG$T9W=S?RE]WJ1O[PL%X^ST=5 ]L!!T M; @RVCS+16<8O!$_)9C2_=_U#RMI[Q0BY^1K0U'_ 3"-QE$-V$_8*!$D@OIN MBC*/.<_2Z GOM*&,\5_74NSA@CH=9A*LNE:C%#+&N 3%YOG M%BDO6U>9R2NZ6-,1JZS;VTRWVY0:M\\%-RGM^UE)82W:SH;45-C^_^.C$5#6 MR),\V/\-+1LJ/A"B3:0950#67U4F_0'X\&B,JYB9]!+Q67G5^"R7+!!K4F#2 MT<1GXO#]B:Z>2^?#[89GN5.P)_13X13L+9[P+)_*)^B"U[S2R((S5YEAO,'9 MNASA1,^]F7XT2[?]V?1M7X,S'T:*T(E,Y).'X&RGE@V#LR8W5I F#JN%:RMJ M83II)+R3*SDW'EKX3;F[[CTFF1K7W:H:II-&5CMI]6VB5<,,D)Y,(EOPNK6+ M3!%'CB_?KO.;%$+,T9NA7%$F!%KX4(AD#\TPFG :FZC)U M.9$%I!@2+DZQ@&;JV1<;3;)D+/-II+KG^T#/[L=OC/LO"1Z9930FX.Q ME^RK]#N ["E<,OX)K#N.:"09T@@>'Y%]':SAAI;=E$G&*)<@;+_PVFC%H(1) MYH E?24_Y:(QAQVEW^CVY_V/YX"@1$,(''$:0Q#09XR??EW=*R^75R:D(0:H M"Y44-]?F@P<7!^G# BQ[W\31BP4%57=M0$ZZCY]R_28_'M]X5338W,8$AN-: M46#L&]J0O+@OYQ),L*0DT'73!B[$5SU#9T7*6^TJ>]\2Z8G@\@6V5F\^#5+Z19I/"^!<8TR7T5@PAS+*,G?3I*7;)-AXY>9F$CM M$!MZL=@8X%]PC;^\';Q,R.J=B)V!@=8OO[?IMZLC+R:ZP-Q M4&VO._E3.[423"?5;PJB[?]+%56V*W*_J0;0@IB<#062D$E:O_6/_C7X)[-! M26].^N\?0&HOJJL"^W[:%8 2! \?H;,B= 8;VR,BVPCJ;+#VI(*5>)"JF' 6 M+HY$''<_;QLQDF=+T,; @T((Z,C!I>Z!X=0!)_()7+3 L0$VCSS:-[W.LX7,53WUH7U(F76['*,\ MNSQ$]!2)RYWQJE&M0@C@GT"Z,' MX?_+]$;D[I0M_,F74J_SFVZFPH\N^R+/AT'8+U\4&^?5-@36;U7;G5:]W*E6 MJ':G6;XZ/KIOU#MMVZMB."?[<6T-J1^;U"A X%WA11!@A =\MQ<*-4Y5>CUJ MW2<;4XO^ZZK4/W_TX46>KXH*)C\."C5[<5#G'%5K5'P 9':&(*LAON/TR[ID M6^W=$$@!STK;:<(N^:PX'QTW@-E"U-,2*Z$>08^!Z$F4Y&*2=&&C.*BY*"K% MW-,<@3^D=H![1&9(-13Y$WA# J_//F][8YCXS9#3,[M>#J:>0&R^?YT+J6+Q M(NM5-88%-4&UVO?_EQTI&O#/2@)P4="4S2X^EBU#JRY+1<\49I+ HI#,LS_! MUIR"SH0:@;XZ.NI:W.XU!=$%A!_O$3E&!"(C"&V@@7X3BPQP?'V>?Y ;#[=F MY9!KIJ)ID"G3A'P3R5A(]BT(C?V:)K-X!F-HJ=D<).!FAA L_N F1R*LLIJM M0*1"R=63#GW(\<)NPJ,N%&,DKEI=QK?;T:O'SZ?K>NOSXZ4X$,.Y"(2:6X![ M7))6(<'2%BJX=#Z?3N>2R\%#NMR#-)/(^5[^QRK<7I9_,RZN_3P6F__(F7OX M7)'>GK(WJW)1,A:IMV% 788E6P\G#\P=]-<[B$7SK1@D@:)V<]MR9F=8KLA1D8E9FX-T_(K0JL2 M"1C@DD>Q!:NB2%_)CVEQF*SFUK$JB[D]).)2*DEO!4!]-=_\-^4SB]*J7($T M] 1Q[)ZXN\P,TY4RR3N1&ZSIVX_/[R\_3-A!D;__;'@UBG@H9^-(5DS1+\O3 M*7^>]F2"\.FT#?&0EX;C88;W+JDPB['W5!K)1J1V]AXJ4I9]S;5GZTEJ-<6$=LVCIUS"9 M?J>9?;7[IWCE8)\S4+%=:&PF?/>XT(A4SB;/EXWKV960NJ#_A@L-]^3WL%FG M++.6";C,6!U:1K[X3;#]S9CXP+AL"4AIB[O7)@2E)-S MWG3L2B9N,]?OOCR-:M&9Q)A#5OH MK-"O+8F.EZF,9,!H+%EX5:9?A8O\P\,.&,215G M$YR)LR7INROIAH#<6FA;LIX)28;.K7ER_>H767$)C9Y0_"H(:UUE?2\!6RV?%Z_L+9W/6TGREAY:FWV=MR^4#[8WNI.5M=NY=ZAC M?^=Q5C D& :]@8/(-$H %.+=C@AI,7/.Z5 %3NG+X(&\&PW*FB=U\''U"\J< MMT,[?WOH#M_3L[E8L8P==S;$"_@)R/4,@>?D_?Z(!]Y[P&ZF\@58=.8/9"9[ M$"X3CG#.:H3Y_)SFJIV+4G+(;8-PKL*^U*.AY -TW?C2I(+-SC M6$'L239W? 0^ C0F9:F9.J.*"/?)Q>%VQAZP'@=3,1'/O>FB/0OCCE(26H98 M>+,X]UZ=C%Q<__R4PFD5[F(+WVBL#F MK&5OLC*&'SP^PI9V,^#H!POB"YA^P\ZHE-_Z^BEAY(4!?M3=7ZE3?!)J#Y./6<$CDK1BN>APY.+8N%[8D4L$/XV>P<,0 M\$\I ]XPD"+KA87,0O1/E&T'2H*%:]8FTA@&%N,!.T9ZGU(PI@XB,,4#L^ - M;KW%OK1H^>]54\>GIQW(=\U>'<10GR(_825[^%8V*&5$;8) ]RZOQ^RD=>!: M2! 21H.4;?K59TC3BM#?=#)KC+^V3VV) MD3F;LN#!G_6[RY=V4^;N+]DM@H;3:" ,K?]D&0@3BIN\MA:W?M0A33&%B$NL MR()578KF:!_ZX#_MDO\$1'K$JF/(X^ 5U>%(4I!^I(I]54#*DYJ*P&E&?E:U M:7>X_)RM[V/LC,_!KS9[EF7;=8I).(-N8502^EMY( J]ZA<(]L;B)_A03^0$ M55=+3R_<;5$YGUW5O"ZAW7;S+S"9_K0&Y'P-H.9ZLR073\;0K2N1E3.JV4,_ M.\5C&Y51NRH>\V[]I7H^5$?WU<'!,0S#Y9O@X@2P98L&'FRBLF=7F;949-^K M5ZWKCN8U^,R':4G=PM9X-ERW].[Q;(C):PI2M$,; MT9F;EC&/KO'(3GD,5CUX(ZY'/. ['<<"?.B#E@M>Q@T$$('K0I)4BTRF)=S. M>EE_(=D%T=BFRZX_9@G*;D9D>J(*;8DL@RA"U5AUYIG631Z$)T+AL8R]>KC2 M+M_H1RUY[Q46@'7;!.@@.R$)NQG9T01 !MXJ/&?'1S"3K I#5D0-P=NQ0OOA MF,U%]DFMY+K/W)N9B[8T?:"DG:"BDX2EO%U(!RP(BP?T?4<'*^[PPJ"]@_*G M5LHGS$1I20$$0V4?HBIP8T75P"K&@CK$O(]&JEF]K8PUX8! M/48[;;G2=E=^:\6&CME4 MZ%[1TM/5K18%.]44 6CJ-79\A%@ MU])FI]ZZBME.5B<8RT[PZ_7S.]C=S>US;OD&I 7F#?43QD3"'6)1ETG+)QA_ MWL0-18!&#>43-Y'ZJM+- EYJ5(ZR11(SRF]/=8O?:U5* M)T^9 OZ)WJXJS:RK2H^/=D"7[@;#:H7L]7Q,SZYNPY7W[[8NW0:/NG1IBO9! M^2'*%-VVHOY-Q*/D2ET<#@5>9,>"-/O.X8(3%\7VS]#]^8+&L2.(.Z9"5K"K M2\"? J&2H,&5HUF3)R&][-!_X+$S7PDC%";4J 34C@>Q2NBX" M.,='X/N2"![/:I0FC*$%!\L79=\'VAO,O=9MO \\ [R=-5E@H"J3_L ]P.7X M:#H0)5AL* M]90R,.BJZ JM$4#PL)0-5X+V8IDSYHHN@,A/X;V_1PRO#'T'O M0G! _B\+.EE61F4,M%Y] IT5V'S/8N9!V7;P&(*A93UY)S%2+HN/M?%W]G%V MWL#<0^''>MW@2C\!L?,@B (DB1H!%@7&!QH,HH\ 9T /'NH-P\F'3_6*K@S% M3AA7LT8&NVD+\B\#*7FOS"X4PQ18%TVQ0V6RN C<:[]>@4P1'^$C$*B&>@CCP^XH$'K0KP]U"1=!5YHA&@*Z R9.2^(,;"E/-D ME8+I.52L3RO!A^TFGWQ^L/5)J=WK3,WT3\5-B<"(V;W7W>:17%"T"^L4J0]@ M3(">H28CO3P?L+[6(UL'1P^+]1$/Z3QBU#KR5'=F5C0CBV:63!*M1713I!;% M3P7'^>R]C[SK,E#_0H?]6AQW6^L@@[[V.K^C&^7BLRB^/*;6B;HW%W'GW!%W M\77>'-4_2W3E[>XE<_*GW@ Q=Y7J%)^J[9AB[BTQV4XON2+T!%6%4<*8_0+? M9(&U&JD*T/"X2YBE))'MBI(XGE%#83Q00/0#31I003SY*@6^"6(+$%K@KSM0 M&\&#)D"K=27H6 U'B@I5/B\"!UN%T11VE16@$UF,UPFX'?\./A9H?: %*8Y5 MU=DI>!K,@N*_VMZNKU$4/)< /L+ZOA]$.UZ_/CZ"#X*ZU+K6KC">"@+6V*H MOH4Z?Y"]QG$,(0-8H&U-.$P1T5*05PA>6_&E'R 8UO(LSLH3APJVSZ/B=G " MX&2)MZ",1)G8#'#@;)]XJ"**"X? FH&5O L2-!F 9R!N)@I=-*!?*+@!]%T5 M/ETW'AX'"\(W$7P ?AOA<@*&!,3UV8-S\V )+ ]Y5S\.&'NC O1#-A=X)!H M:#_P+-DI?@9@"!PVHS7A, P$LS*PD2@PW"LY\U8-T=N;-C< [ ,=-?UH@!$I MHH,IRORU>2P=*!$^IJA@ \-9[8FO<_6C+5T]C:\YB=YI*]6 ,+)>R@Q>CHG: M6!<+C%\!TQ8PHE-DF!2'.14O)&$#*_O?O>+2R/G=;O1+P.C7&UDU-RW/TI.! MP14@,!I)+'@+$ ;AY$^[?%&MW%]7J6:-:E0[5*5:J[9:U0IT#JABNUWMF!Z" M_3^$Q@ASGN($22+@]A>^DPSBFL9 M[E=ZS@ZWC7PRSC69LE]]$B7O9?FZVAB&]:]BZ75>O1,NF?P3<_/Q=A)\#E&. M2_=PO?[=Q5GRN[4:[W//6L[===9-/3:Y!I%)&48B>B#R*B;I^NMHE!PE7X=L MI5-LS+^^6J_S7)&YN"K4:Y_/Z148PD_M$QN33?[P\0. (V,&4A2*HU#@I(!W M.ZE$'L;\"!Z"I-NU'U[J\7]\'DIG?W@JN.!,\!)T#QJ;$SYE![QHN&A7\BZ; M\"^F\MZO)W6\N?/[T7WI21_^=&?R$=/=6]IK0=)>9D?BF)5"RSHMW_8KPW]!3744]TP6%KJ%+'2^^#C53\%ZR.;4SKXZ^+ND(C:RGM#VXW77WP D5K<-0_ 6\Q+06(.W-17L6/8TK$ITLEBX:MZSGX.'U<1 MZ55M*72;W>F_V/C+Y;W%.BNY0/O/2MYX/F7#6V=6W?K2TRM+KW/N[?Q+JK(E M8<[O=+9[4Q<1-0&<+"L9%]D-9>Q[W5"VJ(O [[W.VAVN\6BG:I]A+VX0?)DH:B%SE+Y-S! ML,V'RGG[=#*6"Y5-B[ZO0:PDQC)UB<,H:!@)A>C_A5=I-&AX MR!4'JT;G66W=G9U,Z_I+9_IP)8_->J,UZJ^2H%Y@HIV8JSXAY,D/4;]#JOJ/ M^4&WBTQIPH)M1=5O_HQ=F_X=G?O.K^?*0/<88&#)^G>[?DCD4%W-*:Z28EE!" M ]'ED<:OSX3$)_S4JMS<*NA!V6H1/Q1G1\,HP::.Z6NR))BLZ);8S$XF4UOU@\G.B7$#Y M9VN1B)&]L(R@C:P1UI"]VU+X1O2Z^> T-[6IR0O-]#\FVB ]%:]AQW-(A%)M MQU@Q?X<$JIY85L5XH)]'H-EK4C; M-N5"S";<7\PTXY6Y,2LLEE,SPE*R$9ZR_6$M/GL?;@CGFM#0[T_=XRVD7;H;H65>B]@KS[FBFRDZ,2E86!UH$W\6Y9=;.9-'7F6!FJ@ZI(9 MLP,G8"X BH#AT"(3ZB6!UO0MP\^92 ;USLXC'S^IA? $=_3X[TWURNPI_9"W M-D&B1'ZF'6W"*15RM7+)"2%1&;(9"[VXC%';V*,CQ +%5<1F-$L2([CH(LFF&E09 M\(YQ,Z&)RH@4X19^LBS\[!/%:0,3I@H2.&LG8%_RW_E%:O$?0(@\%R(/0N2Y M$+01 V+H3$SDY(0&/5,AZ&\J$/]P]D)15+&Y7!(/0T@O!.KU^4&B]5GG)WNJ M.F&$F-$TAX5*A(LCM'>%/F2$)GR*E6,DC]I &A.7MDIE%!\"VP?0*09 1=P3 M1L+>EK=ERP!+];N3FJ7AZHQY!>ASX21E4Y?HU%0U/.(6;#.+]I&JC"!UR G) M9_&J'GT+\)@%@PSN$,"FWO4 ")O-@*<07T%'932;QMM1.!\UQ7U%]\+PI,L M;_YO!^N":[^!=5-O>2UG10FD0UC5B1A3^\714'7=(78J04R]GQ__OF':O'S$ MB8BY1FD3 X4FQ=HU!%\X&,-$%@+RF,Z);62^NV(S22R%W;OMI(;-2VH."2/! MK*+V5*U0GME:/.>AS9_=*E+T+'&@YO($DQ#F$$TUNNB M(P!S;JOV@+H1!U)BU+\(7]DMV8Q.J 00$;W([H4M@Z'5>W,NH@T,O3W:5C31 M$#\/8=8]8'@7%<;L4P]BN]U'%H3(3$-RGG2,JHJ*;=#017A>G=V&Q;5Z$/]M M1KP(&X1<9T LSFX%3HSCY[NH!W.-8D&NS [OU$9$'(VAL&:4RYVI7E?L;R5< M&+;7(F+:75RE3?PMGY>:&!GZD72M]NF*_9:.%>!D.Y*4\K'DG8QQ)%VHU!GE M\WXJ0<>CQ5-NO*7!'0K;&; 4IGXQI'S4!H1X]+1#AE%9CI@L T<;SP'SFWE1 M?[[FCB5@A#V2ZI;:Q=JQ=$F#$=?N)0$5%F7QJ0/_,;@4YB_\W,77 ZIJ7^OB M8_ ^WB$;,(241]K7@R[17]F'@?-LT __ 5!+ P04 " K8V%6@W\RZX8. M 2#P $ &9O=E6X\@R! ]B" )R6A!U,@C?SR%EO^?)^ M>)_GNM?^M*]UK_NWKKWN39PDS@)_:*IIJ $@$ BPN3H <0I0!2C(R,C)2"G( MR@8N=AYN+G8.3FOP\3@U_E$^3DY!66$1&^+2TE) M\<#E%&4E%,0DI21^7P*BH*2DH:9AI:5EE>#EY)7XMT5L!J 4@!80# ;Q 210 M$!@*(K8#/ (@7](^"_!"(!0TC)R"DHJ:BO#-@_ !(0&$P" 9.20B!7W>"K M/@"!DM+SBBN3,>C;DO-Y,4J$H7(H^%7*6Y@>#>_ ).V\PRFIF%E8V=@%;L % MA82EI._(R,K)J]Y_H(90U] T,#1Z;&QB:F;OX.CD[.+ZQ._L'AT?')Z=EO+A !OVW_D\NZ!47"00"AI#_ MY@*1^/TV0"&DO.)D],KZY+9>#'P2812,*JB<\A9*?LE'.TQVWL-4S#"I.8'= MWVC_D/W_P,+_([+_ ?M?+CQ P9=A0>& O> K6_"L#2K!#*T+=+/S?N8@[/C MV3HK$QR5[ENBS=^J;[5:Q>+C)K_R2;'!^]O4,5@T.VO%E BP$H%%0RP1P%S5 MD!EF=5IZ]*:"8MX#4?8X.VP,:\DGU(?L9U[=N3DK(5MV#GE8E-^#GY!DH!F#9NBOQE) ML>WY-\M/1$!2JYW ,59I*>%NW(:?0'-6X98U/*7;'L;EELHX9QYB9C%0(M!J M.8=16KY=3=')-DX)I".Y4\E*3ZH-(A[N_-KO^Q%O8B:8RUD9UP: 9A*N<.F" M%&6B%&YQLFA5;?M):C;]A $L.R011BSL1Z\GQD,0+)@'BM4=(ES<4WI-<:US M\Q(J8HN=='K7O.6-2UI(S%7*VBD>L +E]J>9;KT-#XB 0+7&6=NEVX2+72LF M)*^ M+_8^$.*$XU>>D:I(<$FPLI_MD@#OAL5[;Z-\?2X/IH'G8)5ZZA<](\Y M9T:4!(@>0\U:1W7YNM@/G12,,TZ]A;E),V2EX* M6\3_Q)? A3^X(D-1Y?,\C-.A[AUS370P[_6O-#BI"*&GC=X(G_=K&P8/9EW@ M?^('\O+7?3)->I[U< >CU %CD5FWM^YW3<>P6CAT78*>;95+YVRMG?J]E(NB M<9='NK8JB7_5KI<<6=[<&UI<.D%F2V15H']].HJ?7AM[/_:F8,Y=TGA8P3(T M;WK]N\Q1J(.I>]\(\_KD(O<"Q-A3>V^T;__.K=38^O(!1=/Y6!X(CS[0'=>0WI MY7M,H8N..ROG1.!<_GOAZ.WLCU4%>Q?O[YYT$0$^-.8R&$,('Y\\\2$\B(43 M&G*N9I74.XO^>;]U^YW'9TZI?^$$XZREEYV,5/?200F9AT,OS-P6AY\6>QYL MO#7=RC;YD5Z@A@=F(Q#*K43 -*$JEO_Q1"_UC9K;8C-*]I+OCZ(!(B"\UWA+ MHWQ"26RCS'HJYK/V=J')NSN&SN&*;A/PQ#9P=[D"6DT%$=M_T.^?'(,^B=+= MO?P[&CXLIM3C.Q(;P\>BIZ.F%AQ)89*2)RAB:5TN\ZZ!$6^GC#EQY18I(MOG MYMJZ\2?A.FLFPNNGL=$<#Q/^!*/! IV_F[]3_8?SMDS^D6)1 %RB-<[>!4>3 M&%*TZ3: S8(\J;L7K=8X1_; %];OU(_5"0B;+#C8PK],%% +&4FK"\2,LQ$D M^75/JG-FM-IUE^B[\F@,B8#N0*-3#9'=KHC1"AX:T1G/G.9?]N-*EY/;/Q-/G#<(0456)CAL:=#'3))F'9 M='Q9/NK-5N6I[IF41ZU5GU<"@2EUYY!YWW37\NSES>U;-*YA+2T>62G%&(9? M3_"O1.2WDS[>7OG\W6!S"-TQ5 M-:2.Y?_*,%71M]KT/*[HE1*,BKHP#H.)UYEN#O S6M6X/ MD48G;?L\\FG#. N\.'"S/),<6GMMR$#AATDQ+'NX'_92=Q1E@=I]_5692V8*E 1MS@?$?KTR\B;IIYT3(?U M*5N0'($($ :PZ^-+TTK#2"( =?/U6U]8C1\W<) (@QG/56^\: MJ&ZBLS;Q;VZ_L6N[*\9G$V+[DSY[86A$&IDE^<8J\^GJYJ$YK?*OFV*YJ4,D MO7D?Z%0?1IF-BHEU%,L,:LRVT&&"FRN\W06:\1N"=N?DZ;23G84A'HU"PXM0BE=A]47&6I"E#* MFLA$&/@53$XRF1?E?W8Z+^S?Y\G>T*ELJFR*QKEZ,:Y>HXP-:SE02NI_P:W\ M C^^-$1;0 1<-!@[ONWQ[;S=K%D[&0MH4,/-7TNZDY;CX5&2QZ*?W8QB\GXW M?5X&RE8L6C*HBB54R6LUVNN4?^RM;7@MYY41^;4YF%SZ4^')7ZVC"++09W,Z_)9=3\NUBVE)B*#'3OS1,P)P;3U M]UA7C7TWX$>Q#3H(\8:74"/L5/\U;>G2_@LH3M1Q-M6Q*_6]KK7F(C:0,DAQ M(5 &^^'V.2PNST/=LNTU=Q(\&I-@X4EG:CK5Q?1]BD,<]8K-("%+YP 3BMR& MRW7(%9G>1>Y=+4_T3N0>%_?ZT?RAV0^'KE18JE'S2L)H?FDXSN#KF$*+JP]G MIX(GE;_%07Z2,.(0][K=2F M\?NZ?41 \RD[-K*OX@'MB :,]JN117S4T-EC''^%!>(*X_K)@L\U=SI#@#8?>B!#+$!WSK/K#@\]R](9T M'"(YJ[W>M/S&.C=-<^_G1 #%6:;V6/C9I%S+@=1\\Q^40&;$Q,LCKTU' MBY. WN#[Z]#4+4]6=_^2+X(.X&S;X2:HP>3:G0DGR^&4]2$+?TJ*-/$UF MQ*2-T9ESRJM9^179SL S/2IHXXB$P,ZWS.\CTU/2'4GM>1+8+YWBO(>V0UE! M1NY:KL5I].O_O:$UKC9R61KI:H&M7W];C-MQ?*AV1;- ML$AT7S1'MF7;O21U'1 \)>VDB&=[>0'))*?]^O;APO/A02J#'=DO'GA;7&S@3R?T,P,55'E6QN M8\3BP_]\= M:GC%=M[(AC[#A26)Q!5R>%A8C\$HUF/8H#NV]L=@!O>E^6*]#9J'%S;U$;8_ M=-A]4:@VBF5VNF'8(NRUS*T&.))S@M]/5 NBNR,RTL_7 O*2.\24?3DH7$U> MUG IMI"G53#%+@H][<(EFRR)G08Y"U6F+Y3ZEP0(+BH/]/%L9J@^\WJN>NVE M>K-7->?SS9D,B9L\^K$?W0=:ZKV$5TJ'R"&^+0O3=>S_V&6E<#5Z2I-X9>\* M)HF$#PRNI]$;F4_XT4^T>?=AL3E=9^6\EC.RGCIT^FFK+KDH\KMR/<^U3L.3 M,ZB?"IN4#U[WZ\+JM-,8RTC.%Z2^>5*;EFGJA_]?J4!->S5R.2 M:CT>Q354\>F"+:3/@/5G/OJ#>=:P<@1#]VZ]DH\D;5.@*WS2?6'L\26C]_45 M)Y*UM%P-D?[G9.;>$%39->/J(6[%#82FUJN*7]Y]#KXPLO6B8<1W@&'[R2'C MV".&!&?BCW\!4$L#!!0 ( "MC85:)=7/IX@T +2) 1 F=8-NK7LK_1(LU;%"$X=Y+@THG9\ M=QS\*X8^)%2+D,_>#-?T[9U"/B^P^<[M(?.6?D(?!JOKR=D?K__[[B?\=7GS MJ7-VK9AOU,UOUH@JVA^;UD_'PT^KKY^MH3_D!=66>(4$,(9)+QM,OD"\V],C MRUZT3HZ/VZW/P\'4@VOX@.=W!C&_9H&WS\[.6EYO")J"O+NVC9#T:8MU7R.* M(\K02SCPQ*0.,K4$O.Y$"''@URV_,P%*,D'?^* D!-7Q#AS%VM'"NFE!!\"? MG(2 +FTN$%I'P'-$KSVBU'::U%U[P-].0W!HS01-T&2HSF:-:395KRN!H#OV M#D)";]#=8MT,Y[AYW&Z>M$-,I78(=-4+I&&MY#+9SER#0M6 RP(H,6UK9>$YCM MT/"G"S8MSFW+P"HP+K '6(;9M%EGJVN!*VD(1+]L^(^,"M#TZ.AX3DSB#1:L MM[;09*O+98+!HX=RT=H%CI%P*=;'YK^]Y[6-*>!YW ^@(4 ,0'*0-&1HKE$. M9\M*)DK0$&JIDMXZR&"K:;K$V*&^_I)-?#V>@/*84\.1(DT=F\"A$% 1?#(O MNIT@&^1:8H< MQF*3O;SM7Y:4.O"JP35?QZD%2)%T?%\O&9Q HP63/6)@_3 ]4@=1 AJ>Q$0237U*%B:$5!HR'5'3+-=T(!.:6 ;1"(YVYO*( M?.N]97$09!6&15T;PX^..)6GPK@O3!1I*HU4497'(T$<]82I?#62^W)7'*F" MV.V.9R-5'ET)D_% [LK2]" MJ6#@">NPRSH;U48F15IL=\GMY=ODW:Y-%&D@ MJE)/F(B*^D50%7$T%;O,+H>I=/ P$*T[Y-K (\O!$#EM$#R'P7]V)U_E9[LJ M[XY''R5%E3L#21B-56D*RO\BPJ^#U'C^!EYNLVX?[^IYJHZ[']Z/!SU)F?[] M;^].VF]_$:3?9K+ZY2 5W;56*\N/@<9KSU=\0C9X#H>"GU4P',(VX%E+&$\\W_,OX9.H@"]2I][V -N%JLA=YJ=\L-E( M5@_50:U6Q&&1S]8\P6^^WD^R]"ZK0]B'#U*1L@F/6$5W80 4;^"K\G17E?(( ME"D)JOCY0&.5"L'CO://8E%H^^<'BT*%5^&0+ZE%01NI+#ZJ;N( G6_@UP]H M8'_ PS1OZ8T^;MRJR'S3OGFP6.&P31O;VN)&2S?SS9%*Z./[WF%KF+W!U%T# MC^<]#')IQ.-0H@Y9L31]1O'<-09DCGO80<0(:V)EL?CV227WT^Y[J3>#-!.< M84\"=]B5?6<(:T0>>GG_;"KU9P-A(/QS%3YHR1(HC*"K6HJ3"1%F+X7E4.W5H5H(M#7B&U, MS%Z5PY(4(:Z%3U*%B7L$*,'00C3V85H_K_J9;>+"T'P[IBH7^;73%T/QZZG9 M=BH*S#=31J$CI][Z8J7<&FRV@0K \6V3JISDUVA?C).*2Y(OLOT\*RY[<70%"TA.YF ''HODJ3U,@0O9:!>8;Z54T8-KI2A!?K&3KWJ1 M4G?EURD@R=)ELX^([9U]'6+$-,H*ZCEF*X7+MV*JOA&WHCB=SH9^B8-E:3UF MSKXH*\)'<3"3A*$D3F>*Q.KW+V;=75%9%:=]JY"'PS=CJBZ2LQCS2E,';;W2 ME<.\V/&^9/@V3M56[E&*? EL=EYEYILTIY]OJXP3%^&KSA?EIYSF"(-^Y]BV ML:ZB.]C=<*ZOY(%R37*:/IP1@4Y>;5('BC?0JGJ1MQ"?0D2-'$0*_@+BJ@>>@TR]OXDVX/Q /C62!4Q MDJ]:GK,38_]AE[84/!>\RU[G['[198,2=MVN$;0M;3R_;-CZPFB&]W]^!]&. M[E9&",)(2;KRP(; M!Q9NZR%$-M!U69$!!1N/*.N T7]0(6'VE15R9\(^DJC=[2@/*C LG;(")U?; M(\G;BP:)BQOOX5V X);M"&;J/A_O*J9_B71@:1XI#@K[U0SQ MFJRIV3YIGK:/[JB^Y;0,$ULUE&,BQ*O 1,Z%T*SQ:1XX>_ F4]%!HRN@P8W3 M(H-FXK2PX="PY5XL).ZWEF?DVVF<4--O*LW+[CW;8GR$5VZ!AX! U?%!A/B% MW'O8PR-3RB#[;_GFL;,/T_M-*RT([TVLO2FS*.(HX8]J,W-[E;KYUTV'-ME.PN[C'\..PZQ=-7;&'77O]W8$/R-,KIZ?JY;*T1,V<$K M!@DZ<*\I[$DN@[ZR+7=]V?#)$0#9+UJGE&@%H.LC6K>4: 6@ZR":J.M>U(&, M"2*Z;';1FCC("&9>Q'A2PK)(M1>T4T70#*3:"]JM(F@&4AT$G=B6[GK'3=@+ M\S7K3 K% ZB# %FU\Z0$7(@ZB)!^-Y 4@--?,_;#=QJY_*< ZB# ?UP3J[>6 MNK139_V M.Q:R=79.V\::8]D[$R:WMPZL;Z=RWLJL%;L]>TBT)<+&AP^6C?:[-2ZQY1W0"F(#J0[;&N$LFM 03)8#N='D]V[C4%+"I^+5'JJ M^A#4H_?(!N[;_M%V9(CZ_UP:W!/?;^0^"."8(/F] M(=IV-A<%KFY:'5\_HF45O$:;X#-1\7L;WH6 K9!\H+H*YU?;V*=BQ_/X#0?1 MU$5- UYUV70PS!KV04P_JX.N6'H7V_[O3:BVBSM/N)BE604O)2K\WRJAJ_+D M:JLQA;KT([#L,9^E QY ;:4*+MZ%]@I*U;X(OL,>SS-D+8]66PW$2U)A",+\ MN(+AR9_1T>).EN\3^UU5"K752\Q\_MXFFU/L.$;PP<>=&9!$>^;T3DGF(2I!+B9?&W[!(&-]Z-[HW*5'W@]5$'A:K& ;6'!<9 M$__XUB9'IF*@-9'KRH)9#SNWAFTS1QX^2$WD&$"V95+ YQ(3"K8GL5E?N3 M;4^]O7'K.O$]"S8JC9@Z^^,2!2I">9A/71+JNV:J4N5S'-6L>1!/S7X0.$Q< M6UMZQVM]GM/->QGUC_LZWSTQ8YI@)WQ9364-#MS3EJ]?T766EDW^ ,\&L\6. M3:$),!=E81,(E[#"[IZ.78<)P?XX41A88;)8@FL4(?Y "YQ B>;MD[)0W#"[ MCGD=?!WI(:81A\?P(TR!.-Z+R>VBKX1YC]WH:82.$OX*8L=Q?T#!U\2N*':( M60^A/3J=W54N,C^Y\$ [FRW(Q"^*B[?LA7;"C$R2(EJ@">_R?<>MA4NI+/?( M,GW1_>_BR,"K[?JO*+:^M;!??RH.#L\&420.J:17L8'TF,6T';P@)FM_$KL4 MX:IB$!>VUL)0<17()DL&*-&\#.GAU,X=HW* ^;@O"A/K<@@S8>5&F5=.WW-= MNE[\16733\N>R(.68J(>D8-TI\78"DNU032;FE*%8.LAV".8-SK>\\33K"P? MS]@@7AC^Y.8HP\6S-4;Y,&4GVZX93\\A<'H A4@><*UL%+'T+$T4RXE';N(N MYO<9JVR$^-#G5A]5RJ?=L0MP\%SC\]@JSU=&WH)O?Q_W4XVQFCBA5(T_K97K M_.0W)GHR^4VJ_A$'J6F*7:0LF6A,7@7P_RID\?KR?E*U_N! MO>1K>[ ANF7)7'X/4\TF:Y^/X"AQ?O]3'WA@IQ1M[+WAMS<=RW2C5S>9/;4U MP?9+E; $38T8_NF@$?M+W]YW$8#K8+'FWL^[)XT?33?Q&R_>G05D[-%$-D8- MY+YH^5\S@L?_ U!+ P04 " K8V%6T)[2_9$- @G %0 ')D9VPM M,C R,C$R,S%?8V%L+GAM;.U=ZW/;-A+_?C/W/^#4F4XZO^DAXIC,HL[]I]["Z"O&4--ZR/.Q8V&;.>13SV&]7_[U M][\A^//Q'_T^&E-B6Y=HQ,R^YBS9!S3%:W*)KHE#7.PS]P/Z@NV ?\/&U"8N M&K+UQB8^@5]L'WR)WKX^>X=1OR] ]PMQ+.8N=&U/=^7[&^]R,'A\?'SML ?\ MR-R_O-VING-]&?;?>/-G7^NN3_W&&/()"7XUT^>?13CS\W M>NSCQ6OFW@_.W[PY&_QV,S',%5GC/G6XW$S2V_7B5++ZG;U__WX0_G;7--7R MZQ-F(G]4.VECT&Y+?BG_JY9GW_5/SOO M7YR]?O*LWD[XH01=9A.=+!'_"=K;/]7%%F7WQ.8*&_!?#H8,#!(X#;NM7++\ MU'.M>QNHGY^?G6]I?Y=HY#]OP# ]RNVJAP8UGWN%;2XC8T6([Y4]/[-Q"WS< M8IS;#(7<9L@;JWFPYVW W!SLJ%5EQKX8YFRV'*^S<$T]S M#)^9?ZV8;4&T4?\;4/]9F%,A*LW+=(B]U=AFCY5$FNK4E#5Z%*C?NL2#YX0Z M4QS+H/<.78)E.;YBFBQP?!@Q;IE-34H$?*61_;:!)O#0WWNTR*,)ELVPX$&">":S/%3 MN2=G-)46=5J,/NU$H1J,S+E'MX$P25B29XJA.Y)LXSXBQG5NAX;B,J3T5F"3 MV7)$-BXQ::AUU?/IFH]8"X\L WM"EV1$?$SM\L2B)KW&T5 [\.D#4;'K@+EZ MM\0U5I#85H8KDFDK)ZO* MMCB%IOT[.;W:QO/*OBU I%V^=P/0D9SGD&F:=\7S@O5VY(0X;FG.&%,W7/VZ M(=@+W'!"61E*':JM:24K#:BO' %JDC*FZO&IH0I Z2X9].V-27PJ"5Q M76)!%@?63FJ8E "1IOD>$XCJV-[GGSJ,KI7Y%B#2>%Y=U20$NA;Q:&+;#.PP MD9K YT0/\N03QR+6C@YG570!VZ<^;QS5%,Y0GQ<@ FZY\-^H96N<9*]2)S@Z M!S;VRX@A2T#?@0B.HLXHZAWQN./29F:",YN7$]C!NOVN-!,6#9;8NPLK!X'7 MO\=X,^#J&Q#;]W;?A H-E1E]\L V7YA5_"&8X3/DX>%@F(]!L/LAMIBU**Z)F N>^JEWMGL.=LV$ MC:1+.%&+ 0S?ZY!,GX(Q[/HO7;8N$G4D5E8'2EPEP$4//1)ZO_)#[N6H,)HT M>3HQ";#-TWCBEUM?82\QA9U+59@([B[I"::]&TPM]6G#0U6I@G*:BVGF0JIF M"I%V225;,&4ANBOQ*\\/,C72(2E/*+ZC-O4I*1\4L]K*#:O1<@@,#?"-&Q"K M"IQ*1&1;63ZPG,A;030=M4S4R)T'M4MVI%@6Y:BQ?0MYAN8,\8;Z\"'!?4%4%NLN.PD6UEHE M<71)C[&EO;*)9JJE[$186#MY(+NDB!P+BK%>V9L2?<64]:-\98D+HDOJT_G: MH4.L7:$8TK%@'80UR1%94I,6I*@B?<74]U:^^L0%T27UQ9(W7@^OD"25]Y2= M>HABR\]GNZBQEU(.1S5DX9X%XIB%4XK"3K*3C9IZ$A"$F-Y./7S7Q%NV,S0/ MYL?!(K,66'P(^X#-8EG0%@K&KWR M^\@>O,H55XXX0S]]:0J*8I9S']50"K**C*:RELG8$HP^G#R-21'+Z9:R/3]7 MWJGUL6R,77+N";YC;K@U*ISW1(@*YA Y[64[M:A.BO%V23,Z\0APPK<9C& @ ML=F&)RFE"BKI)CN3%M63$/HNJ6M[&MSFY2UK31WJ^=N=6:4**^TH>SE,5&6" M$NB2TO;0MEOK)I 8"(R=\<:=&8O2" [5DY'V'#'9/D$H+X64;YE=2L^FS&%) M2*4QH:"+' R:XQ.7>.7#3ZJA; 4@;=*B,HX$C:XG?XP!(H1+!U)& M?BCM+FL!@#?,:"?;986%G,-_]T:&:TP=CX<>XLT<]8D#"ZBWVKXR(4#]*F#W6<-).B! MI$R^=L-L.Y35-C@4Q;\6'RH[EIY HGDC?$8NT,GDY?0B*O?E#OGDE/@BJ?9! M,]EVG\EU*F]H7_$=4N0>1F1L5S">%]8L:B+4D.3UO.J_AJIT1M M[&U>;8R7QB)JB#HH3N][O&'>!W2XA:#5&E_Z35 )&#_E5BB3Q3Y.!H5TT*N% M@P,+#,7Z0=(Y,.O/P-O6QN=,)Q &3!H>4GDQSCGC#,,4_H&"V*Z>MZ>0]T.D M8OKTH62C;9,C1#Q;%V1WQA9K$KULS2O9 -8EV",CLOVI.>ECM84S ('>LG^5'-#V"S&'FKXA;=F*V+CTQ&_GIV[*1*J+NN-6(' FM$T>*Z8E9 MS;MORVJJB+I+B5\:B;K>V.R9D&CG3DU3*:(B9B _?UL&4B[6;IO%;I$T,G"0 M5A5SR.HM9@;OORTSR!=CE]3/W]ER[!)8%1K_+Y)46D<_SBBS%^([6>4[&FLK M/MY]1QU3!P/2HQPUDX:L+;H;_+PK2;R\&+=X7:JP4T>=N$!OJ7V[I2(YP4I3 MG(OXZY;#5Q;G+A47]NEHR!'0C "X[@40P&D28H7%]'U=PC4P?U=GV3EGD;ZR MEWZ/=C1Q 75)K1SSP4L37VH3T4L5DU_$6MX2ES(KG;M&Q^C4)S.L4/-7MZK+ M)3$+@O"I^9 =U^7(/9W@M9+2G#H4=UF810&D4V?.ZU^0E=CJ\8Z_;IAZILWX M&]CAPY5B: ::C=&MKAKJ=*[,M=D4*=,1,K3KJ3;6ALITCI3A<+:8SK7I-;J= M3;2AIAHM;ETIO54K >GG0TBZ.E'FZ@C=*OK\=S37E:FA##FL-GDNNVPKP?+[ M0Y:'L^D759]K5Q,536=SU0#F?U?@4ZL;A(0V.9V].636F,^&__X\FXQ4W?C^ MNY_/S]Y]0.I_%MK\]U;E6_<2K@28L[3D;V[ X$-,:'8;FLD_T:^*#F8S-T)' M ,>8Z]J0F]2VV6*JS=NUI=0]7@D0YUD@M/D-N&^+7&5=[95@Z^*0+6T*C*EH MKOS6:KAHXOZN!) ?&PN2Z-7N26V^SN/XZ[T2\-\V"'_[G#;!'WO[5P+Z3XV% MAU- S[]"+ $J->;'_?(4?-:^.RP!(S7.&\//ZF@!(R98YD@%VQQJ6\L$A6@W M80JP,-3Q8H(FVEA%KR+J)T(J>+U8 F(J+TA U":+N?9%1:JB3\'+($=0=61\ M5O338&OR@K$XZO-4@G%$O(F>B/:/;%,BE6\F2\!.I2+Y>>N)<56]M"P!*R,Y MR*09?E:FUZ G+3GPG3B"BEV% MED"5REP*4>U'\=/BJG4O6@)F*DN)PU0,8W&S353X\#?B>,>*IJ,ORF2AHAM5 M,1:ZRN<*LO0IRGF.R$=//(247L>6 )JQ M(K*;TDH+JB)WL\5!7*172F)V.E7GD*6.55T'Q4#JS1U535BGE I#"F'ACJ#L MUG)J(RE>]@OC?#M >+/4DKF/V+4*BN:5B,BN2A3IZF"YNX9PNE3W2K$?O2K\ M&,WFDY!=(#E&KV6"Z;16>=:S%;-MLT=>DJV@SZS.LLO4QV@R7QC=.B]=Z0[0 MQ/B8FO'&Q\>Q"O,I91);G$(Z3(=ECX_M'=P_,?^[77/;Q;G)K_YAO#H-3?G;?"LQP]29"*GJ0\#B2 MLD=10?T>#U0H*'?"R[, Q9?@*WMY.4'9(W C7BXJ-VE>'E]Y#@\H94;L E// M)"#[U/#Q'EP@EZ_57\.JT17VB#5D:_Y-V)*_>H.703M&4?"V[$(FI(LTO;06,; M/X26UR]21=GD%I"\!?8(%?_G#J(E?/,_4$L#!!0 ( "MC859]7H]$?BD M '8" P 5 &UL[5U;<^,VLGX_5><_\,Q6 M;66KUO'8;)Q5-018W-.DE*5_RZP] 4A(EL@'P"H## M?=B,;0#L[J\!-!K=C9__[_G>UAZ1YUNN\\NKLQ]?O]*08[I+R[G[Y=7-[*0W MZX]&KS0_,)RE8;L.^N65X[[ZO__][__2\/]^_I^3$VUH(7OY61NXYLG(6;D_ M:6/C'GW6OB '>4;@>C]IWPQ[0W[C#BT;>5K?O7^P48#P'Z(/?];>_7CVP=!. M3CC&_8:O=3$>[<==!\.!_/CU]>GKZT7$?C2?7^\/_T73O^0:C MO7Y^'?\OZOZS;3E_?";_=VOX2,/RF6G-W( M^*_+8-<7+JF$80:PJ1( UN0GTZVS4[(KT[. MSD_>G/WX["]?;7$*A>VY-IJBE4;^BX'>?=4SEI9[AVR"[2GYXVG?Q;J+*0V[ MK3VT^N65M[RS\>CGYV?GT=A_.6@4O#Q@'?8MHH*OM-."W[TP;"*CV1JAP&=] M/[-Q#71<&QYR@C4*+-.P&_]I"/OQ-BUG.6,^O.L598LYR@9YKNQ@GPYG+MVI9I(8ZY4WC(:GB:(AO+ M;8EG2/ R]PS'-TPN#6;UJX:ZONO@M2VP;FTT=@.$)_*+<4L&9*V(U&Y5:6G^ MN53OO,&&Q[T;S<[)0XC&;X:'L0E\K%-3Y >>96+,P@8WCL5>V0L/6!T_5D#F M- ^AARVKH6"$;<5[-#>>V3,YHZFP5:?&U:>>5:@ (7,RH^O@\'!@03.3C[N2 MPU8^1_BH!CM4M"YCDWZYL=%D-4 /'C*M$'7=#ZQ[LF/=^&BUL2^M%1J@P+!L MMF%1<+S*N;'L36 ](MWP'*RN_C7R9FMLV.9G@V\@83,[IF-,5)G06<,NG>;D E*0>& MJ9KVGN]O[J.=$Z_CRY$S-"PO=)1=(.&!,CPC,WM^AD M:6%=)=\/*272Z=P,4AU\Z MN4?WM^1:(!>YAUWKI]6P[7P4AAWJI\MQ@UY>TK9]&M5)M#(V=E!8*;?=#VG& MO[;PCH=;7.(?#^A&SP%REFBYI9P,R'M_%5@!:1S?/IYI)^2J(L@_"JX-CNWV57M\)XA=Q!D+TI"EF&*W3PY7(Q0YZ% M_%["LWCMQ4?(D*2KV&Y-@4-Z\W5>9*E9.;0.;6H "RH\)%P\0)F]KP:1?!A-6Y\5[^3'AX@'"Y+VPK3]RA?5N_< SS #> M:@[;+3Z) 83;0,X@%Y*]L)T^HK&_\4BX("\"1\U% 0'+-PN'+*+E,X(-?]US MEN0_Y"KNT;!)>%\OZ!N>]V(Y=^&5"L46X^DN%BX*#&Y!7L"-7]BDBF[?_2DR M$2:C(&:<,K+@@KOD@^&M=2?'XCCBXE19G-%P(%I!ZTT M*78ESMU($132-$/2?R=6^BRQJ['K4R7\7I2$+RWCUK*QG!"Y>D\'X+ -,=X1 MI#>2BC!!!Q'W/@/C( E@>;/*>>3Z+MY3A@ M$FLD_HVW0"IAE1<286Z&!*%<6$@ M0B[IT\4NS"^PCULDNV[?#0/TD6-28:!TD@&68M8#BRD0.V&.@B)&NGQF>7GD M"EKH9\)\"8?W( P':D9C<2>H_.! Y(.HB/,Q+)>A^ S[VK"6(Z=O/%@!_N& M 8JQQ]-=)>3X&0*Q%.;-2.05L.XGCEJJA% F[2 8PCP2@"(EJ,\]JQ)]50*, MDQL00F$>BRE)8'#0ZK$H2*Q$E2 "J ?O9&5P0V2:OL5][>H:\UR<@5 FW!<_GQXQ?8E_;"*Q(;O.U4&6 MPQO.+ ?MAX/!_M9E/12@NLMZZ+(>7]2 ? M)EW6@WR8*)KU<$@J/GM,O'"=7H;NQ6V),MZ["JB_] %@.=B ,!1F,1S2'A+J M]S;!VO6L/_?G619TQ_T4@RR3?.D,[2R:1[Z_R0M3U$=)B!*D@U:#3/!,-D'X M2H'EW.7#*-%12:".Z0?M;@EN_/+O6QR=I4>-EP?0$I0 .?[MBM))):1R;53" M(B-2!+-V*:"#>LAP[$\RQ#CDV)QHO=3#AW=;^B#F7HCQPLC!G=#;HSNA?5_- M76G)WG65Y\KYRL@!]>\@Z@GQ\6B:Y6C)\?YJ/+C^3UH\;'>UU5UMM>YJ*])M M\A:9ZX21Q7S76]G=%+GBHO$LT>G[B$S6[0K07/!E%U76+@\#\MUY50&,$C=? M9<&KYP*L8K\)Z/#/=#;$WG$Q9BA]AM!\)'NRI5OF$B8S"XI44U$W+7F R"9: MOJL5(/27A0FUV^*#_/BP&0#/;,*P.H[Q98&4W7[Q47YT*)1#L'P4!DL7,$:U MI,7ED'8!8](8SUW 6-,!8^67M2BR*I_93.DDR'IFA\?PD5[U\@8$*@%VR3%Q MU'BE7&/4,+0,R.6D'IU*3<^FB@KET/,8B M:[66 IEBK(";DN"YU"\RES([R1M(RTD[!-';)N=2OX*Y=#S&XIVLR!1C!0+J MG;BY5"[S]DR0X9#CDBZ;9NE\H3G")-+A!?+#D$VR=.Z"4%VBP)K!QB/O0>/) M[$:1:F/T%/Z%ZM+AZ*X 6OQL@-:!9 A&"E@6B!<93%ELH/>)$H&;BA@DZ"-?5X MQNJJ+(3'+(!7BI*A%IMLA6!+]%46MQ0/X*6C9,"%"A?]>NAZ^#3Z:)E%C=;4 M,,K"26,'0E9L/2Q();J3K,&>,I"SH77R#J1?U24%T8BF+^9GB>X03;)2@+ MP;"R2HXA) :M&"L@3D6]3/EPBG2I'%#98ZB)%(T7$"HI?49)OU>B:-$,F;@E M_3664L-*C'MU[(&J(*)% MCE7R(?=0\F->D"409G&N+J*EMP8^W9&L$.3X1B1@CZ3E$_XN7O9-KHT7\JO0 M4(P/A]^P#8DPSY'.#PW+"Q?!,T;X1 U?E%]IZN4<#.80YF@;HV#DF.X]NJ2> MO0Z:R8]B!KF@Z*NNH$DQ.X:D=GZX".W7I@*GI:QA),:D.#L@9A4';5*M@_*@ MP>.HB1J+'Q"VA"M*5!F?ON&OA[;[!%3Q>0^^['!8SX<,HX7C:#_<.,8&&Q=H M^;?Z:OM<&+Z%J;_&6\^FHRUWGB@S49?QJ/AJ-\;S[5>OS^Y M&<]'XR_:]>1RU!_IL_J8G:+P/9YKPPM>YGCC]2-% SCZ>,S15+_LS?6!=MV; MSG_7YM/>>-;K$ZYJ)#EQ;!B[ =J^K9M-\:=CBON3\3=].A]=7.K:>#+79YCV MWWOXISJ+17$5ACI[?4SK;#[I__IUC^>]U2G=7 M)" VLV*[G;PQ<^0A/0B*.N3E+"WWJRNL["%+VN0ZU)&_:[_UIEAGYK-P$N!) M,9^.^D2?HF8WX]&\5D7:/F.:S<-Y%@^C^16>N?41%=E2<^,96%7.WAQ3-1IC MNG1MWOM7G0M%@561NCJ>O:UL==1^V'Y)KETA3%H'N']7(??1=VKD/?>:0./\ M?64K0P.<)V8CC:?43I^,JU0/W4_L.[)[G[CH]7& MOK16:$"*6-@ %ZG=?=;_J@]N\$:)U7*@8\7LCR*UQ'",KL*-_V:F#V\NM<^8+O@Y=HFL]%9DJWV@;-@(4]?00ZI';0@C:S2AMPC2%/T MD!_*8Y=23FF)*8_H>T$">OS3'G;\PV)*_%] L1;\]\2?Q15FR2MG-XM\$(/& MI0WFB&X)WC9HN !+IKS<;-(:A&96I2VNSF+*H.5!@Q/'M$1DNK"L&T@I]_\FP&[T/4Y,SW(3 M>O5WE%!+HH#M!55+RS-Y7$XVI%LS)ZN592(V0''[S.:BBG 5 (C)1N77T:41 M&FX\+,>-AS"'0^N9_(M9[1;N(ZK(4W&L&+Q @!4N^E3?[K5WAQ;8O?:=1964 M+NP7-?/1-U_3> M=#P:?YEIU_I4FWWM386[LWM.8"UCAO?AL?JS:6^P[(98*TC4W":ZBIJLCF62 M4H:,.-3*OB#:-5Z2$VX'>C7?D<;-7K6*@<[X*O$1X[)O;N)>O&0/0'>#U/I1 M"=PGE6J0VYSHFG%CEM;.L7'//-"S>XIQRS2!'X_&I&4HDR^G/MQE]N+(IQN2 M5M97]B4J[KDHYE$JP">7%31%=#:J[*'FHGPX M121/Y0'TW=0G]VT (:_@#]N+>FVMI.0SF(!$+_#UM7);9N^>1,'6=E")AA>6 MRU/SB;E"X4CFQ"L0/AV[W\9DTA"!9+KWSE-)$R4"J>,O:KM/=I&LM;CKNDC6 M+I*UBV3M(EF[2-8NDK5TR&73M[ Y0R[E?+8W<2B),LQ[FV#M>M:?M+HUE$Y8 M@12[#&?%RXY/:8!,L X-XE7IF8#V&[K2^2]Q, M&_R[^(^)9U;A*C*L>^E7P"RF'G,\\5?@*FVI@Y^$+O*D06JKQVK-,FL=P MUT9!<(YH!T^1DLVJBE^G5 XV?K8@1(45N8T?&H[O*2?>U+I;!^,-$=1DM;^0 MZANV3;:&[7UFW)""=9 ]$3FQYL(+7UR_T\H-1P3C8B\#?MZ2>33HH5V$>'7*,Q0R1 M_Q"F'@V;5)3MX>.MY[U@VL-5@&*R\'17"+;\;(&0"G/R['.Z^ZY/LS>/&JH' M4R8#("#"'"L@?XR'>NG]E(2+R0^(GC /RI#($UU:C\3#ATW8.U)3N>?[B"M% MFJ>W>DCRS M]Y&P_34)+QDY-XZ'3!?_^D^TG!O/%\C!0@_\D3]%AN\ZQJW]S+G22S=I17[%U,D$N4&)$ED MK8A9;06?O4 )9X:L97 IT^Y4#@N9=Z?R>$EZSIHAC]1,RU=BC-)I\4[,YD29 M(&XNVB&(WC5:+F!.?/N3U>'YS0K6 M(5.$O[7U,'=U)[ H-GH6@ZQ!FJ\*0<> @A6?/$17D1 !HY2[7'U0M_4,UG21 MNQ*3C.]P)F?!N^0C\HE-@V1G;/#N'483C%W'C'Z +99\XRS.)#ABY[@N+<(= MA+4P2W2 ;H.^ZSPBSP\C*\F_ A+HY0?>ABQ;406],QADWA%4@SC-,ZD#.XD^[N("X46<6*G7LHU0 OR*!T#CAJGGJRJ#$V/#S3 M\FDE=/*/I1KJ13ELYMA;'O8P1:4:U.&A6@(ZBT'0%26TJL.%@0DD00[XT!G5 M"B8YMWG]SWP2O:Z%M\F1XRYB_H>NM4/A.G3]R(AE0M*+ZCRFG-W6) #SH M-9($G5[LIL@WK62H-%\B-&4@9: NPQX$H[ DEYR5%73#7!^V9=X7%1]:&8VH MEF%(1\35,=D=R@F0V54YC/D8@C 45FN$NF!%O\=[SPQYCY99 MN'97:AS5T"W"'>B]$7=#3#%>RT.=/4Q+D*8Q!P*=\-,UF7T6KSDD/2[I3N9+ M/CL_3C[K3\;?].E\='&I:^/)7)]IU[W?>^0G:7+/9FO7"TB-#.)Y2P&<=1[) M;B\ZS^R +NYTLJQ>TF2-T:$!<\5@24B?$D8H3OCSJ=&'66TEB/:@2#_MZ<[F M5;)+BSV1/$]QPCW$A!A2Q$S#0^Z74JN#1E&Z"GC9E M3IJL@QZ%!>(E6C25 ]/&VO7QC3X4 8S^]'B%'F09-\UNCSD?@Y:0-)@J2EPC4JV%>G? M/#M>SB3O:I,<),P.[I*\6P&CK+MWE^2=0I:6$_VQ;4G>'VD!P>(K<+6M'G)N M'WN^JL?"2.MV[JL>WXF@Q+E^N[H8VTBJ89B]O5L M>0(REW<'+RIVF7?M M T>D/^CXV#YD_N?.UN?,-9SI\P,R]#?'BB7ODQ>BW. M!6W'D)*[.4D'YT;5E^$#9(:?35&$?T%%@-UQ<2[HQI4#!%[J01PJOFS-<\QX M#BSG;F/YZ_ 9S14)GJ7OTW /A;9L%MO5U5.H!:$Y_A[S1,CH)V9O9PJ>C5.: M>9EV_7K@DMDFJ!1224_S1Q6^6$?)S.:+\Z<)7E5EB<3L)ZO"3SMII#-63VJA'1EVCS5 MUR*9-VI1FB;IGCY%?N!99A#'Q-Y@A/SI[(:UMU.[+=X*>I>[UA4B]? [2P#@ M->=K<0E%^^N*J&I/;Q.L78^\/ MQ NO":/J.]?("YG@@@OJK!IL=#[ VQX)X$O6QLHQPZ(.JL&4IATTKJ2!9K() M_,!PEOALF .?1"\U04HQ %HFHI ZS-7AWZWH_91 BX<%T+B0 Z_\VQ9??P7Q M*[9Y";LG/R3^TOK/QEJ&9G3T!^28W"!F=E8000H?TEV4'-9]2>0^[DNS7N-S M"V*\2\(UA!)0YN1&.I_BM>>:""W](18",:T,K'N3U:&"DD/K3C'#W]"F:)'Q ME("Z#&L0[L+*2A^2_X?@NV" M@O=Y$__6N*/LEYP#*(%>+E[ ,[N\7G?9WP)104=JXQO4)X%)0)1BZ)B[Q[9/;JX/_ DC6/&!2#_ M.$K 680E$&!A+J1#%_O(,3V$#[L]T_0VA)< 81:X'S0!NBL#)RN-9Z[Q_ >.WT>MY!8T2# H4V&A1E0/7/C'^-:.Q[N=>RRY82S) M%@BV6*_*+=O[?@O%QH\![L@^>%;P M;>I9P?Y7?7!SJ6N3H=;_VAM_T6?::!R]-JA-KN>CR7CWOJ"HQ[^WA2136D"I M,YMH*[A0+NL)P:-VE*9ZR5?Z\ Q-LA7'C5;]\$S3I1AS/CQ3R].#PB.\$S= T0&KAF ]Z%.+ M,T&%'_DMG'I8AM1(V3R!!)^_(7*SB):]1^09=VCK ^*)7:F?@.]*X]B":,:, M;-![ G,_100F_/L^-F<\PPPVACU'WOUY?8Z5 L0HHI\BA )NO2U8,T>880M; MWV;H?&IDE3S\I")Z5Q_KX&&DVKN][-ES7 SCQL'?3CCV2.TN_V#Y#NW6!$LQ MDSGWWO ]87$42:QT4D@&TDEQB1LEY^"7,/BL_D32P^](K&8U\@LIC[BDD,)E M##.YK.F841T1+5"[JH4!Z63%J2PT0K9UBI(<9(9PA"$KN0>2&/0R#$' B0O< M$!NE(R_*)7F"@!8;3E%FC=HR*'KCR$6' @HF0!Z0?Z#S49'Y-85>IFNJ$KSF9WJA2OPO:J7)2T0 UK MD0BHHT5=UE5L6)B/:K:K<"")H2_#$(B<>N5Y#O=B$EE6]S5_ZE,2*TF]+(-J M).]QBI]1,??\G 1\5RI78B<25I2ATLN5A"RR+U^51X#2(@7JWQ^V5C!4Y:MI,B16,''B '4N M<9"4(0UM6UZ&FHCV+EFF*\ LS3=0,R/%U<3[CVOPXC4D-TM>B2VS5 MMQE<#!5->Q1"4(NT509!5GWND$&!H4ON"W1G.4[V$P6-8\$DLE/TVH5;]2FO M-N7/5>R@&FG+6.Q 4L64I#C"P>H>'UH ]ADW% MWVZ%9CTH+4LF@:4'/[8]GJ"34MZXH4 M4U!EEY2@%H.<*^TNZ;?AM7;WW1;I;H/R GW"\M]JQ&G(LBVWW$2U2&%E$2:H MS6V\XJ 79).)Q$[3:Q9MY4$J,NN]#CT]+@TV$86=UME\I08J?< M(T/)$574M*F2)4+T3Q:S6?):)0KJJH!:)T+,!IAE:!?)J@=1_Q97@,Y.WYN0 M+Q@:5(M8K*U#5*G90\%3,./AE?%68H!]0 MJ I&;IG:5"814#F$UR[I^?[F/M+P&Y\XY':O?U\A@]0F(9*BEC)Y3RMETIO- M;J["9[1GVLU,'Y":)L/>:*I]ZUW>Z-J5WIO=3/4K?3P77MND>V:[>V;[^TG M[9[9[K)HNRQ:V;-HI4OU/*9.BK4A=PJM?,G)*?(JO^\45\-S9U$F;$W]^0&9 MV+*&?#9EZU@RO[GX(&N%Q698A_1+WG)&T F.QN\WU\;#V%;P,L5BKR%^B?_C M:BA< S)H9LL0K7D#Z]%:XB.Y +U+?OK[U+J4!$"CNQ4Z-[7\/X8>(GY)Y"$_ M:%#GLC[]?>D<* 'PR"':Y;(;_"%ZU>(/G%6+I_IL/AWU MY_H@+F!\,QYUU8M98W?5B[OJQ5WU8E"+NNK%BIC+TM>=[:H7=]6+RW]-2K=X M*ZL7 Y$06>8KZ ,F/> .+2Y5S&94E8O)=4]1I/;2PDN?:XL?G9/XI*"M.%!D: =MX)H6K-I*[3^+J$^ATM MY(>,B7!P#U)]<74VV+Y5/HER_O^^?+.^-!ZQX(&WWR2XRJ(L, MZB*#VAT9Q$CFF9/59K(:.4L2Q+LQ;#B1$FC:OL@@F-=F7/YY(?O-"M939$?5 M2-?6P]S5';R+O(!A&ED,L@9I/L>3C@$%*SYYB,X)%0&CE$$T]4$M42YJ?VVA ME?Z,S TQO":KE64BCY9"2>D@($^UZ!QS>?FI>F4%@ICZF%JLI,0LI\8NI=HM MSILNM5)>ZA1&P"7P;<6%3B<.XI5Y5M/%^3LEQ0[S DK^7<62OW"Q?3-9#2P/ MF;@/7?;9C1=O!*1N5R!]&C?@=G!6\_PY5YHME:HO-$D^0&F_%18E,T"> M]1BZ/_;>*))51D^'H/=JWQF(BVWI DGVY&X+%)*@75:X.KV7F.0%+L%#6,', MRY234#U84AYOZ@&TR:--'B?FWO\-[GJ[_.&CIHW7B#X9.WR,"#?UE8% M,#)O9I6!)^DVEKC,96UCJ::+++(;V,;HD\/E(!H^&HO"(;Y"9V%PT&PAJ"9R M'OFG"89D+^Z<'.Z6).R"HT[ OEEK;8-,<4@4;KNCC[79I!H*S,Y/R1.0N;P[ M?5&QR[R[%X"FT4ST?VP<-']RYVMWXQO.>6(1Q.5@F!T.T*H'EK[0NJ>"3*X4KRB15V[#K&_C=S_"_?,,, $-8TSCV0 M&.N CHM;CB7Y# !1\,J\;=>H HVZ0/3[!]N-5J,[#X4448_>8/O%N: 4Q:(3 MS.5F"IR1[ZN-3V)$?N_NRF8FPCQ:+IQA S1MWT8)\PJ!]J%1R&*2;AS_ 9G6 MRD)+6A(&I7GS63-TN;H\1#>TE34$@I3;415 -;KA3)SY>I^)S8CC3S==G']L M/JJ9K>(N#]7@=/@H+/"'%$&QG#OZL>N@4?OVD"PN(:@^"@:*Y3T[:B;F>)0E MR4Q9R^OS+")N*?>'8I!(ZAP$)GXXL_'DQPO$Q(&W%+I3+FN0Q;F@6\3L^<'E M%(;Y &?9)]EJ$B9XH%T%F[PI\DTK603I MR-3//U"+L"XC AH]6J'[Q3YP?*B=-$:*P_"'VN17M4M)-"@D$OW\JK/]Z(! M=!#E-"'&Z"G\$S7GC*=_"T'.P3<$NGHUGL=N7/2Q\*L\:LM5+#:I06I MI; RKYM^/YD%6?93+PIJ2<:/6,T6=98"&_;]@V6EZ\; MUQ@TIBU3) M@=NG7)4(!-(?88$QUYYK(K3TAUB.9/W%IWBT8Y*B'O1^[4.?A]]F+G1S@)LL MRQLJX603^('A+/'>.T?>/0POJV?[ .;C6+I;E\Q5:;MI77M64DNW2]%9SE6? M-5S[E*&$&" -^52M7VO[]?#H"SJMCEJU""B0.]#=)/9.*%0:AIT?MFD11@!O M($(":\=D'DS# OS%S_.'W5N(*S_;(.3"''&T[;Z86=0^@-G<@K@*\\T=99G@ MK0$+A++P9K=O'Y8T/D$4BSK;^)Y5CVGP?T?!W+U 4V2Z=X[U)VC,\'9O$7CY MV0:QE#?%MSU/];9'\81(#M3=%C[])=V+I)WNEI(.@SCC^KY6HN4JW8I@8J5 M<&XV_1"A%1 6^%X8_)3UPN!H?J6/Y_(\&=AW;:SY;D1#.G74!/ZQNM -,]V,O JGNP MMWNPM_F2)@/ORC+7!K)__=7UD/,'HWAU=FOUWN)E,%/UB@D(?[?/DC#2 ?)- MSWH LKY(>ZCY(FL):,#FJ-,YP.07@DC8Z2!^S=GG2]_+:MU&'%GL5FU70LN< MA;4'D:\:WLN%ZVRRS,9P44@U;",J%$XYEKXF'?E[NWF,@@%:(<]#R[GQW/-] M%/BQ9S[3I__F];%/?];_J@]N+G5M,M3&^EP;Z$-].M4'VKSW+ZTWF^GSV<[9 M_[<$N[6Q-$18M(8]PF#>(\S4E+R]0&/IC,;24!_HT]ZE-AKW)U=ZR-2T-]>; M8&G' ?*Y[EO>G!\SLB=:GV7>N(2TQYI'_H]<4^'?_#]02P,$% @ *V-A M5K;X9GGQ5P "U % !4 !R9&=L+3(P,C(Q,C,Q7VQA8BYX;6SM??]SXSAR M[^^OZOT/>'NORY$TL[=O*[5%4Y#-+$TJ).6Q M\]<_ /PBDOA*B@1:GDME;VRS&^@&/F@T@$;C7_[M^3%$3SA)@SCZRU=OOOW^ M*X0C/]X$T?U?OOJX.I^LIO/Y5RC-O&CCA7&$__)5%'_U;__ZO_\7(O_W+__G M_!Q=!3C<_( N8_]\'FWC?T8WWB/^ ;W'$4Z\+$[^&7WRPCW]2WP5A#A!T_AQ M%^(,DP]YQ3^@/W[[YI\\='YN4.XG'&WBY.-R7I7[D&6[](?OOOO\^?.W4?SD M?8Z3W])O_?C1K,!5YF7[M"KM^^?OB__+V?\E#*+??J#_<^>E&)'VBM(?GM/@ M+U_1>HMJ/[_[-D[NOWO[_?=OOOO;A^N5_X ?O?,@HNWFXZ]*+EJ*B._-G__\ MY^_8UY*4HWR^2\*RCG??E>)4)9.O@8*^)DD:_) R\:YCW\M8MVNK05(*^MMY M279._W3^YNWYNS??/J>;K\K&9RV8Q"%>XBUB:OZ0O>P(E-* (N&KXF\/"=Z* MA0F3Y#O*_UV$[[T,;VA%?Z85O?E'6M'OBC]?>W<;N&](_7Y*>&B/@Y(Q,8WI1"TB(4%IC5P":&HNRJ M]-AOE!M2:QXGO.YT9F1E;KWTCA6\3\_O/6]'*GC[]CL<9FGYEW/Z%]8(Q1]^ MI7,C?L11-@V]-%UL5UGL_S9Y#M*R'J;D7[XRH/^NK0#EG"2E%E[B:YJBH/C. MC\E$MLO.P[S1<_9M$C\:B5&T66Q _&MX5Y6?-S(10:)(@RS!:;Q/?-RIC^O: MF+9J(>%C2#BHPX:C\X^KK_Z5D:%XBQ@A^H62_N>_?'?G^^M<5L>,XG4SCB'B167 7XEM"CI,$;UCM'_#C'4Y:BG7BM &<'JI0 M"'5@&FY[0,-U-56G#3L4&"FZ&L$KA-KKL@\\*V G*'JV,!UORN7HI5[EPZRUR&X6',A MY'P>H:(8=(X$$ 5F M_BXZFS\)AWWSIQ2=-W]" M(O?,G)'>.0W,9I9L@D,S?]%CSQQ< P_S)%#,S M?VUNY[#K+7(?\S>%:/ZF\>-C'.F-GH#.IJF3BEDWV '/++KTLB&Q:<)+6^V<"% M4!P*@\8'Y[TNDH9SKC,O"](L\(F!^("]=)^PLZ)1SWLT'?W!>PX>]X]"JR#X M;JO#A6*5G=[X"*+C11*U.[^@<3NN/P21NKN;WZUUMTBLJKOK'V%TMT BKKMS M&CB.P&T2[W"2O=P2,;-)M*''SCMJ?BY>UJ1:1=B $:?=LUYC59I'OUHVY_#J M+FL;>-=Q=']^'3P17V)-_LZB6"9IBH>:9B0;.$3@S=ZGWG EJGRS1D%L;6-& M*W"U"2.E=(X6(_'XR(&2'E4,<,S48KL-?*S&D(;6IBE2BELW/D)"YP RD:Z- MGYP6(G:N]F3ME!&OFAC,J^"9_J1>[ZH8;*)(+W@=2G)J,'C2BM@&5<6 O&B# M2A8XT)I$6; )PGU&)M85]O=)D 4XG3W[X7Z#-U>D-VG\WCYC%RH7VW(5?XN3 MU8.7X(L7<0$*KVO4&JUN&([?=(WMQO&J S.\QM>1V^JL,: #Q[@^Y1*G61+X M67%P^9%8"+$]UU);\RKU(E=NI9S4.<[,Y./W,$N&XLB%L8Q]TXN7^A>%*]>E +M';5T5:QZ_F7([ M1V5OD?DICI$A1N?RW&;Z$.#M[)DX8M0CRY?DB71;7TEM:Y/?0.1RRU]!ZAQ+ M9O)Q)HYRH(H%%3QN3X/60182Z>?1)G@*-GLOE)SX2NAL 4$F/&-" M!1<'7P- C @$4D51L\GFDOCGJEWU)HW5 M?7"1>(V=ZSH!&"B(I.)VARD-HD3C;@C_^S["Z\_Q^B'>IUZT67\FL][+%?&G MY1L[6A9KVSN&PE>;/!IZYP#I(&0;+Y0+D>[]X]A[@)?89^5S(I(_R#%CPF4- M-N8J5,C1L\ C[&LR"ZWP?I W7'%UOJGROF(CFYS6E) M)W1]AI+1.H>3H8!F2:NMT5CW1=6Q>HV".!@0R"5V!>F1%#LB.@@?[GZJ+D) MIN2Q>TIE('[S8$K! 9+)E(:1EA\3?C2;^ 8GTN/>*).+L+3VCLAB&(]$P%KX3HO">8\KQ1*<"I1T8W?V(L)&_2VF ML];E*C&K7A<1P>AXA63;(2$.TYRGZ+&PZY\U']?9 \X0=F#%Z$FTZB'"[/'71B_,"7N M$XS5-Q@5Q-:LCE;@RO1(*9T#R4@\SM^HZ%'%X#:2JLK[O?)QY"5!+(FDDM#9 MBJ12BEE&4@F)G -%)QF7:Z,@&==F+*+U WY/C\'IX:?*/Q'16?1/Y&+6_!.> MR'FWZR3C_1-$:!$C+@ZDH7@HGW!*3QL4?DF#PJ8W(A"M[H/4/CL'A%RF-A0* M"C!;%NSFG9?B#;V;AZ.47<[+=Y0)6OT'3'QK]69&EQ*L;G-T5ZVQ 6+.#@9^ MW67F)BA:PCDK@AX?Y=[,P0D^0T4YB"ZYP!@QO=ZRR(I>)Q7:1C-*:0Z86M7+)Q&3.X:.7K0T31LSB M*TIR>]O$)KO$#C>)M7O$D#I=(I5\AWCT +_D0^ _>#C\\<-.$9-O44&/?OP6%2SC^#,I]K^]CY^^V^ @=V7(#PG[64$WRW 0RI6!0-W$?G$)!)Q%N )WJ[L:2RW=&7L<_. MJ^G^M$"#YF=;W2P2JNSE^C<0G2P0B!O;!0D+=K+K:1!E,A5-U_BU$\"%F"@TJ-!9KW3!4)R?5^C@04! M7C Y$FJTC@S[$M\'=&JA(E3' @HS)J&W;?J58K?G B$Q"-"82"B=+>I,J.)R MA*-)%.V]<(EW<:*"3Y/,-FI$0K;!4JTF&D_!% M"PJ.TC8N)**VH=$B X4.L6Q2@%3D;C'"<@>QIU^T(.%)K2\W),)R2X\6'2B< M2(23+TDJ>K=(63W@,*2;ZUZD-R@B8MMHD0O MB:AMW+3(0"%&+)L4*SDY8O3N03*+-D80J>C< *0EIA@>!1% <#0ETT+L$ MQE60^EZ8RW)%_M:.7-/0V@:(5-PV2#A"4$"122<%2\Y08H:Q. 7,S]A+S.!2 MHW0#%DY4,50J,H! :V.7D#*(YFH%F4!3235(AO]H*(#C&)+6S(A"LQT?X. @L2H;C+-8P,43J4 M$SKI^?*4(,INO$>1A1"3V46 6,@F"IHT@) @%$R"A@,MHL1.$#$EEBGQPGFT MP<\_XA>I7AR=74Q(Q&R"HD4$"!5BR22P*(@1HT:$W DP;I/@T4M>5H&OF2IX M0KO0D G:Q$:;"A X)*))T%%0H]5\ZG(F67O/\PT!:K -?';HK$&)E-XN6#1B M-S$C(08$';6$$@01)M3D<@FD>>3'R2ZNA3M,:?:WY&4:;^0>BH;++JB,5&A" M2\D""& F]0$,ZWJFMF9(?%\DZ_BP*SI92.H$,+ZH0, '#A9-.!A3)0?X:RN(0)99>1. ",16HB:%BT\Z(@%U.&G MV)G?*M8.D)'-C99I"BDU,3@,/)$W!M,8EIW8)B=LXS;SP_P4[Y4)< M3.P$'D*!A2!I4,*#BD@\'6!R'D287"RL"[C2 PWA5;+6=WM7@ 5B':X USZ" M (%((OX*<+Y[DA/9[F:*T01[$HO0_&RMDP5"57U<^P:CBWF!N!YFXYK0N!C( MUS&-D7J((WF $]BJZ=EPI6]W?X.HL?@#1NVUI!&\AY=\M]^9/29"1FJ?QX^,^*DYY1'&#$CI;O:P4L^QQ M(1&(WE=)QCWLF=.B)K%E6*SB,/ #FL#Q UE\)H$GTDI$9 L0<@%+-/ 4(* @ M%8O+[581HI+2,@AN$TQ!B$E'L$N .-K@9+'="F=[%;$M4.@%+L$AIP0!$JUX M;; 0AG._QH%R%L1XW,)FGJ9[G'0"CX#%$82DPDN Q-%#A)-,2"VHZ_B=>)MR%3XNKE\2X.)=FGA%2V0* 0L<2!@ 0$%.1RM=%P$Z."%.6T+K)3 M-805J-/Z;@L 0K'*KF]\!-'I(HFXP=_H:T8H08I<6=V%P[TF2$RJI;8-"(7(;'P)24%"1RR>U&14+.O#8SFC)4IS-HVV< M/++ZK\@/ BTE=-9R6JK$K)):BHA 8$0E&9?6,D\Z5R-&E-HV+O:;(,.;7)BK M(/(B/_#"*CVB:$=RL]#\#X M"8?ACU'\.5IA+XTCO,GW4D0G16IZNQ$S&K&;03,28A!P,I%0$CI#F$NFG$]^F%B-PKCS9>(H*0BMCZ MJR-2@;FW1SA*$$#2BB=_AZ3B0"6+9=0L"(:3^CJ."3'/\*/TMH.>Q1:"3(4O M<:2C!X$F0R';F&)LS<4U8T24TV4VHWIR>[F+UR"R[!D+!&PYQC4*$!B1BB5S MB^MO!;C)G;>_"P/_*HP]^2Y+@\9RQCQ>O%:RO ,!( 3P4LE2Y#%"Q"B=]/^% M%_V6['>9_W*;Q#[&-,HJK:R5;O_-D-LN9CJIU$23$2L@G'615X+ 0Q&H5L99 M;<9RN9E'@\9I-K?8_VWUX)$&7.RSE,Z@1##Y+KB2R?+Q@H$"K4,&!0<@Z!F( M*3MP8)R(L9ZAG!G5N!VMS])#%D"\N7A9XBU.Z+V#-7[.+DA%ORE6& :\ME=O MQNJT%W-:1A @["JM;*F7HGH!Z([&B!5%H%]H(8B58OO]'7=-0$9D P9J 2D2Q!3.P: 4BPO\+HG( M7$[)AIW&CP+$=1!AN@78/I96$3H!!B>H$!P5%3R M$53@(22LHW9U#U2)FF* MLW1R1Y]=\=M;,#(BFP@1"UA'1Y,"##*$8G%3R6HU6Z^ H*#8@C$" T=K'Q,2 M<7EHM B!(40LG>S-M)SG!^>(F7KIPR3:T']F_[T/GKR0+G,GV=1+DI<@NO_D MA7N9)V+(:Q-1G=2I(\R($0SBNDC+(9 P.8==<62>+K&/B?C$V;K!F?C\P(S% MJMDR$+YAO13T8"!E("0WZ14L**EXG /K-L$[+]C,GG0: 5DQ70?>71 &68!3XE"Q4\:'.-S@)*6. M5?:B6429L]L$2U>EZG RY04S]W04F,M//)]( M,=@0DE-#Q$^WK:$:H_O]H7*-=^N]T/4=L;#D+\D>;WCU- M+HQ)<+.,[J"9: MU1NP@\%D=YFE:_Y=7@3RH@WR\D+@+.F,P>D:@V90B6=840##K"H4,(!$@QHM&F0L5 _NK\>LUM=./+EL%!R6#WZT(O>./"0DX.9 MKO0R\J](51QL9O+K/,[1U7E[ ^&M%VSFT=3; M!606;JHE6SZ8\5I=Q'51I[%\,V$$@[HNTG)+MHH7L8.W($)^SH[.$9E4GW"2 M!70IMVL"UCE4:Y>&E&$H')EMMTLD9-O7JM. @95$,)%7%4'.&WOWCV[,__N'-V1_? M_HEY9>_^\.[LC^^^/_O'?_H3"FAFR@W[=1[0:-:: MK]NX;3 ",)<"10QL98T+#**-1>UD)?W: ' .QB7.O"#"FYF71/3V[<3W]X_[ MD-Y(N\1;^@:;I&U,&&V"T5R1.ACU7&# :"RJ8)>U)$2;G-(Y[/@ED_':RO5B MU6R1"FOW3"J?>!.M3EZM3QF;<^#H#NA[GNO#"JGH$TH!"W"&THJC>4XHBJ*Y M9KKUDD7"[O1LF =\BQ.68\!H]2]G=K>IHE-(OL\BXP0SG7825[,;4UO& $-D MGN)B4BV?C!J#9W*'0)D"Z;G,'N?*L3O#G; MRJCM(.S/.<(B?$\7DZJC+JVD_(2;9BC>(L:"**%S4+U/XC2]3>*M--RC06$3 M-@+1ZCBI?89U LH+UL8!HT [1N(< 8L=3CQZNZ%(NZ*[%*Z@MXD.K=AUK$B) MP4Q:.@FY%WYN9\O)>G[S'LW^=CN[60&X,TXA3R94%OQVA:4WG7@RN[OR8B&; MV_!-&C @D0C&;[0?R- 64_\EB JG)U_MG=]YQ/&A\8@4;#"R%A.3&B=D'EUB M%K!6C -9E(F$V&HLCU+@1@2/D!(,K)3B<>#R7DB!(9Q+VDN<8M)P-)'A)?'7 MPWA'EY]J^&AX["[8#,1O+LT4#& P92(EO]S*>5@4_^; Y1QB[W%$9N>0YCG8 M/ 910&=F>J5 #3(MEU5GVDR%AH.M9@$#-3,Y.1\\Y\H33S3XX)@VSBDT=1X= MN^)&+CBL19M,/'&8=$6-9N"PDF_$7L?5E@G,O&8J:1ML-XN;\P/@YC?3Q8<9 M^KK8)OC&.?CF489)4VD\=([*[B&>4,3FX5V#!-K6M%@\_LPNIRH]GF.QD6SN M0];A;]Z^>\,Z?7GY_OK7*R(^\:LBG*:+[26^:YL7&9&-+E<+2'M<3.'<2BC% M:G=TC8Z>/VP(I7,[\-X+HI3.F3A=1+-G:N7V0?I %WQ"E'3@L[JP,E6CL;32 M,3F'5U=)N>45X4-?AX3Q&Q1'#''$RM39G0-0.K]VG8^!>#V=O!U8GK1.3/$J MC'"='U9B10#*U^6*#(*G4RX+REB$(-H340N9XRB]P-LXP3G=VGO&*1EAB137KQ);7]&\>H<1CJ [%0 &*#VD;H-X+(,Y.6%5!G&.MWE&+%O>R=1>FNUG\CX#^+- M*O.23#7]*.1L]\R%1W[UW5\H-;V=Y?A*EM$]++>7KTPQ8GCYZ@+?!Q&=J,LW9M>H;_)E]D3\@;\1K/8^;J3J<5=(Q6H4@ M,?)W<8JU)LI0:)!/^DH4R(=53_AQS #P)U'( ( M3C .32=Q1=@["0N89[JF M.P^+[<B5MI(0" JU'0V*2>''358G?![DF8WD7V@),>@[O@ X!47@U3L\J8H..1 MDU3W[!]4N!6+N.YX:S " )Q $6-S>!*0XT758>XD3%W^YZLX*6^5]QB(@C( M(%*MGJDYY J CE.EU-PK8<5GJ!"M)Z_JC5%I(0! JE'0V(2>'$S58LMP>A(F ME7U;[%B0R^P9)WZ02A/?]2@' &KU:IJ:5V$AT+&KE9R#+Z5%,2-&N" &"^)\ M: Z 8F5! &!LH*BQ 3Y)(.M%-T/R29CE)4ZS)/"S(IGTY+.7;%A^G!Z#7U$6 M %R;J6MJHJ4%04>WD?1<:H#51[ PSH?K0#C6%@8 R(8*&QOIDX6RF?@B+ ]E MFB4W[E1#[R=Z+?GHC>O:F^AY:&X6-V-UH8X,_HAY@*%A7"B ML=&Q 7H%&YSDZ.BFAO'P8#L9050;'^QY B"C9++YKWV:L9")=2QY)+R8_90O MJ_0HQ^[[[CW5;#[WWK$0,(CO*[G$#TK1CDCWP%*NTMN*/H@X6SJ@6!K8:2T+ M[(0*?,]B@BY>#B2WW@M[ H(N;8LMR4]DU8M)<^3&X,H+$C9=OI$9D=&JLWY- M8<1&XVX[C% 7F%$VLH*B;1=T3\HG2?9BQ\9D]>!EZ\)XP>F*%.KHM MU?%JKMT[4JJN%,LEO6Y)C6#V@-$+]A('.V!7-'D:L^@'0]]U_T5W],(WA[:VMZ9+U]RC(,N9 MB'HJVEH3=2P%#'Y[B\[MIDY6?T57UXN?T-5R\0$=LC]/INOYI_EZKLZN!F=) M:]=],+A/+Q9/MK)U;CL:.Y=+3#LH"'%#B74\C'49IRIGN]P#-Y9T(WR@>L#8 ML!&5XVYR':JB&WA)61E]G37?6")_I3_3#7:TI]OM082JQ++(JRIR/D[ILI$Z MMXMM'C,6;Y/%.BFZCI0!?%)'M7KXXA(%W%X1 W%].Q3)+ UE!X.")YFDP;AT1JUN RI51 M0Y/G@V(@>\@LS<.15)0 <7B;X)T7;"Z+>,3RQ;5HPU*,3-AP,FX;L\+<8K6+ MPFKTFI0$'\\=M.#?)&"LU?NQS.S&E*VPPP#Q7H[*VSPY#GU$U_<3LA2X/DP7 MG6V!NC 8MME$83-KK2H)VG;V45KH,BOE;RGGW' >4>95GCWNPO@%X^*]^SY( M5Q7A%M]ZY=2HEO,#=I"U0G.FVGLAU83 G>+R::5B;-Y@\[6;B-4M,.7*J ') M\P$&HE18@>UD9C(H&)RC;\AS' M'1:=[4CCV"2&L%YM&T$S\&.0A=-*])3>/ MZS@Z, 1JQ,YQD3JP,-Q9;E%X"/PS:8F:5T'DD4%[?-R9LB *#90U #-BE+ M^"V]19?&G:WRP+.K^>&8%UTN\RR^/I8TKRHHGQI4<-I%J('H=D@IR M:!MO>E$%2[8\]"?>%D>>C&.0TS=I_,-!R&)I>>LEV0O-I"^)>U R6(QW,!"\ M%N>@H'9NM(Q%5 $FR7G0CC*AB'(YMTO$_/H8;]A+S%7D4++R0KS8-N_?19)L213QVR[Q=(%CVTA;(X@-PU<'X5V)8 UDIWH+GI1?7XS M7^#Z)]SO"07XG8R(+HCW>%/L[<22;].R* M<#*#OF?C#C;D.]8/\1%A!_H+MW;.T<7L_?SFAN[H+*[0[6PY7UPZB@O_HC ) M\/Z^$_TEJ)S=7)KAT4YB@/UNE[^CZ(7E/?1YM(V3QSRCE29'@"FWU70!W51J M9 XP8P6SN.\FKQ"0MY/Y);K\N*1F(A&"C"B!I4=F- M%1&*V P+:9" 8]8KC9(2JHR* X *.CA^]I[QJD.%SRAY3 BB:"MH*$6%2" M2$3C,4()448IG>/CAO0,,87SB*9#I!M&T:;:/)IG^%%[ FS.;W4WL*M:C+&^* W2QNSMG4-[_Y-%OE MJ4:(3R8Z_W4_!=9S5.<7LQ]IW')^/U:6L%;'9'4Y;J1 8[&BY "#4",QNZ4. M9PF6:P/&BC"BNCP3ZW>&@J)W8TY@BKB'(OW'/H=&Y:.<#I&=C M:(=)QW)A#Y9^RAP]9+AW)YS[+K4DL]+4^@T21T^FB%/8U[X[QYM"*%4.GC(S M2A"Q$_&0YGPHW[6BJ!HJAD,6@I;NJT3W6B.I(+87>J83^!!V)J-T#A4C\81I M=/+G X:W(Q)TM"YO%H&4N<1%OMVM!C.=B["&I)[*5?CJR \#=?V$UM[,]3XO8J" M >BCY5>]=7Z8BO/494E9: W:U-%K;1*,MORIQF7N7\RC%\#!&MVR!)I[K*: M,SO-%FGHTIIR0LD+TDMJJY[O\1?;\W%!WV>)P\ W2&RM8+!ZZ5PK>.,*N93: MN5DT%E'BQM*0\Y(#TD,-%UX:$'><>"TIC1YAT2+19A7<1\$V\+THXQ5>X^?L M(N1MX3!%VD3G$,K7\7M,>6 0/H 2W)-$D]5\Q8+=EK,5/8IE)[#TL'4U?W\S MOYI/)S=K-)E.%Q]OV#GL[>)Z/H5Q[_9P3V^=>%&:/W.E,[]Z-KLW<,V4:%[# M5?. @:NAH-Q\7[B5C _5&2%99YER-.(TC--]@G7&N%,)$$"I4,T$GP)V\%"5 MR\RA=G8]6<\NT>UDN?X9K9>3FQ4-4EG4]-;[01&-?901VP2@6N ZUL24 M8&"E%*^-($J,#M20C%U3#YUADU*[PY#28$E(@:)(9XBFBYM/L^5Z?G$]0S>+ M]6Q%3-+/$_*;SQ]16<.WA9+Z8__G5Q?3E;KO[A=W]Z^^:?_AG- M_N/C?/WS2!O+!]%J>Y#%45+YL%+CTMEA^U)BPX8KUMIF]("-4&U3#U"F<\LZ ML"*2(Y?\L+$H$95%(E(F.A1:4+%BQS]:-%-/9IF/+LW%L6)/E46'BAV+@@'S MH^7G7= /'Q8WB%ETM+AEJ^ S]--D25;%ZQ7;75S.5NOE?$I7S#G9QYOYVOU2 MF39%D*=Y95'3;"\51W0GU7@%W;$,NS<]>JC7O/C1H0#GZ#Y&:I'%+LI@,1^- M4H NVVLRFSO5.B9'>#5TG]4<$!'9967_X<-\32_,.4=6=>_4V"HJ.9S<^36S M> IR,&C2RRBY#DQ8@)HN@4HZPZ5F<0PQI=%2T4,&F1OQY\7 M2U8N%_LT8$]J/M%G9?%G=N[]HER>:%FLK4$,A:\6&AIZYU#I("07AU!PH9+- MN05:XB<<[3%-RDI]/6H6?PJRA^D^S<@X2-1 ZUN(W6/>/@HV3WJ[E. ) MS=FV-+[%&5K%X9XMF4>R;_1&8AAB/]M[X6U"'W;(7@QLG!&;-3O708G*UAGP M. =41T%%>7M*3E2RCH2C]S%]WY?V4Q(9X$=);@TW!D)7>%'0PL")7L V/A@' M*EBFK(@5!:46CV6=8E3/PG8IK)$^>[%V'U[H)^2S9<(NI4!!I<] M!6\CMT@*1>:X54:0RRX4M;2A\@J'$YA^"5%R2?O'!/)H-JR,RC-$OVCP>M) UAR&L3@IW4J4/0B!$, M!+M(RUE&PHL8,YW:#W:RQN\E6@\+ M&?&"06A'@?GI^QEOT"1-\6CA)]>!3_/67F&LF7&UU-:6IGJ1JY6IG-0Y1,SD M:R.B8$"4P[E]>A_'F\]!&!)@SZ.,B$E?[FQ>JM9MUT=2[$ M.4"/E9Q_M"^K(CA&V7X;ZMB!OF5]'P5T;=3II$'%Y^!P0:^&X#Q!S@0&CZ:2 M\G<;&1^J,3I'W,Q+HB"ZI^\YL1109GC3;7&B^:QBF M>QDPYYU3ME!3&JZO:?ELIJUQ4R%1NH6-0L8V)G)R25Q M.7 QU'WPDM]PEA^<0<"<(O;8<'>Y0P% 8LE-]IF-N<'@L[/(@GS1!Q;GP*SB M^>.E5DM7KO/U5;5SL[5X,&*3VEUV87O6<%87J93D'] W^7,N>E<01 M^=''M3,<,S/9O1B[[]7W4[+Y:GVW,L" N*?@_!J'@AW5DP7'Z]G--??Y>QV.9O.\UQ_]'VU#RQUU7[G/%7-0 M?D(&V2:@4=9/>(7]?1+09,.S9_KB+][D0=R/NWV>#G&Q;>^7:7.(C%"15>]D MM(9J."^#U^)\C(VNFG($SJ\_KN>?9F@V6=+GSU?T45^T^NMD"6GHB=V^>J* MB4\:*\A>E)/.D 6[&5K'-H1X*/4M%>#0.5(5U5"9_G5R\WZV0O-F0@E(PT28 M^:C,H;%(EL']@SQER@#E.1H4_=26C(5NA4$< KTTZ(3\,H,*).Q7 __6>Z'K MG\EG+]G4!SZ-;\QCQM-T_YC_K?=T<4PEKJ>.XQM(-XWTKP'B>!I.+=4@FZQ6 M'S_D*8KH NB2CK:KR7R)/DVN/\[0A]ED]7$Y Y%T0S?="O.0T48;U$OK7(OK M<3= $W7QWSI6 7KD':^7X?P&-!U8?0LF?^%K[3WG88:3:',=>'=!R!:)'4=6 MQ]+*HM'2J>B (Z(/O*KD'\S6Z/+V=5LN22 7T_^1F>A&0"\7V'BO=+[ M*\7!)/5@=:C6\%B]PM# MU !FR(RB%N<>%Y70 56O!AWJ065%B'8LJE7%\O 4E1TNV8#Q5XYL-IU7,USQ M5N]-#-PHC0L6 Y4-9@@.K!!W96.H 0?)+SNRS2:/-)IPG/XHRSZA\=9LC@$' M6U[P:QEI#6W:PVP=9UZ(=C&]\4ZSRE1#+JTJ!N<$83?Y%U MV5- 1MC%"UF(;>;1@JS2/!K,71QFD;&1W];:D[\5'^-(YA(=6ZC=*P!#-$#S M0L Q)8(!^R!J<%?^]DE"MY#BDA!Y53&JL3#FPI2>WL[3=(\WEV0:B.[S#(]L M/DEO\&?V2=C19IR_O@7Y,J&YW,(K2RA@_&C#"D [5@)*61$HPI_S[^XGU#Q' M1!+XTCV5&H'U6W0-P;C+<>PK&'O B<3A@BU"=I0"UE!F&07[C.0FH^6!K.R+ M3O*V.^IF_WA'%HW$%RG&:SZ6S] 3Y7<^9* M <&/HK'7_&[-RHG$JFQ8_:/SOI=)U.[;D@1EA,;1VE#\-,(D MFY*9^87(QBRJT'$V882WR=--;.%C$'&$'HBK F&"V.Q]NEO(4MC)#5"3RK*Q M%XG8,NEU$N>#5RV7P#P75,@'D4=0&DFVR!YP(M=5R00BVJ^A@%&@'^. !"B] MF-P40;^A+7M;@47TI0QGSF%V13SE#%\'3[B=:%T;7VK&:O4^2 =E&M="#/C MP*^#L%R,*6G#^#'PJ]A2 DJT8RGR'7DMRM3#HJY2,L#S4LS$5:95WM32*L.8 MFE;!?<1>4]2;.R@^RLX"Q:K-Z&C9NDS7.>L:I"HS]&U<_;FOI4!OR674HB-"^ M5B'*O&=T5U3I?FQ6T=1+'%(];SWBJJP3+TH]YMZF%R^-+T;A^)W*%RA<\B#&A>GEGZ.ZE]1E*/+RD":XU<>YZ-KO/3I@IT?2- MU#Q@X&HH*.\62= (*S*<7M=.;[T7.AIJFM)#VSPZC#B#-P0!^2^RZ+2.A5@- M*>RE8".$L%,)8'#;2VPN.H460E9=K!24%)C>>>PZ:NWX%-UY(3UD<([G2WR7 M3>.(K'92MHE&?\KHXK-\M#2/2G\C:31S=KM1W-V4:H9SF_&"P6U'@65VEV&T M0JY?%0@?H?D!<7[,W!NGK4) H56H8"?,-DHX'>2*Q!:\PU(40'U:/WY\)#^Q M$]BS(D+0.8*+[/)'NPT]RK%Z2ZROFHT;85T+ 8/FOI)S%RJ+YJ= MOA_;T?)"3J:?#50P[688P6SB7)$3&OUYS]Y#N7@1)W(M]+^*DRT.LCV=M*.\ MC60M.D9-[M^1&J2I].],'54-F ES/-WX@"#2GV%^96\8G[!;^#(_(2QQZ@?1 M!K?'1^]27(*)R'RL5YM5_\GK_-DY0 M6G"8; 8Z6DD?T[_B DZF>S7B=^A=( OHVK,+<9+16R5TD]LL#D?$XNJY#9GP MLK_1"5P<\M#1 D'4"KQ M^+NK+?A< PIEH1(=SMJN/%^=MU!.;ONP5"5T^UA41 L&2QH!N6LF?/R(^R52 MZ\V\BQ>V2C2<\7@.AZ\?BD17O&]8)P>#*+V,RMF.^5=W+XAQ@9GLBGT')IUN MKI/0.MA%$HLKV!EJ$H*!DDHZ;B7-\%(AR'2:&[$3;I/BE:?:AL!DGY'YF(;U MBWI#S0%O264H+W\7MF KTA046;2\BM/Y<&\J=AW\]S[8L+.;_ ..I.GPC#CM M7I,U5D4.12$;&#-A+JL&B6]2$ZB3:'HF MBL&=3R 27.X*U*D!04\C8AM>.0DUFSXQP-Z]>[O9G!*6>(/S%\C9/'!;R6DT MH2BXW4WJ6I7D4[J4%0P N\G+!^.4](:(_'M4H2CR#MSZ>$PE50&&569J6$?- M]9B(/%2BYOD>@G9*_M3&4 36J\B2"]3LTWB#SJT%] M8+PN"TK*WW[X7*2\Q\^X8(%H6<>(W#LE2RN77IWD^\L-W#N-WM4(;]ZY(UW# MN=I'+'6,%TXV_[5/L\-=\I:>6FIKUVKT(E?79^2DSN<&,_G:^#@P(*_B #SN M!WB-Z83&N=Y=9F2FWO+X@1>0'AX"M_8=2B&M:U;:>T=8L)Y4!5Q/]Y1?O*N1 M57>R#+K5P9;]//(33!8:$]]/]BQW,B:RFH6R2GG=;==KU)%OUDL8G3L&?:3E MGR*^RU!0,9^1GW/V,^3E!9"_Y"4X,CKO/2+>=9RF.%U$LV=ZRK4/T@>6/GY+ MQ1=UH);)EK/PY[S[(GQ/L\VL=3Z#N=S<\3+A1%^'A/4;^DP';O#2*61#N)T; M&/&)^I0EF.H>-M'@VCY7%)-96HA+AJN5GZ[MS)"B$DCV4N2O(8*TMQT^@=1JK3A,--*\"'S() M.)]&F#9W^FWR.\DQ]"?BSN!-M4(3[6*-6Y7U@YJ1&HL[H!FX'N>&T()RVL>X MGQBOR^B9HQ4O@SVNO"!A.UO"W8&QZH*WCS"ZIMQV,"')[_-38.6(@I(0YMB@ MHMH5SGSLC!2\)*CG) [<=,J'[; M^ +?!Q%[=?D"2-[Z =OE)TRWMO%F0HRA=X]+9Y-%CX[?*^K:3W30FC3I2$-9 M5?4K'^ &JG./!A8TB!$A,DT)#NBJ8?TMWN(\6H6=/UUYS;0"G94\*.J %0K =%72M'7081>L)>D MW]2-R1F:L7]AF)!A[.Z<:!Y$:> WGF$?S\ZWZSM1)T'<;".Y!V?B_CYA1WVH(D>,7CSWCY4Q6VC;VMDL/D8;G-1VA.GKW&G#OV$O?M8$+QJE M@V_O7AQ[.;S=-_HA&;@[62!9 2!MH9WPNRT83GZ6?\]"V49^S*)=R2G-Y^(& M&G(2;]8 RRD?6BW]KMP]98-RK*E2/^VD_QA[<$-* &I(#M^TG<;K<-6?SF > M7&?CC;B!!KPL$DDA*9&!B5!74?Q@39]2[,4S]5;Q$/+4N0CGR#Y.[B/<0/-Y MZC5&6/W!1:CNP#%6?S!V1H!%61UCP$OUG7HD'84X*:>D5P,/ZI=TDL"Y 7>J MMK%W,I@%.-X_D:6S.*(R@E-8MJ1O@L2QC/VCI6P M)E#34?^F&G+O2E -. =Q-!5-_$?"BS??^2Q]6G@*0U _VW+-X<:3["@&J,$[ M4B,/[$UVDL'Y1.M8\0X>Y< V80C/DHETM.=2E +3JVRHV,^G9$4X!_IQ<@_A M3W8 ,& 7R5$,OMVPN_Q4?A:-ZB+)E>P6A3\K3M?U0;BG 2NH4>*O&X)&J@\3 M!Z(/]3P-H+J,5'S=8)0HVR]6T0G<7 =N@0JH P16,&UARY3"V!\Q.XR@[TJ. M>O]54 ^H'8Z^S33LYF2K$CB#=VP5]7YWC?,U#3H'=UV-:S_1 6I[%6-8]:L> MS$-N.((;Z4/Y*S7%Q/[*,'=='4CG_OZKLR[1WXFU+IKS'5^8[3'0W5GXYLG\ M(G)-E^;"7_9@[I@5NCD E? MR[ O@]UKL0Z:M[EU9U$ .,/9I?K]-^A SX4=E2M\C"SZ)?36N(0;9,JM*A3/ AE)%^,B:9C1I!A.M M K$Z3GA$R5^7'#WW:J>J3V)4]FC,D=]!?=U)6[OK+3_)RGW<,U0^X64_K=-H M+= KJY,C:>"O7@=K\N/7L4>+ LD:P&@*XW.PUV\G9#OVE9+..]! PM=I3XR[ MQHV-T8KG?'T!MTV..0<3V:2S$S!*QMEA+=1W0@;#+.9Z],I>H1-QHMEA&P[- M!V(D'O>/H@82TUE#ODK,"K$B(G!(4PAY]#%)^:$RZJ\@3:A\XA2G2[-1X8GO M+ F2L(U?FW/_S9J*'3:,QDT].):F??(N0!#HA/RT 1I^S'7<"24@!=,$W;>) MQK4.LV>_)F19:6'*E)Z@"9]%S]!"@=P.D@[O/CI.,3K\H%4G(QVQ M/EOW-BUDI>JB;0=7:.P\AR/J"\D? IC@%(BJXWM%IY7^%%(K=/>-7D%.2543 M5@G ;%KO6J4GOL,A:,#19_JJQB]BIF]KVVFFMY-_;BR]#T^M@YCO.TATVK-] MYZ8?=ZXW%N<5S_1=VZ#//'^RQJ+[P;[B 1A8\IVR(3FZ6V %R$ Y7H':(FV3 M\XN_3[/X\0=(HBHO YR6YPTG:AU0IC0G>O>,6W>?T@NXVYALX[3R?>E^4T-CL%EL^8R_9WEU'<($.'4Y_TE HE8/CU38NO,$ES M_RA=:-VK%'+X0(M3\U%T288MUGO*7H4R";&U2H$-/8LJ=U@BUXHXY=$*XL0* M4+9BYTI:'>]@3JE<6P&@V8V=;#+(FT6V6FKG$H4JY"D;D&$ZR-*V0P\)OX3- MA_[-,L@6A"7#=*=OOCOY(M@X8;&-"NT:C+$;3O->T4"U0?0;1M854L)BDS2L MC3\6YJ$FF:@9!RD6U#.LAHW0Z5U639G AL9P&HVP 08ISV]?$W+E!0D;]Y,T MW3^6QF2'?=(T(K_91H4GD8/?N.$&R<&OKYM7"&JQ6=)6.VJ>*^G6.W!D_>"56V$W]=]O5OPX;(VY4.W:D6??I+S3Z M*6SJA@R4%_)D!C@\#Z2S?*_11 #S13H*]\49&3NNR.NW39^88^?,^6A7_SHL MB[A1[1B.9MVO)GM;/[U-?9!\>?/%#'-X+DAG^5ZCH0#F@G04[@MP0?JUR'$N MR*LW35=QLL6!2R=$(,'K,"_2IK5C0+CJOP 3(=/9U!/9EORO?\3OB=KP/)%N MPKTJ.]&I0ZR:$"/)OASKTJ4YCO,^C,S126(>5-0"H(0Q[I0WG2+SA!4F00NG M#4Q@IKC#*?"7"6?S=CG.)CO%?WXM-8O]W^9INL>;RWU"A,E=W7R8LH]%VRQQ MZ@?11I1MNG,1EE%%>N(N3K'\:FY_!>2&+J5\*&:,*"D93\W$53>/JV0XRA%4O3< ="W9JRCO^!:'P0:XCB[0,E0PG:J ,I0[G]1:$SF>GVR3V,=ZD5P08 MU*.C;G6EK^S-.AV3S=G*3($Z1-4<8&8O(S';N"J9$&TD%!1L-9OC''"E I-H MDX^16L@S36@@:0T]FTW0F2I1AYV.!PSP# 65F31$*%'"&%%<"V<'D8A":,\; MJ7(.0ZPTXK)D+SW+LHG3H]353NNZ@L @^ACII3 OG3>THP6,E12LJ*UXH$^T M&<.1V$O6)1;ND'BK^=TY'!1"*7I9NXO@:)[I.L? V4/L)&W':<;Y#+/$9$D8 MT)00;$>!YH>(4ME1OHS8YARA%KB.+C&E\V%M)!Z7 : B+C:><4[.8L[&RPDO MEC']&6?K^ (OL1_?1\'_B V].:^U&:"K.M748,KH'%Q]I#7%6HI><(:R&-UA ME%2%G-J&XRE=1P0W!5K77+XIF=10R@[RT#X*,I-K0">)2D#W5%[!B5U?E;6F M,@\O."L@Z1*%=_IFN9,<9#:5KV(BADV&JJD+VL[ZZ'H:0^N)\D'+JR^TXK+( MX'&K@I]+WZRQCL^BKZ['N16WH%Q?]V&@479\,(;_@#?[$"^VTS@D8L0TON0) MUYJ'[D;<$*!*/J_)3ZGGLZ9:"W+NCUF1U2"0T1JJ,=D-7HOS03BZ:NTAV"@> MU0I@.V3UWYE/AC+BE*$FTR^L_/]T/CH':*GK(,+S##_*CJZ'K<+J62)Z)P# MQT XW@0=2)#W&.^/C_.1F)'+@$ 2TWJ\Y.4BCO;M>59*9I=F$WY'JEQ':,^BP$S(Q\G?AOA%'/^& L:$OJ8.Y#4%.Q\)8V@C3J:SC1.4XN0I\-61V] &"8O3.+[5 MBF* 0K^A9$^4LS).$=!UP=O8S:-THC@Z/[!5-[:@PGCZ0*.,YE'_/=LA"@8 M]1X-80#^#J5"'P[=53ERH]@&!HIA?4'6MMM /7ZFU2S.EL^?4!MW/[=V#[=1/[UOJ8 MU,4N#8MV=KO+S*U%&3.:H!H[JOA1OE3])2]"&7T_;D=>].M('1O$CC246=*1 M%\ [ M'-71;>X3ZFB)Z'TZ^N(4.GIZ5$>WN4^HHR6B]^GH*9".ECP%PW)&%*D:RT2K M_#VL+LRPNKF'Y.(SLH"5@3:L$)0_YY3GRN!>"4B_A=;!5TE^1]H+)YO_VJ<9 M;;).G2PJX'0Z6B%]Y\[>5F4AKRH,4'_G;SOU'=%B[I/H::7H';JY2(H#>E#G MNAXSJN4EG%!G#S.NBPX',[!;24P_1G2KE E.5H&K(DR#ZV!H_/L810RW7F0.5"ZO; MAU6*3XM1EDX!PB!!X,$J:,"%KJ=HKA[NB(?\$-/'X$@]N3EP,^C3?97M4HT1 M*26L7M>)R0UT0E]DZP32)?4W3JN'W\CLLL3DIQS.N5H$NLV-<;$CU:LH6)UZ MM!Z\>2\8Z> M>IR.TEVU[^&N_XDYHDEV2G-5G&/D>,Y]R%);<:=WY(?5T_V$ MYS:YBE(JB^R7Y>1CO'"?#WWOKK=ELQ0_+Q&\5R#O,YD;EP@+$4.ITV4"%T[8 MU$&OF0H R*E4S%<@\VB%LRQD2=X6V]9(:GH] M#T+PP:7H[61) "K>KJ=/UEP .KS\P%YD/,#YRH9(72=^_C(+J?4J(D MTO69@A967^D%;?<1XT %"Y2^41V=+?&C%T3D;S?X,R/I=CC,L\/JP5ZRI8#J\>.4X(;2$5I= E0+P]5!:*\1$2++%Y# M<&P\R43++I\2K?]['^QH:TF"I:24L+I4)Z;@)?N"'E4,3B.=K@.?)=O!.-5Y M&G)26'VBE;/=*04#HAS W8Q\]JSO2I-UHQ_0N^#=@AF$1<#JQ][RB\,9"F)4 M43N9$*_V$1>%D6O$]9^<%%8_:>7DXO,KAEKP2+$U[J13_GT?X?7G>/T0[U,O MVJP_$WE>KH(G+)F<-/2PNL=,V'8?42[T]ONW?W0Z.UUBGU7.R4_^(.D;/0NL M[C&6E\\+EC/27GKKM)>*,,);TC8/7O.1==%W6.TO%J[=V 45*LET_RWVY_D7!ZKVC]9"?F MJJ(@5)34ZE]$"D.LM&I)5#QG"[WGJP"L8_J^*N1D>[^MP?']7Y4('P&[(#FV M_UD1)]S[=?FE?>\5?5_>R$$[UO<[TO=LH8WB? ; >7%N#@>$"3CY1[TO)(]Z M%\U$][5-&E!P&&=9 %B@YE'9 7! M.J?>B/FK\\.!M$.EKP28W35N@W']@%'$".BQ6A&MRX*O/C\$_@/:[L/PA27) MHK%U'OTE#^&GF55+D\HJ1_'!6T<>"_G-2.%W7DA32Y*B,7UCQLLP\KT(W9%_ M]@E]L8.4>(@9WM.% >/CR]^1@E[+**BM;+JO,YV(\NI'3+=VT/HAN?OA9<4X MRE<<.&7@]WQ2.7%)*,Z+(4?^P\E3<3F1QHJP07,8#GE$[.L>%&R5E\ZC_-C+ M];@PE^;5#XW.3:$?'95;GK]SK1DHXELDZ.[EX.ZSFP6MT?%:!D:5KP#*V.@D MT*L?'GU:H^O\P5O^AS@DDT-:CI%#:HH'')4>%0N%>\!!(N"O7<]Z/>.$K>WA MC!)C<;Z ,=*U+81QM(@=+=!9H!(+>0>YZ(R0UNB*S +(H\+1,8#:8Z 2L-P8 MHM>-BM0?G]5[2Z]GU!AM:UA>IW_AHZ5+.XC6]"5VSUOSB6I=?N1BA0RKXG;_ M+D[R?7:14];<)Z#7.ZM] %S;&?O[3D!UPV :1QE-/[3W0AK[?H'O@XC^W>WN M@%:\5S]*CV\;K1=XN"[B'TIBMQO8V..'!IOITOH8.Z,SVN]OHY^C#]'E.OHK M^6?U>\K]Z&5GK!3\[#WN0GQ&J-[\_,X.B4NTZR/G]C>8SVD/!+&JG]F^?8\3J@]\H2F%2O(OQ]D/? M2!T3<]);9*T>^.SJ[0CC55[9:QMZ6DV%^RZ&VR[J79?&Q$?W'_/*'=Z$%D>K M\LUY)V_.FKEJ-J=D6AFK-H X'5G5,8%:M^40@-K8]OE YK#'/7]U7T0$"Q8* M"?L'=;8^5%<7JL4VRKUZ1QWGUU0N92OBF>4=J6>"UK'&$@_?T>^!1W,W_MA, M04\-3*_@7DV9L- QG$*26,H6)%"-T0TJ"FA*P[>;WX'UEE XR07!U&E M>C" MF^2:K)P45NMKY33,H^?R?FQ+A^(1[/1GG*WC"[RLWF;5=9*4$727Z:36=F!9 M "(EH'5,'!ET*,15ZMQT'V9TO$N&%T/JV0;03?5C;:D]A)8'KQ&GP(K$P"<.=S2K296>H1YB5,_"7;UUCN\,B(A MA-7!&BFY=T,JMX(=OVX.#$XZXS+Y$/@/'@Y__#%.+N)HS]]DYTF ]8%,/J[YZX3HCE(Z&0'S MR(\?\=I[IEL-D1^$>7+=FYAFCJ097.]"7&Q,7)'"@R?,W@[87N([_EG18PJ# MU8\#:-+N<;S=$E>2AFP$K'"4><\HH1Y^TJCCC)Y('FJA&ZVTFK/BRAP+'"DK MI%/=AE0)"3KU!R#9^T%>: H4 >M)P$(N-_\< ^MZ4@)J%H&*,A K!!6EV.[7 M?7I^[WF[7R=IBK-TFL>N":U9->SIJQNO NR.CB+X I0 L3P6H>17"\3F\*U+7^*V)HFEQF$UMTL:. MFI8="!4W??.@65$+\U2__@%,0RN$$Z9J+$A_CW)B-,G( OYNG[%8K"RF\R(( MJ$^BC5GOZ'A@#@JUJ(J1P@*0H;]XG<9K>)O$V$,[.M<^ 6E\D%?=V%Z5!.9&C MMEWL,%E&LBL4>0"!J(4Y(D#M+)>-.QTK*:M@"==MGB_HK@D(E*U^((/8[@+I MY"U?+&&_IN3?.&K^\D'B @6BIF^1 &IVF62BIQO9N\@%H:.VOHFCN D41:M+ MB0&UOUY&[ERIQE'AOV!R-P3*,7M%_DZOQ@71GF5,9X+&47J!MW&"JRTKG,Z> ML\2+DTU ]YSG&7Y,B6+L2EPGB'8R.E2, M#C6C.U8U.FPATBV 9F6HK,W5NI6=M=:NF@F7K6VB7]^! 8!<-O'[GF>H1NO. M$B382_$ESO^=1^43[$OLX^"I?=F@"Q^LL6DNKF"0,2;T==RO)- =W4D!PZXORBR=*[929L4A MI[O9B\4GT1K=CB$-YK]UWXE@<9!)P6ZFH"B4 :$HECD?B?X\-1@NH[+ M(T-\@[.#J[*.IU[Z<)O$3\$&;RY>/J8TX5ZU8)O00V+[?20JJ0=SF- #J@'3:3DKU^5/'2WO,:%*!NLT7=% M%I?$LO0*_'"?)U#R'VA4]=++\(S%F@F/O:Q* AGCA3GCN=(P6'8[_Q/+-#>/LKCV MGF\=JMTX 8"LI\#RN_":$L#$8]W$&:9H"^-TGV#A ]2=F0'-EMUE-@KJHH6@ M0RDNWY)N[/@?\3I@;?^??]ANM$H #/WQ=1,>N9RS&E\T4]%V]>[^D#T/0=!\M5OTZP&FEL#<*:=&JGCVUY+MC1*WN=^)7H: VQ M5?V("0#GJG]^LC_99P]Q0E,O?:1/DC!W)E?DEK1/VACN2]H0->4*A;L_J^-& M%@"W!L T@3R[K'693M1F*U]Z'JT22&NGT70;TS;7:CUQA[C'PV:6JWZ=8#72 MV!J$ 3O$1^3#,4L[/WYMT! \KI+60 O%)Q[?()3YG_D4+[8% +"ZUF-.0%"@E$WV1$N=^/5X>NR1 M%'FHV;@U0EM\CZ^H?;^N)L5ISF""=E7LRUNK%,#*Q+ZN%KPQKO+7AUK7JQ#3 MK>XO N']HU^.3ANZ.5+&NP_PJ9YU\H!8-"=SB,LL_BU59%E(R/B'$Y! M*XE.-?;$O,U;%J!Z%DSX4A DN;ZLH6'>'"!?N4GM!CHKL)*"@[*XR<<_: M>\Z3ZU!A\BX+P_BS%XFCL0S8 &V%=9&6>PVFX&4/0Y2O$U3\J"H 2O_=8.'E M&UL[7UMD^.XD>;WB[C_H!M';'@CMJ>GNST>S]B^#95*ZM%. MM21+JF[/?9E@45").RRREJ3JQ;_^ )"2*)( $B2A!-5RV.[N*@!$/D_B+9&9 M^-M_OCSXO2<2Q5X8_/V;=]]^]TV/!&ZX\H+[OW]SNWC37PS&XV]Z<>($*\>3Z+>('QX]$E"Z"_2#__4^_[;=S\XO3=O .U^)L$J MC&[GXWV[FR1YC']Z^_;Y^?G;('QRGL/H]_A;-WR -;A(G&0;[UO[[N6[[#]I M];_Y7O#[3^S_[IR8]"A>0?S32^S]_1OVW>RSSQ^^#:/[M^^_^^[=VW]^NEFX M&_+@O/$"AIM+OMG58JU4U7OWXX\_ON6_W14ME7RYB_S=-SZ\W75GWS+]K2\-^].;=^S:.OQ=#U]9,.\@GL*:J5]3 =.O!GYX;,6I*5*;6EC[-'69Q&)Z7^T&VY/'2]B8AG3TN&0[/1C3#> #63HO MZI%<411MUC$X^YB9A6IT9,E&M D)CQM&&IDPZ1HVV_H8@?5:6*&E>9ENZ5=; MGTS7U^0Q(J['61_&B?? 5JS;F*RW_HVW)MR-") M JJN\8Q$BPW=V.J+ 6L(;61G_9@P56;]-##&19\PNZ?2%4RW':-[+MW.:S9C M:D^FVVUX"VV/[^/C53J?:X]M0"-F^[U;@!KV7-!,VWWOQ_'V(5TYZ3R^&@L3<>)MQ ^4VJ+4:=48*U7;@/KD %I#VC'IST\M?:#MLTX=0>0UV]:M M":&?6I,H(BNZBZ/:3FJH%*"1MOL](G16=_S]_G-.5U?M?@,::7U?K:L2@*JR M/C[F=E(W] ='5T:8GV%6K 3+V&%LTN%=[TW[ 9BRU27_C4MF75D MUQ4_=(^^[C-+?5@PB>]N/;@]/B;NM_?AT]L5\=XR4-A?.#H<&?J/W_B'^G=T MA-/]U*XEW[DC/F__-UJF4.3M"7JU0V))6ZSNU'&)8I_RI/4CMQ=&5$\IUKNV MG,@]HJI\@9&5>/O(K>5OW(WG[UE>1^&#")T,B5#0T3Q0]!.G0;-/O[]B?1CY MSGTUG(4B0#S?80!:*0T6HM5;(AP?R/ MK1,E)/)?(4B7"@/!_AX3;(&$2'AS0Y+'\($ 7BX-1/S/J!L/@8Q(D"\VQ/>9 MJX\3@+2\JCP0]A\P81?+:0'PPR>VOM.E!8Y]K@H0_K_8 G])6B0&9B3RPA5= MTB, ]J7"0-1_Q$1=("$JWL-@!45[7Q1\_L$'NR >$M0C+W8=/^W1B/XLEL-= M41P*.FL(BX-A1SE *H2 M\L28#X/$2UZ9;_AD^W!W,)P>8UTN!<48Y= I$@H%VYVE(4B8R[L,WV))*,8H M9TV9<"@X#Z@\_)ID15Y^(:\RH$M%H4BCG#&EXJ% /8N\!R=Z77BN>M(HEX6" MC7*RE N(@O;2>1FOJ%3C-Z#'/FX@'S[XI> M!^%*.J4K*D+I0#EO:HB.0DI_M:)PQ=D?-UY WLFHJ"P.OB/"(T BIB6PO]># M_3T<=I1SJ%),2V#_H ?[!SCL*&=1I9B8L _H7Z?1,GP6W$ +"T,A1SF+*D3$ M!)RO---H%H5/7AH[JT*]5 ,*/>(152XLJL*GBSQ$VWKA1;& MB>/_/^]1M9.L+@_%'/'@*A/TU ;&E'=FM!"Y$A6*0/%%.:M6BG-J2!G#$7'$ MZGM< @HHR@&T2I@3XWD3LKN/31A([;'E4E!<44Z2(J%./?$R1^)8./1SOP9[ ML*%,JT4Q3@SCE\A+: ]8%, VR&PT@ELQ05$HO"C'/ZEX)X9ZP:,'61SA)[I# MC+Q#+I%CG*O*04%&.>R)!3LQPK.(,*8)W79S/RX6:1!-UVO1S"LK#T4(NZ73WNN[]W=+%C$CF&5*I:!8HQSY M1$*=&-M)N&1!2L']XO7A+O3%X2&5!:$(HQSP)**=&.2C?E3#6R@"!1;E9%2RNV'NANB048)23GDPXM+GW'C3WWFO.O2@G/I%02-BFON%T1$WO M?._>$4>222N XVPP$9>(>NKX/1[RP[)]1@^\'R/ZEVK8!46A@..$2,K$.S74 MVY67D%7:I9$7.(%+CU2'!(4"U)6UH 3@Q% "A48Q[W\AOO]+$#X'"^+$84!6 MZ59?9N$75H&R@'B'J! 7A8+/H;^E*$7<$302C %!42CDB'>' O%P?"]3I^;] MVI.F=98A+JH!!1[Q$E$N+))_6D)8G[TG3FH?H_ YV62QG3*P!16@H"-ZMDI%Q0'_Y1!'GL:_29&O* W.3H (NU!( MK+0;^V2="_[21B1 758>BCMJ8*58T!,C/TTV),KOGWAGQO3<)G-Z4->"LH!R M7(4*C;.VYB+YI4OK43DHWH@'TRK!<&*FMG>^YX[\T)'NRX^*0?%%/(56B(4" M[Y43_!YM'Q/W=1:%+B'L^B3>CS; @0C8 )02Q/.I%A0XYH)#)E2>!SR>;A/^ MRA7MG]1H(*T'I08SB!,@.-(N*#X$>I'5U>N<94IE;@I+\I)S?WI9Z?T-_8"S%ICM_WWO3V5V$\US%M M/XC)JI=5[F6U&^O&VHGO./K;^,V]XSRF"D+\)-[]Y* IV0]^R[WQMK^XFX6I M34"2)SFK#JO=7.L;2;;,O_\ED2$KIQH))=UK=SAH(7L\4@0"Y;-W(5-!AQMA MY^PJHW&Q][FREE%RI% B\'/=SX>N(Q,P\)TXGJ[YOK?_XD%X*%?I(AUE*7)) MO7%(R7?I.GQPO*JU.BM<5=8R&D2J56"D2I)#OOI:3%2\GG3]\>:W!8D\$O=S MCQ'-HNS5"?[U3T1@X62UH971,FQ+X#S&74>:=C:L4CZNFO"AKHR6%+H&'U H MC/(Q:,*'NC):[N(:?$"A:/5 5V?E2%_,46_/B^6 9)CB0KP-+*P1U?)9 GMF MMH6B7RH.3K9KB 4!N%4,"$1%)X*]\=T/5NP/]D[?D^,S>V$_&3A1].H%]_R] M-P@[$P:K\YJ]Z8P=O M ?OT ]YQZX*"/AOF.ZQ%F"XW[5_*UH5P+^]#;H&ABA\ZI#7Q.6C!DFM%D" MD='A[0F(/SAQQ@P5M:;',Z#J\/HZ6\$'(7?H)X$KI4Y:"4JE,2M&PTT) !'T M>;+.CK^%/;Z!]W?:X:P#F_WCRQB%=;>R,)0D8W80;5HD,J/ST5^MN".2X\\< M;S4.!LZC1R?CXRY+-H^PZE#.C-E%M#G3P@6=Q9P+O.K"I%02RHU!RT:-I:E* M6G0:!$J3ZZ_V2#JJ"Z7*F*&CK6%4@0@Z>7.2.%Y 5D,G"EAP#STF;A^V/@M9 MN"9KEEA53!ZD+I0\8Z8/;?+@B*"35Y9-9P>H<4%L#3EBB3M\#%/M?^L;\N$4 MG\(HTM1*+,.F5?I1@S!F'-4-23PWE\KZ*"+C S BH_?'H\;^_1*A84BR2X3& M)4+C$J%QB="X1&@8I>$2H2'9PETB-"X1&I<(#3$?EPB-^C<6]!@QC?@TO.*V MQQF)>-(1Z"6&N'Y7(CKT\+",OC1!3'^;;,+(^]?A6*JBK5P/._:C)E\B *SD MB>>[UN1H5P<[Y*,1/\>"6\F-/+N41+8ZZ:6,[>@:L60ZSU3#FT#]I0I4&3L, M!$R9!A0VT09?HJ25L/?F=6BR=G$J]5&U,@DK8 >(U*?%LC5),]VA2*HZJQ%^ MC$?-E(>GOLTY/!LS74\?251X]O7H)N=/A9N<0]U>N.[E:J-H&TM@^$#V?5)? MU@@K8#DW/)%@2T94XY@K)^O*%R_9#+9Q0KL9#5]F$1/GDOB1>A+ERMQ'>R#KAYS:NGU M[\=_3&>S@-RS#22J@\3'*(SC612N9=Y(1X6PS\%Z]%7(UV%WEFS5"NZS.'1 M?*.D"O9968])I>SH$R53,SI[<^_$$9$%>I1+8A^"U>@6S1?5LJ*30,=G&-&9 M>DZX7V$FCI@*47GLXZXN(7*YT6F94_3HYUDBFFNZ%_+#1S;DE>PHJF$??G5) M J& SM5'$E"Q?!;9NGKP H^)Q-YQ4[*EK(A]'M;E"X@$.F,EN33V _C9#G19 M$4I[#CN[=%-T$U8^GE<$(%\8.Q%"S=U<6=X.LS@)@_!8L$Q%U?MT0%7T7 EZ M%(/!0)\^^5NE)%9O1TH%T1,CP$$.Y9+@VS($CDXC^B&ZY+(W-Z?K:W)7-898 MP8IRZ-D/M-D1"&+)./GH>$',IFH23X/A"Y-JZ\6;U-%=0,UN)Z6NBI[@H.Y8 M L."3J!0PAKKD@79#>H2IH2APUN0PWYJ=]G@!5LJY^'"ZXJLPXBDY9;."XFI MRD8.)GT%OVW," CJOGE3J;,1= MT75.>O<@K("> J*.6@@%QU\:2 (Y>A:*H>=ZT#R25 G9X=&T"Z3?N9]=.;'G MBLD3%$?/ J%'HE1H]''TA7CW&WH2ZC_1Z?Z>I*]&3]"T*.P M%D@V^1]-UX.-$]R3>!Q( N>/_)&^%_DC,7>DK+6>%_3R[?V;\QC&?^UES6*' MF-?+C@:J?@DR;Q1D7B/9QR7*W"@G'8XR3Q5H$#X\A@%SEP1&FE=7ZR(MU9*@ M1YP7NJ4*.A<4MXP0F;(5]WW5 N%/7<# V[WG3(-(6_/1?QJ$6!UEF_-H5S%2 M413;4:$.'4*)T;D0).U3\:*HANVV4(B!+A@S^B3I.N'3_YEH$TW8^4 MVI".0"=*4)T9-+)NU$^U@9^>"Y)?HZ,$,MU,L[I<;R,JV8QWC"=(FI!G_ANI MG0)4W9K-(VBH0N&H3?X3B>["F-A(?*KI]9DOU;=F:UJ3>@$@=JR> DU-LZJR M0._I^C;P9&^6:S9CS9ZUR4 6PF,KJ:D.-F=5V(XUN]U&@[1SO')MG"8;Z1%2 M7=6:B\\F@_((!EL)R_:!M1@[JFO-/6BC =<)SKAVI3\>A=$N&52] 5?1C#7W MI4T&GQ >6TG-9Z-LPJJP'?2X[79&:.>(Y>K(?S=]Y(%7PQ<2N5XLR[-:HRGT M&/!6AJT4)UL93A6S'8JE;:%'DKRG!6XF4KVZFBMD>WLCWT*/9VAK9QPD7O$$F4\(L310[+;Y;.-%7D M\?=[M)I #P=7\Z4O% 9%J=XTXTC4!GIP=B.2Y,C8.G.6[)&Y![$6Q*4EV5._ MSC1Y^P9@NQ6AO_KO;9SPEPV6H>41 M^&P#F!WU/M.](:%"IOH]!LZ4;>;+Z=_3L2'OIM)(B5=1" MVPRROLRB\,FC]%Z]WL9L\[K/T]ZG$_X3/_@"7M94W$T)=( ML\D>C:7[K0^XR320-GA@']DVYL0- ]?SR9&0=-HX#N>+(6;9C/801]&*0V;(&/TF%RX5.:.T!!' M.5896!<[IN,4S&K 8! M*4@1<6)R3=(_<[!D]V2@]\K!;6 'G9QR==>&%GTM*'>Y[[KAEH)%H2+>DSQW M,JPV=@Q+#5I4O(I!.K.Y81:11\=;76>2[)[@"58\I(>]:"\++ZS;'G:LC &- MT0'RS'1H-UAFSBL;*>S!5=>-Z.;XQG/N/%_ALE2W/?3 '(/3#@3)3IN\RJ(/ M'Q[]\)60[ GLFJHC:P4]U,> PJA1LW 'LGL1*]-RNE73H;BJ-GJ$CP%JQ2BA M4]KFEOLTAFH+(H,:JX@)U#O\?!;GL->=R\K!\U]N]9960H^&:L!&,3N^$AL+#=GY7F?; MW)D3):^3,)%<7TGKH$<[-:<4(*4E(Y(*Z1*RX@_J[J]'HX7CD^E:Y>$)J8L> MLM3:^(0CA4XJ7.8V5E,+ I5:(UD?N0YOOIBD['],>Y^H'G.+^NXJG?VB'ZR. M?Y KF?JLEX]-KK]E?K;#%Y>_NSFG\]YPO2:RC=NI^V%/G!1\TX?#U=>JW'MH MKKWX,8P=_V,4;A]I#?IO-WUVGJP.K\X;4FWM7M@3/W8BQ:[)4^?307]]RJT3 M=F(^'L].]3Z?^*3MXZ//@7;\'=#C8!U&#RG7ZB@0: /V1 S"54H3'?33R.&J MQ%LI;I,*!?&#!36A+MX:50IN 2'L1F+IO) 8P$FY+'[X7T-:1.*C,S,) Y?* M,PZ>J-JPXV:PVA\]>9@CP H.;P+*H_E,4AK&;UV$T#G-9[M)PPX>F!=)ZJ N MR1.BJ@=ESYR95)N*XJ/*$& ,A5_D/\XMLB6GGMWL/0JC]/EG^JO<.] "VW8+ M[4*)-6R0 M978Z*@6.J[..P4IQC [*>;S=YW2"##-)>2CLYD*IFPP<)1"FGFX\=FW-[I_3 M7F0Y--9J6K1;@9)E+C"Y"5DU03.9=ZF8@)RNL7-"_[9+MI@MM\>/@PK8;-(@ ME%AC=I5&Q#:'TMCF9:]-Z<0\#A8D2?SL$%50R./55KAC:=(DE&=S;G?-MBG- MX3QA>+C6"@FO#^70F#FGV8JI"U3+D1FGSOITY<0>75=F>9*"U<*[#[RUYSI! MDFDM2RL7^IZ;5]6CG% _]-[TV#V"'\;;B-!_7/47XT5O.NK-YL/%<++L+\?3 M2:\_N>XMQA\GX]%XT)\L>_W!8'H[68XG'WNSZ4$9%>1U,$Y M6=2@?A?#F^NAGV)M/E<$''X:]] M^B^\Q@_]4P\Y47F<@7;<&\"@$E9 'D!R&@K#1B&U!4-$G/[W:'2\^ZXX M.A;+Z>"7GZ'9 MF\[X;O$_>E_Z<[I[7"[XV8^>!9?S\8#M+--BMY/QLMZ64F#J./1(6TS)"&9- MM]*R(?L=K!NRH5VP8&DWB#706V-&:M"KB:\%JRP3PCO.^W\TBM]7C>+Q\M-P MLL1930\=COE5/C]IDX"=LW7VH)K-8'GS[#NIM0"KZB&ONK4H+/GS0*"Q8(#E M' "K1]B'X@@;3^@8&_:6_7]B63OW?=894=)*R+ZG6J-'7@MY[ "H$7F@VCU. M:MA5I5<.[_[4VI5#[X^[+R&]3F'%[8-@EWFUC3V>-O6)Y3XFS_QKKZJMI+)6 M9ZX%0-*TP')[0O M>>H!9>AVGODK^CYQDZWCSZ+PD43)*VR4@6IB/]>@-]0TP#!$Q\>0I>D* Y=$ M 8P&:0WT%Q&TX <(CS[+W<8L24:<> ].=5J8K&"Q'/H+!KJS5+6@Z/C/(B^, MTBP <^+Z3ASS'1R'<9^W[IK$;N1QLXF8(?V6T%\DT.6P+ECH+&?AQ,7D#] M M!+ Z^OL#NGQJP8).XOXQX^DZ^>6D>?J+_U9-B36:0L]>KSVH:N.%SG1V ML&8VGUCC M=*>LB)Y!79LW(!;HG$DNU^&'7[%EU2TN]<'%+* MJ2G<#5EM6:+\:T)UP?4X;;MKLM5M3-9;_\9;$XZ@R@Y7N[5..; TQ Q]0C[T MOT]E7GG^EBT="^)N(YX_?_C"K0\?"X37F8KHLG:4ATBX%O=)@6IY/J76I>E.R1CE?E:E(:.?7;/K-@FA:1 ML6X]J@X>W $UC>;>_48>>55&1[=)M-7E9/I2#V2;U&2O\;/T':_^LQ.M\E@Q M?X24L3C>/J0_:S+G-/D.FLOHZ2>@YG18J67Y>;42*29OVTN;]H?0?&-Q%[J: MA%BP<\X%N\GVQ*5L8/F0-V33QKG$ON6/]&D* MJ]U">#:FWN=7C]T:W98.>ONUV,1S=WO1NQJ-A[X]9ZU^S2;G% M65?H>+K,)_J23;.J%E0#LJ3?MID.50+F'1\MRY!;B$T/] MB3S%5CN>OJ87=Z.C _>8'WL'V0P5DH@K8Y*\)5 K-2%C-; M9!6JSHL2U>,B:'8N-:I5LJ ?/(2SUM7KDGY6,!.KEI%\Y6[/TSJ2YG3+,C)9 M'Z_#!\>31NX"*MM!IH;20GG,"]EP_1!>]Q<_]^<6V:9F3)=0"VLYW[-AF(KI8 MVF)-;2@'P.;:WA?L4!HS0ZX8V=@::(:LO*=3L:O7Z@;DE@NC'[TH8CLXFK&* M-U;-B?.@-*:H:]JA)"<8?""-R2-CQ'RO=7+)O]BJ.F!6E\:VT$ UMW0T$8MN M*,U2E>>=&%726/4>3+/I)2W,7%L>TH=5!7"6\>\YU#*A3T8GGT M%'W-4*\6']ULU7!![#^P$Z.Q?>>N>>Q(U99/A>UN*H\YL,"$5B,D/3-^3=@@ M83!4&M?>E][1:Q"G HO3H6=(>+B5'AF3H6FW-_: MSS344?>WW(&$[QWC_C;9A)'WK\/FKCK7GK!25V^E 4C8Q-;,B:;1(F'!-CSM M^V[S#V)-7!G;;M<&?2IHT&D\MC+"QYVJ'O:S2 T\0B" 6,:;_@B$UL>VXK;$ MH_7C,/=&S70]H-WVDKD7_SY\>>3V!#&1RHK8[S+59A ("3IU$Y*P]VJHG$_> MBJRN7F]CLAH'4RJUP\[@6=H!>@I/D^5NZ<^R7X:!Y+#:M%WLJX#:Q+<#*+I> M\(EG',=;LKK>1LP8P]^I2I>4"7GFOY+P#ZV/_2'07QH2714UQ/(L\5V9ES)7!OE"JSVE)4%O'(=\'U!^&Q>K83SNU/0JK MX4$G<\#>^)NNLQO++#?99,L,&=/UX8)JX/@^6SF*2?;>]\SYVNZ0Y-.O T MFD!_8JI)?)$>3H:&Y.XS2Q(]" ;<<1'TEZ'J#:IO0'3PZ?0Q\!!US1_!DDZ.QP71WXEJ,@56R8P^*H4"39.- MW,E<7@_]@:CV@V&/$$$G;D3W1 FY\9Y(\?E42#@SK#;Z@U"U2=1!!YU*Z6N. M8@X5U=#?>*I-'@B/3J^ .4_;P88YJ8R#VR!*W\_]%\\4>T4"LO:2>!S/B1.' M@7/GO\[".&9ZO$_JR?U;)F&R^X7$?&?J@U ML\_@8Y@#"[R\Y\1G/9PY%)YE MY 2QPS<@0%?N=T57[OGPAN=[G?7GRU][RWE_LN@/^,LS]OAJBT16>VRK:V+[ M;8MZ>/5Z]!NH$[=6^2:H:K*FL)6RH-K/:' M.I($>WNW(!&+XM9+AR2MA.TU+-:MX@!1BX[R'L*2V0RGZW&P\IZ\U=;QQ4'- M@J*6#(\V)C.QD+F%$I&;+UZRX4(P>3;>XS(T2?^CJ Z^SUF'"6[/;8&X'QS'EE]K>$N1O$2;3ESSWSK$_O MQ/3"6\ . J_)K"Y$]G.:1F6EGLI-F"VT@QTG;HK?2KC06*P.SM"P4IIBIA+6/KXVZ$(G3?YCN?9B589&J,P6A/^ M:%(\#E+$),IDXF/8YJ^ZZF8.^-,& Y8GTSF)72_OXP<+")0VA!U&K\MR73DM MV6]H1A(/'7=S7%9YO="D:>P(_9I#OC50\=5C?V#*[/ZI3N]/3Y)C): J=OQ] M77JAH*#3)YV8TI_3Y65!HB?/K9W7IJ(=]!A\$\<((5[=WA=*=L/--434#'KH MOX&SPZGTX]21&=F\QN)%\M9O6&#&^V)@QF Z^3R<+\=7-\/>9+H<+GJS_J]] M]B]KXC*8I?#09W4TAJ@\=@S&8A-&"0NK9QT$AUI4U;+CVEO.BS".HDH@_'") MHUZ5IIVJ(W5U>3NH@2A=Z5Q<+1!^W /K4.[:1^KX5E6VLY14"8,>O7#<*(:=C CUB\I'S8]\B?8$ZCC&*35L&^.5:I6>0Y4@(!^!CP6:N2XRE>VQ#60 M?3;D:Z9T\)3EMB#FF9\F-J%/08O3>!K8IOI#Z57XY73PR\_3F^OA?/%O?_C+ M^W<__+4W_,?M>/FK/;OJ5$#U;KI8#GT7S4BZ>N4V/?@FNES)CK6GF@7QWKDL M!_[6.>^'#-@Y"XK;P0= SR2^[E9MF\\[; 1*CSHX!&\K?0D.:6G_++HXY7$/ M5[E](3#Z@U\B BMCNV2IHT!TI#%[D4#A]0*(SRT6_"A[HR MME>2#A]0*%"BI;K[[*-RK:Y\Z;'EL/3+2X\G?.G1"Y0O/1X707,F4[_T6"4+ MR@1@[/U,(_%:UKR?^=4%H4*F6WFH:2TK432E'$M1^!K&^LO*>.^QI1QYAX(.8^<<9FKMHJ 0C'T]/0ZX%>* MB X\CXJYIH-9OF04BEDR"6DO$04QN(;MVD!E!E+6A@OK'Y7: B>;LG4'1#!NAKXO+/E'I M?R#%'E(1"K\QRS, ?C@ Z+/]\(4]'+WUX@U_SV;-_'GD$[^XAATSD/X:()8H M9Y^TAYXE_9[RJ*"H9P=5*N4#\)07"OO<4,B'H=JZ"HI#)SAS6UB0SLES@5@V MR_$YF\D V-,>BMDQ2&KN:0]BY*X#+$V*$(N"\P^2!"OVF@_$+]W,U^S0A4H] MULV$4$M^[+EU3N(D\MPDN[B_#;PDGB]N57.LHAK4J\28+[S)H5%^0DV-(/I, MG3-(I?' _6VR"2/V_!;("E>NA.Q-+W6C%5OC1,+;1-#,B:81M_NFH;DS$O%N M@X@25\:.3ZG)F H-FYC+A]IK#*M=!>S4-6M\FYUD]VJU?Y(Z[ M>^/]S]9;<5S37Y# !?,GJ(R=(*\^>5(TT)D[CB3-N6P?$D'-Z/F%*'(L YO M3H"GPZ(V,NA7YCGX.F0V99]F3V%ME=;"SUM6?9JMD1Z?G> Z9DQ5Y>$QV$P==Q5V& M[;UD;00W@)Z5KO[4JH0%G<:O)K^PN9QT.NIQFJS"W3LH23,XYA-WYC8KAXRL M$HUKV"Y4N:RP3+4#XOGJT80\\U_5U9='C: M+,R-54+@C#S:!CSGM./W5_^]C9/#&V05K+(:L@KHX24@_E12V#(QL^[P@[9B ML<[*0,&WPII7%@X?;\EXKK_7+E:'LF2%X4X+D@ZO=II/I63EXJR@.NM?_8;! MKB0VJ$M+,';ZR+X3JA^L4JE _BKR6E EL,(F" $ ?:ZW_=5:*PQPC=^J[=[H M/;[O& =N1.C9ON^ZT98)3E>3HMT?=OU;X!.==)7=>)HZKH(;7- MW20JH# 4W)PM_[-MY&[H/"$P(I1*03'&M?Q4=MV2F0_\_"?NF]WFXC);L^=* MP>KP*9=+=Z>^SK@3W-9_I@L]6>W/Z+4*VRPRAG&/B6#W G?\YF'P\^V#!$XG&0F]"S=VCVLAZ] M:/.GTHLV@Y^'U[37S+C MFPA\MBDS_@G#"7)77^DI3G&X:?=3R)D]Q/N EJ,(A"C7/LD\IM:@Q(D2?(M- M.\A\(>PREJSZ])3FW).=70OB7W2*#F G-<%05@@EYZ'"#:P58KSFA&5SHC\? MA $_(6T=GSW+^]ZBI-@Y5Y[32CZF(7A![+C>KG61N+7X2.\$- MQFQ:#3OV_"EZ@[!RJ!63QMP&E*:_@YV2Z&0S:C7 ]J_/PD2@E7(9.@VUV0GL M/$KM:5S[U)CR79)\>I?)*]_G2A<:[B-4HR'LC$NP-; ^1/A32#<W>FJCFL1T4=& MR0:-1I]M,U18R(+I?6O%I] 3O)W0%B/ ^:)_.UQP]JS@#J"GNAUEQ\$3J(GKFOH=\O&J=V6+<:^$'G(#@^&1C,;2#[)GKZP)-Y MH*N1M_=(9GX)VAF519F=3]\-]'2(&D;3WB?/. M(>3A8D$*D[W98F\18/P#?6)2AI M>_2U=2Z^,9X+14.74C'I!P2Y4;)RA6)?!\,%H5[8K\7.7IW#TU/HZ=DZL MUHZVYI\JM3:M5MM6=! $=?V:D#ID_8Y66]&Q$;WHONH&]XK<>T%0_<[9R=D# M=!(],5?WQPA8%0S%&3475LN#NAU\K<[<9:E.=C;3U]$JDIVF!)I5710]-Y81 MC9#!@LVDC0GV>XT29!G:>'0J7Y:E*V<+ M1!M2XN&+F_O8S@$B&T"JI1)2%3VEEJ&E$P[;.=H4(>FYC'X5/9%7AY9#JU*$ MG6XQ;9H*S-#4W[7,8%U94E$2B]DY-^^ST)QX=LY]%S^S6:G".&Q++'%!T\HUT MZ([GQ BV&Q0?]&R-N2%;1@/JA[BY_7K_O" M:8&UVWFK_$_LR.!GJ4YV-N-?0Q<4.W+DG.[&%ZS-'JC_GC>^]R_N1WV/@W[B]OY\--PLKRDTSO=[>?C>:VZ<.7QX)6]I%!J:F*=X!W\1.[F,\ MS3T8=SM4J\YA42;BY]"GS?A>\CJG2!OPY-/Y.'J&'>,/W.A3<9YJ=^T]>2MZ MCD=0NN-/HR>L056Y*AK.2^'F7OS[*"+,:DHHMV-!A^/+&1OM?LT-S.OO&AF#[5;4B"FVOK(:L KIQQ*":Y[T7U*!U M]X1:]C!+-B1:TC-'MIV:A,$3E9^LC$76ZGJ( Z) "]LWZ:MGBX@,F_C"0AF,>I*#%&2[$'Z";V[HV(:A+/>-\C M3:!JQR*@W45T2W_7];[.?[)(:R[B6DO)V!G--[* MI4"[BY=L_Z=2@S->"D9AM"8>\FI0T8GS>R4 \6O17VW5#NLG-3U^G=^[R!8 M!O#9CP?[3/T:68DZE"D& \56K)0-0[*[H/I6+@3PWFD,F YEG;$,8$-CZ=0N MIMJNG/Y_W)/MW#^T +@/ $.97 M(5W2INMK+R(NK2-'7508ZMIB)"U("[C+03 ^L0#G%5VT[9]6+//COR:1]\0M M'0=K%8M4E@==R6N=^;X7A$'.HQ.;V%U27A9^H@JMDM>R@UB(R@JYJA++R$97 MQU)Q,. (I\5]ZH)246S?8HBBE3( "@1&GP[WJ2%2"SZ;+\* S1#R^5!1S8YQ M8]S4(PEK@1R 0]NR7,V*K9K^*HMBNN%*E*A @ ME!1]VLNN#53X%XIANW3J8%\I(3KN?$YEU[V ' >'8I9,0:?(<7 0.C>0D;E2 M+1RE@G;P5:EK(LS-)@7XKVU EL_A:J4_^9[>WT- M+OEOSCW_36,=JO+7F2]N57MR137HI(P7J]A"SAP8%);,ZTRBZ3H'@'Q^%Q2W M8[2:GN<%PN?"J9#6YIQ<5#LG8> ):K2NB MF3/'\.'1#U.MNX\(_[ATQRLI#YU3C44^U52_HS>J57"@/,ZQ-VLN7$)E\D*Q MSYV@J!WCPZ3/G4#P7+3="?G*NG ;Q(_$]=8>6!>OET[*G3FDU&5R+G@ M2%265&?H0C$[F*K0L&JL;3FS"A2*:PQ5*JIXTT \8\E/B-6-@#-*F=I[5>H7 MS$ A@P5]=E/W668C!@NN;R_^8"Q/9#M4VF> M_42BNS FW4QTL-?X1R]*_:$-IF:2?0S;#=*^) 1J:O!7JDK9=#7GJ\LS:@]_ MLMER0I[YKZ1^L[#ZV%Y^.%N*$H#X?-?%81)FF4]*F5$@>U"C7\7V8K1OX= @ MJ].;GH'OQ/%TG;F&3J,Y2\639K":KA?$I0,R\4@\<'R?K*Y>=[DULH*2::UQ MPV>;3[(ER&NK74(B9*6;1:%+R"H>4($*[JHLT?4Q;:*\1O(:,:[OO\?.ST')6*@4VBW6'I$HY+1F87!2N(8KS0U8&2D^'S)85 M4MI"3O7IEN>UK&\=*%:'4MI!TY\.?NALRQ;S>KL?.+?=L^Q!T.KTZ;K@C4T7 M#HJ>9)86E8>J0/>,?W*$#&UKJC\:_TJ297A%YL0-[P/O7\+]#KPZE+<.&=;T M +!D6C:7Q+JS[RR^ZY[A[-0L=GKI,0=69]^B>]<]P]^I6;1CIKY3"WPGN.D_ M%FO_@H#$#F7NB^BQ^&;5TB!+>'<;(B^SA@(?+S"R=TVX Y:IKT$ULD/64Z-X M"2=%C&=#O(3U&_8>R(]5[X&,EY^&DV5K#WRTDO4J%8I9 %CF/'KN)X'KD?C0 M=\FC'SO#N5XSV"]\#$*?RA"FR)>C&%W!K_,AC>"G/MK[EAW!(;4T1OC 1WOH MX+_TT8(LI2FV:JBU^14[=,K4#(U/RI?4FHYC?SE):4RV1:_I"1*YAA]\MR- M0_Q??@FI9+\K,CB*2G?XD22I7$9O4??S+/-2O":Q&WF/@M E5EY<'#E6UL31 M*<^."B=TFWOVK%8,BS^K+HV]@S!)HE1PHT.,&34BPC[D1*]78;"MVCOLWD,M M%L2.!C4]KL3@6&"P/6R8)B2YSJXPELY+/X[)_E'G2MOMA^^*MMO%X.?A]>W- ML#<=]2;#9>]Z.!K.Y\/KWK+_SUY_L1CF7FU&,N6.*9T/A,JG8[B55D)[B"%[ M1&*Z+K$&,D5#JB,O> "RRJ\VP&%!7\]*/9P^$C;-!/JI!MA]_)ML.CX?5PWK_IC2>#Z:FNJDU1?/,<'R*C;8.>VS VA,V10 M$/2*'L?I6-[20_>=3S)W?MK3>WHR#TC,EZF[*LUE;39K$GOGK$%LU?>VI0 Q>ZT4P*_@6#>DE'RVG?=:%LYK4O&1&4# MV%OO=H:[!!OTXY.&DE4[XP["&+)):=9\][;FK>+:)2WA@2.M*$36$G:R,:/< M'Z%E*\V##;ML&0>-3"UMM(V=XZLU5:B!J#W*D:GN%=VKKCW(W%^L@)UWJP&- MU;)WVM:REXW$H&"1#^^+%I:#-66XL"=#,Q+3$N:'1M4$L! A0# M% @ *V-A5D?ACY"4!P ZBX H ( !PBD &5X,S$M M,BYH=&U02P$"% ,4 " K8V%6@%USU6T$ !)'P "@ M@ %^,0 97@S,BTQ+FAT;5!+ 0(4 Q0 ( "MC8590+6H2:BH" (*S& , M " 1,V !F;W)M,3 M:RYH=&U02P$"% ,4 " K8V%6 M@W\RZX8. 2#P $ @ &G8 ( 9F]R;3$P+6M?,# Q+FIP M9U!+ 0(4 Q0 ( "MC85:)=7/IX@T +2) 1 " 5MO M @!R9&=L+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0 ( "MC85;0GM+]D0T ""< M 5 " 6Q] @!R9&=L+3(P,C(Q,C,Q7V-A;"YX;6Q02P$" M% ,4 " K8V%6?5Z/1'XI !V @, %0 @ $PBP( &UL4$L! A0#% @ *V-A5K;X9GGQ5P "U % M !4 ( !X;0" ')D9VPM,C R,C$R,S%?;&%B+GAM;%!+ 0(4 M Q0 ( "MC85:13WB!D3L "(M! 5 " 04- P!R9&=L G+3(P,C(Q,C,Q7W!R92YX;6Q02P4& P # #; @ R4@# end